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ABSTRACT 
Obesity is known to contribute to the risk of developing type 2 diabetes mellitus, non-
alcoholic fatty liver diseases, cancer, osteoarthritis and cardiovascular diseases. Obesity results from 
an imbalance between energy intake and energy expenditure but its aetiology is complex and not 
completely understood. Genetic and environmental factors, (high calorie diet, lack of physical 
activity) strongly influence the onset of obesity and metabolic diseases. Modifications of gut 
microbial–host metabolic interactions by dietary interventions also contribute to obesity and are 
associated with metabolic disturbances. Noticeably, some obese individuals seem protected from 
the development of metabolic diseases which highlight individual predispositions to obesity 
associated metabolic disturbances. It is therefore important to underpin the molecular mechanisms 
linked to obesity and the role of gut microbiota in the degradation of a healthy phenotype in an 
appropriate biological model.  
1H nuclear magnetic spectroscopy and mass spectrometry analysis were employed to 
measure the abundant metabolites in C57BL/6 mouse urine, feces, and plasma. Metabolic profiles of 
mice subjected to dietary interventions were compared using multivariate statistics. Alterations of 
gut microbial ecosystem by dietary interventions were also assessed by 16s rRNA pyrosequencing of 
mouse fecal microbiota. 
When given a high fat diet, the obesity prone and obesity resistant mice showed differences 
in leucine catabolism and tricarboxylic cycle. This may indicate specific regulations of mitochondrial 
oxidative pathways during diet induced obesity (DIO), influencing obesity development and 
metabolic disturbances. Possible roles of gut microbiota in the regulation of mitochondrial oxidative 
pathways were also envisaged. Gut microbial remodelling by the supplementation of different 
prebiotic blends (galactosyl-oligosaccharides, fructosyl-oligosaccharides and inulin or galactosyl-
oligosaccharides and cow milk oligosaccharides) during a high fat challenge also decreased obesity 
and low grade inflammation and affect mouse metabolism. Decreased gut bacterial amino acids 
fermentation by prebiotic supplementation may contribute to the improvement of mouse 
physiology during DIO.  
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triglycerides. Cyt: cytochrome, CPT: citrate protein transporter, MPC: mitochondrial pyruvate carrier, BCAT: 
branched-chain aminotransferase, BCKDH: branched-chain keto acid dehydrogenase .................................... 112 
Figure 26: Experimental design to investigate the effect of prebiotic supplementation on physiological and 
metabolic adaptation of C57BL/6 mice during HF challenge.LF (low fat), HF (high fat), HF_S (HF + glucose-
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galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk 
oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) .................................................... 119 
Figure 27: Impact of different diet interventions on (A.) mouse weight gain, (B.) food intake and (C.) cumulative 
food efficiency during the overall course of the experiment. Cumulative food intake (CFE) = body weight gain 
(BWG) /cumulative food intake. Wilcoxon-Mann-Whitney tests are presented at the last timepoint. 1 star for 
p-value<0.05, 2 stars for p-value<0.01, 3 stars for p-value<0.001 (x: HF vs HF+GOS, ¥ HF vs HF +FOS_IN, ⁰: HF_S 
vs HF+GOS_CMO, ǂ: LF vs HF+GOS, +: LF vs HF+FOS_IN, #:LF vs HF+GOS_CMO). LF (low fat), HF (high fat), HF_S 
(HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and 
cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) ..................................... 130 
Figure 28: Body fat composition of mice fed with different diets at 56 days (D56). Fat mass (red), lean mass 
(blue) and total mass (green) levels of different diet groups are shown. Values are expressed as mean ± SEM. 
Differences between diet groups were assessed by non parametric Wilcoxon-Mann-Whitney tests . P<0.05*, 
p<0.01**, p<0.001*** . LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + 
galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + 
fructosyl-oligosaccharides and inulin) ................................................................................................................ 132 
Figure 29: Time-dependent effect of different dietary interventions on mouse fasting glycaemia. Concentration 
of glucose was obtained at 7 days (D-7) before the diet switch, at 35 (D35) and at 49 (D49) days after the diet 
switch and the values are expressed as mean ± SEM. Differences between groups were assessed by non 
parametric Wilcoxon-Mann-Whitney tests , P<0.05*, p<0.01**, p<0.001***. LF (low fat), HF (high fat), HF_S 
(HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and 
cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) ..................................... 134 
Figure 30: Circulating inflammatory status of mice fed different diets at 70 days (D70) after diet switch. Plasma 
level of IFN-γ, IL-1β, IL-6, IL-10, IL-12, KcGRO, TNF-α were measured in each dietary group at D70 after diet 
switch with the MesoScale Discovery platform.Results are expressed as mean concentration (pg/ml) ± SEM. 
For each cytokine, the differences between groups were assessed by non parametric Wilcoxon-Mann-Whitney  
tests, P<0.05*, p<0.01**, p<0.001***. LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + 
GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN 
(HF + fructosyl-oligosaccharides and inulin) ....................................................................................................... 136 
Figure 31: Mean of 
1
H NMR spectra of urine from LF, HF and HF + prebiotic fed mice from D7 to D70 The 
aromatic region of the spectrum (6.8-7.8ppm) has been zoomed to improve the spectral assignment.4PY : N-
methyl-4-pyridone-3-carboxamide, 2PY: N-methyl-2-pyridone-5-carboxamide*: tentative assignment. ….. 138 
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Figure 32: Mean of 
1
H NMR spectra of feces from LF, HF and HF + prebiotic fed mice from D7 to D70. The 
spectrum has been zoomed in three different regions (0-2.2, 2.3-4.5 and 4.7-8.55ppm) to identify peak 
multiplicity and improve the spectral assignment.*: tentative assignment.......................................................139 
Figure 33: Mean of 
1
H NMR spectra of plasma from LF, HF and HF + prebiotic fed mice from D7 to D70. (A.) 
1
H 
NMR CPMG spectra (B.) 
1
H NMR standard spectra ............................................................................................ 140 
XFigure 34: Global urinary (A) and fecal (B) metabolic profile of each diet group. All urine (n=826) or fecal 
(n=785) samples acquired from 7 days (D7) to 70 days (D70) after the diet switch were used to calculate OPLS-
DA models. For each matrix, 3D score plots showed the three dimensional dispersion of the scores of each diet 
group across time. The 2D projections indicate the biggest variability in the dataset along the first and the 
second component.Both models were built with 6 predictive and 2 orthogonal components. Q
2
Y=0.46 and 
R
2
Y= 0.49 for urinary metabolic profile.Q
2
Y=0.24, R
2
Y=0.46 for fecal metabolic profile: LF (low fat), HF (high 
fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + 
GOS and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin)X.....................X145 
XXFigure 35: OPLS-DA score plot from global urinary (A.) and fecal (B.) metabolic profile highlighting the time-
dependent trajectories: Urine (n=826) or fecal (n=785) samples acquired from 7 days (D7) to 70 days (D70) 
after the diet switch were used to calculate OPLS-DA models. For each matrix, 3D score plots showed the three 
dimensional dispersion of the scores on the 4th, 5th and 6th component which highlights the time      
trajectory............................................................................................................................................................156 
XFigure 36: Identification of specific metabolic effects and partial normalisation of metabolic profiles by 
prebiotic supplementation in urine (A, B, C.), feces (D. E. F.) and plasma (G, H, I) after 70 days of HF diet. For 
each biological matrix, OPLS-DAs were calculated with LF, HF and HF + GOS groups (A, D, G), or LF, HF and HF + 
FOS_IN (B, E, H) or LF, HF_S and HF + GOS_CMO (C, F, I). Q
2
Y and R
2
Y for each model are given in Table 6.. LF 
(low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ 
GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and 
inulin)..................................................................................................................................................................148 
Figure 37: Evaluation of the “metabolic rescue” of different prebiotics during HF challenge in urine, feces and 
plasma. The metabolic rescue of FOS_IN and GOS was estimated (in percentage) by predicting the score of HF 
+ GOS and HF + FOS_IN groups onto the first component of OPLS-DA model built with urinary (A), fecal (C) or 
plasma (E) metabolic profile of HF and LF groups. The “metabolic rescue” of GOS_CMO was calculated by 
predicting HF + GOS_CMO scores onto the first predictive component of the OPLS-DA models built with urinary 
(B), fecal (D) or plasma (F) metabolic profile of LF and HF groups. Negative control group (LF), positive control 
group (HF, or HF_S ) and test groups (HF + FOS_IN , HF + GOS or HF + GOS_CMO ) LF (low fat), HF (high fat), 
HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS 
and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin)...............................151 
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Figure 38: Comparison of metabolic signatures associated to different diet groups. (A) Standard 
1
H NMR 
plasma metabolic profiles (B) CPMG 
1
H NMR plasma metabolic profiles (C) Standard 
1
H NMR urinary metabolic 
profiles (D) Standard 
1
H NMR fecal metabolic profiles. Correlation values (R) of the metabolites are displayed 
by color code. Gradient of red color are for metabolites positively correlated with HF or HF_S (in LF vs HF or LF 
vs HF_S models) or HF + prebiotics (in LF vs HF+prebiotics or HF vs HF + prebiotic models). The gradient of blue 
colors are for metabolites negatively correlated with the same diet groups LF (low fat), HF (high fat), HF_S (HF 
+ glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow 
milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) (PC: predictive components, 
OC: orthogonal components)..............................................................................................................................156 
Figure 39: Global OPLS-DA model comparing plasma lipid and amino acid variations between different diet 
groups measured by targeted LC/direct infusion MS. OPLS-DA score plot (A.) showed the main variations in the 
dataset while OPLS-DA loadings plot (B.) indicated metabolite contributions to the separation between diet 
groups. LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-
oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-
oligosaccharides and inulin)X…………………………………………………………………………………………………………………………159 
XFigure 40: Comparison of the plasma metabolic signature acquired by MS targeted profiling analysis among 
the different diet group at D70 after the diet switch. The correlation matrix summarises the pair-wise OPLS-DA 
models between the different diet groups. Each column represents an OPLS-DA model comparing the two 
groups indicated above each column, and illustrates the variation in circulating levels of lipids, amino acids, 
acylcarnitines and other metabolites. For each model , correlation coefficients were obtained from the OPLS-
DA coefficient plot. Correlation values (R) of the metabolites are displayed by color code. Gradient of red 
colors is for metabolites positively correlated with HF or HF_S (in LF vs HF or LF vs HF_S models) or HF + 
prebiotics (in LF vs HF+prebiotics or HF vs HF + prebiotic models). The gradient of blue colors is for metabolites 
negatively correlated with the same diet groups(Cx:y means x :the number of carbons in the side chains, Y: 
number of insaturations). LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + 
galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + 
fructosyl-oligosaccharides and inulin). LPC (lysophosphocholine) PC/PC-O (phosphocholine) SM 
(sphingomyelin)X..................................................................................................................................................160 
Figure 41: Phylum-level analysis of the fecal microbiota of the isogenic C57BL/6 mice at (A) D-7, (B) D7 and (C) 
D70 of the different dietary interventions. Prior to D-7, animals were fed the LF diet for 2 weeks. Diets: LF, low 
fat; HF, high fat; HF_S, high fat + glucose–lactose–galactose (positive control for GOS_CMO); HF + GOS, high fat 
+ galactosyl-oligosaccharides; HF + FOS_IN, high fat + fructo-oligosaccharides–inulin; HF + GOS_CMO, high fat + 
galactosyl-oligosaccharides–cow milk oligosaccharides (glucose–lactose–galactose). The stacked bar graphs 
show the mean percentage the major phyla which contribute to the total fecal microbiota of the mice at each 
time point. .......................................................................................................................................................... 182 
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XFigure 42: Family-level analysis of the fecal microbiota of the isogenic C57BL/6 mice at D7 and D70 of the 
different dietary interventions. Diets: LF, low fat; HF, high fat; HF_S, high fat + glucose–lactose–galactose 
(positive control for GOS_CMO); HF + GOS, high fat + galactosyl-oligosaccharides; HF + FOS_IN, high fat + 
fructo-oligosaccharides–inulin; HF + GOS_CMO, high fat + galactosyl-oligosaccharides–cow milk 
oligosaccharides (glucose–lactose–galactose). Bar plot intensities for each family of bacteria (arbitrary unit: au) 
correspond to the mean percentage of the total detected bacteria at family level. Significant differences in the 
relative abundances of detected taxa between different diet groups were evaluated using the non-parametric 
Mann–Whitney tests (p value: *<0.05, **<0.001, ***<0.0001). #: NaN X............................................................X183 
XFigure 43: Individual matrix scaling in MFA, adapted from Dumas et al.3 (A) XNMR and Xmicrob correspond to 
NMR and microbiota datasets with KNMR and Kmicrob variables, respectively. (B) PCA of each dataset, which 
enables calculation of the largest eigenvalue (γ). (C) All datasets were individually scaled with 1/γ and merged 
in one block-dataset. (D) Global PCA using the new block-
datasetX....................................................................X185 
XFigure 44: PCA model of the combined data from the fecal microbiota (family level), relevant metabolites (
1
H 
NMR urine, plasma and feces) and circulating inflammatory markers at D70. (A) The PCA scores plot shows the 
dispersion of scores for each diet group: 20 % of the variance in the merged matrix (X) is explained by the first 
component, while 17 % of the variance in X is explained by the second component. (B) The PCA loadings plot 
indicated the contribution of variables from the different datasets in the separation of the diet groups. For 
instance, HF and HF_S groups present in the dotted circle in the score plots showed an increase in several 
metabolites, cytokines and bacterial families highlighted by the dotted circle in the loadings plot. ................X187 
Figure 45: Heatmaps showing bidirectional clustering of Spearman correlation data for families of fecal 
bacteria and (A) plasma, (B) fecal and (C) urinary metabolites at D70. Heatmaps were produced using 
Spearman correlation values generated from family-level microbiota data and statistical recoupling of variables 
(SRV) clusters of 
1
H NMR peak intensities
223
 (see Material and Methods). Each SRV cluster was in turn assigned 
as a metabolite, but several clusters remained unidentified (UA metabolites). Sign of correlation: red, positive 
correlations; green, negative correlations. p Values were determined for Spearman correlations; p value <0.05 
was taken as representing statistically significant correlations ......................................................................... 192 
Figure 46: Bipartite graph showing the correlation network for IL-1β, metabolites (urine, plasma and feces) and 
members of the fecal microbiota. The correlation network was built using significant Spearman correlation 
results using an arbitrary cut-off of IRI >0.3 and p value <0.05. Each node corresponds to an entity (i.e. a 
metabolite, family or cytokine). The nodes colors are associated with the type of entity: brown, fecal 
metabolites; yellow, urinary metabolites; pink, plasma metabolites; blue, fecal bacteria at family level; white, 
circulating cytokine. The edge between two nodes represents a significant Spearman correlation (R) between 
the two entities the nodes represent. The colors of the edges are dependent on the sign of R: green, positive 
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correlation; red, negative correlation. The thickness of the lines indicates the absolute value of R: thinnest lines 
for IRI ≤0.49; medium thickness lines for 0.5 ≤ IRI ≤0.599; and thickest lines for IRI > 0.6. ............................... 193 
Figure 47: Identification of metabolic/biological information from urine and feces samples predicting the long-
term prebiotic effect on obesity development during HF challenge. BWG monitoring of negative control group 
(LF), positive control groups (HF and HF_S) and prebiotic test groups (HF + GOS, HF + GOS_CMO, HF + FOS_IN) 
indicated 2 phases in the physiological adaptation to prebiotic supplementation.  Time-dependant metabolic 
and gut microbial adaptation to each diet intervention underlying the mouse physiological variations was also 
suggested. Therefore, 
1
H NMR metabolic profiles for urine and feces at each time-point, and fecal microbiota 
profiles at D7 and D70 after the diet switch were used to describe the long-term effect of prebiotic on obesity 
development and metabolic disorders. LF:  low fat, HF: high fat, HF_S : HF and glucose–lactose–galactose  
(positive control of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing 
glucose–lactose–galactose). ............................................................................................................................... 208 
Figure 48: Cumulative food efficiency of negative control group Wilcoxon-Mann-Whitney tests are presented 
at the last timepoint. 1 star for p-value<0.05, 2 stars for p-value<0.01, 3 stars for p-value<0.001 (x: HF vs 
HF+GOS, ¥ HF vs HF +FOS_IN, ⁰: HF_S vs HF+GOS_CMO, ǂ: LF vs HF+GOS, +: LF vs HF+FOS_IN, #:LF vs 
HF+GOS_CMO) (LF), positive control groups (HF, HF_S) and prebiotic test groups (HF + GOS, HF + GOS_CMO 
and HF + FOS_IN) overtime. LF:  low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose  (positive 
control of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and 
inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–
galactose)............................................................................................................................................................ 212 
Figure 49: OPLS regression models predicting mouse calorie storage at D70  after the diet switch from urinary 
metabolic profiles of HF and HF + GOS fed mice .(A ,B), HF_S and HF + GOS_CMO fed mice (.C, .D) or HF and HF 
+ FOS_IN fed mice (E, F). For each model, the score plots indicate a good relationship between early metabolic 
profiles and CFE_D70 (.A, C, E). The OPLS-loadings plot highlights metabolites that are positively or negatively 
correlated with CFE_D70 (.B, .D, .F). LF:  low fat, HF: high fat, HF_S : HF and glucose–lactose–galactose  
(positive control of HF + GOS_CMO group,) GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides (containing 
glucose–lactose–galactose) ................................................................................................................................ 217 
Figure 50: Goodness of fit (R
2
Y) and goodness of prediction (Q
2
Y) of OPLS-regression models predicting 
CFE_D70 with urinary metabolic profiles of  HF and HF + GOS groups (A.), HF_S and HF + GOS_CMO groups (B.) 
or HF and HF + FOS_IN groups (C.)  at  each time point. The models were calculated with 1 predictive 
component and various numbers of orthogonal components.  For each model, the number of components is 
indicated at each time point on top of the R
2
Y value.  All  models  were  validated  with  multiple  permutation  
testing. (see Appendices) LF:  low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose    (positive control 
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of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides;  FOS_IN: fructosyl-oligosaccharides and inulin;   
GOS_CMO, galactosyl-oligosaccharides  and  cow milk oligosaccharides   (containing glucose–lactose–
galactose)............................................................................................................................................................ 218 
XFigure 51: Heatmaps highlighting discriminatory metabolites at each timepoint being positively or negatively 
correlated with mouse calorie storage at D70 after the diet switch. Correlation coefficients were  obtained 
from the OPLS-DA coefficient plot of predicting models from urinary metabolic profiles of HF and HF + GOS fed 
mice (A), HF_S and HF +GOS_CMO fed mice (B) or HF and HF + FOS_IN fed mice (C) at each timepoint.  Positive 
values are color-coded in red shades while negative values are color-coded in blue shades. *:  tentative 
assignment LF:  low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose  (positive control of HF + 
GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and inulin; 
GOS_CMO, galactosyl-oligosaccharides and  cow  milk  oligosaccharides ( containing glucose–lactose–
galactose)X............................................................................................................................................................X22
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Figure 52: Goodness of fit (R
2
Y) and goodness of prediction (Q
2
Y) of OPLS-regression models predicting 
CFE_D70 with fecal metabolic profiles of HF and HF + GOS groups (A), HF_S and HF + GOS_CMO groups (B) or 
HF and HF + FOS_IN groups (B) at each time point. The models were calculated with 1 predictive component 
and various numbers of orthogonal components. For each model, the number of components is indicated at 
each time point on top of the R
2
Y value.  *: indicates the models validated with multiple permutation testing. 
(see Appendix 2, Table S7). LF: low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose  (positive control 
of HF + GOS_CMO group,) GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and inulin; 
GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–galactose)
 ............................................................................................................................................................................ 223 
XFigure 53: OPLS-coefficient plots indicating correlation coefficients between bacteria families at D7 and D70 
and GOS (A, B), GOS_CMO (C, D) or FOS_IN (E, F) efficiency in reducing mouse calorie storage at D70 after the 
diet switch. OPLS-DA coefficient plots were obtained from models with HF and HF + GOS fed mice(A,.B), HF_S 
and HF + GOS_CMO fed mice (C,.D) or HF and HF + FOS_IN fed mice (E,.F) at D7 and D70 after the diet switch.  
Correlation values (R
2
) color-coded in red shades are close to 1 while those color-coded in blue shades are 
close to 0X............................................................................................................................................................ 
X226 
Figure 54: Venn diagram indicating the number of specific and common markers of calorie storage at D70 after 
the diet switch among the different prebiotics. GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides (containing 
glucose–lactose–galactose) ................................................................................................................................ 227 
Figure 55: OPLS-regression models predicting long-term physiological outcomes based on the abundance of 
Streptococcaceae (St), p-cresol sulfate (PCS), p-cresol glucuronide (PCG) and phenylacetylglycine (PAG) at D7 
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after the diet switch.  For each model, the scores plots indicate a significant relationship between a specific 
pattern of excretion of these markers and the physiological outcomes (Figure 54.A for CFE_D70, Figure 54.D 
for fat mass, Figure 54.G for circulating IL-1β, Figure 54.J for fasting insulinemia). The OPLS-loadings plot 
indicated the correlation coefficients between the variables and the physiological outcomes Figure 54.B for 
CFE_D70, Figure 54.E for fat mass, Figure 54.H for circulating IL-1β, Figure 54.K for fasting insulinemia). All the 
models were validated with multiple permutations testing (p value <0.05) (Figure 9.C for CFE_D70, Figure 54.F 
for fat mass, Figure 54.I for circulating IL-1β, Figure 54.K for fasting insulinemia) ............................................ 231 
Figure 56: OPLS-regression models predicting organ weight at sacrifice based on the abundance of 
Streptococcaceae (St), p-cresol sulfate (PCS), p-cresol glucuronide (PCG) and phenylacetylglycine (PAG) at D7 
after the diet switch. For each model, the scores plots indicate a significant relationship between a specific 
pattern of excretion of these markers and organ weights (Figure 55.A for mesenteric fat, Figure 55.D for 
epididymal fat, 55.G for caecum weight,). The OPLS-loadings plot indicated the correlation coefficients 
between the variables and the physiological outcomes (Figure 55.B for mesenteric fat, Figure 55.E for 
epididymal fat, Figure 55.H for caecum weight). All the models were validated with multiple permutations 
testing (p value < 0.05) outcomes (Figure 55.C for mesenteric fat, Figure 55.F for epididymal fat, Figure 55.I for 
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XFigure 57: Possible mechanisms linking gut bacterial tyrosine degradation, host inflammatory pathways and 
host physiological disturbances in diet induced obesity and its regulation with 
prebiotics...............................X251 
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ABBREVIATIONS 
2PY N-1-methyl-2-pyridone-5-carboxamide  
4PY N-1-methyl-4-pyridone-3-carboxamide 
AMPK Adenosine Monophosphate Activated Protein Kinase 
anglp4 Angiopoetin Like Protein 4  
APCI Atmospheric Pressure Chemical Ionisation  
ATP Adenosine Tri-Phosphate  
BCAA Branched Chain Amino Acid 
BCAT Branched Chain Aminotransferase 
BCKDH Branched-Chain Keto Acid Dehydrogenase 
BMI Body Mass Index 
BMRDB Biological Magnetic Resonance Data Bank  
BW Body Weight  
BWG Body Weight Gain  
CEC Capillary Electrophoresis Chromatography 
CI Chemical Ionisation 
CID Collision Induced Dissociation  
CMO Cow Milk Oligosaccharide 
CPMG Carr-Purcell-Meilboom-Gill  
CV Cross Validation  
CVD Cardiovascular Disease 
DIO Diet Induced Obesity  
DNTP Deoxynucleotide Tri-Phosphate 
EI Electronic Ionisation  
ESI Electrospray Ionisation  
ERK Extracellular Signal Kinase 
FA Fatty Acid 
FAB Fast Atom Bombardment 
FAS Fatty Acid Synthase  
FFMI Fat Free Mass Index 
FIA Flow Injection Analysis  
FID Free Induction Decay  
FMI Fat Mass Index 
FOS Fructosyl-Oligosaccharide 
FTICR Fourrier Transform-Ion Cyclotron Resonance  
GC Gas Chromatography 
GF Germ Free  
GOS Galactosyl-Oligosaccharide 
GPR G-Coupled Receptor 
HDL High Density Lipoprotein 
HF High Fat 
HILIC Hydrophilic Interaction Liquid Chromatography  
HMO Human Milk Oligosaccharide 
HPLC High Pressure Liquid Chromatography 
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IDL Intermediate Density Lipoprotein 
IFN Interferon  
IGF-1 Growth Factor Receptor-1 
IL Interleukin 
IR Insulin Resistance 
IRS Insulin Receptor Substrate  
JNK c-Jun-N Terminal Kinase  
LCFA Long Chain Fatty Acid  
LF Low Fat  
LPC Lysophosphatidylcholine 
LPL Lipoprotein Lipase 
LPS Lipopolysaccharide 
MAD Median Absolute Deviation 
MALDI Matrix-Assisted Laser Desorption Ionisation 
MAP Mitogen-activated Protein  
MetS Metabolic Syndrome 
MFA Multivariate Factor Analysis  
MRM Multiple Reaction Monitoring  
MS Mass Spectrometry 
MTTP Microsomal Triglyceride Transfer Protein  
MyD88 Myeloid Differentiation Factor 88  
NAD Nicotinamide Adenine Nicotinamide 
NMR Nuclear Magnetic Resonance Spectroscopy  
NLR Nucleotide Oligomerisation Domain like Receptor 
NR Non-Responder 
NRC Nestlé Research Center  
OGTT Oral Glucose Tolerance Test  
OSC Orthogonal Signal Correlation  
OTU Operational Taxonomic Group 
PAG Phenylacetylglycine 
PC Principal Component 
PC(Cx:y/Cx:y) Phosphatidylcholine (x:carbon number, y:unsaturation) 
PCA Principal Component Analysis  
PCG p-Cresol Glucuronide 
PCR Polymerase Chain Reaction  
PCS p-Cresol Sulfate  
PDK 1 Phosphoinositide-dependent Kinase 1   
PI3-K Phosphoinositol-3-OH-Kinase  
PLS Partial Least Squares  
PPAR Peroxisome Proliferator Activated Receptor 
Q Simple Quadrupole  
REE Resting Energy Expenditure 
ROS Reactive Oxygen Species  
SCFA Short Chain Fatty Acid 
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SM Sphingomyelin 
SNP single nucleotide polymorphism 
SOS Son-of-Sevenless  
SPE Solid Phase Extraction  
SR Strong Responder 
SRV Statistical Recoupling of Variables 
STOCSY Statistical Total Correlation SpectroscopY 
T2DM Type II Diabetes Mellitus 
TCA Tricarboxylic 
TG Triglyceride 
TOF  Time Of Flight 
TLR Toll Like Receptor 
TMA Trimethylamine 
TMAO Trimethylamine-N-Oxide  
TNF-α Tumor Necrosis Factor-α  
TSP Trimethylsilyl Propionic Acid  
UA Unassigned Metabolite 
UPLC Ultra-High Pressure Liquid Chromatography  
VLDL Very Low Density Lipoprotein 
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OBJECTIVES 
 
This PhD thesis has two main objectives:  
1) To identify specific metabolic adaptations to obesity prone and obesity 
resistant C57BL/6 mice to high fat diet.  
2) To investigate the effects of gut microbial remodelling by prebiotics on 
C57BL/6 mouse physiology, metabolism and immune system during 
obesity development. 
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CHAPTER I: INTRODUCTION  
 
1. OBESITY 
Obesity is one of the most important global healthcare problems of the 21st century. Studies 
carried out by the World Health Organization (WHO) revealed that obesity increased over the last 20 
years reaching pandemic proportions1. The prevalence of obesity in industrialised countries 
continues to rise in part due to sedentary lifestyle. Interestingly, the obesity epidemic is not 
restricted to industrial countries. In particular, it is significantly rising in several countries of the 
Middle East, the Pacific islands and in Africa. Children are not excluded from this epidemic with 22 
million overweight children under the age of 5 in the world1. 
The WHO estimated that around 1 billion adults are overweight and more than 115 million 
are heading obesity-related problems worldwide1. Obesity occurs when there is an imbalance 
between energy intake and energy expenditure. The development of obesity depends on genetic 
and environmental factors and is associated with various metabolic disorders, impaired hormonal 
signals, and chronic inflammation. Obesity also increases the probability of developing 
cardiovascular diseases (CVDs), type 2 diabetes, hypertension, cancer, respiratory problems and 
osteoarthritis2-4. Infantile obesity might also increase the risk of developing obesity related diseases 
in the adulthood5. Medical services required for prevention, diagnosis and treatment of obesity 
account for a considerable part of the budget in the healthcare system of the western countries. As 
an example, obesity in the European Union costs 59 billion euros every year6. Hence, reducing 
prevalence of obesity has become economically crucial and one of the primary healthcare aims 
worldwide. 
The scope of this thesis aims to expand scientific knowledge on the short-term and long-
term physiological and metabolic effects of obesity in order to help healthcare providers in the 
evaluation and treatment of obesity.  
 
1.1. Definition of obesity and metabolic syndrome 
 Obesity is defined by an excess of adipose tissue and is characterised in human by a body 
mass index (BMI) equal or superior of 30 kg/m2 1. BMI is calculated by dividing the weight (in 
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kilograms) of the individual by its height squared (in square meters)7. This weight for height 
assessment does not require specific/expensive tools and is the most reliable measure of adiposity 
which can be easily recorded in epidemiological studies and compared within and between 
populations.  
On the other hand, defining obesity from the BMI spectrum is an arbitrary cut-off and can 
induce mischaracterisation. A very muscular person or a person who has lost muscle mass can be 
easily misclassified as overweight or underweight7. Hence, measures of waist to hip ratio or waist 
circumferences are more effective than BMI to define obesity as it assesses the proportion of 
abdominal fat. The proportion of lean mass and fat mass, which strongly influences metabolism and 
obesity-related metabolic disorders, also needs to be taken into account. For instance, in non-obese 
individuals, a significant decrease in fat mass has been associated with a reduction of mortality 
whereas a loss of lean mass have been associated with a rise in mortality8. Partitioning BMI into fat 
mass index (FMI) and fat free mass index (FFMI) turned out to be really useful to estimate the levels 
of obesity and leanness. These two indexes can be defined by the following equation: 
BMI (kg/m2)=FFMI (kg/m2)+FMI (kg/m2) 
FMI is measured by skin fold or hydrodensitometry whereas FFMI is calculated by 
tomography or magnetic resonance imaging. However, most of these techniques are really 
expensive and are not necessarily available in clinics9. The comparison of FMI and FFMI in addition to 
BMI can help redefining the cut-off for obesity and avoids false diagnosis. Individuals with muscle 
hypertrophy, people suffering from protein energy malnutrition or sarcopenic obesity (loss of lean 
mass and gain of fat mass) can be distinguished with measurement of FMI and FFMI, while BMI fails 
to identify them. The relative proportion of fat mass and lean mass also varies with age. During the 
puberty, young men tend to increase lean mass whereas young women increase their proportion of 
fat mass. These indices enable us following a spectrum of body compositions, providing additional 
information about risk factors of metabolic disorders during childhood and adulthood8,10. 
Interestingly, lean mass are metabolically active tissues requiring significant amounts of 
calories even during a non-active period. This process is so called resting energy expenditure (REE) 
and largely contributes to the basal metabolic rate, which corresponds to the energy consumed daily 
8. However, these tissues contain metabolically heterogeneous compartments. Skeletal muscles, 
corresponding to 40-50 % of the lean mass, only account for 20 to 30 % of REE. By contrast, the liver, 
heart and kidney, being less than 6 % of lean mass, account for 60 to 70 % of the REE. Hence, subtle 
changes in organs mass/activity may lead to significant variation in energy expenditure8. Inter-
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individual activity in REE may induce various proportions of leanness and fatness which may 
predispose the development of obesity-related metabolic diseases8,10. The fat mass is also 
compartmentalized into upper body fat and lower body fat. The upper body fat, comprising visceral 
adipose tissues and subcutaneous fat, is known to have deleterious effects and have been associated 
with elevated risks for type 2 diabetes and CVDsH8H. In particular dense subcutaneous fat seems to be 
associated with insulin resistance, whereas superficial subcutaneous fat, which is more present in 
women, has been thought to have protective effects by lowering fatty acid storage11,12. Other 
ectopic fat accumulation around tissues and organs can induce lipotoxicity and organ malfunctions 
13. In contrast, lower body fat, comprising leg adipose tissues and glutofemoral fat, is viewed as a 
metabolic buffer enabling to maintain a good balance between energy storage and energy intake 
and protect against ectopic fat accumulation8. Higher proportions of lower body fat compared to 
upper body fat have been linked with reduced cardiovascular and metabolic risks12. Hence, fat 
distribution is an essential criterion to consider an individual’s risks of developing metabolic 
diseases. 
Obesity is often associated with the development of several chronic complications such as (i) 
high fasting glucose (hyperglycemia), (ii) hypertriglyceridemia, (iii) low high density lipoprotein 
(dyslipidemia) and (iv) high blood pressure (hypertension) 14. Individuals having at least 3 of these 
criteria are diagnosed with the metabolic syndrome (MetS)14. MetS was initially described by Reaven 
in 1988 under the name of “syndrome X” and was shown to increase the risks of type 2 diabetes15. 
Lately, MetS has been thought to be a good predictor of CVDs, which caused it to be renamed as 
cardio-metabolic syndrome 14,16 . The underlying causes of MetS are unclear. Most of the individuals 
with MetS have abnormal obesity suggesting that excess of adipose tissue plays a causative role. 
However, this hypothesis has been contested particularly because several epidemiological studies 
identified people having normal BMI but presenting a cluster of metabolic disorders such as high 
triglycerides and high fatty liver14,17. In this case, body fat distribution seemed to be a better 
indicator of metabolic disorders than the actual obesity threshold given by the BMI, as these non-
obese but unhealthy individuals had higher level of visceral fat than healthy individuals. Some 
investigators including Reaven proposed that insulin resistance is the central biological mechanism 
driving MetS, but this remains uncertain16. 
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1.2. Aetiology of obesity and MetS 
As previously mentioned, obesity occurs when there is an imbalance between energy intake 
and energy expenditure and it is closely linked with the occurrence of MetS16. However, the 
aetiology of obesity as well as MetS remains unclear as it results from a complex interaction 
between genetic and environmental factors18. 
Several studies focusing on family associations pointed out the influence of the genetic 
background in the development of obesity. In particular, several investigators observed that 
individuals’ risks of developing obesity rise when people have relatives who are obese19. Genes 
influencing BMI, sum of skin fold thickness and fat mass being involved in obesity-related phenotype 
have also been proved to be heritable up to 70%H19. Genetic linkages for MetS have been evidenced 
as well. An epidemiological study on Mexican-Americans showed heritability ranged from 45% to 
57% for the factors associated with levels of insulin, glucose, lipids and blood pressure. A study on 
monozygotic and dizygotic twins also highlighted the genetic influence on glucose intolerance, 
overall obesity and low high density lipoproteins cholesterol (HDL-C)20. Several investigations have 
been performed to characterise causative genes for obesity and MetS. Zhang et al. identified the ob 
gene in the C57BL/6 mouse model producing the satiety hormone, the leptin which regulates food 
intake and energy expenditure. These findings raised the hypothesis that leptin could be key in body 
weight and adiposity regulation21. However, additional studies on humans revealed that the impact 
of leptin on obesity remains unclear22. Other candidate genes involved in metabolic abnormalities 
have been characterised from rodents and human studies such as genes coding for tumor necrosis 
factor α (TNF-α), peroxisome proliferator activated receptor (PPAR), angiotensin-converting enzyme 
and mitochondrial uncoupling proteins19. More recently, quantitative trait locus mapping analyses 
have revealed that polymorphism in several genes involved in neuronal processes, inflammatory 
pathways, TCA cycle and glycolysis also affect fat and glucose metabolism and contribute to 
abdominal obesity23. 
Nevertheless, as genetic background within populations/countries did not radically change 
over the last three decades, the rapid expansion of obesity and MetS can only be explained by 
environmental changes that induce weight gain and metabolic deregulations. Indeed, western 
societies have marked preferences for a high carbohydrate and high fat diet and a sedentary lifestyle 
(motorised transport, lack of physical activity) which frequently leads to an imbalance between 
energy intake and energy expenditure1H. This environment promoting obesity is qualified as 
“obesogenic” and raises the probability of developping MetS. To limit the obesity epidemic, medical 
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services recommend the selection of low-energy food (wholegrain, cereals, and fruits) over high-
energy food (animal fat, sugary drinks, alcoholic drinks) and encourage physical activity H6. In 
addition, the choice of specific diets rich in unsaturated fatty acids, vitamins and fibres are thought 
to have beneficial effects on energy balance and obesity24.  
As detailed previously, the aetiology of obesity is multi-factorial and the risk factors for 
weight gain vary from individual to individual leading to an individual’s specific predisposition. In 
addition, MetS is defined as a constellation of symptoms involving a variety of risk factors across 
different demographic populations14. In particular age, gender, ethnicity and socio-economic status 
need to be taken into account to understand the onset of metabolic abnormalities. Studies on 
sexual-dimorphic physiology tend to indicate that for a same BMI, women have more fat mass and 
less lean mass compared to men and are prone to excess weight25. Ageing is also positively 
correlated with the prevalence of obesity. Interestingly, aging and particularly menopause in women 
have been thought to modify fat distribution toward central adiposity promoting MetS26.  
With the help of new technologies, other aetiologies of obesity underlying the interactions 
between genetic and environment have recently emerged. In particular, epigenetic regulations 
provide important explanations enabling us to better understand the phenotypic differences 
between individuals27H. Epigenetic mechanisms triggering chromatin modifications such as histone 
acetylation, or DNA methylation regulate the expression level of several genes involved in cell 
differentiation and energy homeostasis28,29. Epigenetic regulations already occur during foetal and 
neonatal life depending on maternal habits and influence the long-term expression of genesH27H. 
However, environmental stimuli such as dietary changes or stress can also trigger epigenetic 
mechanisms during the childhood and adulthoodH29. For instance, an animal study showed that high 
fat (HF) diet decreases gene expression in specific brain areas by increasing DNA methylation of gene 
promoters within the reward-related brain regionsH29. The epigenome is also transmittable from one 
generation to the next. Hence, in the context of “obesogenic” environment, genetic background 
along with epigenetic regulations can predispose or protect individuals of developing obesity30.  
Finally, the mammalian host-gut microbiota metabolic axis represents an important external 
factor involved in several host physiological processes, such as the digestion and the absorption of 
nutrients, and can contribute in the development of metabolic diseases31,32. It has been established 
that specific gut microbiota composition/activity in obese individuals has better ability to extract 
calories from the diet which may encourage obesity development33. These findings highlight that 
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specific gut microbial activity plays a significant role in the onset of obesity and may contribute to an 
individual’s predisposition. This aspect will be further discussed in this chapter (section X2X).  
 
1.3. Obesity and Energy homeostasis  
Obesity is characterised by increased triglyceride (TG) storage in adipose tissues and 
peripheral tissues. This phenomenom results from an imbalance between energy intake and energy 
expenditure. Indeed, energy required to perform vital functions can be supplied by dietary 
constituents (fat, carbohydrates, and proteins) or released from source stored within the cells (TGs). 
Glucose is the primary energy substrate as it is capable of supplying energy to all the cells. However, 
other alternative energy substrates, fatty acids (FAs) and amino acids are also required to carry out 
physiological processes including cell signalling, molecular transports, and energy metabolism. 
Energy supplying pathways involving glucose, fatty acids and amino acids are strongly connected as 
they generate common intermediate metabolites which can feed the tricarboxylic (TCA) pathways to 
produce ATP (XFigure 1X). 
 
Figure 1 Energy supplying pathways connecting glucose, fatty acids and amino acids (Ile: isoleucine, Asn: 
Asparagine, Asp: Aspartate, phe: Phenylalanine, Tyr: Tyrosine, Val: Valine, Leu: leucine). TGs: triglycerides, 
*gluconeogenesis only occurs in the liver, kidney and intestine. 
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In normal physiological conditions, appropriate energy substrate concentration is 
maintained in the blood in order to supply enough energy to all cells in the body. In particular blood 
glucose concentration must be kept around 1g/L during fastingH34. A low glucose concentration can 
induce brain damage while a high glucose concentration is known to trigger multiple organ damages 
H
35
H. Therefore, specific physiological mechanisms enabling the maintenance of calorie supply are 
required to survive starvation and over-feeding periods. In case of nutrient abundance, calories are 
stored in adipose tissues, liver and peripheral tissues under TG form (XFigure 1X). In particular: 
 Glucose is converted into glycogen by glycogenesis. 
 Acetyl-CoA production from glucose degradation is used for FA synthesis via lipogenesis. 
 TGs are produced by esterification of glycerol and FAs.  
When calories are needed, glycogen and TGs are degraded into glucose and free FAs respectively 
which provides energy across organs and other tissues (XFigure 1X). In particular:  
 Glucose is degraded by glycolysis to provide pyruvate  
 FAs are oxidised through β-oxidation to form acetyl-CoA. 
 Protein breakdown is activated to form amino acids which provide intermediate metabolites 
of the TCA cycle.  
The production of pyruvate, acetyl-CoA and other intermediate metabolites activates the 
TCA cycle which generate reduced coenzymes (NADH, FADH). These coenzymes are finally re-
oxidised (NAD+, FAD+) by oxidative phosphorilation to form adenosine tri-phosphate (ATP) which is 
used for intracellular energy. Energy storage and utilization are largely controlled by hormonal 
excretions and insulin in particular. During the post absorptive period, insulin secretion promote 
glucose intake from blood circulation, the activation of glycogenesis and FAs synthesis, and inihibit 
protein beakdown. During fasting, insulin secretion is reduced and an antagonist hormone glucagon 
is released. This promotes glycogen degradation into glucose via glycogenolysis, the up-regulation of 
lypolysis and down-regulation of lipogenesis. In addition, the adipocytes control lipid partitioning 
and energy intake by excreting hormones that regulate satiety via hypothalamic centres and energy 
metabolism H36H. 
In a context of chronic consumption of high energy food, cells are subjected to a saturation 
of stored energy source and aberrant blood concentration of energy substrates. This triggers a 
40 
 
disruption of energy homeostasis, and hormonal secretion which promote obesity development and 
other physiological disturbances. To better understand the onset of obesity and its associated 
disorders, it is important to establish the mechanisms involved in absorption, circulation and 
utilisation of lipids, carbohydrates and proteins. 
1.3.1. Fatty acid metabolism  
Several categories of lipids including TGs, sterols, phospholipids, sphingolipids, eicosanoids, can 
be found in the body and confer various physiological properties:  
 TGs are esters of glycerol and FAs. They constitute the major dietary lipids and provide the 
energy source for the body.  
 Sterols are essential structures of the cells membranes and are involved in the biosynthesis 
of steroids hormones.  
 Phospholipids and sphingolipids are also components of cell membrane and lipoprotein 
interfaces 34,36.  
 Eicosanoids are involved in several cell signalling processes including inflammation36,37.  
Most of the lipids can be synthesised endogenously or brought by dietary products. After a 
meal, lipids are absorbed and digested in the intestinal lumen (XFigure 2X.A). In particular, TGs are 
transformed into free FAs and 2-monoacylglycerol by lipases, which only act at the lipid-water 
interfaces H36H. As lipids are relatively insoluble in water, the lipid digestion requires the presence of 
bile acids which allow lipid emulsification. The digested products enter intestinal epithelial cells 
where they are reconverted into TGs and packed in lipoproteins called chylomicrons. Chylomicrons 
are in turn secreted in the lymph and then in the blood circulation (XFigure 2X.A). When there is a 
surplus of energy substrates in the liver, hepatic glucose is converted into FAs which are used to 
synthesise TGs via insulin stimulated lipogenesis. TGs are ultimately stored in hepatic cells or 
exported from the liver to the blood circulation in very low density lipoproteins (VLDL). 
TGs in chylomicrons and VLDL are finally degraded into FAs by lipoprotein lipase (LPL), an 
enzyme present at the border of capillary endothelial cells. FAs are taken up by the muscle and other 
tissues and then oxidised via β-oxidation to produce energy (XFigure 2X.A). Surplus of circulating FAs 
are converted in TGs and stored in the adipose tissues or liver34. TGs degradation by LPL also induces 
the transformation of chylomicrons and VLDL into chylomicron remnants and intermediate density 
lipoproteins (IDLs) containing relatively low TG levels 34,36. These products return to the liver by 
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endocytosis and are degraded by lysosomal actions. A part of IDLs and other lipoproteins (low 
density lipoproteins (LDL) and high density lipoproteins (HDL)) are also used for cholesterol transport 
between peripheral tissues, adipose tissues and liver (XFigure 2X.A).  
During fasting, TGs in adipocytes and hepatocytes are broken down into glycerol and FAs via 
lipolysis, which are released in blood circulation. The FAs bind with albumin and enter peripheral 
tissues (muscle, kidney) to produce energy. During prolonged fasting, ketogenesis can be activated. 
This mechanism converts FAs breakdown end-products into ketone bodies in the liver which are in 
turn used by muscle, kidney and brain to produce energy34. Glycerol-3-phosphate is usually 
synthesised from glucose by glycolysis. However, when the organism is deficient in carbohydrates, 
glycerol-3-phosphate can be generated from non-carbohydrate sources such as alanine, glutamine 
or pyruvate via glyceroneogenesis 34. This pathway mainly occurs in liver and adipose tissues and is 
regulated by phosphenol-pyruvate carboxylase (PEPCK). Its activation is particularly important in the 
regulation of circulating FA concentrations during fasting or starving periods 34. These metabolic 
pathways are summarised in XFigure 2X.  
Thus during the feeding process, TG synthesis is favoured in adipocytes and liver. In addition 
leptin is secreted by adipocytes to reduce caloric intake, stimulate oxidation of surplus FAs via β-
oxidation in non adipose tissues and limit lipogenesis. This process of caloric homeostasis is useful 
because it protects non adipose tissues (such as muscles, heart and blood vessels) against ectopic fat 
accumulation and FAs overload13,34. For instance, individuals with adipose tissues dystrophy 
(lipodystrophy) suffer from an increased fat accumulation in non adipose tissues and have higher 
prevalence for insulin resistance (IR), type 2 diabetes mellitus (T2DM) and other symptoms of MetS 
13,38. In case of chronic overfeeding, the surplus of energy intake provokes an expansion of the fat 
cell number and an increase of the fat cell size. This adipose tissue overgrowth underlying obesity 
often leads to dysfunction of endothelium as well as the release of adiponectin38. Non adipose 
tissues are also constituted with a small intracellular reserve of lipid which is used to maintain 
essential functions such as membrane structures and intracellular signalling34. In the case of obesity 
development, increased deposition of lipids in organs such as liver, skeletal muscle, kidney and heart 
occurs, which impairs organ and tissues functions in different ways. First, increased fat size around 
the organ can change its structure and function by applying physical compression13. Second, 
prolonged overfeeding is frequently associated with leptin resistance leading to the failure of this 
leptin-induced protective mechanism. Then, TGs level in non adipose tissues rises, which is 
associated with an excess of intracellular FAs and an activation of harmful non-oxidative metabolic 
pathways producing ceramides among other toxic metabolites13. In addition, a variety of lipid-
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derived toxic metabolites from incomplete FA oxidation, such as long chain fatty acyl-CoA, were 
found to be elevated39. This harmful phenomenon is referred as lipotoxicty and is thought to cause 
insulin resistance and to impair cardiac functions13,39. 
 
1.3.2. Carbohydrate digestion and glucose metabolism 
Carbohydrates are other important nutrients providing energy source for the cells and other 
molecules necessary for biosynthesis such as reduced coenzymes (NADH, NADPH) and precursors34. 
Carbohydrates can be constituted of monosaccharide (1 saccharide unit), disaccharides (2 saccharide 
units), oligosaccharides (from 3 to 10 saccharide units) and polysaccharides (more than 10 
saccharide units) 34. Glucose is the most important monosaccharide as it is degraded by glycolysis 
which allows the production of energy in all the cells. Therefore, dietary carbohydrates are 
ultimately converted into glucose to provide energy, excepted for fructose which can feed directly 
the glycolysis34. Starch, which is the most common dietary carbohydrate, is easily broken down by 
several amylases present in saliva and pancreatic secretion into oligosaccharides, such as maltose or 
isomaltose (XFigure 2X.B). Oligosaccharides and disaccharides are further degraded by several 
enzymes present in the brush border of intestinal lumen, forming glucose, galactose and fructose H34. 
The most common dietary disaccharides are sucrose and lactose. Sucrose can be degraded into 
fructose and glucose by sucrase activity, while lactose is broken down into glucose and galactose by 
lactaseH40. Monosaccharides are able to cross the intestinal membrane by binding membrane 
transporters. In particular, glucose and galactose enter the enterocytes via sodium-glucose transport 
proteins (SGLT), while fructose is taken up by the GLUT 5 transporter. They are all transported out of 
the enterocytes by the GLUT 2 transporter and passively enter the capillary blood to reach tissues 
and organs (XFigure 2X.B). In the intracellular compartment, galactose is rapidly converted into UDP-
glucose by a succession of enzymatic reactions involving galactokinase among others. Fructose, on 
the other hand, is degraded into glyceraldehyde-3-phosphate, which in turn may feed the 
gluconeogenic pathway, forming glycerol or glycolytic pathways and generating pyruvate. The 
polysaccharides and fibres not digested by gastrointestinal enzymes transit to the large intestine and 
colon where they can be fermented by the gut microbiota34H (see Chapter I, section 2).  
As previously mentioned, glucose storage and utilisation are largely controlled by insulin and 
glucagon hormones to maintain a normal glycemia34,41. When the glucose availability exceeds the 
amount required for maintaining a normal blood glucose concentration (during the postprandial 
period for exemple), glucose is transformed in the liver and adipose tissues into glycogen34. The 
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surplus of acetyl-CoA from glucose degradation can also promote FA synthesis for energy storage or 
for maintining other physiological processes (cell membrane, or cell signalling) (Figure 2.B) 41.During  
fasting, glucose may be in short supply. In this context, glycogen is degraded into glucose via 
glycogenolysis and FAs synthesis from glucose is down regulated (XFigure 3X). Glucose can also be 
synthesized by gluconeogenesis using lactate in the liver, kidney and intestine. Research in the past 5 
years has revealed the importance of intestinal gluconeogenesis in the control of glucose and energy 
homeostasis. The activation of intestinal gluconeogenesis induces glucose delivery in the portal vein 
and initiates a nervous signal via portal sensors, which is further transmitted to the nucleus of the 
solitary tract and/or the hypothalamus by autonomous afferents. The hepatoportal sensing triggers 
a signal to the brain promoting a satiety effect, and regulates glucose homeostasis 42. Interestingly, 
high protein diet was associated with the increased expression of 3 key enzymes (glutaminase, 
phosphoenolpyruvate carboxykinase-cytosolic form and glucose-6-phosphatase) involved in 
intestinal gluconeogenesis. A recent experiment showed that 15 to 20% of the total glucose 
observed in protein-fed rats during a postabsorptive period was brought by intestinal 
gluconeogenesis. When the same proportion of glucose was infused in the portal vein, a significant 
drop of food intake was noticed without degrading endogenous glucose homeostasis. In addition, a 
better redistribution of glucose in the kidney and intestine as well as a enhanced suppression of 
endogenous glucose production by insulin was observed, notably due to more efficient glycogen 
storage in the liver43. Therefore the intestinal gluconeogenesis has been considered as a key factor in 
the central improvement of insulin sensitivity and participates in satiety regulation in protein 
feeding.  
Finally glucose may be transformed into other monosaccharide such as ribose-6-phosphate 
via the pentose phosphate pathway which produce NADPH and feed the glycolysis H34. Thus, 
depending on the cell requirement, glucose may be transformed into FAs, coenzymes, other 
monosaccharides as well as amino acids (XFigure 3X). However, in the context of an excess of glucose 
intake from the diet, insulin action is deregulated. In particular, circulating glucose is not efficiently 
transported into the cells and intracellular glucose is not sufficiently stored into glycogen. Therefore, 
blood glucose is not maintained within the physiological range which contributes to obesity 
development and promotes physiological disturbances. Impaired insulin action and obesity 
development are further discussed in the section 1.3.4 of this introduction.  
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1.3.3. Amino acid metabolism 
Dietary proteins and amino acids are essential nutrients as they provide the nitrogen source 
for the synthesis of nitrogen containing molecules (nucleic acids, proteins, amino acids) for the 
cells34,44. Protein and amino acid degradations also produce energy for the organisms. Diets provide 
20 different amino acids. Among them, eight are essential because they cannot be endogenously 
synthesized (leucine, isoleucine valine, lysine, methionine, threonine, tryptophan, phenylalanine). 
After protein digestion by proteases in the small intestine the resulting peptides and amino acids 
enter the enterocytes via intestinal peptide transporters (PepT1) (XFigure 2X.C). In the intracellular 
compartment, peptides are further hydrolysed into amino acids, which in turn travel across the 
intestinal mucosa by basolateral amino acid transporters and enter the blood circulation34. Amino 
acids are distributed among all tissues where they can be transformed into other amino acids, used 
for protein synthesis, or be degraded to provide nitrogen (XFigure 2X.C). The balance between 
nitrogen intake and excretion is strictly controlled to keep a constant nitrogen level in the organism. 
The nitrogen waste is processed by the urea cycle which finally produces urea. The final step of urea 
cycle only occurs in the liver, urea is then rapidly excreted in urine ( XFigure 2X.C). Amino acids break 
down is therefore strongly regulated to maintain this homeostasis34,44. Protein and amino acid 
metabolism are also regulated by insulin secretion which increases amino acid uptake in liver, 
muscle and adipose tissues and promote protein synthesis in these tissuesH44. On the other hand, the 
drop in insulin secretion favours amino acid breakdown. 
For many amino acids (leucine, isoleucine, valine, phenylalanine), the first catabolic step is a 
transamination, in which transaminase enzymes transfer the amino group to ketoacetate or 2-
ketoglutarate forming a keto-acid34. This process also produces aspartate or glutamate, respectively. 
Aspartate directly participates in urea synthesis. On the other hand, glutamate is deaminated to 
provide ammonia, which is used to produce another urea cycle intermediate, citrulline. For several 
amino acids (such as arginine, lysine, proline) catabolism occurs by other processes than 
transamination including conversion into different amino acids. Following nitrogen removal, most of 
the keto acids are degraded, ultimately generating TCA cycle intermediates pyruvate and acetyl-
CoA34,44 (XFigure 2XC) which are used to produce ATP and CO2. In addition, amino acids can generate 
glucose via pyruvate in all the tissues capable of gluconeogenesis and can be converted into FAs or 
ketone bodies via acetyl-CoA production. Interestingly, leucine is defined as strictly ketogenic 
because it does not form pyruvate and as a result cannot be converted into glucose34,44. Therefore it 
is important to consider the dietary significance of proteins in the energy supply. Because nitrogen 
balance is strictly controlled via this protein turnover and the production of urea, a high protein diet 
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promotes amino acid degradation, which in turn may trigger uncontrolled FAs production, TGs 
storage and obesity34. 
To conclude, energy supplying pathways are strongly interconnected by common precursors 
which serve as “biological hubs” for various cell functions. Therefore they must be seen as an 
integrated set of metabolic processes which are strongly regulated by hormonal actions. In 
particular, insulin secretion induces a significant and global effect on energy metabolism.  
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Figure 2: Summary of energy metabolic pathways during the postprandial period. A: Fatty acids metabolism, B: 
carbohydrate metabolism, C: Protein metabolism. 1: TG synthesis, 2: glycogenesis, 3: TCA cyle, 4: fatty acid 
synthesis, 5: glycolysis, 6: oxidative phoshorylation, 7: galactose conversion into glucose (Leloir pathway), 8: 
fructose metabolism, 9: pentose phosphate pathways, 10: gluconeogenesis, 11: transamination, 12: urea cycle, 
13: lypolysis, 14: protein synthesis, 15: TG degradation, 16: glyceroneogenesis, 17: Cori cycle, 18: ketogenesis, 
19: proteolysis, 20: glycogenolysis 
A. 
B. 
C. 
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Figure 3: Summary of energy metabolic pathways during a fasting period. 1: TG synthesis, 2: 
glycogenesis, 3: TCA cycle, 4: fatty acid synthesis, 5: glycolysis, 6: oxidative phoshorylation, 7: 
galactose conversion into glucose (Leloir pathway), 8: fructose metabolism, 9: pentose phosphate 
pathways, 10: gluconeogenesis, 11: transamination, 12: urea cycle, 13: lipolysis, 14: protein 
synthesis, 15: TG degradation, 16: glyceroneogenesis, 17: Cori cycle, 18: ketogenesis, 19: proteolysis, 
20: glycogenolysis 
1.3.4. Obesity and insulin resistance: the underpinning mechanisms of 
obesity development. 
Insulin is a hormone secreted by the pancreas in the β cells of the islets of Langerhans which 
regulate glycemia45. Its primary role is to facilitate the uptake of glucose into cells and its secretion is 
driven by the rise in postprandial plasma glucose concentration. The coordinate role of insulin is to 
allow the storage of carbohydrates, lipids and proteins in the cells by stimulation of glycogenesis, 
lipogenesis, and protein synthesis. It also blocks the degradation and the recirculation of 
carbohydrates and lipids by inhibiting glycogenolysis and lipolysis45. By these mechanisms, not only 
does insulin reduce glycemia, but also induces the accumulation of glycogen and fat in cells. The 
effect of insulin is mediated by a tyrosine phosphorylation cascade. Insulin binds to the extracellular 
α subunit domain of the insulin receptor causing the phosphorylation of the tyrosine chain of the 
receptor’s β subunit in the plasma membrane (XFigure 4X). The phosphorylated receptor then binds 
and phosphorylates a number of intracellular proteins, namely insulin receptor substrates (IRS), 
which induce several additional protein kinases signalling systems. In particular, IRS-1 and IRS-2 
interact with the phosphoinositol-3-OH-kinase (PI3-K) via their tyrosine-phosphorylated motif. PI-3K 
then converts the phosphatidylinositol 3,4 diphosphate into phosphatidylinositol 3,4,5 triphosphate, 
generating multiple signals 34,45. This signalling cascade involves the activation of phosphoinositide-
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dependent kinase 1 (PDK1) that stimulates the coupling of the serine and threonine kinases Akt/PKB. 
These proteins then initiate many of the actions of insulin, such as the increase of glucose transport. 
They allow vesicles containing the glucose transporters (GLUT 4 and GLUT2) to fuse with the plasma 
membrane and enable glucose uptake34,45. 
Another pathway is required for insulin-stimulated glucose uptake, and involves the tyrosine 
phosphorylation of the Cbl proto-oncogene (Figure 4). Phosphorylated Cbl acts with the adapter 
protein CAP and the formed complex is translocated into the lipid raft domain of the plasma 
membrane. An adapter protein CrkII is then engaged in the lipid raft domain and creates complexes 
with the guanyl nucleotide-exchange protein C3G. This enables C3G to be translocated and to 
interact with the G protein T10, leading to its stimulation. Finally, activated T10 has an impact on the 
stabilization of cortical actin which might play an important role in GLUT 4 vesicle translocation45.  
The pathway involving the mitogen-activated protein (MAP) kinase is also activated by 
insulin. In this case, the tyrosine phosphorylated IRS and Shc proteins interact with different 
compounds such as the Son-of-sevenless (SOS) exchange proteins and the SHP2 protein inducing the 
activation of RAS protein. RAS then initiates the serine cascade through the activation of MEK and 
ERK, which results in the stimulation of a transcription factor, implicated in cell proliferation or 
differentiation processes. However, this latter pathway seems to have no obvious role in the 
metabolic actions of insulin45. 
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Figure 4: Schema of insulin signalling pathways inspired by R. Saltiel et al H
45
 
The loss of sensitivity to insulin leading to insulin resistance (IR) is a complex mechanism 
which firstly targets adipose tissues, liver and muscle. Excess insulin in blood and sustained 
hyperglycemia seems to be one of the contributors to IR development. One theory proposes that IR 
arises from an adverse effect inherent in the insulin signalling pathways. The decrease of glucose 
transporter levels and insulin receptor substrate levels (IRS-1, IRS-2) in the cell, or the activation of 
the tyrosine kinase, which in turn phosphorylate other key enzymes present in the signalling 
pathways, inducing a negative feedback loop mechanism reducing the glucose uptake 34,46,47.   
Another aspect has emerged, that the accumulation of fat in tissues induces local 
inflammatory responses and the release of cytokines in the circulation, which then contribute to 
desensitizing the insulin signalling pathways in the peripheral tissues48. The impact of obesity-
associated low-grade inflammation on IR will be further discussed in the introduction (section 1.4.4).  
The impairment of insulin action is characterised by hyperlipidemia and fasting 
hyperglycemia and is often associated with other disorders such as dyslipidemia, hypertension and 
fat accumulation in adipose tissues which are characteristic of MetS 45,49. Therefore, the triggering 
event of IR is a complex mechanism and its understanding requires further investigation. However, it 
can be assumed that IR is one of the underpinning factors linking obesity and MetS. 
50 
 
The gastrointestinal tract also releases a number of hormones, including grhelin, leptin, 
glucagon and pancreatic polypeptides, which signal the peripheral and central nervous system and in 
turn regulate food intake, energy expenditure, and body composition50. Using gut hormones as 
therapeutic treatment may represent a promising new area of research to struggle against obesity 
and obesity associated diseases. However, the real efficacy of hormones in the regulation of 
metabolic diseases has not been proven yet.  
1.4. Obesity and low grade inflammation.  
Strong evidence demonstrated that obesity is associated with an aberrant activation of the 
immune system leading to the development of low grade inflammation. The emergence of chronic 
inflammation in obese individuals has been suggested to promote the clinical progression of obesity-
related pathologies such as T2DM and hepatic steatosis. The inflammatory disorders are 
characterised by the overproduction of inflammatory effectors such as cytokines and by immune cell 
infiltration in adipose and peripheral tissues51 52. These effector molecules and cells are primary 
components of the innate immune system but can be involved in the set up and the recruitment of 
the long lasting adaptive immune system.  
1.4.1. Basic mechanisms of innate immunity 
The innate immune system provides the front line of host defense against pathogenic 
microorganisms53. Several immune cells immediately recognize chemical structures present on the 
surface of pathogens and activate a non-specific immune signal. This innate response requires the 
presence of mononuclear phagocytes that are derived from common myeloid progenitor cells 
present in the bone marrow. These cells mature in the blood, giving granulocytes (monocytes) and 
neutrophils53. Monocytes reach the tissues to mature into mast cell, dendritic cells and 
macrophages. The monocyte-macrophage cells are highly heterogeneous so as to adapt the immune 
response according to the exposure of the micro-environment52,53. These immune cells recognize the 
pathogens via receptors also known as pattern recognition molecules, which mediate the innate 
activation signals. Several classes of receptors located in the cell surface can identify and bind a 
specific pattern present in the bacterial cell wall, such as a specific repetition of carbohydrates or 
lipid moieties. For instance, the mannan-binding lectins are well defined receptors that recognize 
mannose and fructose residuals on the bacterial surface52,53. The downstream signal directly initiates 
the phagocytosis of the external body leading to its ingestion and destruction by the macrophages. 
Pathogen recognition and phagocytosis sometimes require the activation of intermediate pathways 
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involving the protein complements. The protein complements system induces a cascade of reactions 
around the pathogen surfaces producing active components that allow pathogens to be identified 
and phagocytosed by the immune system53. A second class of phagocytic cell receptors does not 
bind a specific pathogen pattern but is involved in the recognition of microbial components and 
triggers the appropriate antifungal and antibacterial responses. The most studied family of 
transmembrane receptors in mammals is named Toll like receptors (TLRs)52,53. Their activation 
mediates a large range of inflammatory signals including the myeloid differentiation dependant 
pathways (MyD88). The downstream responses trigger the activation of mitogen activated protein 
kinases pathways including extracellular signal kinases (ERK1/2), c-Jun-N terminal kinase (JNK), p38 
which are also involved in insulin signalling and the inhibitor of K kinase (IKKβ) 51,52. Finally, these 
pathways participate in the activation of transcription factors NF-kB and AP-1 and cytokine 
production (XFigure 5X)52,53. For instance lipopolysaccharide (LPS) is a cell wall component of gram 
negative bacteria and can stimulate an inflammatory response via TLRs activation. LPS binds the 
plasma LPS-binding protein which in turn enables the fixation of the receptor protein CD14 located 
in the plasma or on the cell surface of the macrophage. The generated complex then binds the TLR4, 
which trigger the transduction signals in the nucleus activating NFkB and AP1 and the gene 
expression of several inflammatory effectors (chemokines and cytokines) (XFigure 5XA) 53,54. 
Other intracellular receptors are present in macrophages and dendritic cells, such as 
nucleotide oligomerisation domain like (NOD-like) receptors, to cooperate with TLRs in the 
activation of inflammatory signals. The NOD-like receptors recognize peptidoglycans from gram – 
and gram + bacteria and have been found to be up-regulated in contact with LPS and TNF-α. NOD-
like receptor pathway also induces NF-Kβ and is involved in the recruitment of other effector 
molecules such as those in inflammasome pathways48. Inflammasomes are multi protein complexes 
composed of three proteins: nucleotide binding domain leucine rich protein (NLR), adaptor protein 
(ACS) and caspase-1. Their activation participates in the maturation of the cytokines IL-1β and IL-
8(Figure 5.B)55. 
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Figure 5: Induction of inflammatory signals in pro-inflammatory macrophages. A: Bacterial LPS activate the 
cytokines transcription via the Toll like receptor-4(TLR-4) activation. B: Other pattern-recognition receptors 
involved in inflammasome pathways and leading to IL-1 β and IL-8 maturation.  
 
The early innate responses to infection initiate the production and the recruitment of 
further effector molecules and cells to reinforce the line of defence. The release of pro-inflammatory 
cytokines in turn modifies the cell behavior in a paracrine and autocrine manner and amplifies the 
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inflammatory reactions52. Cytokines are classified in various structural families: the hematopoeitin 
family including growth hormones and many interleukins such as interleukin 6 (IL-6), the TNF family 
including TNF-α, and the chemokine family (interleukin 8 (IL-8)). In addition, interleukin 1 (IL-1) and 
interleukin 12 (IL-12) are grouped in a structurally distinct family 53,56. The recognition of different 
pathogens may result in the production of different cytokines and chemokines. They all have 
important local and systemic effect and both contribute to the activation of the innate and adaptive 
immune systems. In particular, chemokines attract cells containing chemokine receptors such as 
neutrophils from the bloodstream into the site of infection 53,56. The cytokines also induce fever, the 
production of acute phase response proteins and the mobilization of antigen-presenting cells for 
adaptive immune responses. Other co-stimulatory molecules, such as interferon induced by viral 
infection, trigger the activation of natural killer (NK) cells which exclusively target infected cells and 
induce program cell death53. Therefore, NK cells play an important role in the inhibition of viral 
replication. Interferon γ is not exclusively produced in the context of viral infection and has an 
impact on the stimulated responses to intracellular pathogens, in particular by polarizing 
macrophage into pro-inflammatory M1 type macrophage53,57. The major classes of inflammatory 
cytokines are summarised in XFigure 6.  
1.4.2. Basic mechanisms of adaptive immunity 
Innate immunity is an efficient system for preventing the establishment of pathogens. 
However, if it fails to remove the infection, cytokines, chemokines, NK cells, macrophages and 
neutrophils are employed to initiate the development of the adaptive immune system leading to a 
more specific and long lasting immune response to pathogens53. In particular, lymphocyte 
progenitors are requisitioned and give rise to T cells and B cells that recognize a great variability of 
antigens from bacteria and virus. The antigen-recognition molecules of B cells are immunoglobulins 
(Ig) which directly bind specific antigens. On the other hand, antigen recognition receptors of T cells 
are membrane-bound proteins that exclusively recognize short peptides fragments of pathogen 
proteins53. Fully differentiated B cells are able to release their Ig into the circulation as antibodies, 
which mediate the main effectors of adaptive immune system. In particular, this allows the clonal 
expansion and production of highly specific antibodies53. These highly diversified receptors can be 
generated via small mutations into genes that encode for a large proportion of receptors. The most 
important strength of the adaptive immune responses is the ability to produce memory T and B cells 
which will be highly efficient in removing invading agents encountered previously53. Activated T cells 
require the production of cytokine molecules, and particularly the T cell growth factor interleukin-2 
(IL-2) to proliferate and differentiate into armed T cells.  
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Alternatively, the monocyte-macrophages can be matured into type II activated 
macrophages (M2) to promote anti-inflammatory responses53. These macrophages are generally 
characterised by low production of pro-inflammatory cytokines (IL-1, TNF, IL-6) and high production 
of anti inflammatory cytokines, such as interleukin-10 (IL-10) and glucocorticoid hormones, which 
induce various transcriptional programs. For instance, IL-10 secretion deactivates inflammation by 
lowering cytokine production and activating leukocyte molecule signalling involved in adaptive 
immunityH57. It also inhibits the expression of TLR4 in human cells, downregulates NFkB transcription 
and alleviates the production of inflammatory chemokines involved in the pro-inflammatory 
immune system. On the other hand, chemokines induced by M2 macrophages improve the 
recruitment of leukocytes present in tissue repair, as well as remodelling mechanisms and tumor 
progression. In fact, several sub-populations of activated M2 macrophages exist, inducing a wide 
spectrum of cytokine secretion and leading to various effects such as killing and encapsulating 
parasites, reducing allergy responses, immuno-regulation and tissue remodelling57. Therefore, 
generation of M2 macrophages are essential to tune the inflammatory responses triggered by the 
innate and adaptive pro-inflammatory responses. When the pro-inflammatory signal overcomes the 
systemic circulation, the type II alternative system generates negative signals which inhibit the 
recruitment of mononuclear phagocytes at the site of inflammation and help tissue repair 53,57. 
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Figure 6: Important pro and anti inflammatory cytokines secreted by M1 or M2 activated macrophages.  
 
1.4.3. Obesity associated low grade inflammation 
Unlike the classical immune response induced by pathogens, obesity associated 
inflammation is triggered by the excess components of nutrients and/or by a specific type of 
nutrient48,51. As previously mentioned, the hallmark of obesity induced inflammation is characterised 
by an overproduction of effector molecules and cells primarely involved in innate immunityH51. 
Recently, several evidences have also shown increased adipose tissue T cell populations in obesity 
highlighting an environment conducive to adaptive immune activation51,58. In addition, unlike the 
pathogen-induced immune signals, metabolic overload triggers a low grade inflammatory response 
which is maintained as a chronic level and lowers the basal metabolic rate51. 
The starting point of the inflammatory signals is still unclear but nutrient overload has been 
found to stimulate pathogen sensors in metabolic cells such adipocytes, hepatocytes and myocytes 
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by multiple signalling pathways48,54. In addition, in the overfeeding context, several nutrients can be 
identified as biologically harmful molecules which activate inflammatory signals51,54. For instance, 
ectopic fat accumulation and lipotoxocity have been associated with a rise in inflammatory effectors. 
Saturated FAs have been found in particular to activate TLR4 in adipocytes, hepatocytes and skeletal 
muscle, resulting in the activation of intracellular pro-inflammatory pathways (including the 
MyD88/PI3k/Akt pathways) and macrophage stimulation. The direct binding of saturated FA onto 
TLR4 required the presence of the liver-derived circulating glycoprotein, Fetuin-A (Fet-A) which 
serves as an adaptor protein linking FAs and TLR448,54. Interestingly, wild type mice infused with 
saturated FAs exhibit IR while Fet-A knockdown mice are protected from these symptoms. Therefore 
Fet-A may confer therapeutic potential in improving glucose homeostasis and insulin sensitivity in 
obese and T2DM patients. Saturated FAs have also been proven to directly stimulate TLR4 and TLR2 
in β-cells leading to the accumulation of monocyte and macrophage in the islet and β cell 
dysfunction. In addition, several in vitro studies on monocytes have also reported an increase in IL-6 
and TNF-α production, an increase in TLR4 and TLR2 expression, as well as an activation of the NFkB 
pathway under high glucose conditions (XFigure 5X.A) 54,59.  
Nucleotide oligomerisation domain (NOD) 1 and 2 are also sensors found to be activated in 
obese hepatocytes and adipocytes53. In particular, NLRp3 and caspase-1 have been found to increase 
in overweight people and obese mice48,55. The triggering factors of NOD and inflammasome 
pathways in the context of obesity remain to be defined. Adipose tissue expansion due to high 
energy storage can modify cell vascularisation, promote endoplasmic reticulum stress, hypoxia and 
cell damage, which in turn may contribute to further inflammation responses48,51. Several groups 
have reported that FAs, ceramides, ATP, glucose, oxidized LDL, uric acid, cholesterol as well as an 
increase in ROS could activate the NLRp3 inflammasome55. Because all these factors are elevated in 
obesity, it can be suggested that inflammasome signalling pathways are an important link between 
metabolic disruption and obesity induced inflammation. Finally, increased intestinal permeability 
and alteration of gut microbiota activity in obesity promote the entry of LPS into blood circulation. 
This phenomenon is defined as metabolic endotoxemia and has been found to trigger TLR related 
pro-inflammatory responses via the above mentioned mechanism (Section X1.4.1X, XFigure 5X)51,54.  
1.4.4. Links between low grade inflammation and impaired insulin 
signalling. 
Several pieces of evidence have shown that activation of effector molecules of inflammation 
contribute to desensitizing the insulin signalling pathways60. At the molecular level, several 
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mechanisms come into play: IKβ and JNK activation in inflammatory tissues of obese individuals have 
been found to induce uncontrolled phosphorylation of the inhibitory serine site of IRS, triggering a 
decrease of IRS tyrosine phosphorylation and insulin signal attenuation48. However, the 
consequence of JNK and IKβ activation on the obesity and insulin resistance varies depending on the 
tissue site48,54 In particular, tissue specific JNK -/- mice displayed a conditional phenotype. JNK1 
invalidation in myeloid cells decreases obesity-induced inflammation and may promote insulin 
signalling. On the other hand, JNK invalidation in hepatocytes disturbs liver vital function48. Other 
inflammatory kinases involved in various metabolic regulations have been thought to target the 
insulin receptor signalling cascade. Extracellular signal–regulated kinases (ERK) 1 and 2, which belong 
to the MAP kinase pathways, are activated by NOD immune sensors as well as inflammatory 
cytokines such as IL-1β. Besides, ERK1 and ERK2 actions have been involved in a negative feedback 
mechanism altering the interaction between IRS-1 and PI3k as well as IRS-1 and insulin receptors, 
resulting in a disturbed insulin signalling and glucose transportH48.  Therefore, ERK1 and ERK2 might 
be a contributing factor of insulin resistance in the context of obesity induced inflammation. In 
addition, the production of cytokines such as TNF-α, or IL-1β in visceral adipose tissues within 
rodents and human affect insulin sensitivity by altering the expression of genes for insulin receptor 
IRS-1, GLUT4, and PPAR-α 61,62.  
The emergence of obesity-induced inflammatory response leading to the loss of insulin 
sensitivity may occur in adipose tissues as it is a secretory organ producing many inflammatory 
proteins54. Mediators of inflammation are then released to the portal vein and can reach other 
tissues including liver, pancreas, brain or muscle which contribute to maintain inflammatory signals 
and develop systemic insulin resistance. However, Cai et al. have demonstrated that a local 
inflammation in the liver associated with high levels of stored lipids can be a primary cause of insulin 
resistance63. Therefore, the causal relationships between inflammation and IR during obesity require 
further investigation. 
To conclude, the metabolic cells trigger the inflammatory signalling pathways by several 
mechanisms activating the downstream inflammatory responses, which in turn alter metabolic 
homeostasis and insulin signalling. Over time, metabolic overload triggers a low-grade inflammatory 
response which is maintained at a chronic level. This induces the recruitment and activation of many 
mature immune cells in metabolic tissues such as adipocytes (mast cells, macrophages, dendritic 
cells) that modify tissue milieu and reinforce inflammation64.  
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1.5. Obesity, MetS and metabolic diseases 
As previously detailed, obesity is a chronic disorder characterised by a disruption of glucose 
mediated insulin action and increased circulating lipoproteins and FAs which all together increase 
morbidity and mortality13,65. In particular, these metabolic abnormalities have been found to raise 
the probability of developing metabolic diseases including T2DM, CVDs, NAFLD, cancer and 
polycystic ovarian syndrome1,16,65. Low grade inflammation and impaired insulin action, which both 
have a central role in the lipid, glucose and protein metabolism dysregulation, strongly influence the 
development of these metabolic diseases2,48. In the context of IR, an increased insulin production by 
the β cells is needed to meet the increased insulin demand. This results in higher systemic insulin 
levels. However, in the context of prolonged IR, the β cells may not be able to meet the insulin 
demand, leading subsequently to higher circulating glucose levels and lower peripheral glucose 
levels indicative of T2DM. 
Increased fat accumulation leading to low grade inflammatory responses also affects β cells 
functions and may thus contribute to the development of T2DM2. Visceral fat and ectopic fat 
accumulation have been correlated with central IR, T2DM and the development of CVDs. Fat 
accumulation and lipotoxicity in myocytes have been found to promote myocyte degeneration, 
myocyte apoptosis and cardiac dysfunction66. In addition, increased adipose tissue deposits around 
vasculature, releasing local mediators of inflammation, was associated with endothelial lesions and 
vascular dysfunction, promoting CVDs such as coronary artery diseases66. Finally, lymphatic overload 
is known to increase intravascular volume, and peripheral vascular resistance due to an exacerbated 
amount of insulin, cytokines, fat and other nutrients in circulation, which promote hypertension66,67. 
In addition, hepatic fat accumulation leading to NAFLD is considered as an important risk for 
CVDs and has been associated with T2DM3,13. Hepatic TGs accumulation under steatosis is the first 
step in the full spectrum of NAFLD. NAFLD may subsequently progress from steatosis on to hepatitis, 
fibrosis and finally hepatic cirrhosis3. NAFLD alone can be a major cause of mortality and can 
exacerbate the inflammatory status of obese individuals and IR, which contribute to the occurrence 
of T2DM and CVD2,66.  
Yet, although obesity is significantly associated with severe pathologies, many obese 
individuals do not exhibit metabolic dysfunction and therefore seem protected from the 
development of T2DM, NAFLD or CVDs risk. This category of individuals is the subject of intensive 
research to underpin the molecular mechanisms linking obesity and the degradation of the healthy 
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phenotypes. For example, Wildman et al. noted that ethnic differences in healthy middle-age 
women are associated with differential metabolic activity of visceral and subcutaneous adipose 
tissues, which may influence the predisposition of certain ethnicities to develop obesity, CVDs and 
T2DM4. Given the multiplicity of factors that determine the likelihood of developing severe 
pathologies in obese individuals, there is a crucial need to identify early metabolic markers of 
susceptibility to obesity-related metabolic disorders, to prevent the development of metabolic 
diseases. Thus, by measuring prognostic biomarkers or early metabolic signature to stimuli, drug 
efficiency and potential adverse effects could be estimated in a stratified population. This opens the 
field of personalised healthcare, for which clinicians may be able to tailor therapy for a selected 
group of people based on patient evaluation before intervention68. The concept of personalised 
healthcare goes beyond therapeutic treatment and could be used to anticipate the most efficient 
cancer treatment, nutritional intervention or training set for individuals or group of individuals 68,69. 
 
2. ROLE OF THE GUT MICROBIOTA IN THE DEVELOPMENT OF OBESITY 
AND THE METS 
The mammalian host-gut microbial metabolic axis represents an important factor involved in 
several host physiological processes and can contribute, in some cases, to the development of 
metabolic diseases. A deeper understanding of the mechanisms underlying this crosstalk could prove 
to be important in the treatment of obesity and obesity associated diseases31.  
 
2.1. The biological role of symbiotic bacteria  
The term “gut microbiota” refers to the trillions of bacteria living in the intestine. Owing to 
their symbiotic interaction with the host, they play an essential role in the maintenance of human 
physiology. Indigenous or commensal bacteria are involved in the development of the digestive 
tract, can increase the number and maturation of crypts and can also promote the education of the 
immune system throughout the lifetime of the host70,71,72. For instance, B .thetaiotaomicron, one of 
the best characterised members of the normal human distal small intestine and colonic microbiota, 
promotes intestinal angiogenesis and stimulates the development of paneth cells. In particular, B. 
thetaiotaomicron regulates the production of epithelial glycans necessary for the lineage of 
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intestinal cells and the development of mucosal barrier which in turn promotes the gut’s innate 
immune system71,73. Studies on Germ Free (GF) animals also highlight the role of the gut microbiota 
on the physiological, biochemical and immunological development of the host. Rodents without 
gastro-intestinal (GI) microbiota have a larger caecum, a reduction in size of many organs including 
the liver, heart and adrenal glands, and the complexity of their intestinal capillary network is 
reduced and much more primitive than conventional mice. The efficacy of the immune system as 
well as the inflammatory responses are also reduced in the GF animal74. Therefore, the presence and 
activity of commensal bacteria is thought to be essential in maintaining the physiology of the 
digestive tract and in preventing the colonization of pathogenic microorganisms75. 
Intestinal bacteria operate as a metabolic “organ”, actively taking part in digestion and 
degradation of nutrients otherwise undigestible76. Indeed, polysaccharides are not digested in the 
proximal human intestine, but instead, they are transformed into digestible compounds such as 
sugars or short chain fatty acids (SCFAs) by gut bacteria in the distal intestine, providing energy 
substrates usable by colonocytes in particular, and the host in general. In addition, microbiota 
actively regulates fat storage by promoting lipid absorption through the chemical modulation of bile 
acids. The enhanced absorption of monosaccharides also contributes to lipogenesis, leading to an 
increase of hepatic triglyceride production. Backhed et al demonstrated that GF mice re-
conventionalized with bacteria of mouse cecal origin undergo an increase of 60% of the total body 
fat content77. Other metabolic processes undertaken by the gut microbiota involve dietary oxalate 
degradation and vitamin synthesis73. Therefore, the gut microbiota help to enhance extraction of 
calories from the diet and are involved in the control of energy and lipid metabolism of the hostH78.  
The diversity and functions of the gut microbiome was also explored by analyzing the 
composition of the gut microbial community of healthy human populations79,80. The sequencing of 
bacterial 16s ribosomal RNA genes from gut biopsies and feces showed that human gut microbiome 
contain members of seven divisions of bacteria (Firmicutes, Bacteroidetes, Actinobacteria, 
Fusobacteria, Proteobacteria, Verrucomicrobia, Cyanobacteria) 2 bacterial divisions (Firmicutes and 
Bacteroidetes) mainly occupy distal gastro-intestinal tract and influence host phenotype33. Several 
studies have also demonstrated significant differences in gut microbial composition between healthy 
individuals79,81. 
Recently the full sequencing of the gut metagenome has brought new insights in the role of 
the gut microbiome on human health82. In particular; Qin et al established a gut microbial gene 
catalogue by encoding the total DNA of fecal samples from 124 adults. They detected more than 
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1000 bacterial species encoding for 3364 non redundant genes. Interestingly, 57 species were found 
in common in more than 90% of the individuals82. Although they found a significant variability of 
bacterial species among individuals, bacterial gene clustering allowed the identification of a core 
function of the metagenome. Gut microbiome is involved in essential functions of gut microbiome-
host interactions, including synthesis of SCFAs, amino acids, vitamins and the degradation of 
polysaccharides and other undefined functions which may have an important role in gut ecosystem 
and physiology 80,82.  
2.2. Gut microbiota modulation and disease development 
Microbiota colonize mammalian gut after birth and over the first years of life and the 
acquisition of adult-type microbiota is the consequence of several host and external factors72,73 
Transient changes in the intestinal ecosystem occur throughout life through the influence of dietary 
and environmental factors, leading in some cases to the alteration of bacterial-host symbiosis83. Gut 
bacteria also influence the development of various diseases such as Crohn’s disease, irritable bowel 
syndrome, food allergy, and CVDs among others77,84,85. In particular, stress is correlated with a higher 
bacterial translocation and increase of gut permeability. This may trigger inflammatory episodes and 
contribute to enteric inflammatory disorders83. In addition, the release of adrenaline and 
noradrenalin has been shown to encourage the growth of putative pathogenic bacteria such as 
Helicobacter pylori or Clostridium difficile86. In some cases, introduction of drugs, particularly 
antibiotics, also leads to ecosystem alterations and increase the number of pathogenic 
microorganisms in the intestinal lumen. Pathogen overgrowth is often correlated with more 
putrefaction-associated metabolites such as ammonia, amines and indoles and increased bacterial 
translocation, which can be harmful for the host organism. The return to a symbiotic ecosystem may 
be achieved by selective growth and activation of commensal bacteria which can potentially be 
promoted by prebiotic or probiotic supplementation. This aspect will be further discussed in the 
section X2.3X of this introduction. 
It has also been established that ingestion of a diet rich in fat and carbohydrates modulates 
the gut microbiotal composition and encourages obesity development. Turnbaugh et al have 
observed differences in the distal gut microbiota of obese versus lean humans and the relative 
abundance of Bacteroidetes increased as individuals lost weight on either a fat- or carbohydrate-
restricted low calorie diet33. The lower Bacteroidetes/Firmicutes ratio characterised in obese people 
is thought to be more efficient at hydrolysing non-digestible polysaccharides in the intestinal lumen 
and may be able to extract more calories and fat compared to lean individuals77. 
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As previously mentioned, increase in body weight is frequently accompanied by IR and MetS. 
Substantial evidence suggests that gut microbiota also play an active role in IR and obesity 
associated diseases, especially through immune mediated mechanisms. Indeed, the proliferation of 
gram-negative bacteria associated with HF feeding in mice generates hepatotoxic substances such as 
endotoxins and increases production of cytokines which favour liver injury87. It has been shown that 
individuals with relatively increased gram-negative bacteria counts also have elevated levels of 
circulating LPS – being key components of bacterial cell walls. Higher circulating levels of these 
molecules has been correlated with an increase in fasting glucose and insulin, weight gain and 
steatosis in mice73,84,87. Therefore physiological processes associated with imbalanced gut microbiota 
work as a vicious cycle, triggering and promoting the initiation and the progression of 
obesity72,74,78,88. 
Dumas et al established a link between reduced choline bioavailability for the host 
associated to a up-regulation of microbial choline pathways in mice fed with a HF diet and the 
development of IR and NAFLD89. These results confirm that microbial metabolic activity is 
significantly involved in metabolism of endogenous and exogenous compounds, and is associated 
with host welfare. It is therefore essential to understand the role of the gut microbiota-host 
interactions in obesity development, and metabolic diseases (NAFLD, T2DM, CVDs).  
 
2.3. Gut microbial remodelling by nutritional interventions 
Therapeutic impacts of gut microbiome remodelling have been explored using several 
strategies. Antibiotic therapy confers the abilities to remove pathogenic bacteria involved in the 
production of endotoxins and infectionsH90H. As an example, supplementation of the antiobiotic 
rifaximin has been found to successfully reduce hepatic encephalopathy which is partly caused by 
gut derived products (neurotoxins, ammonia, indoles) in sub-clinical trialsH91H. However, antibiotic 
utilization may compromise gut microbial ecosystem and promote the growth of new resistant 
strains. Several studies have reported an increase in Clostridium difficile infections causing diarrhea 
after antibiotic treatmentsH92H. Fecal transplantation is another strategy to shape the gut microbiota. 
It turns to be an efficient way of restoring gut microbial ecosystem after antibiotic treatment. In 
particular, mouth fecal transplantation was found to reduce symptoms associated with Clostridium 
difficileH93H.  
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The selection and enhancement of specific gut microbiota may also represent a new 
approach to control energy intake and reduce the prevalence of obesity. The main strategies to 
improve gut microbial-host metabolic interactions in obesity, and metabolic diseases (T2DM, NAFLD) 
are based on the use of probiotics and prebiotics94. Probiotics or microbial food supplements 
beneficially affect the host by improving intestinal microbial balance and changing the composition 
of the colonic microbiota95. Originally, probiotics were added in yoghurt to improve lactose digestion 
and eliminate symptoms of intolerance for people who were unable to efficiently digest lactose. 
Nowadays, they are used to reduce other digestive symptoms such as diarrhea or bloating and help 
re-establishing a symbiotic ecosystem after drug therapy such as antibiotic treatment H70. By contrast, 
prebiotics are food ingredients that beneficially affect the host by selectively stimulating growth 
and/or activity of one or a restricted number of bacteria present in the colon70. Prebiotics are 
composed of oligosaccharides or short chain polysaccharides. They are easily found in common 
dietary products such as, vegetables and whole grain cereals and can be added in yoghourtH95.  
Recent studies have explored the potential therapeutic use of probiotics in the treatment of 
metabolic diseases. Specific bacterial efficacy has been demonstrated to enhance host energy 
metabolism, for example Bifidobacterium spp have been shown to improve glucose homeostasis, 
reduce weight gain, fat mass and restore glucose mediated insulin secretion in mice fed with HF 
dietH88H. Martin et al also illustrated the contribution of the probiotic Lactobacillus rhamnosus and 
Lactobacillus paracasei in lipid and amino acid homeostasis through the decreased lipoprotein levels 
in plasma, the increased deconjugation of bile acids, and the up-regulation of branched chain amino 
acids (BCAAs) catabolism in mice fed with chow dietH31. It has been established, the reduction of fat 
storage and the increased production of SCFAS due to probiotic supplementation enhance anti-
inflammatory responses, and reduce hepatic injury87.  
The most characterised prebiotics are fructosyl-oligosaccharides (FOS), inulin (long chain 
fructosyl-oligosaccharide), galactosyl-oligosaccharides (GOS) and other oligosaccharides from milk 
(MO), which are transformed by the gut microbiota in SCFAs and simultaneously promote 
proliferation of selected commensal bacteria in the colon96-99. For instance, inulin, has been found to 
stimulate Bifidobacteria and may reduce calorie intake and fat mass in animalsH97. It has been 
recently confirmed that prebiotic stimulation of Bifidobacteria is correlated with increased glucose 
tolerance, improved glucose-induced insulin secretion, and normalisation of inflammation88. GOS 
also modify the monosaccharide uptake from the gut by changing the activity of host 
monosaccharide transporters which in turn results in activation of glycolytic pathways98. Prebiotic 
consumption has been associated with a reduction of hepatic, kidney and plasma lipids in 
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rodents100,101. In particular, GOS supplementation in healthy mice decreased hepatic TGs by lowering 
lipogenic enzyme activity, fatty acid synthase (FAS), and the microsomal triglyceride transfer 
proteins (MTTP) which is involved in VLDL synthesis97,100. Furthermore, higher carnitine, and acyl-
carnitine levels were observed in the urine of prebiotic fed mice, which suggested an increased FA 
oxidation102. Therefore, prebiotic ingestion may promote a shift toward less lipogenic activity and 
more lipolytic activity.  
Human Milk oligosaccharides (HMO) also present various biological activities and provide a 
range of beneficial effect beyond nutritional needs. They are mainly composed of glucose and 
galactose but they also contained fucose, N-acetylglucosamine, N acetylneuramic acids (sialic acids). 
Fucosyl- and silyl-saccharides cannot be digested by intestinal enzymes. Thus HMO can reach the 
large intestine and colon, and may confer prebiotic effects103. For instance, HMO may selectively 
promote the growth of certain Bifidobacteria strains only present in breast fed infant. However, 
given their structural complexity, the large scale industrial production of HMO is unfeasible. 
Alternatively, cow milk oligosaccharides (CMO) may be used as another oligosaccharides source for 
infant formula. Additionally commercial GOS products are not naturally found in human and bovine 
milk. Therefore new mixtures combining CMO and GOS are under development to propose 
nutritional supplements with fermentable properties closer to human breast milk103. Although 
lactose present in milk is the main source of carbohydrates for new borns and infants, 75% of the 
world adult population are unable to digest lactose104. Symptoms of lactose intolerance are bloating, 
cramp, diarrhea and inflammation, and its ingestion may promote inflammatory bowel diseases104. 
Several studies have demonstrated that probiotic supplementation in dairy products (animal milk, 
yogurt, cheese) improves lactose digestion in grownups. Probiotic and prebiotic supplementation 
may also reduce symptom of lactose intolerance105.  
Finally, the concept of a ‘synbiotic’, based on the synergetic combination of prebiotic and 
probiotic is another approach which provides alternative solutions to control gut microbial 
composition and to reduce the risk of developing metabolic diseases such as obesity and type II 
diabetes96. Therefore, by promoting beneficial commensal bacteria, probiotic, prebiotic, and 
synbiotic products may confer nutritional benefits and protect organisms against colonic and 
systemic disorders. In this regard, they are defined as health-enhancing food ingredients and have 
potential pharmaceutical-like applications.  
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3. A METABONOMIC STRATEGY TO UNDERSTAND THE INTERACTIONS 
BETWEEN DIET AND MICROBIOTA IN OBESITY AND METS 
DEVELOPMENT  
Given the complex crosstalk between carbohydrate, protein and amino acid metabolism in 
the context of over-nutrition, and the multitude of genetic and environmental factors affecting these 
metabolic pathways, it is necessary to investigate the onset of obesity and the MetS from a holistic 
point of view. A large number of techniques including genomics, transcriptomics or proteomics 
provide a “top-down” integrated view of the molecular basis of health disorders106,107. However, 
genomic and proteomic studies usually offer limited information about metabolic modulations 
because several biochemical mechanisms cannot be explained by differences in concentration of 
proteins or gene expression levels alone. By contrast, one definition of metabonomics is “the 
quantitative measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification”. This systemic approach allow the 
characterisation of the metabolic signature associated with a genetic modification as well as 
toxicological interventions or dietary influences108. Because metabolic concentrations are dependent 
on gene expression, protein activity, cell kinetics and metabolic flux, metabonomics provide a 
“global picture” of the physiological regulations considering all the influencing factors. By using a 
combination of molecular analytical tools (mass spectrometry (MS) and nuclear magnetic resonance 
(NMR)) and multivariate data analysis, it is possible to capture a ‘snapshot’ of an individual 
metabolic profile from biological matrices and tissues, this profile being defined as a 
“metabotype”109.  
Nutritional metabonomics investigating the metabolic responses to various diet 
interventions has been defined as nutrimetabonomics and turn to be an efficient approach to 
investigate the role of nutrients on obesity and metabolic diseases, whilst also considering genetic 
and environmental factors69. For instance, 1H NMR spectroscopy based metabonomic study has 
characterised a range of metabolic variations to HF diet across five mouse strains susceptible or 
resistant to HF induced IR. The hierarchical metabonomic clustering were found to closely match the 
single nucleotide polymorphisms (SNPs) based phylogenic tree of the 5 inbreed strains which 
supports the concept that individual metabotypes mirror the genetic susceptibility of adaptation to 
HF diet110. Metabolic phenotyping of obese and lean subjects in mouse and human studies, have 
contributed to our overall understanding of the onset of T2DM and IR by highlighting the 
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contribution of metabolites involved in energy metabolism such as TCA cycle, lipid and amino acid 
processing, as well as inflammatory markers to these pathological processes110-112. 
Metabonomics is also suitable for investigating the contimum of mammalians-microbiome 
interactions as metabolic profiles captures endogenous metabolites as well as “mammalian-
microbial co-metabolites”32. These exogenous compounds which originate from diet and/or gut 
microbiota, can enter the host’s system where they can be further processed in the liver and other 
tissues before being excreted in the urine. Thus, urine is an ideal matrix for studying in a non-
invasive manner, the impact of dietary intervention and gut microbiota activity on host 
physiology69,113. Several metabonomic studies have emphasised the importance of the human 
symbiotic relationship with the gut microbiota and its role into the development of metabolic 
disorders. As previously mentioned, Dumas et al identified in a metabonomic study, the link 
between mitochondrial choline metabolism and the development of NAFLD and IR in the host89. A 
recent human study combining 1H NMR metabolic profiles and 16S rRNA sequencing of fecal 
microbiota showed that gut microbiota remodelling by inulin-type fructans tend to decrease 
circulating phosphatydylcholines levels and fat mass in obese women114. Hence, metabonomic 
studies supported by other “omics” technologies are useful to investigate the effect of dietary 
interventions on the gut microbiota-host metabolic axis. 
A recent metabonomic approach named ‘pharmacometabonomics’ illustrated the concept 
of predicting final physiological outcome of a pharmaceutical intervention from predose metabolic 
profiles68. This novel idea could be also transposed to nutritional studies to anticipate the metabolic 
alterations associated to specific diet and set up personalised healthcare solutions111. Therefore, 
given that gut mcirobiota activity and host immune system have been found to influence metabolic 
phenotypes, metabonomics is a promising strategy to investigate the link between overfeeding, gut 
microbiota activity, and host inflammatory responses, in the onset of obesity and its metabolic 
diseases. 
 
4. SCOPE OF THE THESIS  
The complex aetiology of obesity and MetS, combining genetic and environmental factors 
has been largely documented in the literature. This explains the large variability in host 
responsiveness to rich (high fat and/or carbohydrate) diets and the presence of a large spectrum of 
metabolic deregulations and diseases associated with obesity. Substantial evidence has also 
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demonstrated the role of gut microbiota into the host’s metabolic regulation and its potential roles 
in metabolic disorders. Thus, two hypotheses can be formulated:  
- Individual responsiveness to HF diet may be predicted from early or prior metabolic profiles 
- Modulation of gut microbiota activity by prebiotics during HF diet-induced obesity development 
may improve host physiology.  
The scope of this thesis intends to investigate these questions using a metabonomic 
approach. In a first experiment, we aimed to identify the difference in metabolic profiles of obesity 
prone and obesity resistant C57BL/6 mice at 7 days and 60 days after HF feeding. In a second 
experiment, we evaluated the impact of different prebiotics in the modulation of the interactions 
between host’s metabolism, host’s immune system and the gut microbiota in C57BL/6 mice during 
HF-induced obesity development.  
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CHAPTER II: ANALYTICAL METHODS  
 
Metabolic profiling techniques are applied to a wide range of complex samples such as 
biofluids and tissues. Profiles derived from urine yield insight to specific metabolic changes and 
provide indirect information about gut microbial activity as urine contains specific metabolites 
produced by host-microbiotal interactions32. Urine is also particularly useful to investigate gradual 
metabolic changes as its collection is minimally invasive to the subject. Metabolic profiles of 
collected specimens are obtained using nuclear magnetic resonance spectroscopy (NMR) and mass 
spectrometry (MS)115, which are particularly useful tools for elucidating biomarkers without prior 
knowledge of the sample composition116. Summarising various multivariate metabolic profiles by 
mathematical models improves the understanding of host metabolic modulation influenced by 
genetic and external factors117. Targeted approaches using MS are also used to identify and quantify 
known metabolites of interest, often present in lower concentrations. Integrating information 
generated by metabolic profiling obtained from different biofluids such as plasma and urine can 
provide a more systemic view of mechanisms underlying the microbiota-host metabolism interaction 
under different diet intervention32,118. Metabonomic data can be also integrated with other omic 
data to provide a better “picture” of the interactions between genetic, metabolic and physiological 
changes in a perturbed system. In this thesis,16S rRNA gene sequencing data has been correlated 
with metabonomic data to identify the link between gut microbiota composition and host metabolic 
adaptation during dietary interventions115.  
 
1. NUCLEAR MAGNETIC RESONANCE: 
High resolution NMR spectroscopy is a quantitative, non sample destructive, and 
reproducible analytical method used to simultaneously detect a wide range of low molecular weight 
compounds (<1000 Daltons) in a complex sample such as tissue extracts or biofluids. NMR-based 
metabolic profiling is a suitable tool for metabonomic applications as it provides a metabolic 
“snapshot” representative of the sample at the collection time and requires few sample preparation 
steps H108H. The current generation of commercially available high-field spectrometers enables easy 
detection of metabolites in the micromolar range within a short experiment time113.  
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1.1. Fundamental principles of NMR spectroscopy  
The principle of NMR is based on the fundamental properties of the atomic nucleus which is 
composed of protons and neutrons. These particles, also called nucleons, are strongly linked 
together and confer spin properties. The atomic nucleus can also have a nuclear spin which is 
defined as the particular vectorial sum of nucleons spins. The nuclear spin value (I) partly depends 
on the number of nucleons (atomic mass) and the number of protons (atomic number) 119.  
All nuclei with a non-zero nuclear spin are observable by NMR. However the most important 
nuclear isotopes used in biological approaches are those with a spin =1/2 i.e 1H, 13C, 15N, 31P. In 
particular, we focused on 1H NMR spectroscopy as the hydrogen nucleus is the most abundant 
element in biological molecules and, apart from 3H, is the best detected by NMR119.  
When a magnetic field (B0) is applied, the nuclear moments of spins orient themselves and 
the number of possible orientations is given by the equation: 2I+1. For instance if I= 1/2, there are 
two different orientations of the nuclear spins in the external field. The spin corresponding to 1/2 is 
the lower energy, is more stable, and is oriented in the same direction as B0 (position α). On the 
other hand, the spin equal to -1/2 is the higher energy with an opposite direction to B0 (position β). 
For both orientations, the spins move around the magnetic field with a frequency υ (Hz) and an 
angular speed ωo (Rad.s
-1), this motion is defined as the Larmor precession120 (XFigure 7X). 
The population of 2 energy levels are given by the Boltzmann distribution:  
Nupper/Nlower=e
-ΔE/KT 
Nupper and Nlower represent the number of nuclei in the upper or the lower energy state. K is the 
Boltzmann constant and T is the absolute temperature in Kelvin (K). ΔE corresponds to the energy 
difference between the two orientations and the energy required to flip nuclear spins. It can be 
calculated by the following equation:  
ΔE=γhB0/2π  
Where h is the Plank’s constant, γ is the gyromagnetic ratio (nuclear magnetic moment) and B0 the 
NMR magnetic field. The slight excess of spins in α position compared to spins in β position entails a 
net absorption of energy which in turn gives NMR signal. As the coefficient of absorption is a 
constant for any nucleus, the intensity of the signal is proportional to the total number of nuclei in 
the sample119,120. 
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Figure 7: Theory of NMR spectroscopy. (A) .Energy level and transition for a nucleus having a nuclear spin I=1/2 
in a magnetic field B0. (B). Motion of net nucleus magnetisation which relax at the Larmor frequency ω0 in a 
magnetic field B0. The spin resultant gives a stationary bulk magnetization vector prior to radiofrequency (RF) 
perturbation. (C) Effect of RF irradiation with a frequency ω0 on bulk magnetisation vector M0. 
 
The difference of population between these two energy levels gives rise to a resultant 
magnetisation vector M0 following the same direction as B0 (on the Z axis). When a specific pulse of 
radiofrequency radiation B1 is applied at the resonant frequency ω, some nuclear spins in the lower 
energy are forced to adopt higher energy levels leading to a new orientation of M0. When the pulse 
stops, the perturbed spins relax back to recover their equilibrium condition. During the precession 
movement, the component of magnetisation releases an oscillating voltage which gives the NMR 
signal, also called free induction decay (FID). If B1 power is applied such that Mo is reoriented by 90 
degrees, this results in recording the maximum voltage. The relaxation of the nuclear spin 
magnetisation is described by 2 processes: The longitudinal (spin-lattice) relaxation time T1 is the 
time constant for the return of M0 to its equilibrium position (on the z axis). The transverse (spin-
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spin) relaxation time T2 is the the time constant for the nuclear spins to lose phase in the X-Y plane. 
A Fourier Transform is then applied to convert the time domain signal of FID in the frequency 
domain and obtain an NMR spectrum119,120. 
 
1.2. Chemical shifts 
NMR spectroscopy provides extensive information on molecular structure and conformation 
because each nucleus is directly influenced by its chemical environment. Indeed, electric current 
around the nuclei (dependent on electronegativity, local chemical environment, electron density, 
and circulating electron ring currents) generates a local magnetic field in the opposite direction to B0 
and shields the nuclei from the external applied field. Therefore, the nuclear shielding corresponds 
to the difference between the applied field and the field at the nucleus. The chemical shift is then 
defined as the nuclear shielding divided by the applied magnetic field. In the case of an experiment 
in which the exact field is applied and a reference nucleus is used, the chemical shift can be 
characterised by the equation: 
δ (ppm)=[(υ-υref)/oscillator frequency (Hz)] *10
6  
Where υ is the frequency of the nucleus, and υref is the resonance frequency of a chosen nucleus in a 
standard molecule119,120. The new chemical shift scale is independent from the nominal field B0. 
 
1.3. The spin-spin coupling  
Inter- and intra-molecular interactions among individual groups of nuclei in proximity may 
occur, leading to magnetisation transfer. In a liquid solution, molecules are constantly tumbling 
because of thermal motion so that the intermolecular magnetic interactions are averaged to zero. 
Within the molecule, magnetic nuclei can also interact with each other through space or via spin-
spin coupling involving electrons polarisation exchange between atomic bonds. Again, the spatial 
interactions within the molecules are averaged due to the fact that molecules in solution are highly 
subjected to Brownian motion. However, spin-spin couplings from neighbouring groups in the same 
molecule results in a splitting of NMR signals into two or more components that are slightly shifted 
from the original frequency/ chemical shift (in ppm) measured in the absence of coupling. Therefore, 
2 spin ½ magnetic nuclei that mutually interact have their resonance signals split into 2 peaks with 
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equal intensity and separated by a scalar coupling constant J (in Hz). In the case where more than 1 
nucleus is involved in the coupling, further splitting of the resonance signals have to be considered 
leading to doublet, triplet or multiplet with various intensities119,120. In a simple system, the peak 
pattern is given by Pascal’s triangle. The spin-spin coupling is usually transmittable up to 3 bonds, 
but the presence of unsaturated bonds may extend the electrons exchange further121. The J coupling 
is independent of the external magnetic field and gives indications on the molecular structures as it 
depends on the chemical bonds, the the coupled nuclei, the length of interacting bonds and the 
dihedral angles between the bonds120.  
 
Figure 8: Multiplicity and relative intensities of NMR signals from equivalent coupled nuclei with spin number 
I=1/2 (such as 
1
H coupling). 
 
1.4. 1D NMR spectroscopy  
A single pulse sequence used for 1D NMR experiment contains at least 3 parts: the 
preparation time, also called relaxation delay (in seconds), the pulse width (in microseconds) and the 
acquisition time (in seconds). The preparation time is an important period where the spins reach 
their equilibrium state. It should last about three to five times T1 relaxation time for a complete spin 
relaxation. The pulse width corresponds to the length of time to apply a radiofrequency power pulse 
to perturb the spin system. After that, the exited spins relax back to their original state generating 
the FID which is acquired during the acquisition time. Because NMR is a relatively insensitive method 
compared to other spectroscopic tools, it is often required to repeat the pulse sequence several time 
so as to sum up the FID signals. In fact FID is constituted of coherent resonance signals from spin 
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relaxation and incoherent noise signals. Therefore, signal/noise ratio increases by the square root of 
the number of scans119,120.  
  
Figure 9: Standard one pulse sequence (RD: relaxation delay ,pw: pulse width)  
 
In metabonomic studies, three 1D NMR experiments using more complex single pulse 
sequences are frequently employed depending on the biofluids or tissues we want to investigate122.  
 A standard 1-D experiment allows to acquire the resonance of all proton containing 
molecules in the samples including sharp peaks from small molecules (amino acids, simple 
carbohydrates, organic acids, nucleic acids) and broad signals from the macromolecules 
(proteins, long chain fatty acids). This experiment is widely used for acquiring urinary 
metabolic profiles which do not contain large amounts of macromolecules.  
 The Carr-Purcell-Meiboom-Gill (CPMG) experiment attenuates the signals of 
macromolecules and allows a better definition of small molecules signals. This sequence is of 
particular interest for tissues extract and plasma metabolic profiles which contain a large 
amount of proteins and/or lipids.  
 The diffusion edited experiment selectively detects the signals of macromolecules.  
 
1.5. 2D NMR spectrometry  
Due to a large number of overlapped peaks in 1 D NMR metabolic profiles, it is important to 
perform 2D NMR experiments which provide more information about NMR peak connectivity and 
thus help structural elucidation of unknown metabolites in complex biological matrices. Unlike 1D 
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NMR experiment, the signals from 2D NMR experiments are dependent on two time variables t1 and 
t2 and the following FT (which is applied twice) give a spectrum with two frequency variables F1 and 
F2. The sheme of a 2D NMR sequence (standard COSY) is presented below120. 
  
Figure 10: NMR pulse sequence of a standard COSY experiment (RD: relaxation delay, p1: first pulse width to 
reach 90°; t1: evolution time, p2: second pulse width to reach 90°, t2: acquisition time) 
After the relaxation delay, several pulses are applied to induce spin excitation. In turn, the 
spin relaxation evolves during the time t1. A second set of pulses are applied during the mixing time. 
The resulting signal is then recorded during the second time variable t2. The two dimensional signal 
is actually recorded by repeating the pulse sequence several time with increasing t1 value. Usually 
the whole process requires 50 to 500 increments of t1. For each pulse sequence FID is recorded 
during the time t2 only. The nature and the time of pulses during the relaxation delay and mixing 
time determine the information present in the spectrum. A generic 2D NMR spectrum can be 
interpreted as following119,120:  
 A cross-peak is observed with a frequency coordinate of 20 Hz on F1 and 80Hz on F2 which 
means that a resonance signal evolve at 20 Hz during t1 and during the mixing time, the 
same signal transfers its magnetisation to another signals which evolves at 80Hz on t2.  
 If a cross peak has a frequency coordinate of 20 Hz on F1 and F2, it means that the 
resonance signal is not affected by the mixing time and it evolves at 20 Hz during t1 and 
20Hz during t2.  
Therefore, pulses during the mixing time are crucial in creating a 2D NMR signal. In the case 
of no J coupling or inefficient mixing time, a diagonal of cross peaks with equal frequency values on 
F1 and F2 can be observedH120H. Several 2D NMR experiments are frequently employed as aid for 
assignment in metabomomic studies122:  
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 J-Resolved spectroscopy allows the separation of 1H chemical shift and J coupling into two 
dimensions. The first dimension (F2) is quite similar to a 1D NMR spectrum although each 
proton appears as single peak. On the second dimension (F1), proton signals are separated 
by an offset according to the J coupling value. This method helps the interpretation of peak 
multiplicity in complex metabolic profiles123. 
 Correlation spectroscopy (COSY) is used to identify correlation between two 1H which are J-
coupled with each other. The cross peaks present on a COSY spectrum provide connectivity 
information of coupled protons separated by two or three bonds in general124. 
 Heteronuclear single quantum coherence (HSQC) experiments consist in transferring the 
magnetisation by one bond coupling between 1H and 13C. The signal of 1H which is affected 
by the frequency of the singled bonded carbon is directly recoded on the first dimension (F2) 
while the 13C signal is indirectly detected via 1H signal. The generated spectrum provides 
cross peaks with co-ordinates corresponding to chemical shift of J coupled 1H (on F2 
dimension) and chemical shift of 13C (on F1 dimension). This experiment is particularly useful 
for structural elucidation as it gives additional information on the atomic connectivity and 
allows a better dispersion of NMR peaks along the 13C dimension125. 
  
2. LIQUID CHROMATOGRAPHY MASS SPECTROMETRY  
Mass spectrometry (MS) is an analytical technique in which molecules in ionised gaseous 
form are separated in space and time according to their mass to charge ratio prior to detection. 
Detected ions from one or more distinct molecular species are recorded as a mass spectrum which 
can provide information related to both the chemical formula and structure. The analysis of 
biological mixtures such as urine, serum or tissue extracts produces complex spectra with a wide 
range of molecular masses. Therefore, a separation step on a time dimension using gas 
chromatography, high performance liquid chromatography (HPLC) or recently ultra-high 
performance liquid chromatography (UPLC) is frequently employed prior MS to reduce sample 
complexity and improve the ionisation of molecules121,126. 
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2.1. Principles of Liquid Chromatography 
In liquid chromatography, molecules in solution enter a column containing a microparticle 
stationary phase and are eluted out with solvents (also called mobile phase) at different migration 
rates. The relative elution order depends on the chemical structure of the molecules and their 
relative affinity for the stationary phase and the mobile phase. The mobile phase usually consists of 
two miscible solvents that are exchanged to first bind the molecular content of a sample to the 
stationary phase, and then elute it cleanly with sufficient resolution between species of interest. The 
stationary phase is generally composed of particles of silica or cross-linked co-polymers of styrene or 
benzene. While these materials may be used by themselves, they often act as a support structure for 
additional chemically bonded molecules which greatly influence the selectivity of the 
chromatographic separation. The size of stationary phase particles is related to the efficiency of the 
achievable separation, and therefore the use of small particles is particularly important in high 
performance applications such as those required for biofluid profiling. Ultra high performance liquid 
chromatography (UPLC) is achieved with particle sizes <2um, allowing for rapid high resolution 
separations 121,126. Such system has been engineered to withstand the high backpressure (up to 
15,000 psi) that results from the use of these small particles. 
In metabonomic studies, the most common UPLC-MS analyses employ a reversed phase 
separation system and gradient elution which allows the separation of medium to low polarity 
solutes. This chromatographic method most commonly uses a non-polar stationary phase of 
octadecyl groups (C18) bound to silica or polymeric particles. Solute elution is performed by applying 
a gradient of solvents, starting at aqueous conditions for solute binding, and gradually introducing 
an organic solvent such as acetonitrile of methanol to facilitate solute elution.The solvent gradient 
allows changing the polarity of the mobile phase over time which improves the resolution of 
complex mixtures over a wide range of polarities. However, reversed phase chromatography is not 
particularly adapted for the analysis of high polarity solutes because these molecules are not well 
retained on the stationary phase and tend to be eluted with the void volume of the column121. 
Where polar analytes are the analytical focus, alternative chromatographic strategies must be 
sought. Hydrophilic interaction liquid chromatography (HILIC) columns have been developed to 
preferably retain small polar molecules such as amino acids and organic acids. HILIC methods have 
recently been developed which allow for high quality separations over short analysis times with 
excellent detection sensitivity when mated to MS detection127. 
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2.2. Principle of Mass spectrometry  
A basic mass spectrometer is capable of accepting molecular content from an inlet system, 
converting that material to gas phase ions, performing mass analysis of the molecular species 
present, and detecting the signals produced by each. Such a mass spectrometer is thus composed of 
an ion source, a mass analyser, and ion detector121.  
 
Figure 11: Diagram of mass spectrometry. HPLC: high performance liquid chromatography, UPLC: 
ultra high pressure liquid chromatography, gas chromatography, CE: capillary electrophoresis 
chromatography, EI/CI: electronic or chemical ionisation, APCI: atmospheric pressure chemical 
ionisation, FAB: Fast atom bombardment, ESI: electrospray ionisation MALDI: matrix-assisted laser 
desorption ionisation, FT ICR: Fourrier transform-ion cyclotron resonance. 
 
The sample inlet allows a controlled introduction of gaseous or vaporised liquid samples into 
the ion source which is subjected to high vacuum. This injection system can be interfaced with gas 
chromatography (GC), capillary electrophoresis chromatography (CEC), HPLC, UPLC or performed by 
direct infusion. These techniques are chosen according to the physiochemistry of metabolites which 
need to be studied. For instance, GC is preferred for the analysis of small volatile metabolites while 
HPLC and UPLC are adapted for liquid samples121.  
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The ion source which operates under high voltage induces ionisation of the molecular 
content. From this module, the ions are subjected to high vacuum (10-4 to 10-7 Nm-2), except for 
atmospheric pressure ionisation techniques. Several ways of ionizing molecules exist depending on 
the nature of the matrix and the analytical requirement. Electronic ionisation (EI), chemical 
ionisation (CI) and atmospheric pressure chemical ionisation (APCI) are preferably used for the 
analysis of small volatile and thermo-resistant molecules. On the other hand, fast atom 
bombardment (FAB) is more suited for the analysis of small molecules (lower than 6000 Da). In 
biological applications, soft ionisation methods such as electrospray ionisation (ESI) and matrix-
assisted laser desorption ionisations (MALDI) inducing little fragmentation are also frequently 
employed as they conserve molecule integrity and non-covalent interactions. 
The most common method used in LC-MS is ESI because it provides high sensitivity and it 
directly generates ions from liquid phase to gas phase. During ESI ionisation, the analytes in solution 
travel in a capillary tube subjected to a high electric field. This high potential triggers the 
accumulation of charges at the surface of the capillary tip, which are in turn drawn out to form 
droplets. Nitrogen gas and heat are introduced in the source to promote solvent evaporation and 
the formation of smaller highly charged droplets. Finally, when the charge density at the droplet 
surface is high enough, ion desorption occurs leading to the formation of gas phase ions. This 
process usually yields singly charged ions from small molecules (<1000 Da) but it may result in the 
production of multi-charged ions from bigger molecules. ESI can produce both positive and 
negatively charged ions which are typically measured in separate analyses, as each requires the mass 
analyser and related ion optics to be in one or the other polarity. By doing so, the coverage of 
detected molecules may be dramatically improved as many molecules are only visible in a single 
polarityH121H. ESI is a competitive process, however, whereby multiple ions may challenge each other 
for available charge. The resulting suppression phenomenon represents a significant drawback in ESI 
LC-MS of complex biological matrices121.  
The mass analyser enables the separation of ions according to their mass to charge ratio. 
The ions formed in the source are accelerated towards the mass analyser by passing through series 
of ion optics with applied voltages. The mass analyser can be a simple quadrupole (Q), time of flight 
(TOF), ion trap or Fourrier transform-ion cyclotron resonance (FT-ICR) system. Several analysers can 
also be combined to perform multi-stage separations. The most common hybrid analyser 
configurations are the Q-TOF, the triple quadrupole(QQQ), and the Qtrap121.  
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Once the ion species have been separated, they are passed to a detector which records the 
current produced when the ions hit the detector’s surface or pass close to it. The abundance of each 
ion species is detected and the resulting signal of all the ions from a single measurement (known as 
a “scan”) gives a mass spectrum displaying the ion abundance (on the Y axis) and the m/z ratio (on x 
axis). The most intense peak is defined as the base peak. The mass spectrum encodes information 
reflecting the molecular formula and distribution of heavy isotopes in the molecular species. Where 
molecular fragmentation is used (typically in hybrid mass spectrometers such as the Q-ToF or QQQ), 
the mass spectrum can also encode structural information in the form of a characteristic 
fragmentation pattern. 
 
2.3. Multiplex targeted MS/MS assay: the Biocrates kit 
While LC-MS is often employed for metabolic profiling whereby all observable ions are 
detected, it can be also used for targeted analysis when molecular species of interest are known in 
advance of the analysis. In this case, the system is configured for the selective detection of only the 
target analytes, with known masses, fragments, and retention times. The use of standard reference 
curves generated from the purified materials of interest allows for the translation of signal intensity 
to absolute concentration. Use of stable isotope-labelled standards in the sample corrects for any 
ionisation suppression effects that may confound absolute quantification. In this thesis, the 
Biocrates kit containing numerous isotope labelled standards has been used for targeted LC-MS 
analysis using a Qtrap mass spectrometer operating in ESI+ and ESI-.  
The Biocrates “AbsoluteIDQTM p 180 kit allows the identification and quantification of 186 
metabolites from a small volume of sample (10 µl). Several acylcarnitines, amino acids, biogenic 
amines, hexose and phospho- and sphingo- lipids can be analysed quantitatively with the addition of 
stable isotope labelled or chemically homologous internal standards. Multiple reaction monitoring 
(MRM) is preceded by a combination of flow injection analysis (FIA) and liquid chromatography 
(HPLC) and provides high sensitivity and high selectivity analysisH128H. The MRM analysis consists in 
selecting a target molecular species in the first MS analyser (for instance the Q1 in QQQ or Qtrap) 
and excluding all others based on nominal m/z value. That species is passed on to a collision cell, 
where fragmentation occurs by collision induced dissociation (CID). A diagnostic fragment ion 
species is selected in the second MS analyser (for instance the Q3 in the QQQ or the trap in the 
Qtrap) and passed on to the detector which measures the amount of incoming material and 
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translates that into signal intensity. The selection of a molecular species (parent ion) and its 
diagnostic fragment (fragment ion) in the first and the second MS analyser respectively is called an 
MRM transistion. An example of ion fragmentation is given in XFigure 12X.  
 
Figure 12: Example of ions fragmentation in the MS analyser. 
 
The kit is particularly designed for MS/MS analysis on triple quadripole or hybrid quadrupole 
ion trap platforms which provide a wide linear dynamic range. Several operating procedures to 
assess the analysis quality are also carried out during the experiment. The assay work flow is 
separated in 7 modules128.  
1. Sample lists are imported and registered in the Biocrates analyst software using a 96 
well plate format template.  
2. The assay is prepared using a specific 96 well plate design as follows: 
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Figure 13: Protocol for sample preparation using the Biocrates kit 
3. The assay is run with a standardised MS method: 
Acylcarnitines, hexoses, phospho- and sphingo-lipids are analysed by FIA-MS/MS analysis. Analysis 
time is 3 minutes using either positive or negative ion mode electrospray and detection. One 
hundred and fifty-eight MRM transitions are measured in the positive ionisation mode while 2 are 
measured in the negative mode. Therefore, two injections of 20 µl are necessary to perform the 
complete analysis. The flow rate and the gradient of the solvents are detailedin XTable 1X below: 
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Table 1: Gradient and solvents for the FIA-MS/MS analysis of the Biocrates kit 
Step Time (minutes) Flow (µl/min) Biocrates solvent + Methanol 
% 
0 0 30 100 
1 1.6 30 100 
2 2.4 200 100 
3 2.8 200 100 
4 3 30 100 
 
Amino acids and biogenic amines are analysed using a HPLC-MS/MS method. Each sample is 
separated by reversed phase chromatography utilising a 9.5min separation and analysed using 
positive mode electrospray ionisation, monitoring 65 MRM transitions. A 10 µl injection is necessary 
for the analysis and the flow and the gradient of the solvents are detailed in XTable 2 below : 
Table 2: Gradient and solvents the HPLC MS/MS analysis of the Biocrates kit  
step Time (minutes) flow (µl/min) Water + 0.2 % 
formic acid  
A% 
Acetonitrile + 
0.1% formic acid  
B% 
0 0 500 100 0 
1 0.5 500 100 0 
2 5.5 500 5 95 
3 6.5 500 5 95 
4 7 500 100 0 
5 9.5 500 100 0 
 
4. LC-MS based quantification is performed on the Biocrates Analyst Software. After 
manual review of peak integration, the metabolites are automatically quantified using 
the provided quantification methods and known calibrator concentrations.  
5. The data generated from FIA MS/MS analysis are imported and automatically converted 
into concentrations in the Analyst software. The total ion current (TIC) trace is used to 
help identify the time range for integration of MRM results.  
6. Each plate analysis is validated in the Analyst Software by assessing the signal 
reproducibility and accuracy using quality controls (QCs) and blanks. The Biocrates QCs 
correspond to human plasma samples with analytes of known concentrations. Several 
QCs with different concentrations of analytes are used.  
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7. Metabolite concentration from samples and QCs are evaluated and each metabolite 
under a set limit of quantification is discarded. The final results can be exported into 
open source file formats for further analysis.  
This multiplex targeted MS/MS analysis allows the rapid identification of polar (amino acids, 
biogenic acids) and unpolar metabolites (acyl-carnitines, lipids and hexoses) but presents some 
drawbacks. In particular, the analysis gives the degree of unsaturation in the detected lipids but does 
not provide the exact positions of the unsaturations. In addition, the biocrates kit detects the overall 
hexose contents present in the plasma samples but cannot specifically quantify the different types of 
hexoses such as galactose or glucose. 
 
3. STATISTICAL ANALYSIS  
 NMR and MS analyses produce thousands of signals from metabolic profiles, so multivariate 
analyses methods are useful approach to analyse and interpret such data: The data analytical 
objectives are summarizing and visualizing the main sources of variation as well as performing 
multivariate classification and discriminant analysis. Therefore, unsupervised and supervised pattern 
recognition methods are routinely used for modelling two (or multiple) classes of data to drive class 
separation, simplify interpretation and find potential biomarkers 129,130. 
 
3.1. Unsupervised method: Principal Component Analysis 
(PCA). 
PCA is an unsupervised method because no hypothesis on the data is required for the 
construction of the model. This projection method is based on the representation of a multivariate 
data containing n rows (observation) and p columns (e.g. variables of NMR spectrum) in a lower 
dimension space. By calculating principal components (PC) in the p-dimensions, the model defines 
axes or directions describing the dominant pattern in the data matrix. The first PC is built from linear 
least square analysis to maximise variance harvesting in the data and the second PC orthogonal to 
the first one is added to improve the modelling of the data variance. This overview of the data 
uncovers all the information in the data matrix but may reveal groups of observation, trends and 
outliers117,129,130.  
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From a geometric point of view, K-dimensions space is constructed from the K principal 
components and the n observations are projected onto this space according to the value of its 
respective variables. The scores (T) represent the co-ordinate values of the observations in the K-
dimensions space and the loadings (P) represent the directions of the PC in the initial p-dimension 
space, they corresponds to the weight of the variable in the model. (Figure 14) The part of the matrix 
that is not explained by the PCA also called residuals (E) is characterised by the distance between 
each observation and its projection on the PC space. In summary, the matrix X containing the data is 
modelled by the following equation:  
X=TPT+E 
 
 
Figure 14: Construction of the first principal component (PC1) explaining the main variation within the dataset. 
(var: variable). The score (T) of one observation (i), its corresponding residual (E) and the loading of the 
variable 1 for this observation (Pvar1) is also geometrically represented. 
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Information contained in the PCA can be graphically interpreted by the scores plot and the 
loadings plot (XFigure 15X). On the one hand, the scores plot highlights the relation among the 
observations in the new co-ordinate system built by the PCs and points out patterns in the data. On 
the other hand, the loadings plot provides the degree of influence of the variables in the model and 
permits to identify which variables are responsible for this specific pattern117,130. 
 
 
Figure 15: Geometric approach of principal component analysis H117H : Variations within a X matrix 
containing 8 samples and 3 variables are approximate in a lower dimension model plane. Scores plot 
and loadings plot obtained from the model respectively provide information on sample classification 
and on variable influence in the model.  
 
3.2. Supervised methods. 
Most projects in metabonomics are focused on group classification such as treated and 
control groups, or stratification of pathological status therefore it is common to use supervised 
methods where a priori information about class of samples is employed to perform the analysisH130H.  
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Partial least squares (PLS) regression is a method that relates two matrices (X and Y) to each 
other by linear regression. Indeed, PLS components are built in the X space in order to explain as 
much as possible the multidimensional covariance between X and Y. Matrix X generally represents 
spectral or chromatographic data whereas matrix Y contains quantitative values such as time or 
concentration of endogenous metabolites. PLS model can be also used in a discriminant analysis 
(PLS-DA) in which Y matrix comprises dummy variables defining classes or gender. The Y dimension 
can also be a 1D vector. This method is particularly suitable in metabonomics because it provides a 
good predictability even when the number of variables exceeds the number of observations117,130. 
 
 
Figure 16: Principle of PLS regression. The multidimensional X matrix (top left) represents the predictor and the 
multidimensional Y matrix (top right) represents the responses to predict. In each multi-variate space, the 
orientation of the first component must approximate as well as possible the shape of the point cloud and the 
scores T1 and U1 should be maximally correlated. The second component is build perpendicularly to the first 
component using the same principle. 
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However, X matrices such as NMR data or MS data usually contain a certain level of variation 
uncorrelated to the Y matrix which come from other biological variation source or analytical noise 
and can decrease the interpretability of PLS model. Hence, orthogonal partial least square 
discriminant analysis (OPLS-DA) is a recent extension of PLS-DA in which an integrated Orthogonal 
Signal Correlation (OSC) filter is added in the construction of the model130-132. The filter leads to 
partitioning the X variance into a predictive and orthogonal component to the Y matrix. This 
enhances the variation of interest while it minimizes other variation uncorrelated to Y. Hence, X data 
splitting facilitates model interpretation and the analysis of scores plot and loadings plot of the 
orthogonal component can bring about additional information on subgroup structure within the 
data117,131.  
In OPLS regression and OPLS-DA models, R2X and R
2
Y indicate the proportion of explained 
variance from the X matrix and Y matrix and need to be taken into account to estimate the 
robustness of the model. However, in any multivariate modeling, it is easy to obtain an apparently 
good model fitting the training dataset very well but which has not the ability to predict external 
data. This phenomenon is called overfitting. To overcome this, a cross validation (CV) step is 
systematically implemented into the data modelling to assess the real predictability of the model. CV 
is generally performed by keeping out the seventh of the observation and predicts them back into 
the model to test the performance of the model. This step is repeated until every data has been 
once kept out and it results in the determination of the cross validation parameter (Q2Y) indicating 
the proportion (in percentage) of the predicted variance from the Y vector in the model. Generally 
when Q2>0.5, the model is considered as strong enough to be used for data interpretation, however 
this subjective criteria is limited and is often re-evaluated as it depends on the condition of the 
experiment (number of samples, size of dataset) 129,130. A permutation test which estimates the 
significance of the estimated predicted power (Q2Y) can be also used for the model validation. The 
method consists in generating a number of parallel models based on the fit of randomly re-ordered Y 
data. (at least 1000 iterations) Then the real Q2Y is considered as significant if it values is out of the 
distribution of Q2Y values generated with random models129,130. 
As described by Cloarec et al, the OPLS regression coefficient can be displayed using a back-
scaling method and is really useful to interpret NMR data131,133. The coefficients from a model fitted 
with unit-variance scaling are multiplied back by the standard deviation of the corresponding 
variable in order to display them in their initial and more natural scaling. For NMR it produces a 
pseudo spectrum which relates to the covariance between X and Y. The squared regression 
coefficients (R2), proportional to the correlation coefficients between X and Y for a model fitted with 
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unit-variance scaling are then mapped onto the pseudo spectrum by using a colour code starting 
from red to blueH131. The hot colours are allocated to high correlated variables whereas the cold 
colours represent variables with non significant correlation. Hence the pseudo spectrum helps the 
interpretation of the loadings by facilitating the determination of important group of variables which 
represent peaks and individuals variables corresponding to the noise in the spectrum.  
Loadings plot interpretation from MS data is based on the same principle as for NMR data 
but the visualisation tool used for MS analysis is different due to the 2 dimensional structures of the 
data (one feature is defined by its m/z value and its rentention time). In this context, the S plot is 
preferably employed to identify significant features in the OPLS models. This scatter plot is based on 
the same principle as for OPLS regression coefficient plot as it consists in modelling modelled 
correlation (p corr) of each feature versus the modelled covariance between the same feature and 
the predictive score tp. The features that combine high correlation and high covariance are 
considered of potential interest130.  
 
3.3. Biomarker identifications: 
NMR and MS techniques associated with multivariate statistics are applied in metabolomics 
to extract from complex biofluids containing thousands of metabolites, including specific biomarkers 
responsible for group discrimination. These biomarkers can provide indications on time dependant 
biological processes underlying physiological perturbations such as disease development, drugs 
effects or dietary intervention outcome. 
Molecule identification from NMR data is commonly achieved by determining the peak 
shape, coupling values (J) from 1D NMR spectra and cross correlation peaks from 2D NMR spectra. 
The attribution is performed by comparing this information with available literature and existing 
databases such as the Human Metabolome Data Base (HMDB): Hhttp://hmdb.ca/H, or the Biological 
Magnetic Resonance Data Bank (BMRB): Hhttp://www.bmrb.wisc.eduH. However, for several regions, 
the 1D NMR peaks overlap and are not sufficiently distinct to permit a clear assignment. STOCSY 
(Statistical Total Correlation SpectroscopY) is recent technique proposed by Cloarec et al, which 
exploits the correlation between data point amplitudes in the NMR spectra. By calculating the 
correlation matrix of a data point corresponding to the maximum value in a peak, it is often possible 
to extract other data points in the spectrum highly correlated to this selected variable. Therefore 
STOCSY is able to reveal highly correlated variables corresponding to the whole NMR peaks of a 
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single metabolite, but it also highlights in a lesser extent, correlated and anti-correlated variables 
from different molecules involved in the same pathways133. 
Alternative approaches based on biofluid separation methods using solid phase extraction 
(SPE) chromatography or high pressure liquid chromatography (HPLC) has been found useful to 
improve the identification of complex biological sample composition. For instance, a biological 
matrix in solution can be loaded in C18 SPE cartridge and diluted with a methanol/water gradient 
and/or pH gradient. This method allows a reduction of sample complexicity by separating the 
molecules according to their hydrophobicity. The first aliquots contain highly hydrophilic molecules 
while the last aliquots contain less hydrophilic molecules. Each aliquot can be in turn analysed in 1D 
and 2D NMR to perform metabolite identification134. 
 
4. 16S RIBOSOMAL RNA GENE SEQUENCING  
Microbiome-host interaction has been found to play a crucial role in mammalian health and 
disease development32,88. Therefore studying the microbial communities present in various mucosal 
surfaces and mammalian skin has contributed to increase knowledge about the development of 
infectious and immune mediated diseases and diseases susceptibilities135,136. Metagenomics, which is 
defined as the culture-independent study of a set of genome from microbial population or the 
exploration of the entire microbial genome, has largely expanded due to the growing interest on the 
role of the microbiome on human biology137. Improved DNA-sequencing technologies have also 
enabled enhanced capabilities for sequencing large scale data sets. However the complexity of 
microbial populations makes metagenomic studies challenging. The genetic content of the 
metagenome can be up to approximately 100 times greater than the human genome and a large 
part of bacterial taxa are still unknown. In addition, around 80 % of the human gut bacteria 
sequenced by metagenomic studies are not cultivable in vitroH137.  
In this thesis, fecal microbiota from C57BL/6 mice fed with different diets have been 
investigated using pyrosequencing of bacterial 16S ribosomal RNA gene (16S rRNA). This new deep 
sequencing method has been proved to be a convenient platform for analysing the human microbial 
composition by carefully targeting short length of DNA. Pyrosequencing employs the polymerisation 
chain reaction technology (PCR) which consists in the amplification of a piece of DNA sequence in 
several orders of magnitudes. In a PCR experiment several thermal cycles occur where a short DNA 
fragment or primer containing the complementary sequenced to the targeted DNA piece is fixed to 
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the genetic material and DNA polymerase and dNTP are used to replicate the targeted sequence. In 
particular, 16S rRNA gene contains highly conservative regions (C1-C9) interspaced by highly 
informative hypervariable regions (V1-V9) which allow PCR primer to be designed in such way that 
they are complementary to universally conserved regions flanking the variable region. Then the 
amplification, sequencing and comparison with database allow the identification of bacterial 
lineages and their proportion in community. It is important to note that sequencing different 
hypervariables regions introduces various degrees of variability and efficacies in identification of 
bacterial species. For instance V2 and V3 regions have been the most effective for bacterial 
identification at genus level. In addition, the identification of bacterial classes, families or genus may 
differ according to the taxonomic classifications employed137. 
 
 
 
Figure 17: Scheme of 16S rRNA gene sequence containing hypervariable regions (V) and highly conserved 
regions (C) adapted from Petrosino et al 
137
.  
 
The pyrosequencing procedure is detailed as follows: A specific primer is hybridised to a 
DNA template which is immobilized into streptavidin coated beads and incubated with DNA 
polymerase, deoxynucleotide triphosphates (DNTPs), ATP sulfurilase, adenosine-5-phosphosulfate 
(APS), luciferase and apyrase, and luciferin. The sequencing procedure is performed by a stepwise 
elongation of primer strand upon the sequential incorporation of the different DNTPs. The PPi 
released due to the nucleotide incorporation is converted into ATP by the presence of ATP 
sulfurilase and APS. ATP is then consumed by luciferin to produce oxyluciferin. This process catalysed 
by the luciferase generates visible light which is measured by a camera and processed by a specific 
program137,138. The luminescence is directly proportional to the number of bases that have been 
incorporated. After the addition of each base, a washing step is carried out in which incorporated 
nucleotides and ATP are eliminated by the apyrase. These steps are repeated in cycles and the DNA 
sequence is deduced based on the light sequence that has been detected137.  
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Results.
 
 
Figure 18: Principles of pyrosequencing and chemical reactions involved in the determination of DNA 
sequences adapted from Petrosino et al H
137
H. 3 main steps are involved in one sequencing cycle and several 
cycles are performed to identify the nucleotide sequence.  
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CHAPTER III: EARLY METABOLIC ADAPTATION IN C57BL/6 MICE 
RESISTANT TO HIGH FAT DIET INDUCED WEIGHT GAIN INVOLVES AN 
ACTIVATION OF MITOCHONDRIAL OXIDATIVE PATHWAYS.  
 
1. INTRODUCTION 
Obesity results from a complex interaction between genetic and environmental factors, such 
as a high calorie diet, and lack of physical activity18 and recent research has also suggested that the 
gut microbiota may play a role in the development of obesity94,139,140. Ectopic fat deposition, 
particularly in a central distribution, is thought to contribute to a range of metabolic disorders such 
as hypertriglyceridaemia, hypertension, high fasting glucose and insulin resistance (IR)3,17,20. Yet, 
although obesity is significantly associated with severe pathologies, many obese individuals do not 
exhibit metabolic dysfunction and therefore seem protected from the development of type 2 
diabetes (T2DM), non-alcoholic fatty liver diseases (NAFLD) or cardiovascular diseases (CVDs) risk. 
This category of individuals defined as “clinically healthy obese” are the subject of intensive research 
to underpin the molecular mechanisms linking obesity and the degradation of the healthy 
phenotypes.  
Given the multiplicity of factors that determine the likelihood of developing severe 
pathologies in obese individuals, there is a crucial need to identify early metabolic markers of 
susceptibility to obesity related metabolic disorders to prevent the development of metabolic 
diseases. McKay et al. used genetically identical strains of mice as they are useful models to 
investigate the impact of environmental and epigenetic factors on metabolic disease development 
regardless of genetic backgroundH141H. Burcelin et al demonstrated that isogenic C57BL/6 mice can be 
partitioned in 3 sub-phenotypes based on body weight and blood glucose distributions after being 
fed a high fat diet for 2 months: obese diabetic, lean diabetic and lean non-diabeticH142H. 
Transcriptomic analysis of each sub-phenotype indicated that specific activation of lipogenic genes 
contributed to the obese phenotype143. These transcriptional differences associated with weight gain 
variability in a genetically identical mouse population suggest the existence of an altered metabolic 
phenotype. However, the metabolic heterogeneity of HF-fed mice in these sub-populations of 
C57BL/6 mice has not been determined. 
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The C57BL/6 mouse is particularly predisposed to diet induced obesity due to its genetic 
background144. Indeed C57BL/6 mice fed with a HF diet develop obesity, mild to moderate glycemia 
and hyper-insulinemia145. In that regard, this strain of mice is a suitable model to investigate obesity 
development during HF challenge.  
In this study, the longitudinal metabolic response to high-fat (HF) diet-induced obesity (DIO) 
in the C57BL/6 mouse strain, which is predisposed to IR and obesity has been investigated. The 
short-term (7 day) and long-term (60 day) metabolic response of mice fed a low fat (LF) diet (n=24) 
or high fat (HF) diet (n=56) was recorded using 1H NMR spectroscopy of urine samples collected at 
these time points. Based on the observation of a significant correlation between body weight after 
one week and final body weight,  the early metabolic signatures associated with the high phenotypic 
variability in the response to high fat diet was explored. Using the variability in weight gain of mice 
at 7 days and 60 days post HF diet intervention, strong responders (SR) (n=14) and non-responders 
(NR) (n=10) to diet induced obesity (DIO) were selected and  the specific metabolic differences 
underlying these sub-phenotypes were interrogated.  
 
2. MATERIALS AND METHODS 
 
2.1. Animal handling procedure and sample preparation 
The experiment was carried out under appropriate national guidelines at the Nestlé 
Research Center (NRC, Switzerland). Animals were permanently maintained in individual cages under 
12h-12h of light-dark regime and fed ad libitum during the overall experiment. A total of 80 C57BL/6 
female mice aged of 6 weeks, firstly received a standard chow diet (Baseline 3437, see Appendix 1 
for diet composition Table S1) for 7 days and during this period, baseline samples of urine were 
collected (d0). Mice were then split in 2 groups: 24 mice were fed a LF diet (Low Fat 12450B, 
Research Diet, New Jersey USA, see Appendix 1 Table S1 for detailed composition) in which the rate 
of proteins, vitamins, minerals and carbohydrates differed from the acclimatization standard diet. 56 
other mice were fed with HF diet (High Fat 12492, Research Diet, New Jersey USA, see Appendix 1, 
Table S1 for detailed composition) in which the dietary composition apart from the level of 
carbohydrate and fat, were comparable to LF diet. Urine samples were then collected 7 days (d7) 
and 60 days (d60) after the diet switch. All the samples were snap-frozen at -80 ⁰C until analysis. 
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Urine collection was performed in the morning by gently pressing the abdomen146. All mice were 
also weighted at d0, d7and d60 in order to monitor the weight gain in both HF- and LF-fed mice. 
Differences in body weight and body weight gain between HF and LF mice were assessed by non-
parametric Wilcoxon-Mann-Whitney tests. Individual food intake (FI) and cumulative energy intake 
of each mouse was also recorded at d7 and d60. There was a significant decrease of FI in HF-fed 
mice compared to LF-fed mice overtime (see Appendix 1 Table S2 and Table S3 for detailed FI 
values). The statistical difference of FI between groups was calculated by Wilcoxon-Mann-Whitney 
tests (see Appendix 1 Table S2 and Table S3 for p values).  
 
2.2. Measurement of body weight gain and identification of 
NR and SR mice 
Body weight gain (BWG) for each mouse was calculated by subtracting mouse weight at a 
given timepoint (7 days or 60 days) from mouse weight before diet intervention (d0). Identification 
of NR and SR mice was based on BWG distribution of HF-fed mice at 7 days and 60 days. Mice 
consistently found within the first tercile of the BWG distribution at both 7 days and 60 days after 
diet switch were designated as NR mice (n=10). Mice consistently in the third tercile of the BWG 
distribution were designated as SR mice with the exception of 4 mice being in the third tercile of 
BWG distribution at d7 and in the second half of the BWG distribution at d60 (n=14). These mice 
were added to increase sample size in multivariate models both at 7 days and at 60 days. This point 
was crucial to follow the time dependant metabolic changes of the same animals. Significant 
difference in body weight and BWG was noticed (using Wilcoxon-Mann-Whitney test) between NR 
and SR mice at d7 and d60 (XFigure 19X). SR mice also had higher FI and cumulative energy intake than 
NR mice at both time points (see Appendix 1 Tables S2 and S3 for detailed FI values). 
 
2.3. 1H NMR spectroscopy 
A volume of 40 μL of urine was diluted in 20 μL of phosphate buffer solution (NaHPO4, 0.6M 
pH=7.0, 100% D2O) containing sodium azide (3 mM) and trimethylsilyl propionic acid (TSP) (0.5 mM). 
After centrifugation, samples were transferred into 1.7 mm diameter NMR tubes by using a syringe. 
1H NMR spectra were then recorded on a 600MHz Avance III Bruker NMR spectrometer (Bruker 
Biospin, Rheinstetten, Germany) operating at 600.13 MHz, by performing 64 scans of a sequence 
(noesypr1d) with a mixing time of 100 ms and 98K data-points. The temperature of NMR experiment 
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was maintained at 300 K. Processing of urine spectra was carried out by using the software TOPSPIN 
2.0 (Bruker Biospin, Rheinstetten, Germany). For each spectrum, the free induction decays were 
multiplied by an exponential function corresponding to a line broadening of 1 Hz, prior to undergo 
Fourier transformation. Spectral phase and baseline were manually corrected and the chemical 
shifts were calibrated on TSP signal at δ0.0. Metabolite assignments were achieved by matching the 
recorded signals with NMR spectral databases, published assignments and also using the technique 
of Statistical TOtal Correlation SpectroscopY (STOCSYH133H) to facilitate the extraction of putatively 
coupled signals from the complex spectra of urine samples102,113,122. In addition 2D NMR 
spectroscopy was performed on selected samples using 600.13 MHz DRX Bruker NMR spectrometer 
using homonuclear (1H-1H COSYH147H and 1H-1H TOCSYH148H) and heteronuclear (1H-13C HSQC) coupling 
experiments for identification.  
 
2.4. Data processing and multivariate data analysis 
The spectral data (from 0.2 to 9.5 ppm) were finally imported into Matlab software (2011 
version, the Mathworks Inc, Natwick MA) and were digitalized onto 22K data-points. Water peak 
resonance (4.7-5.05 ppm) was removed from each spectrum in order to eliminate the variability 
linked to the water resonance presaturation. 1H NMR spectra were first normalized on total area to 
account for global dilution effects and scaled to unite variance to emphasize the contribution of 
minoritary compounds. Pre-processed spectra were analyzed with multivariate data analysis 
methodologies such as Principal Component Analysis (PCA), Orthogonal Projection on Latent 
Structures (OPLS) and Disciminant Analysis based on Orthogonal Projection on Latent Structures 
(OPLS-DA). To identify relevant features in the metabolic profiles, OPLS regression coefficients were 
back-scaled using a back-scaling method which allows the estimation of the proportion of variance 
for each NMR variable. Correlation heatmaps were generated by compiling the Pearson correlation 
coefficient values for discriminating metabolites between HF and LF-fed mice or SR and NR mice at 
each timepoint. To facilitate their reading, there was set arbitrarily a cut off at 0.3 to keep the most 
relevant features.  
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2.5. Pathways-specific analysis using univariate statistical 
approach  
Intermediates metabolites from β-oxidation, BCAA catabolism, TCA cycle and NAD pathways 
assigned in urine 1H NMR spectra were relatively quantified (see Appendix 1 Table S5 for chemical 
shifts and mean of integral values) in order to assess the urinary excretion of these metabolites 7 
days and 60 days after diet switch in LF and HF-fed mice or NR and SR mice. For each metabolite, the 
integral at 7 days and 60 days was divided by the integral at t0 (during the pre-intervention period) 
in order to normalize the urinary excretion of these metabolites to the baseline. The ratio obtained 
for each metabolite was compared between LF, HF, NR and SR groups at each time point using 
Wilcoxon-Mann-Whitney tests (see Appendix 1 Table S6 for detailed p values). 
 
3. RESULTS 
 
3.1. Body weight gain variability in C57BL/6 mice fed a HF 
diet 
In order to study the contribution of diets to the development of obesity, 80 C57BL/6 mice 
were fed with a chow diet during a pre-intervention period of 1 week, followed by a diet switch 
where mice were fed with a LF diet (n=24) or a HF diet (n=56) for 60 days. Body weights were 
measured during the pre-intervention period and 7 and 60 days after the diet switch ( XFigure 19X.A). 
Body weight monitoring showed a significant increase of weight in HF-fed mice compared to LF-fed 
mice through the course of the study. In particular, the average weight of HF-fed mice was 1.5 g 
higher (p = 3.9 x 10-7) at 7 days and 4.5 g higher (p = 2.36 x 10-8) at 60 days compared to control 
mice. The body weight distribution also revealed a strong heterogeneity within the HF group at 7 
days (coefficient of variation CV = 0.05), which was even more noticeable at 60 days (CV = 0.120) 
(XFigure 19X.B). In addition, a significant correlation between mouse body weight gain (BWG) at 7 days 
and mouse body weight at 60 days (XFigure 20X) was observed. This result highlights the existence of a 
strong and sustainable phenotypic variability within the HF group. It also suggests the existence of 
early and specific metabolic signatures associated to these obese-sub phenotypes. 
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Figure 19: Variability of body weight gain in a population of n=56 mice fed a HF diet. (A) Experimental design. 
(B) Body weight distribution of mice after 7 days and 60 days of HF diet feeding. (C) Body weight and (D) body 
weight gain monitoring of control (LF, n=24), NR (n=10), and SR (n=14) mice before the diet (t0), after 7 days 
(t1) and 60 days (t2), after diet switch. (n=average ± standard error, significant differences in body weight and 
body weight gain between LF-fed mice and NR mice or LF-fed mice and SR mice were evaluated using non 
parametric Wilcoxon-Mann-Whitney test, p value: *<0.05, **<0.001, ***<0.0001.)  
98 
 
Correlation between 1st week of weight 
gain & final weight (10 weeks)
-2.0
0.0
2.0
4.0
6.0
8.0
10.0
0.0 10.0 20.0 30.0 40.0 50.0 60.0
final BW
1
s
t 
w
e
e
k
 g
a
in
 
Figure 20: Correlation between mouse BWG after 1 week of HF diet and mouse BW 60 days after diet switch 
 
In order to characterise the “Strong-Responders” (SR) and “Non-Responders” (NR) to HF feeding, the 
mouse population was stratified according to BWG after 7 days and 60 days of HF feeding. Mice 
being consistently found within the first and the third terciles of the BWG distribution were 
designated as NR and SR mice respectively. In addition, 4 mice being in the third tercile of BWG 
distribution at 7 days and at the second half of BWG distribution at 60 days were included in SR mice 
group. These thresholds were selected in order to obtain enough samples in each group (NR mice 
n=10 SR mice=14) and to perform powerful statistical tests. The average body weight trajectory 
overtime for NR, SR and LF-fed mice (XFigure 19X) revealed that SR mice gained significantly more 
weight than NR mice and LF-fed mice during the experiment. Interestingly, there was no significant 
difference in body weight between the NR group and the LF diet group at 7 days (p = 0.10), but 
significant difference in body weight was identified at 60 days (p = 7.67 x 10-5). In addition, the NR 
mice body weight gain trajectory (XFigure 19X.D) (β-coefficient of the slope=3.85) was similar to LF-fed 
mice (β-coefficient of the slope=3.57) whereas SR mice tended to gain weight faster (β-coefficient of 
the slope =8.05). This early and sustained inflexion of body weight gain trajectory, defining strong 
responder and non-responder subgroups suggests the existence of a differential predisposition to 
DIO in C57BL/6 mice. Hence, the ability to discriminate NR and SR mice based on early (7 days) and 
late (60 days) metabolic profiles was tested.  
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3.2. 1H NMR urine metabolic profiling of LF- and HF-fed mice 
identifies a sustained metabolic signature associated to DIO 
To investigate the specific metabolic signature associated with diet-induced obesity 
development, urinary metabolic profiles were acquired at 1 week before, at 7 days and at 60 days 
after the dietary intervention using 1H NMR spectroscopy (XFigure 21X.A, XFigure 21X.B). Urine metabolic 
profiles from LF and HF-fed mice were then compared at each time point by using OPLS-DA models. 
Each model was calculated by using one predictive component and one or several orthogonal 
components. The optimal number of orthogonal components was determined by R2Y (goodness of 
fit) and Q2Y (goodness-of-prediction) statistics (see Appendix 1, Table S4). The OPLS-DA score plots 
for models at 7 days (XFigure 21X.C) and 60 days (XFigure 21X.D) showed strong metabolic variations 
associated with HF feeding highlighted along the X axis (predictive component, Tpred). At the same 
time, the Y axis, (first orthogonal component, Torth) reflected within-group variations related to diet-
independent effects.  
For pair-wise OPLS-DA models, the metabolites with the highest correlation coefficients 
between LF and HF-fed mice were identified and summarised in a heatmap (XFigure 21X.E). The OPLS-
DAs loadings plots of each model are also presented in the XFigure 23X.A and XFigure 23X.B, and the 
metabolite assignments are summarised in Table 3. Specifically, urinary excretion of carnitine, 
hexanoylglycine, and intermediates of branched chain amino acid (BCAA) catabolism 
(isovalerylglycine, α-keto-β-methylvalerate and α-ketoisovalerate were significantly increased in the 
HF group at 7 days and 60 days. Conversely, the levels of trimethylamine (TMA) and trimethylamine-
N-oxide (TMAO) respectively produced from microbial bioconversion of choline and mammalian 
phase I detoxification reaction of the former, as well as phenylacetylglycine which is a phase II 
detoxification conjugate of gut bacterial phenylalanine degradation end-products were decreased in 
the HF group during the whole experiment. In particular, the degree of variation in the urinary 
TMAO level between 7 days and 60 days suggests a time-dependent shift in the conversion of TMA 
to TMAO under HF feeding. Hence, HF diet may involve significant changes in gut microbial activity. 
Time-dependent metabolic adaptation to HF feeding was also characterised by a significant 
reduction of indoxylsulfate in urine of HF-fed mice for 7 days. N-1-methyl-2-pyridone-5-carboxamide 
(2PY) and N-1-methyl-4-pyridone-3-carboxamide (4PY), which are end products of nicotinamide 
adenine dinucleotide (NAD) pathways, were also positively correlated with mice fed a HF diet for 60 
days. Isovalerylglycine, α-keto-β-methylvalerate and α-ketoisovalerate excretion was significantly 
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and consistently increased in the HF-fed group compared to the LF-fed group overtime, so they 
constitute qualitative and stable candidate biomarkers of DIO. 
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Figure 21: 
1
H NMR urine metabolic profiles of C57BL/6 HF-fed or LF-fed mice 7 days and 60 days after the diet 
switch. (A) Mean 
1
H NMR spectrum of urine from LF-fed mice or (B) HF-fed mice. (C) OPLS-DA score plot of 
urine metabolic profiles of LF and HF-fed mice at 7 days (D) OPLS-DA score plot of urine metabolic profile of LF 
and HF-fed mice at 60 days. (E) Heatmap obtained from the OPLS-DA coefficient plots showed metabolites 
found to be significantly different in HF and LF-fed mice. Correlation values of the metabolites are displayed by 
color code (Gradient of red color for metabolites positively correlated with HF-fed mice and gradient of blue 
colors for metabolites negatively correlated). 
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3.3. 1H NMR urine metabolic profiling of NR and SR mice 
highlights a specific metabolic adaptation associated to 
obesity prone and obesity resistant phenotype. 
The acquisition of distinct metabolic signatures between SR and NR mice enabled to identify 
metabolites associated with the highest divergence in BWG. Comparisons of 1H NMR spectral data 
between NR and SR were performed using pair-wise OPLS-DA models at 7 days and 60 days (XFigure 
22X.A, XFigure 22X.B). Results addressing the suitability of both models are displayed in supplementary 
information (See Appendix 1, Table S4). OPLS-DA score plots at 7 days (Figure 22.C), and 60 days 
(Figure 22.D) displayed a good discrimination (as confirmed by Q2Y and R2Y values in see Appendices 
Table S4) between NR and SR mice along the predictive component (Tpred). The Y axis illustrates 
orthogonal variation to strong obesity-associated-response. Interestingly, no differences in urinary 
metabolic profiles of NR and SR mice were identified before the diet switch, which highlights that 
C57BL/6 mice all have similar phenotypes and metabotypes when they were fed a chow diet. 
103 
 
 
Figure 22: Specific metabolic signature of NR and SR mice. (A) Mean of 
1
H NMR spectra of urine from NR mice 
or (B) SR mice. (C) OPLS-DA scores plot of urine metabolic profile of NR and SR mice at 7 days (D) and 60 days. 
(E) Heatmap obtained from the OPLS-DA coefficient plots showed metabolites found to be significantly 
different in NR and SR mice. Correlation values of the metabolites are displayed by color code. (Gradient of red 
color for metabolites positively correlated with SR mice and gradient of blue colors for metabolites negatively 
correlated). * Tentative assignment  
 
A heatmap (XFigure 22X.E) summarised discriminant metabolites between NR and SR mice 
during short-term (7 days) and long-term (60 days) HF feeding. The OPLS-DA loadings plots of each 
model are shown in.XFigure 23XC and XFigure 23X.D and metabolite assignments are summarised in 
XTable 3X. In particular, a specific metabolic signature involving leucine catabolism, β-oxidation and 
production of short chain fatty acids, was associated with BWG variability. Indeed, hexanoylglycine, 
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isovalerylglycine, leucine, acetate and isobutyrate were negatively correlated with SR mice during 
the overall experiment. As these metabolites are consistently down-regulated in SR mice, they 
constitute stable candidate markers of obesity-resistant phenotype. An unknown metabolite 
tentatively assigned as vinylacetylglycine (see Appendix 1, Figure S4 for structural assignment) also 
increased in NR mice compared to SR mice. Vinylacetylglycine is likely to be the glycine conjugate of 
vinylacetyl-CoA, however existence of vinylacetylglycine and vinylacetyl-CoA in rodents and human 
have been poorly reviewed in the last decades and their origin in urine remains uncertain149,150. 
Metabolic signatures between SR and NR mice at 7 days and 60 days also showed a time dependant 
metabolic signature associated with BWG variability. A lower urinary excretion of acetate was 
observed in SR mice after 7 days of HF diet. By contrast, a higher urinary excretion of sucrose was 
noticed in SR mice at the same period. Surprisingly, taurine was positively correlated with SR mice 7 
days after of HF feeding and negatively correlated with SR mice after 60 days. The urine metabolic 
profile of SR mice after 60 days of HF diet was also marked by an increase in creatine, 
guanidinooacetate, tartrate, hippurate, and hydroxyphenylacetylglycine. Interestingly, 
hexanoylglycine and isovalerylglycine, which were initially characterised as qualitative candidate 
markers positively associated with DIO in this model, were also identified as stable candidate 
markers of obesity-resistant phenotype. These results point out that leucine catabolism and β-
oxidation taking place in the mitochondria are key metabolic pathways in onset of DIO and their 
specific regulation might contribute in obese phenotype variability. 
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Figure 23: Loadings plot of OPLS-DA models showing the comparison of the urine metabolic profile between 
HF and LF-fed mice  7 days (A), at 60 days (B) or OPLS-DA models showing comparison between urine 
metabolic profile of NR and SR mice at 7 days (C) and 60 days (D).  
R
2
: square of Pearson correlation coefficient 
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Table 3: List of metabolites assigned in the loadings plot of OPLS-DA models (shown in Figure S3). **Chemical 
shifts of carbons and protons were assigned only from resolved peaks present in 
1
H NMR standard spectrum 
and 
1
H-
13
C HSQC spectrum 
 
metabolite 
key  
metabolites **Chemical shift (1H ppm)  **Chemical shift (13C ppm) 
M1 Hexanoylglycine (CH3) 0.88 (t), (CH2) 1.32 
(m), (CH2) 1.66(m), (CH2) 
3.76 (d)   
(CH3) 13.8, -, (CH2) 22.2, 
(CH2) 46.5 
M2 Isovalerylglycine (CH3) 0.92 (d), (CH2) 2.04 
(m), (CH2) 2.17 (d),  
(2CH3) 24.5, (CH2) 27.2, 
(CH2) 46.32 
M3 α-Keto-β-methylvalerate   (CH3) 1.10 (d)  (CH3) 16.60 
M4 α-Ketoisovalerate (2CH3) 1.11 (d) (2CH3) 19.20 
M5 Leucine (2CH3) 0.96 (t) (2CH3) 25.06 
M6 Vinylacetylglycine  (CH2) 1.88 (d), (CH2) 6.05 
(d), (CH) 6.82 (m) 
 (CH2) 24.1,-,-,- 
M7 Putrescine (tentative 
assignment) 
(2CH2) 1.75 (m) (2CH2) 27.74 
M8 Isobutyrate (2CH3) 1.157 (d) (2CH3) 19.1 
M9 Acetate  ( CH3)1.92 (s) (CH3) 30.4 
M10 N-acetylglycoproteins (CH3) 2.07  - 
M11 Creatine (CH3) 3.03 (s), (CH2) 3.93 
(s)  
(CH3) 39.80, (CH2) 56.68 
(3CH3) 47.5 
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M12 Carnitine  (CH3) 3.21 (s)   (CH3) 56.83 
M13 Trimethylamine   (3CH3) 2.88 (s)   (3CH3) 47.5  
M14 Trimethylamine-N-oxide (3CH3) 3.27 (s) (3CH3) 62.3 
M15 Taurine (CH2) 3.27 (t), (CH2) 3.44 (t) (CH3) 50.2, (CH2) 38.40 
M16 Phenylacetylglycine (CH) 3.66 (s), (CH) 7.35 
(m), (CH) 7.36 (m), (CH) 
7.40 (m) 
(CH) 45.1, (CH) 132.15, (CH) 
130.36, (CH) 132.15  
M17 Sucrose  (CH) 3.83 (m),(CH) 4.23 
(d), (CH) 5.42 (d) 
 (CH) 65.57, (CH) 79.4, (CH) 
95.2  
M18 Hippurate  (CH2) 3.96 (d), (2CH) 7.54 
(m), (2CH) 7.81 (m) 
(CH2) 46.7,-, (2CH) 130.0 
M19 Guanidoacetic acid (CH2) 3.80 (s) (CH2) 46.26  (s) 
M20 Tartrate (2CH) 4.34 (s) (2CH) 76.81 
M21 Unassigned metabolite 4.53 (m) - 
M22 Hydroxyphenylacetylglycine (2CH) 6.88 (d), (2CH) 7.17 
(d) 
(2CH) 118.54, (2CH) 133.52  
M23 N-methyl-2-pyridone-5-
carboxamide: 2 PY 
(CH) 6.66 (d), (CH) 7.83 
(dd), (CH) 8.32 (d), (CH3) 
3.64 (d)  
(CH) 120.7, (CH)130.0, (CH) 
144.52(CH3) 45.08 
M24 N-methyl-4-pyridone-3-
carboxamide : 4 PY 
(CH) 6.69 (d), (CH)7.97 
(dd), (CH)8.54 (d), (CH3) 
3.90 (s)   
(CH) 123.0, (CH) 142.74, 
(CH)149.29, (CH3) 56.59 
M25 Indoxylsulfate  (CH) 7.27 (m), (CH) 7.36 
(s), (CH) 7.50 (d), (CH) 7.70 
(d) 
 (CH) 124.5,-, (CH) 115.8, 
(CH) 120.43  
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3.4. Univariate analysis of intermediate metabolites from 
candidate pathways pointed out specific deregulations of 
mitochondrial metabolism in HF-fed mice that may be 
exacerbated in SR mice 
The variation in mitochondrial metabolism in HF-fed mice was further investigated by a 
complementary univariate data analysis using Wilcoxon-Mann-Whitney tests (XFigure 24X). Urinary 
excretion of β-oxidation intermediates: hexanoylglycine, carnitine and acylcarnitine was consistently 
increased in urine of HF-fed mice compared to LF-fed mice which suggests an increase in fatty acid 
overflow in the mictochondria and an activation of β-oxidation151. The end product of NAD pathways 
(2PY, 4PY) also constantly increased in mouse urine after HF feeding which indicates an increase in 
NAD/NADH recycling. This red-ox complex enabling electron transport is required in TCA cycle and 
oxidative phosphorylation in the mitochondria to produce energy152. The relative quantifications 
confirmed that leucine, valine, isoleucine as well as intermediates of BCAA catabolism 
(isovalerylglycine, α-keto-β-methylvalerate and α-ketoisovalerate) were significantly and 
consistently increased in HF-fed mice (see Appendix 1 Table S6 for detailed p values) supporting the 
fact that HF diet induced an up-regulation of BCAA catabolism (XFigure 24X). TCA cycle was also partly 
regulated in HF-fed mice as noted with a short-term urinary increase of succinate in mouse 7 days 
after HF diet compared to LF-fed mice152. These results support the hypothesis that valine and 
isoleucine catabolism is up-regulated inducing the formation of succinyl-CoA and the production of 
the following TCA cycle intermediates153,154. Interestingly the other TCA cycle intermediates (citrate, 
cis-aconitase, α-ketoglutarate) were not significantly different (p value > 0.05, see Appendix 1 Table 
S6 for detailed p values) between LF and HF-fed mice suggesting a disconnection between BCAA 
catabolism and β-oxidation producing acetyl-CoA, and TCA cycle. A part of TCA cycle flux could be 
diverted toward other metabolic pathways (Figure 25). In particular oxaloacetate may be redirected 
toward phosphoenolpyruvate (PEP) to produce glucose via gluconeogenesis152. Hence, in case a 
concomitant activation of BCAA catabolism and gluconeogenesis occurs, TCA cycle may be partly up-
regulated between succynyl-CoA and oxaloacetate152. These results confirm that HF diet induce an 
up-regulation of mitochondrial oxidative pathways which might lead to partial saturation of TCA 
cycle.  
Univariate data analysis using Wilcoxon-Mann-Withney tests also enabled us to better 
understand the link between β-oxidation, BCAA catabolism and TCA cycle in the context of BWG 
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variability. Integration of BCAA catabolism intermediates showed that only isovalerylglycine was 
significantly higher (p value=0.030 at 7 days, p value=0.018 at 60 days) in urine of NR mice compared 
to SR mice or LF-fed mice indicating that obesity-resistant mice were associated with up-regulation 
of leucine catabolism exclusively. Leucine catabolism mainly produces acetoacetate which in turn 
induce the formation of ketone bodies (acetone and 3-D-hydroxybutyrate)152. Leucine degradation 
also forms a small amount of acetyl-CoA which may enter TCA cycle, but this pathway cannot 
produce substrate for gluconeogenesis152. Hence NR mice may preferably activate ketogenic 
pathways. Hexanoylglycine was also significantly higher (p value at 7 days: 0.023, p value at 60 days: 
0.001) in urine of NR mice compared to SR mice during the overall experiment whereas the urinary 
excretion of carnitine and acylcarnitine stayed unchanged. Hence, even though the carnitine shuttle 
system which is essential for mitochondrial oxidation of fatty acids seemed to be unaffected, β-
oxidation might be disturbed in NR mice compared to SR mice152. Interestingly, no difference in TCA 
cycle activity between NR and SR mice was observed after 7 days of HF diet. At 60 days, succinate 
was significantly higher in urine of SR mice suggesting an up-regulation of TCA cycle. In addition, the 
level of 2PY, 4PY and nicotinurate tend to increase in SR mice compared to NR mice after 60 days of 
HF diet, which support the hypothesis of an exacerbated utilization of mitochondrial oxidative 
pathways in obesity-prone mice. However, no significant difference in the variation of these 
metabolites was observed between NR and SR mice (See Appendix 1 Table S6 for detailed p values), 
which may be due to the small number of samples and the significant within group variability ( XFigure 
24X). Our results indicate that after a long-term period of HF diet, obesity prone mice are associated 
with an impairment of energy metabolism152,155. 
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Figure 24: Mapping of urinary metabolite excretion pattern involved in BCAAs, NAD metabolism, TCA cycle, β-
oxidation, ketogenesis and gluconeogenesis. The bar plots showed the mean ratio with standard error of 
metabolite integrals at day 7 to day 0 or day 60 to day 0. The Y axis indicates the value of the mean for LF, HF, 
NR and SR mice (arbitrary unit). Significant difference between mean ratios of LF and HF or NR and SR were 
calculated with non parametric Wilcoxon-Mann Whitney test: * <0.05, **<0.001, ***<0.0001 (values of mean, 
standard errors and p values in Appendix 1 Tables S5, and Table S6). Indirect metabolic reactions are 
highlighted with dash arrows. PEP: phosphoenolpyruvate. 
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4. DISCUSSION 
This study, showed that HF feeding led to a rapid development of obesity in C57BL/6 mice, 
but isogenic mice responded differently to HF diet, generating within-group variability of the obesity 
phenotype.H142H Burcelin et al. already reported that dietary or/and unidentified environmental 
factors may be involved in the differential regulation of glucose metabolism and may contribute to 
induce variable obesity outcomes in C57BL/6 mice. Our metabonomic results also demonstrated 
that specific activation of mitochondrial metabolic pathways including β-oxidation, and BCAA 
metabolism under HF diet has a determinant role in weight gain variability.  
 
4.1. HF diet-induced obesity is associated with a rapid up-
regulation of fatty acid breakdown and BCAA catabolism 
The abnormal fatty acid influx in the organism generated by HF diet induces obesity 
development and a strong change in energy metabolism through the modulation of fatty acid and 
BCAA metabolism156,157. In this experiment, mice fed a HF diet displayed a urinary increase in 
hexanoylglycine, carnitine and acylcarnitine over time. Hexanoylglycine is respectively obtained from 
the conjugation of hexanoyl-CoA with glycine in the liver and are then excreted in urineH152H. 
Hexanoyl-CoA is an intermediate metabolite of the β-oxidation158 and  carnitine is responsible for 
the uptake of fatty acids in mitochondria, a key initial step in the β-oxidation process156. These 
results confirm an up-regulation of fatty acid breakdown through β-oxidation and emphasize the 
saturation of oxidative fuel in the mitochondria, which might alter energy homeostasis. In particular, 
the accumulation of hexanoyl-CoA being a C6 fatty acid, suggests an up-regulation of the early steps 
of β-oxidation. Besides, the increase in several TCA cycle intermediates and NAD catabolism end-
products (2PY and 4PY) in urine of HF-fed mice brings further support to the energy over-production 
hypothesis. In particular, increased NAD catabolism has been shown to correlate with activation of 
β-oxidation and peroxisome proliferation159. The chronic increase in mitochondrial oxidative 
pathways has been thought to be deleterious for mitochondria leading to the impairment of 
oxidative pathways and energy metabolism151. In addition, excess free fatty acids can be stored as 
triglycerides in adipose tissue as well as lean tissue which promotes organ dysfunctions and 
metabolic diseases such as hepatic steatosis or cardiovascular diseases13. In this context, urinary 
increase of 2PY and 4PY in obese mice is suggestive of hepatic fatty acid accumulation159. Hence, 
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high fat feeding results in over-activation of fatty acid breakdown and reprocessing, which might 
contribute to obese associated metabolic disorders and ectopic fat accumulation. 
The rapid and sustained increase in isovalerylglycine, α-keto-β-methylvalerate, and α-
ketoisovalerate in urinary metabolic profiles of HF-fed mice at 7 days and 60 days also illustrates a 
consistent dysregulation of BCAA catabolism in obese mice during this experiment. BCAAs (leucine, 
isoleucine, valine) are degraded into keto-acids via reversible transamination by branched chain 
aminotransferase (BCAT)152. These keto-acids are in turn decarboxylated by branched-chain keto 
acid dehydrogenase (BCKDH) to produce acetyl-CoA and succinyl-CoA which eventually enter TCA 
cycle to produce ATP (XFigure 25X)152,154,160. Isovalerylglycine derives from the conjugation of glycine 
and isovaleryl-CoA, which is an intermediate of leucine catabolism. Similarly, α-keto-β-
methylvalerate and α-ketoisovalerate have been shown to be intermediates of isoleucine and valine 
degradation pathways respectively152,161. BCAA catabolism primarily occurs in skeletal muscle where 
it stimulates muscle protein synthesis and participates in energy production154. To a lesser extent, 
BCAA catabolism takes place in other tissues such as liver, kidney, heart or brains to provide energy 
substrates154,162. 
In the present experiment, the amount of carbohydrates in HF diet is significantly lower than 
the LF diet (see Appendix 1 Table S1 for detailed composition of diets). Carbohydrates represent the 
primary energy supply for the organism and are essential nutrients for several tissues such as brains, 
central nervous system and red blood cells152. In case of low carbohydrate dietary intake triggering a 
drop in blood glucose, several metabolic pathways using non-carbohydrate sources are activated to 
synthesize glucose152,163. In particular, BCAAs stimulate hepatic gluconeogenesis via alanine 
production and contribute to maintain glucose recycling163. Therefore, BCAA catabolism may be 
activated in HF-fed mice to induce gluconeogenesis and compensate the relative lack of 
carbohydrate. Several studies have highlighted the activation of gluconeogenesis in T2DM patients 
contributing to fasting hyperglycemia164,165. In obese individuals or with T2DM, up-regulation of 
gluconeogenesis might be associated with increased fat mass and lypolysis, which favours the 
production of gluconeognesis substrates such as glycerol165. In addition, the accumulation of 
isovaleryl-CoA, α-ketoisovalerate, and α-keto-β-methylvalerate suggests that the activity of BCAT 
and BCKDH enzymes in the early steps of BCAA catabolism exceed the capacity of the downstream 
enzymes in processing these keto-acids and incorporating acetyl-CoA in TCA cycle. α-
ketoisocaproate, α-keto-β-methylvalerate and α-ketoisovalerate formed by the transamination of 
BCAAs (XFigure 24X, XFigure 25X) are thought to be potent activator of BCKDH complex which promote 
BCAA catabolism166. In the present study, it is most likely that HF diet feeding associated with high 
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excretion of keto-acids, up-regulates BCAT/BCKDH expression and provokes an activation of the 
initial steps of BCAA catabolism. Stimulation of fatty acid oxidation and particularly the activation of 
peroxisome proliferator-activated receptor α (PPAR α) has been also suggested to down-regulate 
BCKDH kinase expression in rat liver leading to an activation of the BCKDH complex and to the 
promotion of the second step of BCAA catabolism166.  
Additionally, increased protein degradation may also occur to provide enough essential 
amino acids such as BCAAs to maintain vital processes leading to a higher excretion of leucine, valine 
and isoleucine in urine of HF-fed mice. BCAAs are thought to have therapeutic potential162, in 
particular, leucine improves diet-induced thermogenesis, increases muscle protein synthesis, 
enhancing satiety and stabilizing glycemic regulations153,163,167. However, BCAA supplementation has 
shown controversial biochemical effects. Zhang et al demonstrated that leucine-supplemented HF 
diet improves glucose and cholesterol metabolism and stimulates insulin secretion in obese rats167. 
On the contrary, Newgard et al observed an exhibited impaired phosphorylation of insulin signalling 
intermediate kinases (akt/protein kinase B) in skeletal muscle and liver when rats were fed with HF 
diet enriched with BCAAs (leucine, isoleucine, valine)153. In particular, they explained that BCAA 
associated impaired insulin action occurs only in the context of HF feeding153. From these results 
they suggested that an increase in BCAA catabolism combined with fatty acid overflow rather than 
the up-regulation of BCAA catabolism alone is responsible for the development of metabolic 
disorders. The cross-talk between BCAA, carbohydrate and lipid metabolism needs to be better 
understood, however, BCAA catabolism in the context of high lipid intake might contribute in the 
deregulations of energy metabolism and in the development of metabolic disorders. It is important 
to note that HF and LF-fed mice had a different food and cumulative energy intake (see Appendix 1, 
Table S2). Therefore, variation in mitochondrial oxidative pathways might be partly driven by 
difference in food/energy intake between LF- and HF-fed mice. Indeed BCAA intermediates (α-keto-
β-methylvalerate and α-ketoisovalerate) and leucine were positively correlated with cumulative 
energy intake throughout the experiment while 2PY, 4PY, nicotinic acid, and valine were positively 
correlated with energy intake 60 days after diet switch (see Appendices Figure S1). 
To summarise, in response to fatty acid overflow, increased protein content and reduced 
carbohydrates, the HF-fed mice might switch from glucose to other substrates for acetyl-CoA 
synthesis and incorporation into TCA cycle. Consequently, there is an up-regulation of the early steps 
of fatty acid catabolism and BCAA catabolism. However, the influx of acetyl-CoA substrates seems to 
exceed the capacity for incorporation in TCA cycle and as a result there is an accumulation of β-
oxidation (hexanoyl-CoA) and BCAA (isovaleryl-CoA, α-ketoisovalerate, and α-keto-β-methylvalerate) 
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intermediates, which can be exported out of the mitochondria. The activated intermediates 
(hexanoyl-CoA and isovaleryl-CoA) are then conjugated with glycine. Altogether, our results suggest 
that HF-fed mice tend to rely on fatty acid and BCAA catabolism to generate acetyl-CoA to be 
incorporated into TCA, in response to the reduced proportion of carbohydrates in the diet. Yet, an 
additional study with a better control of mouse energy intake and specifically focused on the 
balance between fat, carbohydrate and protein would be crucial to clearly establish the effect of low 
carbohydrate, high fat and high protein diets into obesity development. 
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Figure 25: Summary of mitochondrial oxidative pathways and energy production. Glycolysis, β-oxidation, and 
BCAAs oxidation enable the production of reduced co-enzymes, which in turn are used to synthesize ATP. 
These pathways are also interconnected with TCA cycle, which contributes in energy production. Mitochondria 
nutrient overload leading to an up-regulation of oxidative pathway might increase the level of mitochondrial 
reactive oxygen species (ROS) formation, which triggers damage in mitochondrial (mt) DNA, proteins and 
lipids. Alternatively ROS can be detoxified via the glutathione pathway. This figure highlights in a simplified 
way, the general metabolic pathways occurring in the mitochondria and does not reflect any tissue-specific 
mitochondrial activity. GSSG: oxidized glutathione, GSH: reduced glutathione, LCFA: long chain fatty acid, TG; 
triglyceride. Cyt: cytochrome, CPT: citrate protein transporter, MPC: mitochondrial pyruvate carrier, BCAT: 
branched-chain aminotransferase, BCKDH: branched-chain keto acid dehydrogenase 
 
4.2. SR and NR mice develop specific metabolic adaptations 
to HF diet based on BCAA catabolism and β-oxidation. 
An increase in hexanoylglycine, and isovalerylglycine was observed in NR mice compared to 
SR mice which indicate an up-regulation of β-oxidation and leucine catabolism152. By contrast, TCA 
cycle seemed to be down regulated in NR mice after a long-term period of HF diet indicating a 
regulation of energy metabolism. Even though leucine degradation can produce a small amount of 
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acetyl-CoA, this pathway is exclusively ketogenic and cannot form glucose via gluconeogenesis152. 
These results suggest that the rapid activation of alternative pathways favouring ketogenesis may 
alleviate the over activation of TCA cycle and gluconeogenesis in NR mice and may maintain energy 
homeostasis154. Moreover, Adams et al hypothesised that a reduction in BCKDH activity in high fatty 
acid containing tissues would alter the flux between BCAA catabolism and TCA cycle leading to 
anaplerotic stress168. Therefore increasing BCKDH activity in a DIO context could improve TCA cycle 
and mitochondrial functions. Interestingly, the activation of several mitochondrial oxidative 
pathways associated with the obesity resistant phenotype under HF diet was observed in the 
comparison between LF and HF diet model. In the NR vs SR model, a conditional metabolic 
phenotype which is the consequence of HF diet was identified. This metabolic phenotype 
determines the individual adaption to the diet, eventually affecting the obesity phenotype75. To 
summarise, HF-fed mice segregate into a spectrum of obesity phenotypes, which is suggestive of 
various adaptations to the HF diet challenge. In response to fatty acid overflow, NR mice present a 
relative up-regulation of the initial β-oxidation and leucine catabolism steps, leading to an increase 
in hexanoyl-CoA and isovaleryl-CoA production, which can form acetyl-CoA for energy purposes. 
Hexanoyl-CoA and isovaleryl-CoA are also ketogenic substrates, which can lead to the formation of 
acetoacetyl-CoA and ketone bodies. In the NR group, ketogenic pathways rather than TCA cycle 
seemed to be up-regulated which may maintain energy homeostasis. Overproduction of hexanoyl-
CoA, and isovaleryl-CoA can then be exported out of the mitochondria for conjugation with glycine. 
In the SR group, this ketogenic response was not observed; on the contrary, there is an increase in 
succinate, which could be suggestive of substrate availability for gluconeogenesis. These results 
highlight that specific mitochondrial activity under HF diet has a determinant role in weight gain 
management. 
 
4.3. Influence of gut microbiota on host energy metabolism 
Other environmental factors such as gut microbial activity might encourage obesity 
development and modify mouse physiology/metabolism. The variation in urinary excretion of 
microbial-mammalian co-metabolites between NR and SR mice supports this hypothesis, as 
described by an increase in hippurate and hydroxyphenylacetylglycine in SR mice compared to NR 
mice 60 days after diet switch31,89,102,169. Interestingly, the differences in urinary microbial co-
metabolites between NR and SR mice were observed at 60 days but not at 7 days after diet switch. 
This may reflect a divergence of gut microbial functions between NR and SR mice after long-term HF 
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challenge. Nutritional intervention-based experiments on germ free and conventional mice have 
highlighted the influence of gut microbiota on host energy homeostasis and metabolism. In 
particular Backhed et al have shown that gut bacterial colonization in germ free mice down-
regulates the expression of genes involved in adipose tissue fat storage in the intestine (suppression 
of fasting induced adipose factors (FIAF)) and mitochondrial fatty acids oxidation in the liver and 
skeletal muscles (suppression of adenosine monophosphate activated protein kinase (APMK))77. In 
our experiment, the variation in gut microbiota activity may contribute to the differential adaptation 
of mitochondrial oxidative pathways in NR and SR mice. 
 
4.4. Fatty acid overflow is associated with saturation of 
mitochondrial oxidative pathways which might be involved in 
obesity development. 
Mitochondria play a crucial role in maintaining energy homeostasis particularly through ATP 
synthesis by oxidative phosphorylation. In this process, nutrients such as fatty acid are oxidized to 
generate electron chemical gradient across the mitochondrial inner membrane. This gradient is then 
used for energy and heat production or for the transport of substrates and ions H170-172. Overflow of 
intracellular fatty acid generated by an imbalanced diet has been shown to saturate the 
mitochondria in fuel oxidation and in turn lead to dysfunction in mitochondrial oxidative 
pathways170. In particular, incomplete β-oxidation has been associated with mitochondrial nutrients 
overload resulting in accumulation of incomplete oxidized lipid derivatives metabolites and 
acylcarnitines151. BCAA catabolism may also be strongly affected by mitochondrial nutrient overload, 
which would contribute in the dysregulation of BCAA metabolism in obese mice.   
Impaired mitochondrial activity has been closely associated with a range of metabolic 
disorders such as IR, obesity, T2DM151,171,172. In addition, incomplete mitochondrial β-oxidation was 
observed in patients with NAFLD173. Several hypotheses have been proposed to explain the relation 
between a reduced mitochondrial respiration and development of obesity and IR. In particular, the 
increase of oxidative activity in mitochondria has been associated with a raise of reactive oxygen 
species (ROS) level which in turn may interfere with mitochondria themselves resulting in DNA 
mutation, lipid peroxidation and mitochondrial protein damage172,173. Hence, saturation of 
mitochondrial oxidative pathways associated with HF diet may be a contributing factor of 
mitochondrial dysfunction leading to disorders in energy homeostasis. By contrast, NR mice under 
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HF diet may lower the production of oxidized molecules and maintain normal mitochondrial 
respiratory capacities by activating specific mitochondrial metabolic pathways. Interestingly, NAD+ is 
a key regulator of stress resistance, and cell longevity174. Several mouse studies have reported a 
change in NAD metabolism in liver, heart, and kidney associated with mitochondrial oxidative 
stress175,176. In the present experiment, NAD catabolism was up-regulated in HF-fed mice compared 
to LF-fed mice and tends to be down-regulated in NR mice compared to SR mice. These observation 
supports the hypothesis that fatty acid overflow may saturate mitochondrial oxidative pathways 
leading to the production of oxidative species whereas NR mice may alleviate chronic oxidative 
damage by developing specific metabolic adaptations.  
Other studies have revealed that mitochondria health influence the activity of adipose tissue 
which regulates food intake, energy harvest and energy expenditure via multiple endocrine and non-
endocrine processes172. Alteration of adipose tissue functions not only affects lipid processes in 
adipocytes but also overall lipid metabolism contributing in obesity development and T2DM172. 
However, it remains unclear whether mitochondrial dysfunction is a cause or a consequence of 
obesity and IR. Finally, despite its limitations, the current pre-clinical study provided novel molecular 
insights with which to re-evaluate under human clinical conditions the short-and long-term 
implications of significant changes in diets for disease management, as for instance with the Atkins 
diet including high-protein, high fat and low carbohydrate consumption. Future studies focusing on 
the balance and type of carbohydrate, proteins and fat would be required to further establish the 
competitive and complementary role of proteins, fat and carbohydrates in the development and 
nutritional management of obesity.  
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5. CONCLUSIONS 
This study provides explanations on physiological mechanisms related to HF induced obesity 
development and particularly highlighting the specific metabolic adaptations associated to obese 
phenotype variability. High-fat diet provokes a rapid and consistent up-regulation of BCAA 
catabolism, β-oxidation, and TCA cycle, which might lead to a saturation of mitochondrial oxidative 
pathways. Upon HF-fed mice, obesity-resistant metabotype, was characterised by activated leucine 
catabolism, β-oxidation to produce substrates for ketogenesis and TCA cycle. Our results suggest 
that under HF challenge, ketogenesis tends to be preferably activated rather than TCA cycle in NR 
mice thus maintaining energy homeostasis and protecting mitochondria against fuel overloading. 
Additionally, the overproduction of β-oxidation and leucine catabolism intermediates is diverted 
towards glycine conjugation. Variation in gut microbial co-metabolites between NR and SR mice 
after long-term HF challenge also suggest that gut microbial activity participate in the differential 
physiological and metabolic adaptation to HF diet. This study further highlights the role of 
mitochondrial homeostasis in obesity development and its associated metabolic disorders.  
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CHAPTER IV: THE PREBIOTIC STUDY 
A TOP-DOWN METABONOMIC APPROACH TO INVESTIGATE THE LONG-
TERM EFFECTS OF PREBIOTICS ON C57BL/6 MOUSE PHYSIOLOGY AND 
METABOLISM DURING DIO.  
 
1. INTRODUCTION 
A substantial number of studies have reported that the composition of gut microbiota 
changes significantly in response to weight gain and obesity. The Gordon group first demonstrated 
this by showing variations in several bacterial phyla in the gut of obese humans and genetically 
obese mice33,177. Gastric bypass surgery which consists in reducing stomach volume is an effective 
treatment to induce weight loss and has been observed to be accompanied by a modulation of gut 
microbiotal population178,179. In the chapter III (section X3X and X4X), it has been showed that mice 
resistant to HF-induced obesity specifically modulated BCAAs and lipid metabolism. In addition the 
results point out specific aspects of the regulation of gut bacterial metabolism in C57BL/6 mice 
predisposed to obesity, which supports the hypothesis that gut microbial activity may be a 
contributing factor of weight gain. As a result, re-shaping the gut microbiota may be a promising 
strategy to prevent obesity development. 
The supplementation of prebiotics and/or probiotics in the diet is the most common 
approach to modify the functional interactions between the gut microbiota and host metabolism180. 
Depending on the physiological context (healthy/unhealthy subjects), and the administrated dose, 
prebiotics and probiotics have been shown to confer immunomodulation, anticarcinogenic, 
antidiabetic and hypocholesterolemic effects (see Chapter I, section X2X)181. The use of prebiotics are 
often advocated over probiotics for several reasons: As the complexity and variability of the gut 
ecosystem depends on its location in the gut, the selection of beneficial bugs by feeding the bacteria 
with suitable nutrients may be more effective than supplementing external strains in the diet. 
Prebiotics are also naturally stable compounds with a long shelf-life and are resistant to the 
digestion process before they reach the colon where they are degraded by bacteria95. On the other 
hand, living microorganisms such as probiotics are more likely to be affected during manufacturing 
process (e.g. heating), and gastrointestinal process (e.g. gastric acids, bile salts) leading to a loss of 
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functionality and/or efficacy181. From an industrial point of view, probiotics might be more expensive 
to produce and to manufacture than prebiotics.  
In a second study, we aimed at establishing the health implication of gut microbiota 
modulation by supplementation of several prebiotics and monitoring the gradual development of 
diet-induced obesity in C57BL/6 mice. This experiment investigates the physiological and metabolic 
effects of several prebiotic blends composed of galactosyl-oligosaccharides (GOS), a mixture of GOS 
and cow milk oligosaccharides containing glucose, lactose and galactose in addiction to 
oligosaccharides (GOS_CMO) or a mix of inulin (long-chain fructosyl oligosaccharides, n ≥ 20) and 
short-chain fructo-oligosaccharides (n < 20) (FOS_IN) during HF challenge. FOS, inulin and GOS have 
already proven to benefit circulating lipids and glucose-induced insulin secretion95,100. On the other 
hand, GOS_CMO is a specific prebiotic blend developed by Nestlé; its impact on the physiology and 
metabolism of rodents is investigated hereafter.  
It is important to note that C57BL/6 mice like many rodents and other mammalian may 
suffer from lactose mal-absorption as they exhibit a deficiency in lactase activity/expression, 
enabling lactose hydrolysis into galactose and glucose in the small intestine104. Hence, lactose 
ingestion may cause gastrointestinal disorders and bowel inflammation to these mice182. A portion of 
undigested lactose reaching the colon can also influence mouse gut microbiota activity and alter 
host metabolism182. In the present study, GOS_CMO blend containing lactose and GOS allow us to 
investigate prebiotic effect on mouse physiology and metabolism suffering from lactose 
malabsorption.  
Male mice aged 6 weeks were fed a low fat (LF) diet for a pre-intervention period of 3 
weeks. Then, the animals were separated into 6 groups and each fed with different isocaloric diets 
for 70 days. First, the low fat (LF) group constituted the negative control group and enabled us to 
establish the normal physiological and metabolic status of C57BL/6 mouse strain. Second, those 
mice fed high fat (HF) or high fat containing the free sugars: glucose, lactose and galactose (HF_S) 
constituted the positive control groups for the development of obesity and glucose intolerance. 
HF_S diet having the same amount of free sugars as GOS_CMO was added in the experimental 
design to provide an appropriate positive control group for GOS_CMO intervention. In the 3 other 
prebiotic test groups, mice were fed with high fat and galactosyl-oligosaccharides (HF + GOS), or high 
fat and a mix of GOS and cow milk oligosaccharides (HF + GOS_CMO), or high fat and a mix of short-
chain fructo-oligosaccharides and Inulin (HF + FOS_IN), to investigate whether prebiotics under HF 
diet modulate the obese phenotype. The physiological status of mice was assessed at several time 
122 
 
points in the experiment. For each mouse, body weight (BW) and food intake were recorded weekly 
and fasting glycaemia and fasting insulinemia were measured 7 days before the diet switch (D-7), 
plus 35 (D35) and 56 (D56) days after the diet switch. An oral glucose tolerance test (OGTT) was 
performed 56 days after the diet switch. Plasma inflammatory markers were measured at the end of 
the experiment. Urine and feces were sampled every week in order to monitor metabolic variations 
across time. Plasma samples were collected from the tail at D7, D35 and D56 to perform the OGTT 
test as well as fasting insulinemia and glycaemia measurements. At sacrifice (D70) plasma samples 
were collected from the portal vein. 
 
 
Figure 26: Experimental design to investigate the effect of prebiotic supplementation on physiological and 
metabolic adaptation of C57BL/6 mice during HF challenge.LF (low fat), HF (high fat), HF_S (HF + glucose-
galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk 
oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin). 
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Table 4: Treatment and sample collection during the experiment  
 
In this chapter, phenotypic states of mice fed LF, HF or HF + prebiotics at different time 
points was established through several physiological measurements ( XTable 4X). A top-down 
metabonomic approach using 1H NMR was performed on urine, feces (from D7 days to D70 after 
Days of study 
D-
21 
D-
14 
D- 
7 
D0* D7 D14 D21 D28 D35 D42 D49 D56 D63 D70 
Arrival X              
Randomization    X           
Body 
composition 
           X   
Weight X X X X X X X X X X X X X X 
Fasting glucose 
& insulin 
measure  
  X      X      
Oral 
glucose/insulin 
tolerance test  
           X   
Blood 
postprandial 
measures  
     X         
Faecal sample 
collection 
 X X X X X X X X X X X X X 
Urine collection  X X X X X X X X X X X X X 
Blood plasma 
collection 
  X   X   X   X  X 
Tissue sampling              X 
Sacrifice              X 
124 
 
diet switch) and plasma (D70 after diet switch) samples to establish the metabolic adaptation 
associated with prebiotics supplementation during HF challenge. Plasma, urinary and fecal metabolic 
fingerprints capture essential information associated with host energy metabolism and trans-
genomic co-metabolism. To further investigate variations in amino acid and lipid metabolism in the 
context of HF + prebiotics diets, plasma phospholipids and amino acid profiles of the different diet 
groups were measured using targeted MS approach. 
125 
 
2. MATERIALS AND METHODS.  
 
2.1. Animal handling procedure and sample preparation 
The experiment was performed at the NRC (Switzerland) following the national guidelines. A 
total of 90 C57BL/6 male mice aged of 6 weeks were housed in individual cage in 12h-12h of light-
dark regime and fed ad libitum for the entire course of the experiment. Due to the high number of 
animals and the frequency of the intervention, the study was performed on two sub groups of 
animal treated one day delay. During a pre-intervention time of 3 weeks, all mice were fed with 
normal LF diet (see Appendix 2, Table S1 for diet composition). Then, 6 groups of 15 mice with a 
similar weight and glycemia distribution were selected to be submitted to different dietary 
treatment for 70 days: 
 LF group: mice are kept under the standard LF diet  
 HF group: mice received a standard HF diet (see diet composition in Appendix 2, Table S1). 
 HF_S group: mice were fed with HF diet and glucose, lactose and galactose. This group 
constitutes the positive control group for HF + GOS_CMO diet which also contains free 
sugars (see diet composition in Appendix 2, Table S1). 
 HF + GOS group: mice were fed with HF and galactosyl-oligosaccharides (see diet 
composition in Appendix 2, Table S1). 
 HF + GOS_CMO group: mice were fed with HF and a blend of galactosyl-oligosaccharides and 
cow milk oligosaccharides containing glucose, lactose and galactose (see diet composition in 
Appendix 2, Table S1).  
 HF + FOS_IN group: mice were fed with HF diet and a blend of fructosyl-oligosaccharides and 
inulin (see diet composition in Appendix 2, Table S1). 
All diets were iso-caloric (diet compositions in Appendix 2, Table S1 and Table S2). In 
particular; HF diet contained the same proportion of proteins, fat, carbohydrate and fibres as HF + 
prebiotic diets. LF diet contains the same amount of fibres and proteins as the other diets, but less 
fat and more carbohydrate than HF and HF + prebiotic diet to maintain the same calorie supply. 
Urine and feces samples were collected weekly (n=1260 for each biological matrix) for the entire 
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course of the experiment (D-21, D-14, D-7, D0 before the diet and from 7 days (D7) to 70 days (D70) 
after the diet switch). 2 feces pellets were collected at each time point for metabolic profiling and 
gut bacterial profiling. Blood samples were also collected at 7 days before the diet switch (D-7), 14 
days (D14), 35 days (D35), 56 days (D56) and 70 days (D70) after the diet switch by gently cutting on 
the side of the mouse tail vein (n=450). Plasma sample was extracted from the blood samples after 
centrifugation. All the samples were snap-frozen at -80 ⁰C until analysis. Only the plasma samples at 
sacrifice (D70) were used for 1H NMR metabonomic and MS targeted profiling. After 70 days of 
dietary intervention, mice were finally euthanized by anesthesia with isofluarane. Organs (kidney, 
liver, caecum), epididymal and mesenteric fat were also collected and weighted at sacrifice (n=90 for 
each tissue).  
 
2.2. Measurement of body weight, body weight gain, fat 
mass, food intake and food efficiency 
Mouse body weight and food consumption were weekly measured during the experiment. 
Mouse cumulative food intake at a given time point (CFI (t)) was calculating by adding the amount of 
weekly consumed food from day 0 before diet switch up to the given time point. CFI(t) before diet 
intervention was calculated by adding the amount of consumed food from the first week of the 
experiment (D-21) up to day 0 before diet switch. Body weight gain (BWG (t)) was calculating by 
subtracting mouse weight at a given time-point from mouse weight just before diet switch (day 0). 
Body weight gain during the pre-intervention period was calculating by subtracting mouse weight at 
a given time point to mouse weight at the beginning of the experiment (21 days before the diet 
switch). Finally, cumulative food efficiency at each time point (CFE(t)) was determined by dividing the 
BWG by CFI (t). 
BWG(t)=BW(t)-BW(day 0) 
CFI(t)=FI(day0)+FI(t-1)+  FI(t) 
CFE(t) =BWG(t)/CFI(t) 
Differences in body weight and body weight gain, food intake and food efficiency between LF, HF 
and HF + prebiotics groups were assessed by non-parametric Wilcoxon-Mann-Whitney tests.  
 
127 
 
2.3. Measurement of body composition 
Body fat composition was measured 56 days after the diet switch by using magnetic 
resonance spectroscopy (MRS). This non-invasive technique detects the signal of 1H proton from 
methyl groups of lipids, excited by a magnetic field. The MRS signal produces a spectrum of 
resonances that corresponds to the level of different metabolite in the body tissues. It is often used 
to assess full body composition as well as to investigate metabolic changes in malign cells such as 
brain tumours, strokes or Alzheimer’s disease183,184. In vivo MRS spectrum can be obtained by placing 
the patient into a whole body magnetic resonance tomography unit. Depending on the machine 
design, small animals such as mice or even humans can be analysed. The scanner emits a strong 
magnetic field of 1.5 T, which aligns the nucleic spin orientation of hydrogen at a lower energy state 
in a patient. To change the direction of the nuclear spin to a higher energy state, a radiofrequency 
signal is emitted into the body. Similar to an NMR spectrometer, the resonance frequency receiver 
coil of the scanner detects the energy released by the hydrogen-bounded molecules returning to a 
lower energy state.The strength of the energy emission from hydrogen atoms which produce the 
signal is proportional to the magnetic field strength of the scanner183. Therefore, this technique 
suffers from the inherent low sensitivity of NMR. More sophisticated devices with increased 
magnetic strength at 3 T and 7T are currently tested to improve sensitivity. Although the spectrum 
quality of these new generation scanners is generally improved, safety and patient health outcomes 
are still under evaluation183. Additionally, contrast agents based on gadolinium complexes or iron 
oxides nanoparticles are sometimes administered to the patient to lower the relaxation times of 
biological water, which improves the quality of MRS signal184. 
 In the present experiment, mice were placed in the instrument for 30 seconds. The 
recorded data provided information about total body fat, total body water and lean mass.  
 
2.4. Glucose tolerance and insulin secretion test  
Oral glucose tolerance was performed in overnight fasted mice, 56 days after diet switch. 
Mice were subjected to a gavage with a glucose solution (30%W/V) on the stomach. Blood samples 
(5 µl) were collected from the till of the tail before the intervention as well as 15, 30 and 60 minutes 
after intervention. Plasma samples were kept in -80° C until prepared for immunoreactive insulin 
test. The blood samples collected before intervention provides information about blood glucose and 
circulating insulin level at baseline. Cumulative glycemia (CumG) and cumulative insulinemia (CumI) 
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were calculated as an increment of the glucose and insulin concentration respectively, during the 
course of the experiment. The maximal glucose or insulin concentration (CmaxI or CmaxG) 
corresponds to the highest peak value during the OGTT test. Importantly, very low values of insulin 
concentration in the different diet groups during the OGTT test were noticed which may be 
explained by inefficient immunoreactive insulin tests. These values were below the normal range of 
postprandial insulin level for C57BL/6 mice and therefore CumI and CmaxI were discarding for the 
analysis. Mouse fasting glycemia were also measured by quantifying the plasma glucose with 1H 
NMR spectroscopy at D-7, D7 and D35. 
 
2.5. Measurement of circulating cytokines with Multiplexed 
Elisa assay (Meso Scale platform) 
Circulating excretion patterns of several pro- and anti-inflammatory cytokines in the 
different diet groups 70 days after the diet switch were measured in mouse plasma samples (n=90) 
using Meso Scale platform (MSD). This multiplex Elisa kit use electrolumescence technology where 
specific antibodies are coated at different spots on an electronic wired microplate to measure 
multiple inflammatory mediators simultaneously. In this experiment, 7 mediators (IL1-β, IL-12 p70, 
IFN-γ IL-6, KcGRO, IL-10, TFN-α) were measured in duplicate using the mouse pro-inflammatory 7-
Plex ultra-sensitive MSD Kit. A volume of 50 µl per sample was required to perform all the analysis. 
The sample preparation and analysis were carried out as previously detailed185. Several calibrators 
prepared from the dilutions series of a standard cytokine mixture were run on each plate in 
duplicates. The standard curve calculated from the calibrators was used to measure the 
inflammatory mediator concentrations in mouse plasma. The final cytokine concentrations in each 
sample correspond to the average value of the duplicate signals. All signals below the limit of 
quantification were discarded from the analysis.  
 
2.6. Sample preparation and 1H NMR spectroscopy  
Because the volume of urine samples collected during the analysis was very low (<20ul), the 
samples preparation and 1H NMR analysis was carried out at NRC (Switzerland) using a 600 MHz 
Avance III Bruker NMR spectrometer with an adapted 1.7 mm TXI NMR probe. On the other hand, 
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Plasma and feces samples were prepared and run in at Imperial College (London) using an Avance III 
Bruker NMR spectrometer and 5 mm NMR TXI probe. 
2.6.1. Urine 
A volume of 10 μl of urine were homogenized in 50 μl of phosphate buffer solution (NaHPO4, 
0.6M pH=7.0, 100% D2O) containing sodium azide (3mM) and TSP (0.5 mM). After centrifugation, 
samples were transferred in 1.7 mm diameter NMR tubes by using a syringe. A 1H NMR sequence 
with water suppression (noesypr1d) was performed on 600.13 MHz spectrometer using a relaxation 
delay (RD) of 2 s, a mixing time (tm) of 100 ms and a 90⁰ pulse set at 10.75 μs ( (RD)-90
o-t1-90o-tm-
90o- acquisition) ). 1H NMR spectra were recorded with 64 free induction decays (FIDs) of and 98K 
data-points. The temperature of the NMR experiments was maintained at 300 K. 
2.6.2. Plasma  
A volume of 30 μl of plasma samples were diluted into 30 μl of phosphate buffer solution 
solution (NaHPO4, pH=7.4, 80% D2O, 3mM NaN3) and then transferred in 1.7 mm NMR tubes. No TSP 
was added in the phosphate buffer solution as it can interact with proteins in plasma.  1H NMR 
sequences with water suppression (noesypr1d) with a mixing time of 100 ms were acquired. Spin 
echo Carr-Purcell-Meiboom-Gill (CPMG) sequences (RD–90o–(D–180o–D)n–acquisition) attenuating 
the signal of macromolecules were also recorded using a RD of 2s, a delay (D) of 30 ms and 90⁰ pulse 
set at 10.50 μs. Both 1H NMR spectra were generated with 256 FID and 64K data points at a 
temperature of 300 K. 
2.6.3. Feces 
Feces samples were weighted and homogenized in 700 µl of phosphate buffer solution 
(NaHPO4, pH=7.4, 0.01% TSP, 80%D2O, 3mM NaN3) by using a tissue lyser (7 minutes, frequency: 
1/25). After centrifugation (15minutes at 13 000 rpm), 500 µl of supernatant were transferred into 5 
mm diameter NMR tubes. 1H NMR spectra were recorded using a 1H NMR sequence with water 
suppression (noesypr1d) which applied the following acquisition parameters: RD of 2 s, a mixing 
time (tm) of 100 ms and a 90⁰ pulse of 9.50 μs. All the experiments were achieved at a constant 
temperature of 300K using 256 FIDs and 32K data points. 
 
2.7. 1H NMR spectra pre-processing  
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Processing of 1H NMR spectra was carried out using TOPSPIN 2.1 software package (Bruker 
Biospin, Rheinstetten, Germany). For each spectrum, the FID was multiplied by an exponential 
function corresponding to a size of 1 Hz for urine samples or 0.3 Hz for plasma and feces samples. 
The FIDs were then transformed into spectrum by a Fourrier transformation. The spectra were 
manually phased, baseline corrected and calibrated using the TSP signal at δ 0 for the urine and 
feces spectra and the glucose signal at δ 5.23 for plasma spectra.  
 
2.8. 1H NMR Data processing  
The spectral data (from δ 0.2 to δ 9.5) were finally imported into Matlab software (version 
R2012b, the mathworks Inc, Natwick MA) and were transformed into 22K data-points. Resonance of 
water peak (δ 4.7-5.05) was also removed from each spectrum. 1H NMR spectra were aligned using 
an in-house algorithm and normalized in order to remove variation in metabolite concentration 
linked to osmolarity and/or dilution error. Total area normalisation was suited to correct 1H NMR 
spectra of urine and feces samples. On the other hand, 1H NMR spectra from plasma samples 
containing broad peaks from lipid and proteins was corrected using median full change 
normalisation. Poor quality or highly diluted spectra were discarded from the subsequent analysis. 
2.9. MS targeted profiling using the Biocrates kit  
A Multiplex targeted MS/MS assay was carried out in mouse plasma samples collected at 
sacrifice (n=90) using the Absolute IDQ, P180 kit (BIOCRATES Life Science AG, Innsbruck, Austria). 
This analysis was conducted at NRC (Switzerland). As previously mentioned in Chapter II (section 
X2.3X), this technique allows identifying 180 metabolites by using reverse phase liquid 
chromatography (Zorbax Eclipse XDB C18 column, 3.0x100mm 3.5micron) and direct flow injection 
with tandem mass spectrometry method. The analysis was carried out on Qtrap ABsciex 5500 using 
the protocol published previously128. Several Quality controls and reference samples were 
introduced to monitor the analytical reproducibility. Data processing and metabolite quantification 
were achieved by using MetIQ software package provided with the Absolute IDQ kit as previously 
describedH128H. After the cleaning procedure, 173 metabolites including amino acids, biogenic amines, 
acyclacrnitines, spnhigomyelins (SMs), lysophosphocholines, diacylphosphocholines (PCs) and one 
hexose were used for statistical analysis. Because of the large number of samples, the experiment 
was run in two different plates 
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2.10. 1H NMR metabolic data and MS targeted data analysis  
Multivariate statistical models (PCA, OPLS, OPLS-DA) were performed in Matlab software 
(version R2012b, the mathworks Inc, Natwick MA) and SIMCA-P 12.1 software (Umetrics, Umea, 
Sweden) using UV scaling. Q2Y value was determined by plotting the score (T) against the cross 
validating scores (Tcv) to estimate the goodness of fit and level of overfitting of the OPLS and OPLS 
DA models. All models were subjected to a 7-fold cross validation and were validated by multiple 
permutation tests (permutation number =1000). Pair-wise OPLS-DA models with 1H NMR metabolic 
profiles or MS targeted profiles were also performed between the different diet groups to identify 
the specific metabolic signatures related to each dietary intervention. OPLS coefficient plot from 
pair-wise models was used identify the relevant 1H NMR peaks in metabolic profiles of the different 
diet groups as described by Trygg et al 117. The most relevant metabolites in pair-wise models with 
MS data were flagged by using S plot (see Chapter II, section X3.2X for more details on the S plot). 
Correlation heatmaps were generated by compiling the Pearson correlation coefficient values of the 
relevant metabolites from 1H NMR metabolic profiles or MS targeted profiles. An arbitrary cut off 
values (R2>0.35) was selected to facilitate data interpretation.  
 
3. RESULTS  
 
3.1. Physiological data 
Physiological measurement data were acquired for the duration of the experiment, and at 
specific time points to determine whether prebiotic supplementation during HF diet challenge had a 
beneficial impact on obesity development and impaired insulin metabolism. 
3.1.1. Body weight gain, food intake, cumulative food efficiency and fat 
mass 
Body weight gain (BWG) of mice was calculated by subtracting the baseline body weight 
(BW) at D0 (before diet switch) from each mouse from BW measured at each time point after the 
diet switch (from D7 to D70). BWG of mice during the pre-intervention period was calculated by 
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subtracting mouse BW at the beginning of the experiment (D-21) from the mouse BW measured 
from D-14 to D0. Mean BWG of mice (XFigure 27X.A) fed with LF diet (negative control group), HF, 
HF_S diets (positive control groups) and HF + prebiotic diets (test groups) at each time point are 
presented in XFigure 27X.A. Significant differences in mouse BW and BWG between the diet groups 
were evaluated using non parametric Wilcoxon-Mann-Withney tests.  
Both HF and HF_S groups showed significantly higher BWG than LF and HF + prebiotics 
groups. All HF + prebiotics groups had similar BWG growth curves overtime. In addition, no 
significant difference between BWG of HF + prebiotics and LF group was observed between D0 and 
D28. These results confirm that both positive control groups (HF and HF_S groups) quickly become 
overweight compared to negative control group (LF group) and GOS, GOS_CMO or FOS_IN 
supplementation during the HF challenge limited BWG. These statistical analyses also highlighted the 
different group trajectory in BWG curves. HF + GOS_CMO and HF + FOS_IN fed mice had significantly 
higher BWG than LF-fed mice from D35 after diet switch while HF + GOS fed mice had significantly 
higher BWG after 42 days of diet switch. As a result, mice fed HF + prebiotics for a long-term period 
became overweight compared to the negative control group (LF group). These results showed that 
prebiotic supplementation during HF challenge limited but did not prevent the development of 
obesity.  
Statistical analyses on weekly food intake (XFigure 27X. B) also indicated that mean food intake at each 
time point was significantly higher in the LF group (3 g difference per week in average) than in all the 
other groups and significantly higher in both HF groups (1.7 g difference per week in average) 
compared to the HF + GOS and HF + GOS_CMO groups, during the overall course of the experiment. 
However, the food intake of HF + FOS_IN was only significantly lower from both HF groups on D49, 
D63 and D70 (with an average of 0.9 g difference per week). Hence, the ingestion of a prebiotic in 
addition to HF diet may increase satiety which may partly explain the lower BWG in HF + prebiotic 
groups over time. Noticeably, weekly food intake for each diet group plotted in the XFigure 27X.B was 
consistent along the study except at D21 after the diet switch. During this week, a dietary challenge 
with postprandial blood collection was performed which may have led to an increase of food intake 
for all animals.  
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Figure 27: Impact of different diet interventions on (A.) mouse weight gain, (B.) food intake and (C.) cumulative 
food efficiency during the overall course of the experiment. Cumulative food intake (CFE) = body weight gain 
(BWG) /cumulative food intake (CFI). Wilcoxon-Mann-Whitney tests are presented at the last timepoint. 1 star 
for p-value<0.05, 2 stars for p-value<0.01, 3 stars for p-value<0.001 (x: HF vs HF+GOS, ¥ HF vs HF +FOS_IN, ⁰: 
HF_S vs HF+GOS_CMO, ǂ: LF vs HF+GOS, +: LF vs HF+FOS_IN, #:LF vs HF+GOS_CMO). LF (low fat), HF (high fat), 
HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS 
and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin). 
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To determine the physiological effect of prebiotic supplementation on BWG during the HF 
challenge, cumulative food efficiency (CFE) was calculated for each diet group at each time point by 
dividing the BWG by the cumulative food intake (see formula material and methods). This parameter 
estimates the mouses efficiency at storing calories, from the first week after diet switch (D0). The 
mean CFE of each diet group calculated from D0 until the end of the experiment (D70) is 
summarised in XFigure 27X.C. Non parametric Wilcoxon-Mann-Whitney tests on the CFE indicated that 
all prebiotic supplementations during HF challenge induced significantly lower calorie storage than 
both HF groups during the course of the experiment except for HF + GOS_CMO group, which was 
only significantly lower than HF_S from D21. Interestingly, the different prebiotic groups had similar 
CFE across the study, and no prebiotic group showed a significant difference in CFE with LF group 
during the first 4 weeks after diet switch. A significant difference between HF + GOS_CMO and LF 
groups appeared at D35 after the diet switch, whereas it appeared at D42 after the diet switch for 
HF + FOS_IN and HF + GOS groups. These results highlighted that each prebiotic supplementation 
enable to maintain normal calorie storage during a short-term period of HF challenge. However, 
prebiotic benefits were not sustainable after a month of HF challenge, which resulted in divergence 
in CFE between HF + prebiotic and LF groups. Noticeably, CFE values took 2 weeks to reach a stable 
pattern: CFE was significantly higher in all HF containing diet groups at D7 compared to the other 
time points, indicating that all mice challenged with HF had a boost in calorie storage 1 week after 
the diet switch. CFE values also dropped in all the animals at D14 due to a longer fasting period 
before the dietary challenge. 
135 
 
***
***
***
***
***
 
Figure 28: Body fat composition of mice fed with different diets at 56 days (D56). Fat mass (red), lean mass 
(blue) and total mass (green) levels of different diet groups are shown. Values are expressed as mean ± SEM. 
Differences between diet groups were assessed by non parametric Wilcoxon-Mann-Whitney tests . P<0.05*, 
p<0.01**, p<0.001***. LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + 
galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + 
fructosyl-oligosaccharides and inulin). 
 
Assessment of fat and lean mass was also carried out for each diet group 2 weeks (D56) 
before the sacrifice (XFigure 28X). An analysis of variance showed no significant difference for lean 
mass between all groups of mice. However, fat mass was significantly higher in HF and HF_S groups 
compared to LF and all prebiotic groups. In addition, mice fed with HF + prebiotics had the same 
amount of fat mass as LF fed mice. These results showed that supplementation of prebiotics during 
HF challenge induced a reduction of calorie storage, which is physiologically characterised by a 
restriction of fat mass accumulation and overall limited obesity development. 
3.1.2. 118BSystemic insulin and glucose homeostasis. 
The regulation of glucose homeostasis and insulin secretion in mice fed with different diets 
was assessed 8 weeks after the diet switch (D56) by oral glucose tolerance test (OGTT). All HF + 
prebiotic groups presented significantly lower fasting glycaemia than HF and HF_S groups 
(5.97±0.43mM for LF group, 6.69±0.70mM for HF group, 6.82±0.75mM for HF_S group, 
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6.38±0.63mM for HF + GOS group 6.16±0.63mM for HF + GOS_CMO group, 6.01±0.70mM for HF + 
FOS_IN group). Fasting insulinemia was also significantly lower in prebiotic groups than in both HF 
groups and not significantly different from the LF group indicating that prebiotics improved glucose 
associated insulin secretion at systemic level. Analysis of glycaemia pattern during OGTT showed 
that HF + GOS and HF + FOS_IN groups had lower cumulative glycaemia (CumG) and lower maximal 
glucose concentration (CmaxG) than HF group, but not HF + GOS_CMO group (CumG of 571±80.1 
mM min-1, CmaxG of 14.6±2.4 mM; for LF group, CumG of 906± 129.9 mM min-1 and CmaxG of 
18.6±2.5 mM for HF group, CumG of 847.4± 98.1 mM min-1 and CmaxG of 17.7±2.33 mM for HF_S 
group, CumG of 783.7±77.2 mM min-1 and CmaxG of 16.5±1.9 mM for HF + GOS group, CumG of 
821.0± 158.8 mM min-1 and CmaxG of 17.9±2.5 mM for HF + GOS_CMO group, CumG of 787.7 
±102.5 mM min-1 and CmaxG of 16.8±2.3 mM for HF + FOS_IN). These differences were essentially 
due to variation of glycaemia at baseline. Indeed when the effect of the baseline value was removed, 
no difference in response to glucose was observed between HF + prebiotics groups and both HF 
groups. However, HF challenge with or without prebiotic supplementation induced an increase in 
fasting glycaemia, CumG and Cmax compared to LF group indicating relative glucose intolerance. 
Fasting glycemia was also measured before the diet switch (D-7), and 5 weeks (D35) and 8 
weeks (D56) after the diet switch for each group. As shown on the histogram ( XFigure 29X), no 
significant increase in blood glucose was observed in LF-fed mice indicating that glycaemia was 
maintained at normal values between D-7 and D56. On the other hand, blood glucose significantly 
increased in both HF and HF_S groups, in HF + GOS and HF + GOS_CMO overtime with a maximum 
glucose level reached at D35. The values of fasting glycaemia at D35 and D56 for these groups were 
characteristic of impaired glucose tolerance (glucose concentration between 7.8 and 11 mM) but not 
diabetes (glucose concentration > 11mM). Only mice fed with HF + FOS_IN had stable glycaemia 
between D-7 and D56 with values of blood glucose similar to those found in LF group. Even though, 
mice fed with HF + prebiotic showed a lower fasting insulinemia compared to HF and HF_S groups, 
HF ingestion induced a profound deregulation of glucose homeostasis overtime generating impaired 
glucose tolerance in all HF diet groups. However, amongst all prebiotics, FOS_IN exhibited the 
greatest capacity to attenuate glucose intolerance as suggested by limited fasting hyperglycemia. 
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Figure 29: Time-dependent effect of different dietary interventions on mouse fasting glycaemia. Concentration 
of glucose was obtained 7 days (D-7) before the diet switch, 35 (D35) and 49 (D49) days after the diet switch 
and the values are expressed as mean ± SEM. Differences between groups were assessed by non parametric 
Wilcoxon-Mann-Whitney tests , P<0.05*, p<0.01**, p<0.001***. LF (low fat), HF (high fat), HF_S (HF + glucose-
galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk 
oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin). 
 
3.1.3. Inflammatory markers  
Using multiplexed Elisa essays, the concentrations (pg/ml) of 7 inflammatory cytokines (IFN-
γ, IL-1β, IL-6, IL-10, IL-12, KcGRO, TNF-α) in plasma of each diet group 70 days (D70) after the diet 
switch, were measured in order to establish the long-term effect of HF and prebiotic 
supplementation on systemic inflammation. As displayed in the following histogram (XFigure 30X), HF 
and HF_S feeding tended to raise the level of pro-inflammatory (IFN-γ, IL-1β, IL-6, IL-12, KcGRO, TNF-
α) and anti-inflammatory (IL-10) markers in the circulation compared to LF feeding. However, due to 
a low plasma concentration of cytokines in all mice, the recorded signals of each cytokine were close 
to the limit of quantification inducing high variations into the measurements (as indicated by a large 
error bars). Significant differences among the cytokine concentrations between diet groups were 
calculated using non-parametric Wilcoxon-Mann-Whitney tests. No difference in the plasma 
concentrations of IFN-γ, IL6 and IL12 were observed between LF, HF and HF_S groups indicating that 
HF ingestions did not significantly affect the circulating pattern of these cytokines. However, IL-1β 
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level was higher in HF and HF_S groups than LF group and IL10, KcGRO, TNF-α levels significantly 
increased in HF_S group compared to LF group. Prebiotic supplementation also triggered significant 
variations in the circulating cytokine pattern. In particular, HF + GOS group was associated with a 
reduction in IFN-γ, IL-1β, IL-10 and IL-12 compared to HF and HF_S groups. HF + GOS_CMO 
supplementation induced a drop of IFN-γ and IL-1β compared to HF_S group whereas HF + FOS_IN 
supplementation decreased plasma concentration of KcGRO and IL-1β compared to HF and HF_S 
groups. By contrast the level of TNF-α in circulation was significantly higher in HF + GOS_CMO and 
HF + FOS_IN groups compared to LF group which pointed out a specific prebiotic induced 
inflammatory response. Prebiotic supplementation tended to decrease the global inflammatory 
status of mice as plasma concentration of all cytokines except TNF-α decreased in HF + prebiotic 
groups compared to HF and HF_S groups even though variations between groups were not all 
significant. 
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Figure 30: Circulating inflammatory status of mice fed different diets 70 days (D70) after diet switch. Plasma 
level of IFN-γ, IL-1β, IL-6, IL-10, IL-12, KcGRO, TNF-α were measured in each dietary group at D70 after diet 
switch with the MesoScale Discovery platform. Results are expressed as mean concentration (pg/ml) ± SEM. 
For each cytokine, the differences between groups were assessed by non parametric Wilcoxon-Mann-Whitney  
tests, P<0.05*, p<0.01**, p<0.001***. LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + 
GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN 
(HF + fructosyl-oligosaccharides and inulin). 
 
3.2. Metabonomic data 
3.2.1. Characterisation of 1H NMR urinary, fecal and plasma metabolic 
profiles of C57BL/6 mice 
Mean 1H NMR spectrum of urinary, fecal or plasma from LF, HF, HF_S and HF + prebiotic fed 
mice were assigned with the help of 2D 1H-1H and 1H-13C NMR experiments and appropriate 
database (1H NMR metabolites assignment in XTable 5X). Urinary metabolic profiles (Figure 31) present 
140 
 
a numerous signals from organic acids (acetate, butyrate, citrate, hippurate, α-keto-β-
methylvalerate, isovalerate), gut microbial co-metabolites32 (phenylacetylglycine (PAG), p-cresol 
sulfate (PCS), p-cresol glucuronide (PCG), indoxylsulfate) and other metabolites such as aliphatic 
amines (dimethylamine (DMA), trimethylamine (TMA), trimethylamine-N-oxide (TMAO)). Amino 
acids (leucine, isoleucine, alanine) sugars (D-glucose, D-galactose), creatine and creatinine were also 
observed in urine of C57BL/6 mice. 
In fecal metabolic profiles (Figure 32) resonances of organic acids (acetate, 3-D-
hydroxybutyrate, formate, succinate, glycerate, butyrate, propionate), and sugars (α/β-D-glucose, 
xylose) were identified. 1H NMR fecal spectra were also characterised by signals of amino acids (such 
as leucine, isoleucine, valine, threonine, methionine, asparagines, phenylalanine, glutamate, and 
lysine) and nucleic acids derivatives (hypoxanthine, xanthine and uracil).  
Plasma CPMG 1H NMR spectra (Figure 33.A) showed small molecule resonances such as 
acetate, pyruvate, and amino acids (glutamate, leucine, isoleucine, valine). On the other hand, 
plasma standard 1H NMR spectra (Figure 33.B) mainly displayed lipid signals from unsaturated and 
saturated compounds, lipoproteins (overlapped resonances of very low density lipoproteins (VLDLs) 
and low density lipoproteins (LDLs)) and sugars (D-glucose).  
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Figure 31:Mean of 
1
H NMR spectra of urine from LF, HF and HF + prebiotic fed mice from D7 to D70. The 
aromatic region of the spectrum (6.8-7.8ppm) has been zoomed to improve the spectral assignment.4PY : N-
methyl-4-pyridone-3-carboxamide, 2PY: N-methyl-2-pyridone-5-carboxamide. 
*: tentative assignment.  
 
142 
 
 
Figure 32: Mean of 
1
H NMR spectra of feces from LF, HF and HF + prebiotic fed mice from D7 to D70. The 
spectrum has been zoomed in three different regions (0-2.2, 2.3-4.5 and 4.7-8.55ppm) to identify peak 
multiplicity and improve the spectral assignment.*: tentative assignment 
 
.  
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Figure 33: Mean of 
1
H NMR spectra of plasma from LF, HF and HF + prebiotic fed mice from D7 to D70. (A) 
1
H 
NMR CPMG spectra (B) 
1
H NMR standard spectra.  
 
*: tentative assignment 
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Table 5: 
1
H NMR chemical shifts from metabolites assigned in urinary, fecal or plasma metabolic profiles. (Only 
resonances identified in the spectra are reported and signals of unassigned metabolites are not included in the 
table).  
Metabolite 1H NMR ppm multiplicity group  
Biologica
l matrix 
obseved 
N-methyl-2-pyridone-5-
carboxamide  6.66 (d) C3H, 7.83 (dd),C4H, 8.32 (d) C5H,  U 
3-D-Hydroxybutyrate 1.20 (d) CH3, , 4,16 (Dt) CH P/F 
N-methyl-4-pyridone-3-
carboxamide  6.69 (d) C3H, 7.97 (dd) C4H, 8.54 (d) C5H  U 
Acetate 1, 92 (s) βCH3 U/P/F 
Acetyl-Carnitine 3.183 (s) (CH3)3, 2.31 (s) CH3 U 
Alanine 1.46 (d) (βCH3) U/P/F 
Allantoin 5.38 (s) CH, 6.02 9 (s) (NH) U 
Asparagine 
2.86 (dd) (1/2βCH2), (dd) 2.96 (1/2βCH2), (dd) 
4.00(αCH) F 
Aspartate 2.68 (dd) (1/2βCH2), 3.91 (dd) (αCH)  F 
Bile acids  0.68 (m) CH3, 0.70(m) CH3  F 
Butyrate  0.88 (s) γCH3, 1.55 (m) βCH2, 2.14 (m) αCH2 F 
Carnitine 3.23 (s) CH3 U 
Choline 3.22 (s) N-(CH3)3 U/P 
Citrate 2.55 (d) 1/2 γCH 2.7 (d) 1/2 γCH,  U/P 
Creatine 3.03 (s) N-CH3, 3.94 (s) N-CH2 U/P 
Creatinine 3.05 (s) N-CH3, 4.06 (s) N-CH2 U 
Dimethylamine 2.72 (s) CH3 U 
Formate 8.46 (s) HCOOH  U/F 
Fumarate 6.51 (s) CH F 
Glutamate 2.02(M) βCH2 2.34 γCH2 3.76 (dd) αCH P/F 
Glutamine 2.15 (m) βCH2 2.44 (m) γCH2 3.77 (t) αCH F 
Glycerate 3.81 (m) CH, 4.14 (m) CH2 F 
Glyceryl of lipids 4.06 (m) CH2OCOR P 
Glycine 3.55 (s), αCH2 U 
Hexanoylglycine 0.88 (t) CH3, 1.62 (m) CH2 U 
Hippurate  7.55 (t) mCH, 7.64(t) pCH, 7.84 (d) oCH U 
Hydroxy-phenylacteylglycine 3.58 (s) CH2, 6.88 (d) C1H & C4H, 7.21 (d) C3H & C3H F 
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Hydroxy-phenyllactate 
3.04 (dd) CH2, 4.35 (dd) CH, 6.85 (d) C1H & C4H, 7.17 
(d) C2H & C3H U 
Hypoxanthine 8.18 (s) CH, 8.20 (s) CH F 
Indoxylsulfate 7.27 (m) C4H, 7.36 (s) CH, 7.50 (d) C5H, 7.70 (d) C6H U 
Isoleucine 0.94 (t) γCH3, 1.02 (t) δCH3, U/P/F 
Isovalerate  0.94, (CH3)2, 1.94 (m) CH  U 
Isovalerylglycine 0.94 (d) ɛCH3, 2.00 (d) δCH2, 2.20 (d) γCH2,  U 
Lactate  1.33 (d) βCH3, 4.12 (q) αCH U/P 
Leucine 0.93 (d) δCH3 0.94 (d) βCH2 1.71 (m) γCH U/P/F 
Lysine 1.71 (m) δCH2, 1.84 (m) βCH2, 3.01(t) ɛCH2 F 
Methionine 2.13 (s) δCH3, 2.14 (m) βCH, 2.6 (t) γCH2 F 
N and O-Acetylglycoproteins  2.04 (s) N/OHCOCH3 U/F 
p-Cresol glucuronide 2.3 CH3, 7.06 (m) C2H & C6H, 7.23 (m) C3H & C5H U 
p-Cresol sulphate  2.34 (s) CH3, 7.11 (m) C2H & C6H, 6.80 (m) C3H & C5H U 
Phenylacetylglycine 
3.68 (s) CH2, 3.75 (d) CH2, 7.37 (m) C2H & C6H ,7.43 (m) 
C3H & C5H  U 
Phenylalanine 
3.12 (dd) 1/2-βCH2, 3.26 (dd) 1/2-βCH2, 7.33 (m) C3H & 
C5H, 7.35 (m) C4H, 7.4 (m) C3H & C6H F 
Propionate 1,05 (t) βCH3, 2.183 (q) α CH2 F 
Putrescine 1.80 (m broad) βCH2 U 
Pyruvate 2.35 (s) CH3 P 
Succinate 2.41 (s) CH3 U 
Sucrose 
5.4 (d) C1H, 3.87 (dd) C5H (glucose), 3.89 (dd) C1H, 4.04 
(dd) C2H, 3.67 (m) CH2 (frutcose)  U 
Taurine 3.26 (t) N-CH2, 3.43 (t) S-CH2 U 
Threonine 1.32 (d) γCH3, 3.6 (d) αCH, 4.25 (m) βCH F 
Trimethylamine-N-oxide  3.27 (s) N-(CH3)3 U 
Trimethylamine  2.88 (s) CH3 U 
Uracil 5.80 (d)C5H 7.54 (d) C6H,  F 
Urea 3.4 (s) α,β NH2 U 
Valine  0.98 (d) γCH3 1.04 (d) γCH3, 3.62 (d) αCH P/F 
Xanthine 7.89 (s) CH F 
Xylose * 5.19 (d) C1H F 
α-D-Galactose 5.26 (d) C1H, 3.72 (m) C2H & C5H, 3.72 (m) CH2 U 
α-D-Glucose 
3. 42 (m) C4H, 3.72 (m) C3H, 3.73 (m) ½-C6H,3.77 (m) 
½-C6H, 5.24 (d) C1H U/P/F 
α-Ketoglutarate   2.44 (t) βCH2 3.01 (t) γCH2 U 
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α-Ketoisocaproate 0.94 (d) (CH3)2, 2.61 (d) CH2 U 
α-Ketoisovalerate 1.11 (d) (CH3)2  U 
α-Keto-β-methylvalerate 1.10 (d) CH3 U 
β-D-Glucose 
3.25 (m) C2H, 3.49 (m) C4H, 3.49 (m) C5H, 3.5 (m) C3H, 
3.91 (d) ½-C6H, 4.66 (d) C1H P 
myo-inotisol* 3.29 (t) C5H, 4.06 (t) C2H U/P 
scyllo-inotisol 3.35 (s) CH P 
Lipid fractions 
0.90 (m) CH3, 1.20 (m) (CH2)n, 1.97 (m) & 2.0 (m) 
CH2C=C, 2.23 (m) CH2CO, 2.72 (m) C=CCH2C=C, 5.29 (m) 
CH=CH P 
U: Urine, P: Plasma, F: Feces. * Tentative assignment 
 
3.2.2. Effect of prebiotics supplemented HF diet at D70 after the diet 
switch in C57BL/6 mice 
Physiological data showed that prebiotic supplementation had beneficial impacts on HF 
induced obesity. To understand biological processes inducing phenotypic changes in mice fed HF + 
prebiotics, a fecal, urinary, and plasma metabonomic analysis was performed. Firstly, urinary and 
fecal metabolic profiles of all diet groups from D0 to D70 were compared to identify specific patterns 
of metabolic adaptation to different isocaloric diets over time. Secondly, the impact of HF and 
prebiotic in urinary, fecal and plasma metabolic variations at D70 after the diet switch were 
identified. To assess the prebiotic-induced improvement of the metabolic phenotype towards a 
“healthy metabolic profile”, a metric of the metabolic signatures was calculated in plasma, urine and 
feces, using the metabolic phenotypes of the negative (LF) and positive (HF or HF_S) control groups. 
The position of the metabolic phenotypes of HF + prebiotic fed mice onto these metrics estimates 
the “metabolic rescue” induced by prebiotics supplementation during HF challenge in each biological 
matrix. Thirdly, pair-wise OPLS-DA models comparing the different diet groups were performed to 
establish the urinary, fecal and plasma metabolic signatures associated to HF diets and different 
prebiotics supplementation during HF challenge at D70 after the diet switch. Finally pair-wise 
comparison of lipid and amino acid profiles of different diet groups acquired by a MS targeted essay 
provided additional information on prebiotic associated variations of lipid and amino acid 
metabolism. 
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3.2.3. Global OPLS-DA models of urine and feces samples describe 
metabolic adaptations associated with nutritional interventions. 
Global OPLS-DA models were performed on urine and fecal samples to assess overall 
differences related to urinary or fecal metabolic profiles of mice fed various diets. For each biological 
matrix, the model grouped together all 1H NMR spectra of each group between D7 and D70. The Y 
matrix was built with 5 dummy variables identifying the diet groups and 1 continuous variable 
defining the time-points. Therefore, the models categorise the different diet groups as separate 
classes of samples and look for linear variations linked to time effect. Numbers of components and 
goodness of fit statistics corresponding to each model are summarised in the XTable 6X. In both 
models, the first three components separated the different diet groups whereas the time trajectory 
was modeled from the fourth component which demonstrates that nutritional intervention induced 
greater variability in the mouse urinary and fecal metabolic profiles than time effect. The OPLS-DA 
score plots obtained from urinary metabolic profiles (XFigure 34X.A) showed that HF and HF_S groups 
were separated from LF group along the first predictive component. This highlights that HF feeding 
introduced the strongest source of variability in the metabolic profiles. The second and the third 
predictive components described the metabolic variation related to the different prebiotic 
supplementation. By contrast, the OPLS-DA scores plots of fecal metabolic profiles showed a 
separation between HF + GOS_CMO, HF + FOS_IN groups and the other diet groups along the first 
component (XFigure 34X.B). Such observations suggest that prebiotic supplementation induced a 
greater metabolic variation than HF diet. The second predictive components discriminated mice fed 
with HF, HF_S and HF + GOS_CMO from mice fed with LF, HF + FOS_IN and HF + GOS. Both urinary 
and fecal metabolic profiles of HF + FOS_IN and HF + GOS fed mice approached LF-fed mouse 
metabolic profiles. On the other hand, HF + GOS_CMO fed mice had specific metabolic pattern and 
were closer to HF and HF_S mouse metabolic profiles. Hence, ingestion of the prebiotic FOS_IN and 
GOS during HF challenge tended to shift urinary and fecal metabolic profiles of mice towards an 
healthy metabolic profile. In addition, HF + GOS_CMO diet had lower fibre contents than HF + GOS 
or HF + FOS_IN diets. Therefore differences in fibre percentage may lead to dose dependent 
metabolic responses in urine and feces.  
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Figure 34: Global urinary (A) and fecal (B) metabolic profile of each diet group. All urine (n=826) or fecal 
(n=785) samples acquired from 7 days (D7) to 70 days (D70) after the diet switch were used to calculate OPLS-
DA models. For each matrix, 3D scores plots showed the three dimensional dispersion of the scores of each 
diet group across time. The 2D projections indicate the biggest variability in the dataset along the first and the 
second component.Both models were built with 6 predictive and 2 orthogonal components. Q
2
Y=0.46 and 
R
2
Y=0.49 for urinary metabolic profile.Q
2
Y=0.24, R
2
Y=0.46 for fecal metabolic profile: LF (low fat), HF (high fat), 
HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS 
and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) 
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Figure 35: OPLS-DA score plot from global urinary (A) and fecal (B) metabolic profile highlighting the time-
dependent trajectories: Urine (n=826) or fecal (n=785) samples acquired from 7 days (D7) to 70 days (D70) 
after the diet switch were used to calculate OPLS-DA models. For each matrix, 3D scores plots showed the 
three dimensional dispersion of the scores on the 4th, 5th and 6th component which highlights the time 
trajectory. 
 
3.2.4. Comparison of urinary, fecal and plasma metabolic profiles of LF, 
HF and each HF + prebiotic groups using OPLS-DA emphasize 
prebiotics induced metabolic rescue. 
Long-term effects of each prebiotic on mouse metabotype were further investigated by 
using OPLS-DA models at D70 after the diet switch. OPLS-DA scores plots (XFigure 36X) exhibited the 
various group comparisons for each biofluid and enabled to visually decompose the metabolic 
adaptation associated to HF, the partial normalisation of the metabolic profile induced by the 
prebiotic supplementation and the specific metabolic responses associated to prebiotic 
supplementation (statistics of the models in XTable 6X). The range of metabolic adaptations to each 
diet group varies according to the biofluid. In fact, on the OPLS-DA scores plot built from urinary 
metabolic profile (XFigure 36X.A), the first component discriminated LF-fed mice and HF-fed mice (with 
or without prebiotics supplementation). The second component highlighted the secondary effects, 
which were mainly characterised by the specific effects of prebiotics. The urinary metabolic profiles 
of mice fed with HF + prebiotics and particularly HF + FOS_IN were also partially normalised 
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compared to the negative control group as their scores got closer to those of LF-fed mice. On the 
contrary, the main source of variation in fecal metabolic profiles was associated with specific effects 
of prebiotics supplementation, as the biggest separation was observed between HF and HF + 
prebiotic along the first component (XFigure 36X.B). The separation of LF and both HF groups was 
mainly noticeable on the second component. The comparison of plasma metabolic profiles between 
the different groups (XFigure 35X.C) showed a combination of diet and prebiotic effects influencing the 
dataset. HF ingestion during a long time period triggered the main variation in the systemic 
metabolic profile as LF and HF group were discriminated along the first component. However, the 
long-term supplementation of prebiotic during HF challenge lead to a significant improvement of the 
metabolic profiles as the score plots of all HF + prebiotics groups were significantly closer to those of 
LF group in each score plot. The second component mainly highlighted the separation between LF 
and HF + prebiotics, which was associated with prebiotic specific effects. The decomposition of the 
effect involved in metabolic variations pointed out that HF ingestion strongly disturbed circulating 
metabolic flux and excretion of C57BL/6 mice which was characterised by a modulation of urinary 
and plasma metabolic profiles. On the other hand, prebiotic supplementation tended to specifically 
affect nutrient ingestion and gut metabolism as it triggered the greatest variability in fecal metabolic 
profiles.  
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Figure 36: Identification of specific metabolic effects and partial normalisation of metabolic profiles by 
prebiotic supplementation in urine (A, B, C.), feces (D. E. F.) and plasma (G, H, I) after 70 days of HF diet. For 
each biological matrix, OPLS-DAs were calculated with LF, HF and HF + GOS groups (A, D, G), or LF, HF and HF + 
FOS_IN (B, E, H) or LF, HF_S and HF + GOS_CMO (C, F, I). Q
2
Y and R
2
Y for each model are given in Table 6.. LF 
(low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ 
GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) 
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Table 6: Statistics of global OPLS-DAs models and OPLS-DAs models with three groups generated with 
1
H NMR 
urinary, fecal or plasma metabolic signatures. (PC: predictive components, OC: orthogonal components) 
OPLS/OPLS-
DAs 
Class/continious variables 
(Y) 
time 
points 
components 
(PC+OC) R2Y Q2Y p value 
Urine 
LF, HF, HF_S, HF+GOS, 
HF+GOS_CMO, 
HF+FOS_IN, time 
from D7 
toD70 6+2 0.49 0.46 0.01 
LF, HF, HF + GOS D70 2+4 0.97 0.88 1 10-3 
LF, HF, HF + FOS_IN D70 2+4 0.9682 0.8519 1 10-3 
LF, HF_S, HF + GOS_CMO D70 2+5 0.97 0.8922 1 10-3 
Feces 
LF, HF, HF_S, HF+GOS, 
HF+GOS_CMO, 
HF+FOS_IN, time 
from D7 
toD70 6+2 0.46 0.24 0.03 
LF, HF, HF + GOS D70 2+3 0.96 0.63 1 10-3 
LF, HF, HF + FOS_IN D70 2+2 0.95 0.5301 1 10-3 
LF, HF_S, HF + GOS_CMO D70 2+2 0.96 0.37 1 10-3 
Plasma 
 1H NMR 
cmpg 
spectra 
LF, HF, HF + GOS D70 2+3 0.91 0.38 0.03 
LF, HF, HF + FOS_IN D70 2+3 0.94 0.35 0.02 
LF, HF_S, HF + GOS_CMO D70 2+4 0.92 0.49 0.02 
 
To confirm these observations, we aimed at estimating the percentage of “metabolic 
rescue” of urinary, fecal and plasma metabolic profiles induced by the supplementation of prebiotic 
during HF feeding (XFigure 37X). This percentage was estimated by predicting the scores of HF + GOS, 
HF + FOS_IN and HF + GOS_CMO onto OPLS-DA models generated with the negative control group 
(LF) and the positive control group (HF or HF_S). Therefore, a metric of the metabolic adaptation is 
built based on the scores of of LF and HF groups. The projections of the scores of the HF + prebiotic 
groups onto this metric are exclusively driven by changes in metabolic pathways affected during HF 
challenge and not by prebiotics derived metabolites. Significant differences between the predicted 
scores and the score of the negative control group (LF) or the positive control group (HF or HF_S) 
were estimated by non parametric Wilcoxon-Mann-Whitney tests (XTable 7X). Importantly, FOS_IN but 
not GOS and GOS_CMO supplementation induced significant “metabolic rescue” in urine. (HF + GOS: 
0.5% p value=0.09, HF + FOS_IN: 16.9 %, p value= 9.110-4, HF + GOS_CMO: 7.3% p value=0.11) 
However, all prebiotics triggered significant “metabolic rescue” in feces and plasma (XTable 7X). As 
previously observed, the “metabolic rescue” induced by prebiotics was more prominent in plasma 
(HF + GOS: 56.6%, HF + FOS_IN: 58.8%, HF + GOS_CMO: 51.7%) than feces (H F+ GOS: 13.5%, HF + 
FOS_IN: 38.5%, HF + GOS_CMO: 49.5 %). This indicates that FOS_IN, GOS and GOS_CMO enhanced 
circulating metabolite fluxes, which are crucial to maintain homeostasis in the organism. FOS_IN 
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triggered a greater “metabolic rescue” of urinary and plasma metabolic profiles suggesting that it 
was the most effective prebiotic for the maintenance of homeostasis. On the other hand, GOS_CMO 
had higher percentage of metabolic rescue in fecal metabolic profiles, which may indicate a greater 
ability to rescue the pattern of nutrient absorption. 
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Figure 37: Evaluation of the “metabolic rescue” of different prebiotics during HF challenge in urine, feces and 
plasma. The metabolic rescue of FOS_IN and GOS was estimated (in percentage) by predicting the score of HF 
+ GOS and HF + FOS_IN groups onto the first component of OPLS-DA model built with urinary (A), fecal (C) or 
plasma (E) metabolic profile of HF and LF groups. The “metabolic rescue” of GOS_CMO was calculated by 
predicting HF + GOS_CMO scores onto the first predictive component of the OPLS-DA models built with urinary 
(B), fecal (D) or plasma (F) metabolic profile of LF and HF groups. Negative control group (LF), positive control 
group (HF , or HF_S ) and test groups (HF + FOS_IN , HF + GOS or HF + GOS_CMO ) LF (low fat), HF (high fat), 
HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS 
and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin). 
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Table 7: Significance (p values) of the differences between the predicted scores (FOS_IN, GOS, or GOS_CMO) 
and the negative control group (LF) or the positive control group (HF or HF_S), p values were calculated by non 
parametric Wilcoxon-Mann-Whitney tests  
p values Urine feces plasma 
LF vs GOS 3.65 10-12 1.35 10-12 1.04 10-11 
HF vs GOS 0.09 0.04 1.88 10-14 
LF vs FOS_IN 2.11 10-09 5.56 10-12 5.03 10-08 
HF vs FOS_IN 9.18 10-4 7.29 10-08 1.02 10-10 
GOS vs FOS_IN 0.01 5.00 10-3 0.41 
LF vs GOS_CMO 6.69 10-15 2.14 10-09 7.93 10-16 
HF_S vs 
GOS_CMO 0.11 2.96 10-09 7.03 10-17 
 
3.2.5. 1H NMR spectral data of urine, feces and plasma samples at D70 
were compared between the diet groups using pair-wise OPLS-DA 
models  
In each biological matrix, metabolic variations associated with different HF feeding were 
derived by comparing metabolic profiles of LF group with either the metabolic profiles of HF, HF_S or 
each HF + prebiotic groups at D70 after the diet switch. To identify the individual metabolic response 
of each prebiotics, metabolic profiles of HF + GOS or HF +FOS_IN group were compared with those 
of HF group. Similarly, metabolic profiles of HF + GOS_CMO group were compared with those of 
HF_S group. Metabolic variation between mice fed with HF or HF_S diets were also investigated to 
evaluate the impact of free sugars and particularly lactose supplementation on the mouse 
metabolome during HF challenge. The heatmaps (XFigure 38X) showing metabolites with highest 
correlation coefficient values provide clearer information about the metabolic variations associated 
to the ingestion of HF, to the supplementation of prebiotics or lactose and the variation in the level 
of common metabolites between the different groups. 
High-fat ingestion strongly disturbs mouse fecal, plasma and urinary metabolic profile. 
Consumption of HF diet for 70 days led to a disruption in nutrient digestion process. In 
particular, the bile acid pool responsible for the emulsion and digestion of lipids increased in feces of 
HF-fed mice (XFigure 38X.D)H152H. Fecal glycerate level was also higher in HF and HF_S fed mice whereas 
fecal valine level exclusively increased in HF group (XFigure 38X.D). 
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Long-term HF feeding markedly affected plasma metabolic profiles which were characterised by an 
increase in D-glucose, LDL and unsaturated lipids in 1H NMR standard spectra of the HF and HF_S 
groups (XFigure 38X.A, XFigure 38X.B). Leucine, valine and citrate levels were also similarly reduced in 
plasma of the same groups. In addition, resonances of scyllo-insitol and myo-insitol were significantly 
lower in all HF containing diet groups excepted for the HF + GOS group in which myo-inositol level 
was comparable to those of the LF group. 
HF diet with or without prebiotic supplementation was remarkably associated with a urinary 
metabolic signature involving an increase in branched chain amino acids (BCAAs) catabolism 
intermediates (ketoleucine, α-keto-β methylvalerate and α-ketoisovalerate) and an increase in 
putrescine (XFigure 38X.C). TMA is produced by gut microbial degradation of choline, and TMAO is 
formed in the liver by TMA detoxification process. Both metabolites significantly decreased in 
urinary profiles of all HF groups compared to the LF group with the exception of the HF + FOS_IN 
group which had urinary TMAO level comparable with those of the LF group. With the exception of 
HF + FOS_IN group, urinary metabolic profiles of HF, HF_S and HF + prebiotics groups were 
characterised by an increase in glucose and unassigned o-acetyl-glycan. This result confirms the 
physiological data which indicated that FOS_IN supplementation during HF challenge enabled to 
maintain normal fasting glycaemia over time. HF, HF_S, HF + GOS, HF + GOS_CMO but not HF + 
FOS_IN groups were associated with an increase in 2 PY and 4 PY which are end-products of 
NAD/NADP pathways and an increase in carnitine known as an essential transporter allowing fatty 
acid (FAs) uptake in mitochondria for β-oxidation. Sucrose resonances were also decreased in HF and 
HF + prebiotic groups compared to LF group. This is explained by the fact that LF diet, rich in 
carbohydrate, contained more sucrose than all HF diets (see Appendix 2, Table S1). However a 
urinary increase in sucrose was noticed in the HF + GOS_CMO group compared to the HF_S group 
even though none of the diets were supplemented in sucrose. The presence of sucrose in HF + 
GOS_CMO diet may arise from the commercial fibres or CMO blends.  
Supplementation with GOS, GOS_CMO and FOS_IN triggered various metabolic rescue effects. 
The estimation of “metabolic rescue” of prebiotics in each matrix indicated that prebiotics 
consumption during HF challenge improved the metabolic profiles by reducing the range of 
metabolic variations observed between mice susceptible to develop obesity (HF and HF_S groups) 
and healthy mice (LF group). OPLS-loadings plots interpretation from pair-wise OPLS-DA models 
enabled us to identify which metabolites are significantly recovered by prebiotic supplementation in 
each matrix. In particular, prebiotic supplementation rescued lipid levels and circulating LDL as no 
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difference in standard 1H NMR spectra from plasma was noticed between LF and HF + prebiotics 
groups with the exception of HF + GOS_CMO group, which had higher LDL level than LF group. GOS 
and FOS_IN supplementation specifically enabled to maintain plasma scyllo-inositol and citrate levels 
similar to those of the LF group. As previously mentioned, FOS_IN supplementation improved the 
urinary metabolic signatures, as it maintained the urinary concentration of D-glucose, unassigned o-
acetyl-glycan, TMAO, indoxylsulfate, carnitine, 2 PY and 4 PY similar to those observed in the LF 
group. 
Prebiotic supplementation triggered common metabolic regulations 
Prebiotic supplementation during HF challenge initiated a common urinary metabolic 
signature involving gut microbial activity. The excretion of PCS, PCG, phenylacetylglycine (PAG) and 
hydroxyphenylacetic acid, which are end-products of gut bacterial amino acid metabolism, were 
found in significantly lower levels in urinary metabolic profiles of all HF + prebiotics compared to HF, 
HF_S and LF groups. Common changes in fecal metabolic profiles were observed as all prebiotics 
induced an up-regulation of 3-D-hydroxybutyrate, butyrate and succinate compared to LF and HF 
and HF_S groups.  
The differential metabolic signature associated with prebiotics supplementation results from a 
complex interaction between diet composition and secondary metabolism.  
Each prebiotic supplementation induced a specific metabolic signature, which resulted from 
a complex interaction between diet composition and secondary metabolism. The increased urinary 
galactose and glucose excretion in HF + GOS fed mice or HF + GOS_CMO fed mice was exclusively 
due to a higher galactose and glucose supply from the diet as GOS fibres were made from polymers 
of galactose and glucose. On the other hand, GOS and FOS_IN groups were associated with a urinary 
increase in α-ketoisovalerate and ketoleucine respectively, characterising a modulation of BCAAs 
metabolism. FOS_IN supplementation also induced higher circulating levels of pyruvate, acetate and 
3-D-hydroxybutyrate whereas GOS_CMO supplementation was positively correlated with urinary 
carnitine and acylcarnitine excretion. These results suggest prebiotics specific variations of 
mitochondrial oxidative pathways and energy metabolism. In addition, fecal metabolic profiles of HF 
+ FOS_IN and HF + GOS_CMO fed mice were marked by a higher excretion of xanthine and uracil, 
which are respectively purine and pyrimidine base. 
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Free sugars supplementation effects during HF challenge 
There was no significant difference in fecal, and plasma metabolic profile (CPMG and 
standard 1H NMR spectra) between HF and HF_S groups indicating that lactose ingestion does not 
induce significant variation in plasma and fecal metabolism as detected by 1H NMR analysis. 
However, urinary metabolic profile exhibited an increased concentration of galactose and glucose in 
HF_S fed mice and an increased concentration of sucrose in HF-fed mice. This is explained by the fact 
that sucrose was the only carbohydrate source in HF diet. This disaccharide is predominantly 
digested by sucrase in the small intestine to form glucose and fructose which are in turn absorbed by 
the mucosal barrier and further metabolized in the liver152. However, a small amount of undigested 
sucrose can directly cross the intestinal barrier and reach the blood or being bypassed in urine186. In 
case of inadequate nutrition, stress, or critical illness, sucrase activity can be altered and/or mucosal 
barrier integrity can be compromised leading to increased absorption of undigested sucrose187. In 
the present experiment, long-term ingestion of HF diet may modify mucosal permeability and brush 
border enzymes activity such as sucrase, favouring sucrose absorption.  
On the other hand, HF_S diet was exclusively supplemented by free sugars i.e: glucose, 
galactose and lactose (glucose+galactose). The increased urinary glucose level in HF_S fed mice 
might arise from dextrose absorption or from lactose digestion into glucose and galactose followed 
by the absorption of these free sugars. HF_S diet also induced a decrease in PAG and PCS in 
comparison to HF diet. This suggested that free sugars supplementation during HF challenge affects 
gut bacterial activity and/or host conjugation metabolism compared to sucrose supplementation. 
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Figure 38: Comparison of metabolic signatures associated to different diet groups. (A) Standard 
1
H NMR 
plasma metabolic profiles (B) CPMG 
1
H NMR plasma metabolic profiles (C) Standard 
1
H NMR urinary metabolic 
profiles (D) Standard 
1
H NMR faecal metabolic profiles. Correlation values (R) of the metabolites are displayed 
by color code. Gradient of red color are for metabolites positively correlated with HF or HF_S (in LF vs HF or LF 
vs HF_S models) or HF + prebiotics (in LF vs HF+prebiotics or HF vs HF + prebiotic models). The gradient of blue 
colors are for metabolites negatively correlated with the same diet groups LF (low fat), HF (high fat), HF_S (HF 
+ glucose-galactose-lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow 
milk oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin) (PC: predictive components, 
OC: orthogonal components). 
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3.2.6. Targeted LC/direct infusion MS analysis of plasma samples 
reveals strong variations in lipid and amino acid metabolism with 
prebiotic supplementation after 70 days of HF challenge. 
Targeted MS analysis of plasma samples using internal isotopically labeled standards was 
performed to further investigate the regulation of lipid and amino acid metabolism in different diet 
groups. A global OPLS-DA model comparing all diet groups together was performed to identify the 
general difference in lipid and amino acid profile between groups. The Y matrix of the models was 
built with 5 dummy variables to categorise the different diet groups in separate classes (statistics of 
the model in XTable 8X). The OPLS-DA score plot (XFigure 39X.A) showed a good separation between the 
negative control group (LF) the positive control groups (HF and HF_S groups) and the prebiotic 
groups (HF + GOS, HF + GOS_CMO, HF + FOS_IN). The corresponding loadings plot ( XFigure 39X.B) 
highlighted HF associated increase in phosphatidylcholines (PCs and PC-Os), sphingomyelins (SMs) 
and lysophosphatidylcholines (LPCs), which is in accordance with 1H NMR plasma metabolic profiles 
indicating higher lipid content in circulation with HF diets. On the other hand, several 
lysophospholipids (LPCs), acylcarnitines and amino acids followed an opposite trend as they were 
positively correlated with LF group or prebiotics groups. Additionally, pair-wise OPLS models were 
calculated to obtain correlations between metabolites and group separation (statistics of the models 
in XTable 8X). For each model, significant correlations were used in a correlation matrix to determine 
common patterns of regulation of circulating lipids and amino acids between groups. The correlation 
matrix emphasised several metabolic clusters (XFigure 40X) indicating significant trends in lipids and 
amino acids variations. The cluster grouping PC and PC-O indicated that HF ingestion with or without 
prebiotic supplementation triggered an increase in long chain fatty acid (LCFAs) containing 
phosphatidylcholines with various levels of unsaturations. In addition, SM C16, SM C16:1, SM-OH 
C16:0, SM C18:0, SM C18:1 and LPC C17:0 and C18:0 were positively correlated with HF containing 
diets. On the other hand, LPC a C18:1 and LPC a C16:1 increased in LF group compared to all HF diet 
groups as observed on LPC cluster (XFigure 40X). Interestingly, the comparison of correlation 
coefficients between OPLS-DA model built with LF and HF groups or LF and HF_S groups showed that 
ingestion of HF_S tended to increase the level of circulating LCFAs and very long chain fatty acids 
(VLCFAs) containing PCs with several insaturations. However, some of these lipids (such as PC C30:0, 
C30:2, C40:6 and PC-O C30:0 and PC-O C38:4) were negatively correlated with HF + GOS_CMO 
compared to HF_S (as indicated in the 8th column in the correlation matrix). This result highlighted 
that GOS and CMO supplementation during HF challenge improved circulating LCFAs containing 
lipids. It is also important to note that no significant difference in plasma lipid and amino acids 
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profile between HF and HF_S groups was identified by OPLS-DA model suggesting that lactose and 
free sugars supplementation in HF diet had a subtle effect on lipid metabolism. Lipid profiles of HF 
and HF_S fed mice were also marked by a reduction in short chain acetyl-carnitines (C2), propionyl-
carnitine (C3), butyryl-carnitine (C4), isovaleryl-carnitine (C5), palmitoyl-carnitine(C16), palmitoleyl-
carnitine C16:1 oleyl-carnitine (C18:1) (XFigure 40X). Prebiotic supplementation during HF challenge 
allowed to recover acylcarnitine profiles as C2, C3, C4, C5 increased in HF + prebiotic diets compared 
to HF or HF_S diets and were not significantly different between the HF + prebiotics and the LF 
group. In addition, the linoleic acid (C18:2) which is an essential FA exclusively increased in mice fed 
with HF + prebiotic. 
Circulating amino acid profile was not significantly modulated by HF ingestion and prebiotic 
supplementation with the exception of FOS_IN supplementation that triggered an increase in several 
amino acids during HF challenge as observed in the “amino acids” cluster. In addition, circulating 
kynurenine, which is the end-product of tryptophan degradation, was found in higher levels in LF 
group compared to all HF containing diet groups excepted for HF + FOS_IN. All together, these 
results indicated a specific regulation of amino acid metabolism in HF + FOS_IN fed mice.  
Overall, targeted MS method are corroborating the results obtained by untargeted 1H NMR 
profiling as significant increase in circulating lipids in HF-fed mice compared to LF-fed mice were 
observed. Targeted MS analysis gives also additional information in lipid class differences between 
the diet groups. Interestingly, it showed that HF + prebiotics fed mice exhibit an increase in several 
lipid classes compared to LF-fed mice whereas no significant difference in circulating lipids content 
was found by 1H NMR between these groups. In addition, the targeted MS method, which offers a 
better sensitivity (see Chapter II, section X2.3X for more details on the MS targeted analysis) enabled 
us to spot difference in several amino acids between HF + FOS_IN and HF-fed mice not detectable by 
the 1H NMR untargeted metabolic explanation approach. Therefore, MS targeted method provide 
highly reliable results on semi-quantitative metabolite differences and improve the level of 
information on specific metabolic pathways already selected by 1H NMR untargeted profiling. 
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Figure 39: Global OPLS-DA comparing plasma lipid and amino acid variations between different diet groups 
measured by targeted LC/direct infusion MS. OPLS-DA score plot (A.) showed the main variations in the 
dataset while OPLS-DA loadings plot (B.) indicated metabolite contributions to the separation between diet 
groups. LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-lactose), HF + GOS (HF + galactosyl-
oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk oligosaccharides), HF + FOS_IN (HF + fructosyl-
oligosaccharides and inulin). 
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Figure 40: Comparison of the plasma metabolic signature acquired by MS targeted profiling analysis among the 
different diet group at D70 after the diet switch. The correlation matrix summarises the pair-wise OPLS-DA 
models between the different diet groups. Each column represent an OPLS-DA model comparing the two 
groups groups indicated above each column, and illustrates the variation in circulating levels of lipids, amino 
acids, acylcarnitines and other metabolites. For each model, correlation coefficients were obtained from the 
OPLS-DA coefficient plot. Correlation values (R) of the metabolites are displayed by color code. Gradient of red 
colors is for metabolites positively correlated with HF or HF_S (in LF vs HF or LF vs HF_S models) or HF + 
prebiotics (in LF vs HF+prebiotics or HF vs HF + prebiotic models). The gradient of blue colors is for metabolites 
negatively correlated with the same diet groups. Cx:y is the abbreviation of lipid chain (x :the number of 
carbons in the side chains, Y: number of insaturations). LF (low fat), HF (high fat), HF_S (HF + glucose-galactose-
lactose), HF + GOS (HF + galactosyl-oligosaccharides), HF+ GOS_CMO (HF + GOS and cow milk 
oligosaccharides), HF + FOS_IN (HF + fructosyl-oligosaccharides and inulin). LPC (lysophosphocholine) PC/PC-Os 
(phosphocholines) SMs (sphingomyelins). 
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Table 8: Statistics of the OPLS-DAs models calculated with MS targeted metabolic profiles of plasma samples at 
D70 after the diet switch (PC: predictive components, OC: orthogonal components). 
Groups 
components 
(PC+OC) R2Y Q2Y p value 
LF, HF, HF_S, 
HF+GOS, 
HF+FOS_IN, 
HF+GOS_CMO 
4+1 0.48 0.23 0.04 
LF vs HF 1+2 0.99 0.95 1 10-3 
LF vs HF_S 1+2 0.98 0.95 1 10-3 
LF vs HF+GOS 1+4 0.99 0.91 1 10-3 
LF vs 
HF+GOS_CMO 1+2 0.98 0.94 1 10-3 
LF vs HF+FOS_IN 1+2 0.98 0.88 1 10-3 
HF vs HF+GOS 1+3 0.97 0.67 1 10-3 
HF vs HF+FOS_IN 1+1 0.92 0.86 1 10-3 
HF_S vs 
HF+GOS_CMO 1+2 0.95 0.73 1 10-3 
HF vs HF_S 1+1 0.8 -0.51 0.8 
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4. DISCUSSION 
 After a pre-intervention period of 3 weeks (where all mice were fed a LF diet), C57BL/6 mice 
were divided among 6 groups of similar weight and glycemia and fed with either LF, HF, HF_S, HF+ 
GOS, HF+GOS_CMO or HF+ FOS_IN diets for 70 days. Physiological measurement (BWG, food intake, 
glycemia, insulinemia, fat mass) were performed across the experiment and circulating cytokines 
were measured at D70 after the diet switch. 1H NMR metabolomic analysis (urine, plasma, feces) 
and targeted MS analysis (plasma) were carried out across the experiment and particularly at D70 
after the diet switch.  
The present study showed that long-term HF challenge triggered progressive development 
of obesity, disturbed lipoprotein profiles and caused fasting hyperinsulinemia and hyperglycaemia. 
After 70 days, the physiological status of HF and HF_S fed mice met enough criteria 
(hyperinsulinemia, hyperglycaemia, and obesity) for the metabolic syndrome which is known to raise 
the occurrence of metabolic diseases such as T2DM NAFLD and CVDsH188. Our results also 
demonstrated that supplementation of different prebiotics during HF challenge led to a strong and 
similar preventive effect on BWG as well as a comparable reduction in fat mass. Inflammatory 
responses associated with long-term HF diets were also partly reduced with prebiotic 
supplementation. In addition, by using a 1H NMR and targeted MS profiling of urine, plasma and 
feces, specific disruption of energy metabolism and gut microbial–host metabolites interactions 
were identified during HF challenge which are partly prevented with prebiotic supplementation. This 
study highlighted the role of prebiotics in the improvement of mouse phenotype and metabolic 
homeostasis under diet induced obesity (DIO). 
  
4.1. HF ingestion induce a saturation of hepatic lipid 
metabolism 
1H NMR and MS profiling both showed an increase in serum lipids and PCs content for HF 
and HF_S fed mice. In particular, an increase in LDL in HF and HF_S fed mice compared to LF-fed 
mice was associated with an increase in LCFAs and VLCFAs containing phosphocholines in both HF 
groups. Importantly, plasma collections were carried out at fast which provides insight about 
endogenous lipid recirculation with the different diet interventions. During a fasting period, 
triglycerides (TGs) are broken down into FAs in the adipose tissues which are in turn released in the 
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peripheral tissues (see introduction). FAs in peripheral tissues (such as kidney, muscle, liver) are 
finally degraded via mitochondrial β-oxidation to produce ATP. However, in the context of prolonged 
HF feeding leading to high calorie supply, lipids in the liver can be redirected toward peripheral 
tissues in the fasting periodH189H. Hepatic TG, PCs or SMs are compartmented in VLDL and secreted in 
the blood. TGs packed in VLDL reach capillaries in organs and tissues and are degraded into FAs by 
lipoprotein lipase (LPL). FAs are finally absorbed in tissues and organs152. Therefore, high fat 
ingestion is often associated with increased FAs in circulation and dyslipidemia49,189.  
In this experiment, it is most likely that the increase in several circulating PCs and 
lipoproteins during a long-term HF challenge was triggered by a saturation of hepatic lipid storage. 
The overproduction of hepatic TGs associated with HF ingestion and impaired glucose metabolism 
might promote lipid exportation from the liver to peripheral tissues where they can be used to 
produce energy or being transformed and stocked into TGs. This ectopic fat accumulation is 
commonly observed in obese subjects and contributes to host metabolic dysregulation (see 
introduction) 189. 
HF diet was also associated with an increase in LPCs and SMs. Alteration of lipid composition 
is believed to play a role in chronic inflammatory and metabolic disorders via various signalling 
pathways. LPCs are one of the most important oxidation products derived from phosphatydylcholine 
in oxidized LDL. This biologically active class of lipids has been though to promote the release of 
cytokines by activating the TLR-4, affects the permeability of endothelial cells and raise oxidative 
stress. LPCs may also impair insulin secretion via the activation of protein kinases (IKβ and JNK) (see 
Chapter I, section X1.4X)190. SMs obtained via the transfer of phosphocholine head groups from 
phosphatyldycholine onto ceramides are also biologically active molecules. They interact with G-
protein receptors that result in activation of downstream signalling pathways including the inhibition 
of phosphatidylinositol-3-kinase (PI3K)/Akt protein kinases pathways191,192. Both LPCs and SM have 
been shown to increase in genetically obese rats or mice193,194. Although physiological functions of 
these lipids are still under investigations, it seems clear that HF ingestion leading to an increase in 
circulating lipids in the form of SMs and LPCs and PCs contributes to the deregulation of glucose 
metabolism, inflammation and the development of metabolic diseases. To summarise, long-term HF 
feeding triggered dyslipidemia and increased several biologically active lipids in circulation probably 
due to an hepatic TG saturation. This might contribute to DIO associated metabolic and 
immunological disturbances. 
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4.2. HF challenge alter mitochondrial oxidation efficiency 
Circulating acylcarnitines profiles at fast were also modulated with long-term HF challenge 
as indicated by an increase in C18, and a decrease in C2, C4, C18:1, C18:2, C16 and C16:1 in HF and 
HS_S mice compared to LF-fed mice. Carnitine is essential for the transport of FAs from the cytosol 
to the mitochondria for subsequent β-oxidation. Acylcarnitines are carnitine-esters derived from FAs 
or amino acids transferred into the mitochondria. While odd acylcarnitines exclusively result from 
the BCCA catabolism even acylcarnitines are produced from β-oxidation and C4 can be produced 
from both152.  
Decreased in C16:1, C18:1, C18:2 in HF and HF_S mice suggests a greater mitochondrial β-
oxidation of long chain mono or poly-unsaturated FAs with HF diet. In addition, a decrease in short 
chain fatty acylacrnitines (C2, C4) also support the hypothesis of an effective β-oxidation of SCFAs. 
On the other hand, higher circulating C18:0 in HF and HF_fed mice might reflect an incomplete 
oxidation of saturated FAs. Altered circulating acylcarnitines profiles have been already observed in 
obese and T2 DM subjects195,196. Moreover, reduced skeletal muscle β-oxidation of LCFAs and MCFAs 
has been already associated with insulin resistance and T2DM151. Our results indicate a differential 
mitochondrial efficiency in FAs oxidation with HF challenge which might contribute to impaired 
glucose metabolism and metabolic disturbances151. This might be explained by a mitochondrial fat 
overloading leading to altered β-oxidation and generation of incomplete β-oxidation end-products 
(C18:0).  
In the previous Chapter III (section X3X and X4X ), a urinary increase in BCAAs intermediates, TCA 
cycle intermediates and NAD pathways end-products (2 PY, 4 PY) were identified in HF-fed mice 
compared to LF-fed mice 7 days and 60 days after the diet switch. From these findings, HF diet has 
been suggested to provoke a rapid and consistent up-regulation of BCAAS, β-oxidation and TCA cycle 
which might lead to a saturation of mitochondrial oxidative pathways 151,153,170. In the present 
experiment, urinary metabolic profiles of HF and HF_S fed mice also exhibited a higher excretion of 
BCAA catabolism intermediates (isovalerylglycine, α-keto-β methylvalerate, α-ketoisovalerate), 2 PY 
and 4 PY than LF-fed mice which highlight a saturation of mitochondrial oxidative pathways and 
energy metabolism in the context of HF induced obesity. By contrast, the concentration of short-
chain acylcarnitines (C2, C3, C4, C4-OH, C5) decreased in plasma of HF and HF_S fed mice. This 
suggests a reduced transport of BCAA catabolism end-products in the general circulation and 
increased clearance of intermediate metabolites of BCAA catabolism in urine. Altogether, these 
results highlight an altered activity of β-oxidation and BCAA catabolism in HF-fed mice which might 
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results from an mitochondrial oxidative fuel overloading. Mitochondrial activity, which play a crucial 
role in energy production have been found to affect insulin signalling151. Therefore, impaired 
mitochondrial metabolism may be the triggering factor of insulin resistance and host metabolic 
disturbances in DIO. 
 
4.3. Prebiotic supplementation during HF diet limit 
dylipidemia improves mitochondrial oxidative pathways.  
This experiment showed that supplementation of different prebiotics during HF challenge 
led to a strong and similar limitation of BWG as well as a comparable restriction of fat mass. In 
addition, prebiotic supplementation induced specific metabolic regulations allowing a partial return 
of internal homeostasis as characterised by a significant proportion of “metabolic rescue” in feces, 
and plasma of HF + prebiotics fed mice. Interestingly GOS and GOS_CMO induced “metabolic 
rescue” was significant in feces and plasma but not in urine. In addition, the metabolic rescues of 
FOS_IN were significant in all biological matrice but more important in feces and plasma than in 
urine. In a perturbed system such as HF-fed mouse, plasma is strongly regulated to maintain 
effective biological processes but this requests the activation of specific metabolic pathways 
allowing compensation for the metabolic stress. Urinary metabolic profiles on the other hand, 
contain end-products of metabolic pathways and products of degradation from the organism; hence 
it reflects the “homeostatic effort” i.e the prebiotic-specific metabolic adaptation necessary for the 
organism to maintain “this biological robustness”.  
1H NMR and MS metabonomic data exhibited a partial rescue of lipid profiles toward a 
healthy status due to prebiotic supplementation. In particular, no difference in plasma lipoproteins 
were found between LF and HF + prebiotic fed mice at D70 after the diet switch was noticed. This 
highlights a prebiotic induced-reduction in mouse dyslipidemia during HF challenge. In addition, 
changes in several plasma acylcarnitines levels were observed in HF + prebiotic fed mice compared 
to HF and HF_S fed mice at D70 after the diet switch189. All HF + prebiotic diets showed an increase 
in C2, and C4 compared to HF and HF_S fed mice and no difference of C2 and C4 level with LF-fed 
mice. These variations might be explained by a reduced utilization of short chain fatty acylcarnitines 
to from energy or by an activation of the last β-oxidation steps producing short chain fatty acids 
(SCFAs) which could then be transported out of the mitochondria. If the last scenario is true, this 
would indicate that prebiotic supplementation enhance a complete β-oxidation of FAs. Previous 
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studies have already shown positive correlations between increased muscle acylcarnitines and 
enhanced FA oxidation197,198. HF + FOS_IN diet was also marked by an increase in C16, C16:1, C18:1, 
while HF + GOS diet was positively correlated with C16, C18:1, C3:1 and C4:1 compared with HF fed 
mice. On the other hand, C4, C4:1, and C16 levels were not different between LF and HF + FOS or HF 
+ GOS fed mice. GOS or FOS supplementation during HF challenge may specifically improve β-
oxidation of unsaturated FAs and increase mitochondrial oxidative efficiency toward those of LF-fed 
mice as indicated by similar acylcarnitine levels. Interestingly, C18:2 were also found to be elevated 
with HF + prebiotic compared to LF, HF of HF_S fed mice. This is also suggestive of a specific 
regulation in mitochondrial β-oxidation of poly-unsaturated FAs. In addition, urinary level of 
NAD/NADP pathways end-products (2PY and 4PY) in HF + FOS_IN fed mice were similar to those of 
LF-fed mice which displayed a normalization of mitochondrial oxidative activity with FOS_IN 
supplementation151,159,199. 
Interestingly, isovalerylglycine and α-ketoisvalerate which derived from leucine and valine 
catabolism respectively were found elevated in HF + FOS and HF + GOS fed mice compared to HF and 
HF_S fed mice152. BCAA catabolism also occurred within the mitochondria and its activation is 
affected by mitochondrial fuel overloading151,170. Therefore, increased en-products of BCAA 
catabolism intermediates (isovaleryl-CoA and α-ketoisvalerate) might reflect an activation of 
mitochondrial BCCA oxidation with prebiotics.  
Altogether, our results suggest that prebiotic supplementation decreased ectopic fat 
storage, lowering dyslipidemia and improving mitochondrial oxidative pathways. Furthermore, by 
enhancing mitochondrial metabolism, prebiotic supplementation may favour the transport of 
mitochondrial oxidative end-products, (i.e acylcarnitines and BCAA catabolism intermediates), and 
reduced oxidative product accumulation which is deleterious for host cells172,173.  
 
4.4. FOS_IN activate amino acid metabolism involved in 
insulin signalling and mitochondrial metabolism 
Based on the percentage of “metabolic rescue” in urine and plasma, FOS_IN was the most 
effective prebiotic in recovering partial internal homeostasis. In addition, only FOS_IN 
supplementation during HF challenge maintained normal fasting glycemia which is consistent with 
previous nutritional studies indicating that FOS improves glucose secretion95,200. Interestingly, 
circulating amino acid concentration increased in response to FOS_IN supplementation (Asp, Gln, 
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Glu, His, Lys, Met, Ser, MetSo, Phe, Pro, Thr, Tyr, Ile, Val). Amino acids are known to regulate key 
metabolic pathways that are involved in cell signalling, inflammation and hormone secretion44. In 
particular, leucine and arginine have been though to stimulate insulin signalling pathways. Gunnerud 
et al have also demonstrated that drinking beverage containing 5 insulinogenic amino acids before 
any meal limits glucose postprandial responses201. Therefore, increased circulating amino acids 
might trigger or at least contribute in the improvement of glucose homeostasis in HF + FOS_IN fed 
mice.  
Additionally, FOS_IN like the other prebiotics was found to improve mitochondrial oxidative 
pathways during HF challenge. This might be explained by an activation of amino acid metabolism. 
Amino acids play a crucial role in energy homeostasis since they are precursors of TCA cycle 
intermediates and activate mitochondrial enzymes44. BCAAs have been reported to up-regulate 
mTOR which promotes cells oxidative capacity and PGC-1 mediated mitochondrial gene expression 
and results in enhanced mitochondrial biogenesisH202. Higher mitochondrial biogenesis has been 
thought to favour amino acid catabolism. On the other hand, mTOR is also a key regulatory enzyme 
of protein synthesis44. In line with this, BCAA transaminase KO mice displayed higher level of 
circulating BCAAS and were associated with increased muscle proteins synthesis, decreased fat mass 
and increased body energy expenditure203. This continuous synthesis and protein degradation is 
characterised as proteins turns over and consumes a large amount of ATP44,152. Hence, FOS_IN 
supplementation during HF challenge probably elevates protein turnover rate resulting in increased 
energy expenditure and improved energy homeostasis.  
Interestingly, FOS_IN supplementation were found to specifically increase urinary 
isovalerylglycine, which is a glycine conjugate of leucine catabolism intermediate: isovaleryl-CoA. 
Higher ketone body level (3-D-hydroxybutyrate) in plasma metabolic profiles of HF + FOS_IN 
compared to HF-fed mice also indicated an up-regulation of ketogenesis with FOS_IN 
supplementation. In the previous chapter (Chapter III, section X4X), HF diet containing relatively low 
carbohydrate content induced an increase in BCAA catabolism which in turn might activate 
gluconeogenesis and exacerbate glucose intolerance in HF-fed mice. However, obesity resistant mice 
under HF challenge tend to preferably activate leucine catabolism which is a ketogenic pathway thus 
protecting mitochondria against fuel overloading and limiting the formation of glucose via 
gluconeogenesis. Hence, HF + FOS_IN fed mice exhibit a significant lower fasting glycemia than all HF 
containing diet groups. Hence, FOS_IN might specifically up-regulate leucine catabolism and 
ketogenic pathways which in turn might alleviate HF induced impaired mitochondrial oxidation. A 
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specific activation of ketogenic pathways rather than gluconeogenesis with FOS_IN supplementation 
might also protect the organism against impaired glucose homeostasis.  
Nevertheless the exact reason why FOS_IN but not GOS or GOS_CMO activated amino acid 
metabolism remains to be explained. FOS_IN supplementation during HF diet challenge may 
increase dietary amino acid absorption by selecting specific gut microbial activity/composition which 
in turn may modulate the internal amino acid metabolism. However, it is important to note that 
these amino acid variations occur during a fasting period. Several amino acids such as phenylalanine, 
tryptophan, lysine and methionine are mainly absorbed intact in the organism but recent studies 
have shown that up to 30% of the extracted dietary amino acids are oxidized in the small intestine44. 
Of note, Kong et al demonstrated that herbal powder supplemented diet improves dietary amino 
acid extraction and absorption which results in elevated amino acid in circulation in post weaning 
pigs204. In the present trial, all prebiotics triggered a similar down regulation of bacterial amino acids 
degradation in the large intestine. However, specific regulation of amino acids processing in the 
small intestine could not be monitored by our experimental design. 
 
4.5. Prebiotics supplementation during HF challenge 
improves mouse health by modulating colonic bacterial 
fermentation. 
The inflammatory responses triggered by ingestion of HF have also been partly balanced by 
prebiotic supplementation since the concentration of circulating cytokines tended to decrease in HF 
+ prebiotic groups compared to HF and HF_S groups with the exception of TNF-α. Common 
metabolic signatures associated with various prebiotic supplementations have been identified at 
D70 after the diet switch and involved a specific gut microbial activity. Indeed, higher excretion of 
SCFAs was observed in feces of mice fed HF + prebiotics compared to mice fed a fibre content 
matching HF diets, which might indicate an increase production of SCFAs in the colon. Different 
types of nondigestible polysaccharides including resistant starch, non-digested oligosaccharides, 
undigested portions of oligosaccharides and sugars alcohols enter the large bowel where they are 
fermented by colonic bacteria which produce SCFAs mainly acetate, propionate and butyrate205. The 
proportion of fermentation of these carbohydrates varies according to host, nutritional, and dietary 
factors, which affect the yield and the type of SCFAs produced by the gut microbiota205,206. To a 
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certain extent, SCFAs promote saccharolytic bacteria in the gut and induce various physiological 
impacts on host body206.  
Many of health benefits conferred to prebiotics can be largely attributed to fermentation 
process and SCFAs production95. In particular, SCFAs have been associated with a large range of anti-
inflammatory properties in the literature. They interact with GTP-binding proteins (GPCR41, 
GPCR43) in the immune cells of human colons and promote chemokine expression in the 
epithelium207,208. They also repress NF-kB and they differently affect the production of pro-
inflammatory markers in the leukocytes such as IL-2 and IL-10209. Production of SCFAs has been also 
reported to reduce food intake and hunger feeling by various physiological processes. Higher SCFAs 
concentration in the lumen stimulates upper gut motility and decreases transit time, resulting in the 
modulation of nutrient digestion and absorption. Butyrate enhances satiety by increasing peptide YY 
and proglucagon synthesis in epithelial cells and by inhibiting the expression of neuroendocrine 
factors such as leptin209,210. For instance, Delzenne, et al highlighted that oligo-fructoses 
consumption reduces food intake and reverses diet-induced insulin resistance in mice. These 
phenomena are likely to be caused by increased SCFA production such as butyrate200. Elevated 
concentrations of succinate in fecal content of HF + prebiotic groups suggest an increased 
fermentation in the gut. However this metabolite may be an intermediate product of fermentation 
from carbohydrates as well as proteins, endogenous and exogenous glycoproteins206. The higher 
level of ketone body (3-D-hydroxybutyrate) in feces of HF + prebiotics groups also pointed out an 
increased butyrate oxidation in the mucosa of the distal colon. All SCFAs are metabolised to provide 
energy to epithelium, however butyrate is the main source of fuel for colonocytes and its oxidative 
product can enter TCA cycle or being oxidised by mammalian enzymes into ketones bodies. Indeed, 
butyrate is absorbed by colonic epithelial cells and transformed into butyryl-CoA by CoA 
transeferase. Butyryl-CoA can be then oxidised into crotonyl-CoA by the butanoyl-CoA 
dehydrogenase which in turn induce the formation of acetoacetate. Finally acetoacetate can trigger 
the formation of ketone bodies or being transformed into acetyl-CoA before entering TCA cycle152. It 
is acknowledged that higher utilisation of butyrate as energy source for the colonotcytes stimulates 
cell growth and differentiation which is essential in maintaining gut health206H In addition, De Vadder 
et al, have recently demonstrated that SCFAs stimulate intestinal gluconeogenesis by 
complementary mechanisms which contribute to the metabolic benefits of fibre enriched diets 211. In 
particular, propionate acts as an agonist of the fatty acid receptor FFA3 and initiates the gut brain 
neural circuit in the peripheral afferent neural system which triggers the activation of intestinal 
gluconeogenesis gene expression. On the other hand, butyrate directly activates intestinal 
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gluconeogenesis gene expression in the enterocytes by increasing cAMP211. As previously mentioned 
in the introduction (section 3.2), intestinal gluconeogenesis is suggested to play an important role in 
satiety control and in the regulation of glucose homeostasis. Therefore, activation of intestinal 
gluconeogenesis by SCFAs may be among the underlying mechanisms contributing to the decreased 
energy storage and fasting glycaemia in HF + prebiotic fed mice in our experiment. However, no 
gene expression or enzyme activity of intestinal gluconeogenesis have been measured to support 
this hypothesis.  
The modification of the balance of the intestinal ecosystem by different prebiotic 
supplementation has led to a regulation of other bacterial fermentation processes. In particular, the 
fecal content of HF + prebiotics groups was marked by a reduction of PCG and PCS which derived 
from end product of gut bacterial degradation of tyrosine31,102. In healthy subjects, the normal 
population of bacteria produces a limited amount of these molecules. However, previous studies 
have shown that a modulation of gut microbial composition leading to an increased enzyme activity 
involved in bacterial proteolysis, triggers an increased level of phenol derivatives in the colons (i.e. 
nitrosamines, heterocyclic amino acid, indoles, phenol, p-cresol) which may have carcinogenic 
effects87,212. By contrast, the diminution of pH associated with increased ingestion of fermentable 
carbohydrates and SCFA production has been though to decrease bacterial proteolysis181. GOS, FOS 
and GOS_CMO may therefore, promote the growth of commensal bacteria, which in turn may 
promote a more favourable micro-environment in the intestine (ideal pH, reduction of potentially 
harmful bacteria) and inhibit gut bacterial amino acid degradation. 
 
4.6. GOS supplementation alleviated inflammatory 
responses induced by the combination of HF and lactose mal-
absorption. 
C57BL/6 mice as many other rodents suffered from lactose mal-absorption. Lactose is a 
disaccharide composed of galactose linked by β, 1-4 glycosidic bond to α or β-glucose and are 
present in various dietary foods such as milk and dairies. Dietary lactose is digested in the small 
intestine by lactase releasing glucose and galactose which are then absorbed in the organism152,213. A 
small proportion of lactose that escapes digestion enters the large intestine where it can be digested 
by bacterial enzymes such as β galactosidases105. Individuals suffering from lactose mal-absorption 
are deficient in lactase enzymes and cannot breakdown lactose in the small intestine104. As a result, a 
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significant amount of lactose reaches the large intestine and is degraded by colonic bacteria, which 
induces the production of gases (H2, CO2, CH4) and fermentation end-products (formate, SCFAs) and 
causes gastrointestinal discomfort such as bloating, rumbling, diarrhea and abdominal pain. 
Therefore lactose mal-absorption is accompanied with lactose intolerance symptoms. However, the 
causes of these symptoms are not well understood. Recent studies have suggested that colonic 
bacterial fermentation of lactose, galactose and glucose participate in the onset of lactose 
intolerance 214. 
In the present experiment, C57BL/6 mice fed with HF_S diet containing HF, free lactose, 
glucose and galactose, showed subtle variations in phenotype and metabotype compared to HF-fed 
mice. Although all diets were isocaloric, HF_S diet tended to lower energy storage compared to HF 
diet. However, the difference in CFE between these groups was not consistent along the experiment. 
In addition HF and HF_S diets induced similar increases in body fat mass. Lactose ingestion did not 
seem to affect lipid metabolism and energy homeostasis as 1H NMR plasma and fecal metabolic 
profiles and plasma lipid profiles were not different between HF and HF_S groups at D70 after the 
diet switch. On the other hand, lactose and other free sugars supplementation seemed to 
exacerbate inflammatory responses under HF diet as the production of cytokines in circulation 
tended to increase in HF_S group compared to HF group. However, none of the measured cytokines 
were significantly different between HF and HF_S groups probably due to the large within group 
variability. Ingestion of HF_S diet also induced a significant increase of KcGRO compared to LF diet 
which was not observed with HF diet. Gut inflammatory responses are often observed in lactose 
intolerant individuals104,215. In severe allergy reaction, it can also result in the development of auto-
immune diseases such as inflammatory bowel diseases215. 
Urinary metabolic profiles of HF_S group exhibited higher concentration of galactose and 
glucose than HF group. In addition, lactose resonances were not observed in 1H NMR fecal metabolic 
profiles of HF_S fed mice which suggested that lactose was mainly digested into galactose and 
glucose in the intestine, absorbed in the organism before being by-passed to the urine. Interestingly, 
the excretion of bacterial saccharolytic fermentation end-produtcs (succinate, lactate, acetate, 
SCFAs) in urine, feces and plasma did not increase with HF_S diet suggesting that monosaccharides 
were rapidly absorbed in the organism limiting the colonic fermentation of carbohydrate by gut 
bacteria206,214. Altogether, these results tend to indicate that in C57BL/6 mice, lactose is still digested 
in the small intestine. The lactose digestion end-products (galactose and glucose) may in turn be 
rapidly absorbed in the host which limits their fermentation in colon. However, decreased PCS and 
PAG in urinary metabolic profiles of HF_S group compared to HF group pointed out that lactose and 
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free sugar supplementation during HF diet lower bacterial amino acid fermentation102,212,214. Lactose 
digestion in the small intestine may trigger changes in the gut environment (pH, transit time, 
motility, gut bacterial composition and gut bacterial cross-feeding) which in turn may reduce colonic 
amino acid fermentation and affect physiological status of mice. In particular, it may lower calorie 
extraction from the diet resulting in reduced calorie storage216. 
GOS_CMO supplementation containing lactose and galactose alleviated inflammatory 
responses induced by the combination of HF and lactose mal-absorption. In this experiment, 
GOS_CMO as well as other prebiotics were proved to enhance mouse health by modulating bacterial 
colonic fermentation. Since the disruption of colonic lactose fermentation may be a contributing 
factor of lactose intolerance, GOS supplementation is likely to beneficially affect gut lactose 
processing, gut microenvironment and reduce symptoms of lactose intolerance105. In particular, milk 
products consumption containing probiotics have been found to improve the physiological status of 
lactose intolerant individuals by modifying pH, increasing β-galactosidase activity and reducing 
colonic time transitH217. However, probiotics supplementation alone showed inconsistent effects on 
lactose intolerance 217,218. Prebiotics such as GOS favour the growth of Bifidobacteria and Lactobacilli 
species containing specific galactosidase activity and provide laxative effect which increased the 
availability of carbohydrate in distal colon for fermentation and reduce pH95. Thus, these 
physiological processes may underlie the beneficial effect of GOS_CMO on inflammatory status of 
mice suffering from lactose mal-absorption. However, it is important to note that HF diet ingestion 
triggered a larger disruption of physiological and metabolic status than lactose ingestion in C57BL/6 
mice. Hence, to clearly identify the role of GOS on lactose mal-absorption in C57BL/6 mice and to get 
rid of confounding factors associated with HF diet, it is necessary to investigate the effect of diets 
containing GOS and lactose under LF diet condition. 
 
5. CONCLUSION 
Prebiotic supplementation during HF challenge improved mouse phenotype by reducing BW 
gain, energy storage and the circulating inflammatory status, although it did not prevent obesity 
development. High fat diet significantly increased circulating lipid levels, and altered mitochondrial 
oxidative pathways compared to low fat diet. On the other hand, prebiotic supplementation reduced 
plasma lipoproteins and modifies plasma acylcarnitines profiles which might reflect a lower 
dyslipemia and an improved mitochondrial oxidative capacity. In addition, prebiotic 
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supplementation activated colonic carbohydrate fermentation and reduced bacterial amino acid 
fermentation which might beneficially affects the mouse inflammatory status. FOS_IN was the most 
effective prebiotic in recovering partial internal homeostasis and it was enabled to maintained 
normal fasting glycemia during HF challenge. 1H NMR and MS metabonomics indicated that FOS_IN 
specifically activate amino acids metabolism and ketogenesis which might contribute to improve 
mitochondrial metabolism and maintain glucose homeostasis.  Our results also highlighted that 
lactose and free sugar supplementation affect gut bacterial amino acid fermentation and may 
increase mouse circulating inflammatory responses to HF diet. On the other hand, GOS and CMO 
supplementation (containing lactose) lower mouse inflammatory status. However, HF diet ingestion 
triggered a greater disruption of mouse metabolic status than lactose ingestion which might hide 
lactose specific effect on mouse metabolome and inflammation.  
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CHAPTER V: THE PREBIOTIC STUDY  
CORRELATIVE ANALYSIS OF FECAL MICROBIOTA, 1H METABOLIC PROFILES 
AND CIRCULATING CYTOKINE LEVELS. 
 
1. INTRODUCTION 
Changes in the composition of the colonic gut microbiota can be either the triggering factor 
or the protective agent in intestinal and systemic disorders. Repeated utilization of antibiotics, 
infection by intestinal pathogens (e.g. [Clostridium] difficile or Escherichia coli) and/or reductions in 
overall species diversity contribute to the etiology of intestinal pathologies such as ulcerative colitis, 
antibiotic-associated colitis, diarrhea, and Crohn’s disease219,220. At the systemic level, altered activity 
of the gut microbiota has been associated with gut-origin septicemia, pancreatitis and multiple 
organ failure syndrome179,221. Alteration of the diversity/activity of the gut microbiome by high-fat 
(HF) diet has been associated with a range of metabolic disorders and may contribute to obesity, 
type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD)72,77,89. However, 
modulation of the gut microbiota and its activity by ingestion of functional foods (i.e. probiotics and 
prebiotics) has been effective in reducing colonic inflammation, which is a potent factor in gut 
microbiota-induced intestinal and systemic diseases88,95. Prebiotics (non-digestible fermentable 
carbohydrates), in particular, have been shown to reduce serum triglycerides and cholesterol in 
healthy and T2DM individuals; as a result these functional foods may help prevent or attenuate the 
development of obesity and obesity-associated metabolic disorders94,97,222. There is no evidence to 
suggest that prebiotic supplementation of infant formulae improves growth or clinical outcomes, or 
causes adverse effects in term infants. Prebiotic effects are able to reduce the incidence of atopic 
disease in children; however, confirmation of effectiveness is needed to support available data223. 
Studies in adults and the elderly vary in quality and outcomes, but prebiotics have been shown to 
modulate the fecal microbiota and immune function in elderly individuals, and to reduce markers of 
metabolic syndrome in overweight adults224,225. 
In the previous chapter (Chapter IV), the effects of dietary supplementation with different 
prebiotic blends (fructo-oligosaccharides–inulin (FOS_IN), galactosyl-oligosaccharides (GOS), and 
galactosyl-oligosaccharides–cow milk oligosaccharides (GOS_CMO)) for 70 days (after 2 weeks on a 
low-fat (LF) diet) on the development of obesity and metabolic profiles in C57BL/6 mice fed a HF diet 
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were tested. The results highlighted that all prebiotics induced a significant reduction of weight gain 
and fat mass during HF challenge, while FOS_IN specifically prevented HF-diet-induced fasting 
hyperglycemia. A systemic inflammatory response, indicated by an increase in plasma IL-1β levels 
was noticed in HF-fed mice. This inflammatory response was exacerbated when mice were fed with 
HF + glucose–lactose–galactose (HF_S), as increases in plasma IL-1β, KcGRo and TNF-α were 
observed in HF_S-fed mice compared with LF-fed mice. Conversely, prebiotic supplementation 
during HF challenge and HF_S challenge tended to alleviate this central inflammatory response 
mainly by reducing levels of circulating IL-1β. Ingestion of prebiotics during HF-feeding also increased 
microbial carbohydrate fermentation and decreased microbial amino acid fermentation in the colon, 
and affected host mitochondrial oxidative pathways. Significant variations in metabolic profiles 
associated with each dietary intervention are summarised in XTable 9X. 
In this chapter, the work presented previously on the short-term (7 days, (D7)) and long-
term (70 days, (D70)) effects of LF, HF, HF_S and HF + prebiotic (FOS_IN, GOS and GOS_CMO) diets 
on our mouse model was extended to specifically examine the effects of these diets on the gut 
microbiota of the isogenic C57BL/6 mice. Community diversity and abundance of the fecal 
microbiota in the different feeding groups were examined using high-throughput 16S rRNA gene 
sequence analysis (pyrosequencing) at D-7 before the diet switch, D7 and D70 after the switch from 
the LF maintenance diet. To highlight the contribution of the gut microbiota to the modulation of 
host metabolism, correlation analyses between microbial profiles and relevant metabolites from 
urinary, fecal and plasma metabolic profiles at D70 were performed using the total variance of each 
dataset (n = 90). In addition, the relationships among gut microbiota composition, host metabolism 
and central inflammation were investigated using multiple correlations testing analysis on plasma 
inflammatory markers, fecal microbiota profiles and metabolic profiles of urine, feces and plasma 
samples collected at D70. 
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Table 9: Metabolites that varied significantly between feeding groups after a 70-day dietary intervention. 
Effect with: Comparison* Metabolic variations† Biological interpretation 
HF diet/HF 
diet + sugars 
LF vs HF 
LF vs HF_S 
↑ Urinary BCAA intermediates (α-keto-β-
methylvalerate, isovalerylglycine, α-ketoisovalerate) 
↓ Plasma acetyl-carnitines (C2), butyryl-carnitine (C4), 
palmitoyl-carnitine (C16), palmitoleyl-carnitine (C16:1), 
oleyl-carnitine (C18:1), linoleic acid (C18:2) 
↑ Plasma stearoyl-carnitine (C18:0)  
↑ Urinary 2PY, 4PY 
↑ Plasma lipoproteins (VLDL/LDLs) 
↑ Plasma SMs, LPCs, PCs 
Up-regulation of 
mitochondrial oxidative 
pathways
151,152
 
Increased fasting 
dyslipidemia
49,152,189
 
HF diet + 
sugars 
HF vs HF_S ↓ Urinary p-cresol sulfate, phenylacetylglycine Decreased fermentation of 
amino acids by gut bacteriaH
226
H  
Prebiotics 
HF vs HF + GOS 
HF vs HF + 
FOS_IN 
HF vs HF + 
GOS_CMO 
↓ Plasma lipoproteins (VLDL/LDLs) 
↑ Plasma acetyl-carnitines (C2), butyryl-carnitine (C4), 
palmitoyl-carnitine (C16), palmitoleyl-carnitine (C16:1), 
oleyl-carnitine (C18:1), linoleic acid (C18:2) 
↑ Plasma propionyl-carnitine (C3), isovaleryl-carnitine 
(C5) 
↑ Urinary α-keto-β-methylvalerate, isovalerylglycine 
for HF + FOS_IN and HF + GOS groups exclusively  
Reduced dyslipidemia
49,152
 
Increased complete 
mitochondrial β-
oxidation
151,152
 
Enhanced mitochondrial 
oxidative pathwaysH
152
H  
↑ Fecal butyrate, 3-D-hydroxybutyrate, succinate Increased carbohydrate 
fermentation by gut 
bacteria
205,210
 
↓ Urinary p-cresol sulfate, p-cresol glucuronide 
Decreased fermentation of 
amino acids by gut bacteriaH
226
H  
HF diet + 
FOS_IN 
HF vs HF + 
FOS_IN 
↑ Plasma amino acids 
↑ Plasma 3-D-hydroxybutyrate 
↓ Urinary 2PY, 4PY 
Increased protein 
degradation
44,152
 
Activation of ketogenic 
pathways 
Reduction of mitochondrial 
oxidative pathways
152,227
 
*Diets: LF, low fat (negative control); HF, high fat; HF_S, high fat + glucose–lactose–galactose (positive control 
for GOS_CMO); HF + GOS, high fat + galactosyl-oligosaccharides; HF + FOS_IN, high fat + fructo-
oligosaccharides–inulin; HF + GOS_CMO, high fat + galactosyl-oligosaccharides–cow milk oligosaccharides 
(glucose–lactose–galactose). 
†BCAA, branched-chain amino acid; 2PY, N-methyl-2-pyridone-5-carboxamide; 4PY, N-methyl-4-pyridone-3-
carboxamide; VLDLs, very-low-density lipoproteins; LDLs, low-density lipoproteins; SMs, sphingomyelins; PCs, 
phosphatidylcholines; LPCs, lysophosphatidylcholines. 
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2. MATERIALS AND METHODS 
 
2.1. Animal handling procedure and sample preparation. 
See Chapter IV, section X2.1X (Materials and Methods).  
 
2.2. Measurement of circulating cytokines with Multiplexed 
Elisa assay (Meso Scale platform). 
See Chapter IV, section X2.5X (Materials and Methods). 
 
2.3. Sample preparation and 1H NMR spectroscopy. 
See Chapter IV, section X2.6X (Materials and Methods). 
  
2.4. 1H NMR spectra pre-processing and 1H NMR data 
processing. 
See Chapter IV, section X2.7X (Materials and Methods) for 1H NMR spectra pre-processing and 
Chapter IV, section X2.8X (Materials and Methods) for 1H NMR data processing. 
 
2.5. 1H NMR data binning using statistical recoupling of 
variables. 
Prior doing correlative analyses between 1H NMR metabolic profiling and other multivariate 
data (fecal microbiota profiles or cytokines profiles), 1H NMR spectra were reduced using statistical 
recoupling of variables (SRV)228. This method employs the degree of correlation to covariance 
profiles of consecutive variables along the chemical shift axis to identify the spectral dependency 
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and group all the consecutive variables corresponding to the same biological and chemical entities in 
a cluster. This method allows discarding unstructured noise and reducing 1H NMR data 
dimensionality to facilitate correlative analysis between multivariate dataset. A default resolution of 
0.00055 ppm was used to perform the data reduction. Full resolution 1H NMR (44K data-points) 
spectra were then reduced to 296 clusters for fecal metabolic profiles, 420 clusters for urinary 
metabolic profiles and 86 clusters for plasma metabolic profiles (1H NMR CPMG spectra).  
 
2.6. 16S rRNA gene sequencing of fecal microbiota.  
This DNA extraction and pyrosequencing were carried out at NRC (Switzerland). DNA was 
extracted from fecal samples at baseline (D0) D7 and D70 after the diet switch (n=180) using the 
QiAamp Stool DNA mini kit (Qiagen, Hilden, Germany) as previously described by the manufacturer. 
Additional mechanical disruption steps (11X45sec) using a FastPrep apparatus and Lysing Matrix B 
tubes (MP Biochemicals, USA) (Junick 2012 AEM) were also performed to help the extraction. PCR 
amplification was carried out using two sets of primers matching the hypervariable regions (V) 1 to 3 
(V123), and 4 to 6 (V456) of the 16S rRNA gene. In particular, The V123 region was amplified by 
combining a mixture of forward primers in order to ensure optimal coverage of bacterial 
phylogenetic diversity, as previously described229. The primers were designed according to the 
reference publication of Hamady et al 230. V123 forward primer 1, 5’-
CTATGCGCCTTGCCAGCCCGCTCAGTCAGAGTTTGATYMTGGCTCAG-3’; V123 forward primers 2, 5’-
CTATGCGCCTTGCCAGCCCGCTCAGTCAGGGTTCGATTCTGGCTCAG-3’; V123 forward primer 3, 5’-
CTATGCGCCTTGCCAGCCCGCTCAGTCAGAGTTTGATCCTGGCTTAG-3’; V123 forward primer 4, 5’-
CTATGCGCCTTGCCAGCCCGCTCAGTCAGAATTTGATCTTGGTTCAG-3’; V123 reverse primer, 5’-
CGTATCGCCTCCCTCGCGCCATCAGNNNNNNNNGGTTACCGCGGCTGCTGGCAC-3’; V456 forward 
primer, 5’-CTATGCGCCTTGCCAGCCCGCTCAGGCCRRCACGAGCTGACGAC-3’; V456 reverse primer, 
CGTATCGCCTCCCTCGCGCCATCAGNNNNNNNNAGGCCAGCAGCCGCGGTAA-3’.(where the adapter 
sequences for Roche 454 FLX Titanium sequencing are italicized, the linkers are underlined, 
NNNNNNNN sequences designate the sample-specific 8-base barcodes used to tag each PCR 
product, and bold sequences correspond to broadly conserved 16S rRNA gene regions). V123 
forward primers 1, 2, 3 and 4 were mixed in 4:1:1:1 ratios. For each PCR amplification reaction, we 
used 2 µl of DNA extract, 50 µM dNTPs, 200 nM forward primer (mix of forward primers for V123 
region), 200 nM reverse primers, 1x Expand High Fidelity Reaction Buffer and 2.5 U of Expand High 
Fidelity enzyme blend (Roche Applied Science, Switzerland). The PCR experiments followed specific 
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conditions: 94°C for 2 minutes followed by 25 cycles of 94°C for 30 sec, 49°C for 30 sec, and 72°C for 
1 min, and end with a last step of 72°C for 7 min. After purification, the PCR products were pooled in 
equimolar amount, and sequenced using the 454 FLX Titanium technology (Microsynth AG, Balgach, 
Switzerland). Low readers were excluded according to the following criteria (adapted from Huse et 
al).  
- The reads could not be unambiguously assigned to any of the PCR samples due to undefined 
sequence key. 
- 5’ primer sequence could not be recognised.  
- 5’ primer sequence contained more than one error. 
- Ambiguous characters (N’) were noticed. 
- The reads were not matching the expected length. First, primer sequences were removed 
using the vectorstrip software (-besthits 1, - mismatch 30, -besthits parameters). The reads 
with less than 100 bp were discarded. Subsequently, the median length and the Median 
Absolute Deviation (MAD) of the remaining reads were calculated separately for each of the 
8 different primer pairs. All reads shorter than the median -5 * Mad were discarded. 
- The reads were not matching any BLAST (1) hit to the ARB29 16S DNA database (Evalue cut-
off:10-10). These reads are likely to not represent regions of 16S DNA genes. 
All high-quality reads were classified into Bergey’s taxonomy using the RDP-Classifier (80% 
confidence cut-off). The sequences unassigned to any taxonomic group at a certain rank (phylum, 
class, order, family or genus) were classified as “Unknown” at that rank. Conversely, the “Unknown” 
category was defined for each rank. Reads were also grouped into Operational Taxonomic Groups 
(OTUs) based on their best BLAST hit to full-length reference 16S DNA using the RDP database using 
BLAST. The reads were iteratively grouped into OTUs according to their sequence identity matching. 
The perfect matching corresponded to a sequence-identity of 100%, the remaining reads were then 
attributed using different sequence-identity cut-offs of 98%, 95%, 90%, 80% and 70%. However, in 
this experiment, we focused our analysis at the phylum and family like taxonomic levels.  
 
2.7. Multiplatform data analysis  
A multivariate factor analysis integrating NMR metabolic profiles from urine feces and 
plasma, MS targeted profiles and cytokines profiles of all mice was conducted in SIMCA-P 12 
software (Umetrics, Umea, Sweden). This method consists in performing a PCA on a merged dataset 
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integrating several matrices with the same number of individuals, Xmicrobiora, XNMR, Xcyokines . For each 
matrix, an individual PCA was built and the largest eigenvalue (γ) was determined by calculated the 
standard deviation of the score T1. The X matrix was then weighted by 1/γ to correct for individual 
matrix dimensionality. The MFA finally was conducted with the merged dataset using mean-
centering and UV scaling.  
A functional correlative analysis was also carried out to investigate transgenomic 
relationship between host metabolism and gut microbiota. The hierarchical clustering and the 
Spearman correlation heatmaps between fecal microbial profiles and 1H NMR SRV clusters (feces, 
urine or plasma) of all mice 70 days after diet switch were performed in Matlab software using in-
house scripts developed by JTM Pearce.  
A bipartite graph was also used to highlight a correlation network between host 
inflammatory responses, host metabolism and fecal microbiota. Multiple Spearman correlations 
were computed between plasma cytokines profiles, fecal bacteria composition and 1H NMR SRV 
clusters (feces, urine or plasma) of all mice at D70 after the diet switch. All correlation coefficients 
with an absolute value IRI>0.3 were selected and tested against the null hypothesis H0. Noticeably, 
none of the absolute correlation coefficients values among the entities were above 0.5.  
 
3. RESULTS 
 
3.1. HF diet and prebiotic supplementation during HF 
challenge induce significant changes in the composition of the 
fecal microbiota 
Analysis of microbiota data at D-7 (baseline) showed that all animals had essentially the 
same fecal microbiota at the start of the dietary intervention (Figure 41) although subtle differences 
were observed in Bacteroidetes and Proteobacteria levels among the groups. After 7 days of dietary 
intervention, gut microbiota composition differed from that of the pre-intervention period in all diet 
groups. In particular, levels of unclassified bacteria, Actinobacteria and Verrucomicrobia were 
elevated and the level of Proteobacteria was reduced in HF, HF_S and HF + prebiotic-fed mice at D7 
compared to D-7. 16S rRNA gene sequence analysis of the fecal microbiota also disclosed significant 
184 
 
changes in composition between the different dietary groups at D7 and D70 after the switch from 
the maintenance diet. At the phylum level at D7 (Figure 41.B), increases were observed in the 
proportions of the Bacteroidetes and Verrucomicrobia and a decrease was observed in the 
proportion of Firmicutes in mice fed HF, HF_S and HF + prebiotic mice compared with the LF-fed 
mice. Prebiotic supplementation, particularly with FOS_IN – during the HF challenge also induced a 
proliferation of Actinobacteria at D7. At D70 (C), the general microbiota profiles of each diet group 
were conserved and early trends were amplified: in particular, the Bacteroidetes-to-Firmicutes ratio 
at D70 was higher than those at D7 in all HF-containing diets. The proportions of Actinobacteria in 
HF + prebiotic-fed mice also increased at D70 by comparison with those at D7. 
Compositional differences occurred at the phylum level, but more subtle variation was 
observed at lower taxonomic levels (data not shown). Analyses presented herein are focused at the 
family level (which, similar to the phylum-level analysis, contained a limited number of unclassified 
species) and enable investigation of subtle diet-specific modulation of the gut microbiota (Figure 42). 
HF challenge with or without prebiotic supplementation led to a significant increase in 
representation of the Porphyromonadaceae and Bacteroidaceae (Bacteroidetes) and 
Lachnospiraceae (Firmicutes), and a decrease in the Erysipelotrichaceae (Firmicutes) compared to 
the LF-fed mice at D7 and D70. The decrease in abundance of members of the phylum Firmicutes in 
HF- and HF_S-fed mice was due to the decrease in Erysipelotrichaceae, which was the most 
abundant family of bacteria in the feces of the mice examined in this study. Interestingly, the 
abundance of the Lachnospiraceae was similar in the LF- and the HF + FOS_IN-fed mice at D7 and 
D70, which suggests that FOS_IN and/or its by-products were not a preferred nutrient source for this 
group of bacteria. In addition, abundance of the family Coriobacteriaceae (Actinobacteria) was 
significantly higher in the HF- and HF + prebiotic-fed groups compared to the LF group at D7 and 
D70. The abundance of Coriobacteriaceae in the HF_GOS-fed animals was notably higher than in the 
other diet groups at D7, but dropped to levels similar to the HF + GOS_CMO group at D70. 
Abundance of the Coriobacteriaceae in the fecal microbiota of the HF + FOS_IN-fed animals fell at 
D70, but was still significantly higher than that in the LF-fed mice at the same time point. The 
representation of Enterobacteriaceae were also found to increase in HF and HF_S fed mice 
compared to HF + GOS and HF + GOS_CMO fed mice at D7. However, it important to note the large 
intra-group variability in the relative abundance of this bacterial family as indicated by a large 
standard deviation in HF, HF_S, HF + GOS and HF + GOS_CMO groups. In addition, no read 
corresponding to Enterobacteriaceae was measured in LF and HF + FOS_IN fed mice.  
185 
 
Prebiotic supplementation during HF challenge increased the abundance of several families 
of bacteria within the fecal microbiota of the C57BL/6 mice (Figure 42). In particular, HF + GOS-fed 
mice had significantly higher levels of the Bacteroidaceae (Bacteroidetes) than HF- and HF_S-fed 
mice at D7 and D70. Similarly, Lachnospiraceae (Firmicutes) were more abundant in the HF + 
GOS_CMO group than the other HF groups at D7 (representation was lower at D70, but still higher 
than in the other HF groups). Specific families within the phyla Firmicutes (Streptococcaceae, 
Ruminococcaceae and Peptostreptococcaceae) and Bacteroidetes (Rikenellaceae) were present at 
significantly higher levels in the HF and HF_S groups than in the HF + prebiotic-fed animals at D7 and 
D70. These results showed that the HF diet induced consistent changes in the composition of the gut 
microbiota, with prebiotic supplementation able to attenuate or contribute to these family-
dependent compositional changes. Prebiotics also triggered specific variations in the gut microbiota. 
HF + prebiotic-fed mice showed an increase in the abundance of the Verrucomicrobiaceae 
(Verrucomicrobia) compared with the LF-, HF- and HF_S-fed mice at D7 and D70. FOS_IN 
supplementation during HF challenge specifically increased the abundance of the Bifidobacteriaceae 
(Actinobacteria) at D7 and D70. GOS supplementation also led to an increase in the abundance of 
the Bifidobacteriaceae, but this was only noticeable at D70. GOS_CMO supplementation did not 
have a significant effect on the Bifidobacteriaceae, but did induce an increase in the abundance of 
the Lactobacillaceae observed at D70. 
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Figure 41: Phylum-level analysis of the fecal microbiota of the isogenic C57BL/6 mice at (A) D-7, (B) D7 and (C) 
D70 of the different dietary interventions. Prior to D-7, animals were fed the LF diet for 2 weeks. Diets: LF, low 
fat; HF, high fat; HF_S, high fat + glucose–lactose–galactose (positive control for GOS_CMO); HF + GOS, high fat 
+ galactosyl-oligosaccharides; HF + FOS_IN, high fat + fructo-oligosaccharides–inulin; HF + GOS_CMO, high fat + 
galactosyl-oligosaccharides–cow milk oligosaccharides (glucose–lactose–galactose). The stacked bar graphs 
show the mean percentage of the major phyla contributing to the total fecal microbiota of the mice at each 
time point. 
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Figure 42: Family-level analysis of the fecal microbiota of the isogenic C57BL/6 mice at D7 and D70 of the 
different dietary interventions. Diets: LF, low fat; HF, high fat; HF_S, high fat + glucose–lactose–galactose 
(positive control for GOS_CMO); HF + GOS, high fat + galactosyl-oligosaccharides; HF + FOS_IN, high fat + 
fructo-oligosaccharides–inulin; HF + GOS_CMO, high fat + galactosyl-oligosaccharides–cow milk 
oligosaccharides (glucose–lactose–galactose). Bar plot intensities for each family of bacteria (in au : arbitrary 
unit) correspond to the mean percentage of the total detected bacteria at family level. Significant differences 
in the relative abundances of detected taxa between different diet groups were evaluated using the non-
parametric Mann–Whitney tests (p value: *<0.05, **<0.001, ***<0.0001). #: NaN  
188 
 
3.2. Integration of D70 family-level fecal microbiota, 
metabolomic (1H NMR urine, plasma and feces) and plasma 
cytokine data 
Family-level analyses of the fecal microbiota of the mice showed that HF and HF + prebiotic 
diets triggered significant changes in the composition of the gut microbiota. In the Chapter IV 
(section X3.1X), it was demonstrated that long-term prebiotic supplementation during HF challenge 
lowered gains in body weight, reduced cumulative food efficiency (CFE), the levels of circulating 
inflammatory markers and triggered a strong modulation of mouse metabolism. To investigate the 
contribution of the gut microbiota to metabolic variation and inflammatory status in the mice in the 
different diet groups, a multivariate factor analysis (MFA) integrating data derived from the host’s 
fecal microbiota, metabolism and immune system at D70 was carried out ( XFigure 43X). First, common 
variation patterns in the different datasets were captured using a principal component analysis 
(PCA) model with the combined dataset comprising microbiota profiles, circulating inflammatory 
markers, and plasma, urinary and fecal metabolic profiles. Each dataset was mean-centered and 
individually scaled to remove all variations exclusively associated with individual matrix 
dimensionality. In this case, the PCA was built from common characteristics among all the matrices 
and no particular matrix dominated the first component(s). The scaling method was described by 
Dumas et al. The variance-covariance associated with each dataset (X) was modeled by PCA which 
allowed calculation of the largest eigenvalue (γ)231. The X matrix was then corrected by 1/γ. 
Secondly, relationships among gut microbiota, metabolic variations and circulating inflammatory 
markers were confirmed by correlation analyses using the total variance of each dataset. 
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Figure 43: Individual matrix scaling in MFA, adapted from Dumas et al. (A) XNMR and Xmicrob correspond to 
NMR and microbiota datasets with KNMR and Kmicrob variables, respectively. (B) PCA of each dataset, which 
enables calculation of the largest eigenvalue (γ). (C) All datasets were individually scaled with 1/γ and merged 
in one block-dataset. (D) Global PCA using the new block-dataset. 
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3.2.1. MFA highlights similar patterns of variation in the composition of 
the fecal microbiota, metabolic profiles and circulating 
inflammatory markers in the different diet groups 
MFA of combined metabolic (1H NMR urine, plasma and feces), fecal microbiota and 
circulating inflammatory marker data at D70 captured the main variations responsible for the 
separation of the dietary groups in these datasets. The PCA score plot ( XFigureX 44.A) showed that the 
LF- and HF + prebiotic-fed groups were separated from the HF- and HF_S-fed groups along the first 
principal component (PC1). This showed that supplementation of the HF diet with prebiotics for 70 
days maintained metabolic profiles, circulating inflammatory markers and fecal-microbiota 
composition in the HF + prebiotic-fed mice so that they were more similar to the combined data of 
the LF-fed mice than to those of the HF- and HF_S-fed mice. The second principal component (PC2) 
tended to cluster the HF + prebiotic-fed groups of mice together and separate from the LF-fed 
group. The PCA loadings plot (XFigureX 44.B) revealed similar behavior between the variables of the 
different datasets and highlighted which variables were responsible for diet-group discrimination. A 
similar increase in urinary p-cresol sulfate (PCS) and p-cresol glucuronide (PCG), fecal bile acids, 
plasma lipids and IL-1β, and fecal Streptococcaceae, Ruminococcaceae and Peptostreptococcaceae 
was identified in the positive control (HF, HF_S) groups. The LF-fed group was separated from the 
other feeding groups because of its increased urinary excretion of taurine, inositol and 
indoxylsulfate, an increase in plasma scyllo-inositol and a higher abundance of Erysipelotrichaceae in 
the fecal microbiota. Clustering of the HF + prebiotic-fed groups was because of their high 
abundances of Verrucomicrobiaceae, Bacteroidaceae and Bifidobacteriaceae in the fecal microbiota 
and higher levels of plasma pyruvate, 3-D-hydroxybutyrate and fecal butyrate compared with the 
other feeding groups. Within the HF + prebiotic-fed groups, the HF + FOS_IN group was separated 
from the other prebiotic-fed groups by its higher abundance of fecal Bifidobacteriaceae and higher 
levels of plasma citrate, acetate and glutamate, while the HF + GOS group tended to cluster 
separately because of its higher abundances of fecal Bacteroidaceae and Porphyromonadaceae and 
higher level of urinary galactose. LF-fed mice were also anti-correlated with Lachnospiraceae, 
Rikenellaceae and Coriobacteriaceae in the fecal microbiota and urinary excretion of N-methyl-4-
pyridone-3-carboxamide (4PY), α-keto-β-methylvalerate, isovalerylglycine, isovalerate, α-
ketoisovalerate, choline and o-acetylglycoproteins. This highlights a reduction in levels of these 
metabolites and bacterial families in LF-fed mice compared to the other diet groups. With the 
exception of IL-1β, circulating cytokines tended to cluster in the center of the PCA loadings plot, 
indicating that they did not strongly influence the separation of the diet groups. 
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Figure 44: PCA model of the combined data from the fecal microbiota (family level), relevant metabolites (
1
H 
NMR urine, plasma and feces) and circulating inflammatory markers at D70. (A) The PCA scores plot shows the 
dispersion of scores for each diet group: 20 % of the variance in the merged matrix (X) is explained by the first 
component, while 17 % of the variance in X is explained by the second component. (B) The PCA loadings plot 
indicated the contribution of variables from the different datasets in the separation of the diet groups. For 
instance, HF and HF_S groups present in the dotted circle in the scores plot showed an increase in several 
metabolites, cytokines and bacterial families highlighted by the dotted circle in the loadings plot. BA, bile acids; 
3-D-HB, 3-D-hydroxybutyrate; A-KIC, α-ketoisocaproate; A-KMV, α-keto-β-methylvalerate; A-KV, α-ketoisovalerate; IV, 
isovalerate; IVG, isovalerylglycine; NAC, N-acetylglycoproteins; A-D-Glc, α-D-glucose; A-D-Gal, α-D-galactose; 4PY, N-methyl-
4-pyridone-3-carboxamide; PCS, p-cresol sulfate; PCG, p-cresol glucuronide; PAG, phenylacetylglycine; IS, indoxylsulfate, 
SyI, scyllo-inositol; Bacterio, Bacteroidaceae; Bifido, Bifidobacteriaceae; Clostri, Clostridiaceae; Corio, Coriobacteriaceae; 
Erysip, Erysipelotrichaceae; Lachnos, Lachnospiraceae; Lactob, Lactobacillaceae; Peptostre, Peptostreptococcaceae; 
Porphyro, Porphyromonadaceae; Rikene, Rikenellaceae; Ruminoc, Ruminococcaceae; Strepto, Streptococcaceae; Unclass, 
unclassified bacteria; Verrucom, Verrucomicrobiaceae; IFN-G, IFN-γ; IL-1B, IL-1β; TNF-A, TNF-α; Bact_families, families of 
bacteria. 
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3.2.2. Correlation analyses of the family-level microbiota and 
metabolic (1H NMR urine, plasma and feces) data from D70 
confirm microbiome-metabolome associations. 
Correlation matrices were built (from which bidirectionally clustered heatmaps were 
generated) to confirm the associations between the diet-specific fecal microbiota and host 
metabolic plasma (Figure 45.A), fecal (Figure 45.B) and urinary (Figure 45.C) variations at D70. For 
each biofluid, different correlation patterns were found between metabolites and families of 
bacteria. For the plasma metabolites (Figure 45.A), the data appeared to separate the fecal 
microbiota into two main blocks. The first ‘block’ represented fecal Erysipelotrichaceae, 
Verrucomicrobiaceae and Clostridiaceae, which were negatively correlated with lipids and positively 
or not correlated with the metabolites grouping TCA cycle intermediates (pyruvate, citrate), acetate, 
unidentified (UA) metabolites, scyllo-inositol and glutamate. The second ‘block’ of bacterial families 
contained the Lachnospiraceae, Rikenellaceae, Streptococcaceae, Ruminococcaceae, 
Peptostreptococcaceae and unclassified bacteria, which were positively correlated with lipids and 
negatively correlated with the other metabolites. Lactobacillaceae, Bifidobacteriaceae and 
Porphyromonadaceae were negatively correlated with scyllo-inositol, while the Coriobacteriaceae 
were positively correlated with this metabolite. The Enterobacteriaceae were also negatively 
correlated with scyllo-inositol, but positively correlated with lipid_CH3. 
For the fecal metabolites (Figure 45.B), the Erysipelotrichaceae were negatively correlated 
with lipids_CH2CO and positively correlated with lipids_CH2C=C and UA_1.17ppm. Lachnospiraceae 
and Lactobacillaceae were negatively correlated with UA_1.17ppm. Coriobacteriaceae and 
Lachnospiraceae were negatively correlated with lipids_CH2C=C, with the former family positively 
correlated with glutamine and the latter family also negatively correlated with butyrate. The 
Verrucomicrobiaceae, Bifidobacteriaceae, Enterobacteriaceae, Porphyromonadaceae and 
Bacteroidaceae were positively correlated with two or more of the following metabolites: butyrate, 
3-D-hydroxybutyrate, uracil, pyruvate and UA_1.24ppm. The Bacteroidetes (Porphyromonadaceae, 
Bacteroidaceae and Rikenellaceae) were also negatively correlated with lipids_CH2C=C, while the 
Bifidobacteriaceae were negatively correlated with bile acids, glycerate, glutamine and two UA 
metabolites. Unlike the other members of the phylum Bacteroidetes, the Rikenellaceae were 
positively correlated with glutamine, UA_3.73ppm, bile acids and lipids_CH2CO. The Clostridiaceae, 
Peptostreptococcaceae, Streptococcaceae, Ruminococcaceae and unclassified bacteria were 
negatively correlated with four or more of the following metabolites: butyrate, 3-D-hydroxybutyrate, 
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uracil, pyruvate, UA_1.24ppm and UA_1.17ppm. In addition, these families were positively 
correlated with four or more of the following metabolites: valine, glutamine, bile acids, 
lipids_CH2CO, glycerate, UA_2.29ppm and UA_3.73ppm. 
Bidirectional hierarchical clustering of the urinary metabolites with family-level microbiota 
data clustered the metabolites in two ‘blocks’ (Figure 45.C). However, no obvious patterns of 
clustering were observed for the families of bacteria. The first ‘block’ of metabolites grouped small 
molecules (taurine, creatine, creatinine, inositol) and bacterial co-metabolites (PCS, PCG, 
phenylacetylglycine, indoxylsulfate) together. With respect to the bacterial co-metabolites, 
Peptostreptococcaceae, unclassified bacteria, Ruminococcaceae, Streptococcaceae, Rikenellaceae, 
Lachnospiraceae and Coriobacteriaceae were negatively correlated with indoxylsulfate, while the 
Bifidobacteriaceae were positively correlated with this co-metabolite. Several families of the phylum 
Firmicutes (Clostridiaceae, Peptostreptococcaceae, Ruminococcaceae, and Streptococcaceae) and 
the family Rikenellaceae were positively correlated with PCS, while Porphyromonadaceae, 
Bacteroidaceae, Lactobacillaceae, Verrucomicrobiaceae and Bifidobacteriaceae were negatively 
correlated with this co-metabolite. Correlation results observed for PCG and phenylacetylglycine 
broadly reflected those presented for PCS. The second ‘block’ of metabolites classified intermediates 
of BCAA catabolism (α-keto-β-methylvalerate, isovaleric acid, isovalerylglycine, α-ketoisovalerate, 
ketoleucine), choline, 4PY and sugars (glucose, galactose, sucrose, O-acetylglycoproteins) together. 
Bacteroidaceae, Porphyromonadaceae and Coriobacteriaceae were positively correlated with all 
metabolites in block 2, while the Erysipelotrichaceae were negatively correlated with all metabolites 
in this block. Clostridiaceae were negatively correlated with seven of the 11 metabolites in this 
block; Peptostreptococcaceae were negatively correlated with ketoleucine, galactose and O-
acetylglycoproteins; Bifidobacteriaceae were negatively correlated with choline and 4PY. 
Enterobacteriaceae were positively correlated with galactose and sucrose; the remaining families of 
bacteria were positively correlated with three or more of the metabolites in block 2. 
Some of the trends identified in the global PCA model (Figure 44) were verified in the 
different correlation matrices. For instance, the family Erysipelotrichaceae was found to be positively 
correlated with urinary inositol and taurine and plasma scyllo-inositol, and negatively correlated with 
intermediates of BCAA catabolism (α-keto-β-methylvalerate, isovalerylglycine, isovalerate, α-
ketoisovalerate) and the NAD/NADP pathway end-product 4PY. Verrucomicrobiaceae was positively 
correlated with fecal levels of 3-D-hydroxybutyrate and pyruvate, while Bacteroidaceae, 
Bifidobacteriaceae and Porphyromonadaceae were positively correlated with fecal butyrate, uracil, 
pyruvate, and 3-D-hydroxybutyrate. Correlation analyses also confirmed the positive association 
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between Lachnospiraceae, Rikenellaceae, Coriobacteriaceae, Porphyromonadaceae and 
Bacteroidaceae and the urinary intermediates of BCAA catabolism, the NAD/NADP pathway end-
product 4PY and choline, as already described in the PCA loadings plot (Figure 44.B). Noticeably, 
Streptococcaceae, Ruminococcaceae and Peptostreptococcaceae were clustered together in the 
heatmaps for the fecal and plasma data (Figure 45, B). These families of bacteria were all positively 
correlated with fecal bile acids and glycerate and negatively correlated with fecal butyrate and 
pyruvate; they were also negatively correlated with plasma pyruvate, citrate and acetate. However, 
Peptostreptococcaceae were not clustered with Streptococcaceae and Ruminococcaceae in the 
heatmaps with urinary metabolites. Bacteroidaceae, Bifidobacteriaceae and Porphyromonadaceae 
were found to be negatively correlated with urinary phenylacetylglycine, PCS and PCG, previously 
noticed in the PCA loadings plot (Figure 44.B). Finally, it is important to note that the families 
Bacteroidaceae and Lactobacillaceae were not significantly correlated with any plasma and fecal 
metabolites, respectively. 
A correlation analysis between circulating markers of inflammation, the (family level) fecal 
microbiota and metabolites from urine, plasma and fecal samples at D70 was carried out. Of the 
circulating cytokines measured with a multiplex ELISA assay (as described in Chapter IV, section 
X2.5X(Materials and Methods) and section X3.1.3X (Results)), only IL-1β showed significant correlations 
with the fecal microbiota and metabolites. The correlation network around IL-1β was summarised in 
a bipartite graph (XFigure 46X). With a correlation cut-off IRI >0.3 and the corresponding p value <0.05, 
IL-1β was connected with nine entities (three families of bacteria and six metabolites), which were in 
turn correlated with each other. In particular positive correlations were found between circulating 
IL-1β, fecal Streptococcaceae (R=0.34), Peptostreptococcaceae (R=0.40), fecal bile acids (R=0.34), 
urinary PCG (R=0.42) or PCS (R=0.39), the last two metabolites being associated with bacterial 
fermentation of amino acids.H226H In addition, fecal Bifidobacteriaceae, fecal levels of butyrate and 
plasma levels of citrate, which were positively correlated with each other, were all negatively 
correlated with IL-1β (R=-0.33 for correlation between IL-1β and butyrate, and R=-0.33 for 
correlation between IL-1β and citrate). These results highlight the link between specific members of 
the gut microbiota, microbial fermentation of amino acids and levels of circulating markers of 
inflammation. However, it is important to note that no correlations between IL-1β and other entities 
were found when the correlation cut-off was set at 0.5, which indicates that this inflammatory 
marker was not strongly correlated with the fecal microbiota and host/bacterial metabolites.
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Figure 45: Heatmaps showing bidirectional clustering of Spearman correlation data for families of fecal 
bacteria and (A) plasma, (B) fecal and (C) urinary metabolites at D70. Heatmaps were produced using 
Spearman correlation values generated from family-level microbiota data and statistical recoupling of variables 
(SRV) clusters of 
1
H NMR peak intensitiesH
228
H (see Material and Methods). Each SRV cluster was in turn assigned 
as a metabolite, but several clusters remained unidentified (UA metabolites). Sign of correlation: red, positive 
correlations; green, negative correlations. The p values were determined for Spearman correlations; p value 
<0.05 was taken as representing statistically significant correlations 
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Figure 46: Bipartite graph showing the correlation network for IL-1β, metabolites (urine, plasma and feces) and 
members of the fecal microbiota. The correlation network was built using significant Spearman correlation 
results using an arbitrary cut-off of IRI >0.3 and p value <0.05. Each node corresponds to an entity (i.e. a 
metabolite, family or cytokine). The nodes colors are associated with the type of entity: brown, fecal 
metabolites; yellow, urinary metabolites; pink, plasma metabolites; blue, fecal bacteria at family level; white, 
circulating cytokine. The edge between two nodes represents a significant Spearman correlation (R) between 
the two entities the nodes represent. The colors of the edges are dependent on the sign of R: green, positive 
correlation; red, negative correlation. The thickness of the lines indicates the absolute value of R: thinnest lines 
for IRI ≤0.49; medium thickness lines for 0.5 ≤ IRI ≤0.599; and thickest lines for IRI > 0.6. 
 
4. DISCUSSION 
Ninety C57BL/6 mice were fed a LF diet for 3 weeks. The mice were then divided among six 
groups of animals with similar distributions of weight and glycemia. One group of animals was kept 
on the LF diet, while the animals in the other groups were fed HF, HF_S, HF + FOS_IN, HF + GOS or 
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HF + GOS_CMO. At D-7, D7 and D70, the composition of the fecal microbiota of the animals was 
determined using 16S rRNA gene sequence analysis. Metabolites (1H NMR urine, plasma and feces) 
and circulating markers of inflammation were also examined for the D70 samples. 
 
4.1. HF diet induced rapid changes in the composition of the 
gut microbiota 
Analysis of 16S rRNA gene sequence data obtained from the fecal microbiota of the mice at 
D7 of the dietary intervention showed that the HF diet with or without a sugar blend or prebiotics 
modulated the gut microbiota. In particular, supplementation of the HF diet with various prebiotics 
(FOS_IN, GOS, and GOS_CMO) affected the population levels of a number of different phyla and 
families of bacteria (Figure 41 and Figure 42). A marked prebiotic effect, as evidenced by statistically 
significant increases in the abundance of fecal Bifidobacteriaceae, was observed for the HF + 
prebiotic-fed animals at D7 and D70 of the study. This effect was most obvious with HF + FOS_IN or 
HF + GOS at D70). Correlation analyses done using the total variance of the fecal microbial profile (at 
the family level), 1H NMR metabolite (urine, plasma and feces) data and levels of circulating markers 
of inflammation at D70 pointed out the substantial influence of the gut microbiota on the regulation 
of host inflammatory status and host metabolism. 
 It was found that Firmicutes and Bacteroidetes dominated the fecal microbiota of the mice 
(Figure 41). However, a lower ratio of Firmicutes-to-Bacteroidetes was observed in mice fed HF and 
HF_S compared with the LF-fed mice at D7 and D70. These results do not support the work of those 
who have demonstrated a higher Firmicutes-to-Bacteroidetes ratio in the cecal microbiota of 
genetically obese ob/ob mice, and the feces of obese humans and pigs77,177,232,233. This is not the first 
time the findings of studies have been contradicted with respect to the Bacteroidetes-to-Firmicutes 
ratio and its association with obesity: studies in humans have shown a higher Bacteroidetes-to-
Firmicutes ratio in overweight individuals or no significant difference between obese and lean 
individualsH234-236. At the phylum level, the composition of the fecal microbiota in the different diet 
groups was similar at D7 and D70, but the difference in the relative abundances of Bacteroidetes and 
Firmicutes in the HF-fed groups compared with the LF-fed group observed at D7 was pronounced at 
D70. 
At the family level, more subtle variations in the composition of the fecal microbiota 
occurred (Figure 42), which illustrated the need to study the gut microbiota at lower taxonomic 
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levels. In particular, HF- and HF_S-fed mice were associated with increases in Ruminococcaceae, 
Peptostreptococcaceae, Streptococcaceae and Lachnospiraceae, and a decrease in 
Erysipelotrichaceae (all phylum Firmicutes); in addition, they had increased levels of Rikenellaceae 
and Porphyromonadaceae (both phylum Bacteroidetes) compared with the LF-fed mice. Variations in 
the composition of the fecal microbiota were obvious at D7 of the dietary intervention, with these 
variations consistent with those observed at D70. These results indicated a rapid remodelling of the 
gut microbial environment, which persists over time. However, time-dependent changes in the fecal 
community profiles were not monitored: these would have given substantial information about the 
stability of the fecal microbiota in the different diet groups. Dietary changes have been proven to 
induce strong and rapid changes in the composition of the gut microbiota237,238. Wu et al. pointed 
out variations in the human gut microbiota 1 day after the initiation of controlled feeding. However, 
gut microbial enterotypes are altered only after long-term dietary changes237. To summarise, in our 
experiment, ingestion of a HF diet induced a rapid remodelling of the intestinal bacteria belonging to 
several families within the phyla Firmicutes and Bacteroidetes and long-term dietary intervention 
contributed to the maintenance of this modulated ecosystem. 
 
4.2. HF-induced modulation of the gut microbiota 
accompanies changes in host lipid storage and metabolism 
The families Streptococcaceae, Ruminococcaceae and Peptostreptococcaceae (all phylum 
Firmicutes) and Rikenellaceae (Bacteroidetes) were positively correlated with circulating lipids and 
bile acids excreted in feces of the C57BL/6 mice when D70 data from all feeding groups were 
combined (Figure 45). Examination of the abundance data for these families demonstrated that all 
four were present at significantly higher levels in the feces of the HF- and HF_S-fed mice compared 
with the LF- and HF + prebiotic-fed mice (Figure 42). In the Chapter IV (section X3.2.5X), it was 
demonstrated that the HF and HF_S diets led to increased production of BCAA and circulating lipids 
compared with the LF diet, while the HF + prebiotic diets led to increased butyrate, 3-D-
hydroxybutyrate and succinate (a precursor for microbially produced propionate) production and 
decreased levels of circulating lipoproteins (XTable 10X). A Firmicutes-rich gut microbiota in obese 
people has been suggested to increase the capacity of the microbiota for energy harvesting from the 
diet as many of these bacteria harbor genes that encode enzymes which enable the extraction of 
energy from undigested polysaccharides and proteins33. However, these observations must be 
interpreted with cautious given the importance of some of these bacteria in the production of the 
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short-chain fatty acids (SCFAs) butyrate (e.g. Roseburia and Faecalibacterium spp.), propionate and 
acetate in the human intestine either directly or via cross-feeding on acetate, lactate and succinate 
and which confer beneficial effects on human health239. In addition, genome analysis of Bacteroides 
thetaoitaomicron, a member of the Bacteroidetes, has shown this gut bacterium has a capacity to 
utilize undigested dietary polysaccharides and host-derived glycans that exceeds that of Clostridium 
perfringens, Bifidobacterium longum and Escherichia coli71. It has been shown here that at least one 
family of the Bacteroidetes, Rikenellaceae, is positively correlated with bile acids and lipids in the 
mouse model, implicating members of both the Firmicutes and Bacteroidetes in host lipid 
metabolism in the presence of a HF or HF_S diet. Therefore, the role of Rikenellaceae in host lipid 
metabolism warrants further attention. 
Increased microbial fermentation of polysaccharides, such as prebiotics, in the colon results 
in higher production of SCFAs, which activate signal transduction pathways through GPR41 and 
GPR43232,240-242. GPR41 liberates peptide YY, which reduces appetite by reducing motility and gastric 
emptying and thereby increases efficiency of digestion and improves nutrient absorption210,241,243. 
GPR43 is involved in anti-inflammatory processes and the secretion of peptides (including peptide 
YY) in the colon, and participates in adipocyte differentiation and inhibits lipolysis in adipocytes. H244H 
Activity of these receptors in the intestinal tract was not monitored in the current study but it was 
found that prebiotic supplementation of the HF diet led to significant decreases in weight gain and 
fat mass during HF challenge (see Chapter IV, section X3.1.1X), with increases in fecal butyrate and 
succinate detected in the prebiotic-fed animals (XTable 10X). This suggests that appetite suppression 
caused by SCFAs produced by the gut microbiota from fermentation of prebiotics in the intestine 
may contribute for decreases in weight gain and fat mass. This hypothesis is supported by the fact 
that HF + prebiotic fed mice were found to decrease their weekly food intake compared to HF and 
HF_S fed mice (see Chapter IV, section X3.1.1X). Peptostreptococcaceae, Streptococcaceae and 
Ruminococcaceae were negatively correlated with fecal butyrate, while Bifidobacteriaceae, 
Bacteroidaceae, Porphyromonadaceae and Enterobacteriaceae were positively correlated with this 
metabolite.(Figure 45.B). Abundance data for these families in the different diets demonstrated that 
Peptostreptococcaceae, Streptococcaceae and Ruminococcaceae were present at significantly 
reduced levels in the HF + prebiotic groups, while the Bifidobacteriaceae, Porphyromonadaceae and 
Bacteroidaceae were present at significantly higher levels in these feeding groups (Figure 42); 
Enterobacteriaceae were also present at lower levels in the HF + prebioitc groups compared with the 
HF and HF_S groups at D7 and not measurable in LF and HF + FOS_IN fed mice at D7 and D70. 
However, the variation in the representation of Enterobacteriaceae in the diet groups as well as 
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correlations between Enterobacteriaceae and metabolites needs to be interpreted with cautious 
given the large within-group variability in the measurement of this bacterial family. A positive 
correlation between the Bifidobacteriaceae, Poryphyromonadaceae and Bacteroidaceae and fecal 
butyrate does not indicate these bacteria are responsible for butyrate production, particularly as 
data from human gut-derived isolates demonstrate members of Clostridium clusters XIVa and IV are 
responsible for butyrate production in humans and not the aforementioned families (though 
butyrate-producing Butyricimonas spp. (family Porphyromonadaceae) have been isolated from rat 
faeces and detected in human faeces)239,245. However, increase in the abundance of fecal 
bifidobacteria during intervention studies is considered indicative of the beneficial effect of 
prebiotics. The bacterial remodelling by prebiotic enhancing gut ecosystem might indirectly favour 
the production of SCFAs.  
To summarise, HF diets in the presence or absence of small sugars such as glucose, lactose 
and galactose cause a change in the gut microbiota that leads to a proliferation of seemingly 
‘undesirable’ members of the gut microbiota (Peptostreptococcaceae, Streptococcaceae and 
Ruminococcaceae), at the expense of those known to be of benefit to host health. This modulation 
of the microbiota is correlated with changes in circulating lipids in the host. HF + prebiotic feeding 
appears to overcome some of the undesirable effects associated with HF-feeding. Much more work 
is required to determine the exact effect of the gut microbiota on host lipid metabolism, and 
whether members of the families specifically mentioned here play a role in this metabolism or 
merely indicate perturbation of the system by a HF diet. 
 
4.3. Prebiotic supplementation during HF diet leads to 
increased representation of Bifidobacteriaceae or 
Lactobacillaceae in the fecal microbiota 
Prebiotic supplementation during HF challenge increased the proliferation of health-
promoting bacteria in the current study, which is in accordance with the literature H95H. FOS_IN 
promoted a rapid and consistent increase in representation of Bifidobacteriaceae, detectable at D7 
and D70 after the diet switch (Figure 42). By contrast, GOS supplementation induced an increase in 
representation of Bifidobacteriaceae only at D70 after the diet switch, which suggests the microbiota 
took more time to adapt to utilization of this prebiotic. In addition, there were transitory increases in 
the representation of Lactobacillaceae in the HF, HF + GOS and HF + FOS_IN groups at D7 after the 
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diet switch. GOS_CMO supplementation triggered a sustained increase in representation of the 
family Lactobacillaceae. This is unsurprising given that GOS_CMO contained lactose, a preferred 
substrate for lactobacilli, in addition to the prebiotic GOS. A recent study identified that GOS 
supplementation specifically triggers expression of a cluster of genes in Lactobacillus acidophilus 
encoding intracellular proteins involved in galactose and lactose metabolism246. These findings, along 
with results presented herein, suggest that lactose and galactose metabolism in members of the 
family Lactobacillaceae is boosted by GOS supplementation, allowing better utilization of the 
prebiotic and the glucose–lactose–galactose in GOS_CMO, which in turn might increase the 
representation of these bacteria in the gut105,246. In summary, it appears that the prebiotic effect 
elicited by GOS and FOS_IN was bifidogenic in nature, whereas that elicited by GOS_CMO favoured 
the lactobacilli.  
In vitro studies have pointed out that prebiotic effects on the gut microbiota depend on 
monosaccharide composition, glycosidic bond between monosaccharides and finally the length of 
the resulting polysaccharide chain181,247-249. For instance, Roberfroid et al demonstrated that the 
ability to grow bifidobacteria was almost directly proportional to the degree of polymerization of the 
prebiotic248. In vitro studies have demonstrated that galactose-containing oligosaccharides are more 
efficient than FOS or inulin in promoting growth of bifidobacteria, which results presented here do 
not support. However, it is important to note that in vitro experiments do not take into account the 
time-dependent adaptation of gut microbiome to prebiotics. The bacterial ecology of the intestinal 
tract is much more complex than a controlled culture medium, which may affect the fermentation 
activity of specific strains181,250. In addition, the activity of rodent bifidobacteria with respect of their 
ability to digest prebiotic have been less characterised in vitro, so their prebiotic preference is not 
known. Oligosaccharide fermentation in the human colon results from a sequence of enzymatic 
reactions performed by numerous bacteria that are not necessarily present in vitro250. A cross-
feeding phenomenon occurs in vivo where some bacteria digest complex carbohydrates and release 
degradation products that are used as substrates by other bacteria. These bacteria might also have 
dietary preferences for a type of fibre and release different bacterial products according to the 
carbohydrate availability, which in turn preferably stimulates the growth of other bacteria. For 
instance, Duncan et al found that Roseburia hominis A2-183T was able to growth better on complex 
carbohydrates in pure culture than Roseburia inulinivorans A2-194T, although A2-183T was unable to 
digest complex sugars. Growth of Roseburia inulinivorans A2-194T, which can digest carbohydrates, 
was significantly increased when inulin was added to the carbohydrates cultures251. 
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Impurities in prebiotic formulations, dosage, and additional nutritional interventions also 
influence the fermentative process of prebiotics and the gut microbiota composition in vivo249. 
Unfortunately, no information about the degree of polymerization and the type of glycosidic bonds 
of our commercial prebiotic blends was provided. However, it can be suggested that FOS_IN is more 
easily fermented by colonic bacteria than GOS, leading to greater and more rapid increases in 
representation of bifidobacteria at D7 (Figure 42). This might be explained by the fact that these 
anaerobic bacteria have a substrate preference for FOS_IN over GOS. 
 
4.4. Prebiotic supplementation during HF challenge changes 
the proportions of families belonging to the phyla 
Bacteroidetes and Firmicutes 
Prebiotic supplementation during HF challenge was found to change the relative abundances 
of all taxa from the phylum to family level. All prebiotics increased the representation of the families 
Porphyromonadaceae and Bacteroidaceae (both phylum Bacteroidetes). These bacteria are among 
the most abundant saccharolytic microorganisms in the mammalian gut and play a major role in 
polysaccharide digestion in the human large intestine181. Bacteroidetes spp. colonize mainly the 
ileum and the colon; therefore, increased polysaccharide availability in the colon due to prebiotic 
supplementation triggered the proliferation of this family of bacteria above levels seen in the HF- 
and HF_S-fed animals (Figure 42). The Porphyromonadaceae and Bacteroidaceae were positively 
correlated with urinary excretion of galactose, glucose and sucrose, which supports the evidence of 
increased FOS_IN and GOS fermentation with Bacteroidetes proliferation. These results are in line 
with the literature, highlighting a higher representation of several members of phylum Bacteroidetes 
with prebiotic supplementation181,252. 
HF + prebiotic diets also led to a decrease in representation of four families belonging to the 
Firmicutes (Streptococcaceae, Clostridiaceae, Ruminococcaceae and Peptostreptococcaceae) 
compared with the HF- and HF_S-fed groups and an increase in Verrucomicrobiaceae (phylum 
Verrucomicrobia) at D7 after the diet switch (Figure 42). This is consistent with results published with 
Everard et al, who identified in prebiotic-fed genetically obese C57BL/6 mice, a decrease in six 
genera of the phylum Firmicutes such as Ruminococcaceae as well as an increase in 
Verrucomicrobiaceae252. Verrucomicrobiaceae have been associated with decreased obesity in 
animals and human models 236,252. Akkermansia muciniphila, a member of the Verrucomicrobiaceae 
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family, has also received particular attention since it has been inversely correlated with type 1 
diabetes and body weight in humans and mice252,253. This mucin-degrading bacteria living in the 
mucus layer represents 3 to 5% of the microbial ecosystem in healthy individuals and is the 
dominant colonizer of nutrient-rich environments in human gut254. It has been found to increase 
around 100-fold in genetically obese mice after oligofructose administration and may participate in 
the beneficial role of prebiotic on obesity252. Everard et al have recently demonstrated reduced A. 
muciniphila abundance in obese C57BL/6 mice, and the restoration of A. muciniphila abundance 
with prebiotics improves systemic inflammatory status, and lowers diet-induced body weight gain, 
fat mass and fasting hyperglycaemia independently of food intake. This reduced energy storage is 
explained by an activation of adipose differentiation, lipogenesis and fatty acid oxidation255. Everard 
and co-workers also provided the evidence that A. muciniphila activates the endocannabinoid 
system, which is implicated in the control of gut barrier and inflammation255. In particular, 2-
oleoyglycerol, which was found elevated with A. muciniphila supplementation, is involved in the 
stimulation of glucagon-like peptides secretion from the intestinal cells, regulating gut barrier 
function. 2-arachidonoylglycerol, also increased with A. muciniphila supplementation, was 
associated with reduced endotoxemia and circulating inflammatory cytokines255. High circulating LPS 
level has been previously found to inhibit adipogenesis (adipose differentiation and lipogenesis), 
disturbing adipose metabolism and promoting obesity256. Therefore, their findings suggest that A. 
muciniphila restores gut function via a stimulation of the endocannabinoid system limiting metabolic 
endotoxemia, improving adipocyte physiology and lowering host inflammatory status. In the present 
experiment, Verrucomicrobiaceae was negatively correlated with circulating lipid levels and urinary 
PAG, PCS and PCG levels. Therefore, prebiotic supplementation during HF challenge may increase 
the representation of Verrucomicorbiaceae and A. muciniphila species particularly, which improves 
gut barrier function and adipose metabolism, and lowers dyslipidemia by the above mentionned 
mechanisms. In addition, reduced urinary PCS and PCG in HF +prebiotic fed mice may result from A. 
muciniphila proliferation and improved gut permeability, which lowers the transfer of microbial co-
metabolites into systemic circulation. However, additional experiments evaluating A. muciniphila 
abundance in each diet group and its impact on circulating PCS, PCG and lipoprotein levels are 
needed to confirm these hypotheses.  
Interestingly, significant changes in Firmicutes and Verrucomicrobiaceae abundance 
associated with HF + GOS and HF + GOS_CMO supplementation occurred before the proliferation of 
the Bifidobacteriaceae and Lactobacillaceae, respectively (Figure 42). These results suggest that 
prebiotics modify the gut ecosystem independently of the increase in representation of beneficial 
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bacteria during the initial stages of dietary supplementation. Several studies have shown that 
prebiotics, and particularly FOS, are able to stimulate many other groups of bacteria251. In this 
context, bifidobacteria may not be the most responsive bacteria to prebiotics 251,257. For instance, 
several Clostridium and Roseburia strains were found to be stimulated by inulin supplementation in 
a complex culture of fecal bacteria251. Prebiotic preferences of bacteria are not completely 
understood as researchers have tended to focus on characterization of ‘beneficial bacteria’ in pure 
and mixed cultures, but utilization of prebiotics by the mixed microbiota involves bacterial cross-
feeding and changes in gut environment (pH, hydrogen release, nutrient availability), factors that 
influence the viability of different bacteria in different ways257. In addition, possible mechanisms by 
which prebiotic receptors could competitively bind pathogenic bacteria and reduce their 
colonization have been envisaged258. 
To summarise, GOS, FOS_IN and GOS_CMO supplementation during HF diet differently 
affect gut environment and bacterial cross-feeding, leading to a remodelling of the gut microbiota 
that is independent of increases in representation of the Bifidobacteriaceae or Lactobacillaceae. The 
development of this new ecosystem might also participate in the overall improvement of host 
physiology during prebiotic intervention. It is important to better understand the mechanisms by 
which prebiotics favour the growth of some bacteria over others, as it would enable us to develop 
more selective prebiotics targeting the inhibition and/or the proliferation of specific bacteria. It 
would also enable us to identify the primary prebiotic utilizers rather than those bacteria that are 
used to measure a prebiotic effect (i.e. the bifidobacteria and lactic acid bacteria). Finally, it is 
necessary to further investigate the effects of these other members of the gut microbiota on host 
physiology as they may hold probiotic properties. 
 
 
4.5. Correlation analysis highlights associations between 
Lachnospiraceae, Bacteroidaceae, Porphyromonadaceae, 
Rikenellaceae, Coriobacteriaceae, or Erysipelotrichaceae and 
host mitochondrial oxidative pathways. 
Data integration between fecal microbiota profiles and urinary, plasma or fecal metabolic 
profiles acquired by 1H NMR were performed using the total variance of the dataset at D70. 
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Lachnospiraceae, Bacteroidaceae, Porphyromonadaceae, Coriobacteriaceae and Rikenellaceae, 
which increased in all HF-fed mice (Figure 42), were positively correlated with a urinary increase in 
BCAA catabolism intermediates (α-keto-β-methylvalerate, α-ketoisovalerate, isovalerate, 
isovalerylglycine) and 4PY (Figure 45.C). Erysipelotrichaceae, which decreased in HF-fed mice (Figure 
42), were negatively correlated with the same metabolites (Figure 45.C). The β-oxidation and BCAA 
catabolism provide substrate for TCA cycle and energy production in the mitochondria. Therefore, 
these results suggest that HF-diet-induced remodelling of the gut microbiota is linked with host 
mitochondrial activity. Relationships between gut microbiota and host mitochondrial activity have 
been already evidenced. Backhed and co-workers showed that GF mice re-conventionalized with gut 
bacteria (mainly Bacteroidetes and Clostridium spp.) produced 60 % more fat mass, and had 
increased hepatic triglycerides and fasting blood glucose compared to GF mice despite comparable 
energy expenditure and less food consumption77. They also highlighted that the gut microbiota 
promoted fat storage by suppressing the expression of angiopoetin-like protein 4 (anglp4) in the 
ileum, an enzyme which controls fatty acid oxidation and storage in skeletal muscle cell and 
adipocytes through the regulation of peroxisomal proliferator activated receptor coactivator (PGC-1) 
α expression259. A recent publication has reported correlation between Lachnospiraceae and the 
expression of mitochondrial transporter Slc25a25, which is responsible for the shuttle of ATP–Mg2+ 
and inorganic phosphate across the mitochondrial membrane. The suppression of this transporter 
modulates mouse metabolic efficiency260-262. However, the mechanisms involving the interactions 
between gut microbiota and host mitochondrial activity has not been clearly defined in the 
literature. Mitochondrial oxidative pathways as well as gut microbial activity are strongly affected by 
nutritional intervention: this relationship requires further investigation. 
 
4.6. Correlation analysis highlighted an association between 
circulating inflammatory status of mice and gut microbial 
activity/composition 
On the one hand, the HF diet raised the levels of pro- and anti-inflammatory markers in 
C57BL/6 mice. On the other hand, prebiotic supplementation during HF challenge tended to alleviate 
this inflammatory response, particularly by limiting the levels of circulating IL-1β (see Chapter IV, 
section X3.1.3X). Bifidobacteriaceae was negatively correlated with circulating levels of IL-1β, PCG, PCS 
(XFigure 46X), suggesting that prebiotic supplementation during HF-feeding can lessen inflammation in 
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obese individuals and fermentation of proteins by the gut microbiota. Conversely, Streptococcaceae 
and Peptostreptococceae were positively correlated with IL-1β levels and those of products of 
microbial amino acid fermentation. In the previous chapter (Chapter IV, section X4.1X), the link 
between adipose tissue expansion, hepatic triglycerides saturation, ectopic fatty acid accumulation 
and the development of sub-clinical inflammatory status during a prolonged weight gain, HF-feeding 
period was discussed. It is suggested in this chapter that the activity of specific members of the gut 
microbiota and/or their metabolites may have an effect on the inflammatory status of mice fed a HF 
diet. 
It is well documented that bacteria or by-products of bacterial metabolism can enter host 
circulation, provoking an inflammatory response and in some cases metabolic dysfunction263,264. For 
example, the endotoxin lipolysaccharide (LPS) derived from the outer cell membrane of the Gram-
negative bacteria. LPS has been shown to activate Toll-like receptors (TLRs) via several processes, 
leading to intracellular activation of NFkB and in turn the stimulation of the innate immune 
response263,265,266. LPS contains a lipid structure that is able to cross the gastrointestinal mucosa by 
infiltrating chylomicrons in the intestine or via damaged intestinal tight junctions265-267. Once it 
reaches systemic circulation, LPS infiltrates tissues such as liver or adipocytes enhancing the 
production of pro-inflammatory cytokines and metabolic dysfunction266. The metabolic endotoxemia 
phenomenon has been previously correlated with obesity and other metabolic disorders in mouse 
and human models78,264,266,267. Interestingly, an increase in gram-negative bacteria of the family 
Rikenellaceae (phylum Bacteroidetes) was observed during HF and HF_S feeding (Figure 42), with 
these bacteria also positively correlated with urinary PCS, and plasma lipids (Figure 45.A, Figure 
45.C). In addition, it is interesting to mention that Enterobacteriaceae (phylum Proteobacteria) was 
increased in HF and HF_S fed mice compared to LF and HF + prebiotics fed mice at D7 although a 
large within-group variability was observed in the abundance of this bacterial family. Several gram-
negative bacteria belonging to Enterobacteriaceae family including Salmonella spp and Shigella spp 
have been responsible for multiple intestinal and systemic infections by endotoxic activity of 
LPS268,269. Other gram–negative bacteria, Porphyromonadaceae and Bacteroidaceae (both phylum 
Bacteroidetes) were found at significantly higher levels in the HF + prebiotic-fed mice than in the HF-
fed mice (Figure 42). These families were positively correlated with faecal butyrate (Figure 45.B), 
negatively correlated with products of microbial amino acid fermentation (Figure 45.C); and were 
not correlated with plasma lipids. Therefore, it is clear that the role of gram-negative bacteria in LPS-
induced inflammation is not fully understood. It should be noted that none of these families 
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belonging to the Bacteroidetes were significantly correlated with circulating cytokines in the present 
study. 
A negative correlation with IL-1β and the family Bifidobacteriaceae, which itself was 
positively correlated with faecal butyrate, was found. SCFAs interact with different cell types 
involved in inflammatory responses in the gut206,270. They modulate the production and the release 
of chemokines which are responsible for the recruitment of neutrophils and macrophages to the 
infection site.H271H They change the expression of adhesion molecules in neutrophils and endothelial 
cells which disturb the interaction between these leukocytes and the gut membranes270. Finally 
SCFAs, and butyrate in particular, suppress the production of pro-inflammatory cytokines in 
neutrophils and macrophages while they may activate the release of the anti-inflammatory cytokine 
IL-10H270-272. For instance butyrate supplementation has been found to reduce IL-1β levels in patients 
with sepsis, which diminishes tissues injury and multiple organ dysfunctions in rats273. Bifidobacteria 
were found to reduce endotoxemia in mice and rats88,274. Cani and co-workers tested the effects of 
prebiotic-stimulated growth of Bifidobacterium spp. on intestinal endotoxin level and metabolic 
disorders in HF-fed mice. They found an increase in intestinal endotoxemia and plasma levels of 
cytokines IL-1α, IL-1β and IL-6 in HF-fed mice. However, prebiotic supplementation during HF 
challenge reduced intestinal LPS levels and prevented increases in levels of circulating pro-
inflammatory markers. Representation of Bifidobacterium spp. was also anti-correlated with adipose 
tissues, glucose intolerance, body weight gain, increased fasted insulinemia and inflammatory 
markers, highlighting the strong relationship between gut microbiota composition/activity and the 
development of metabolic disorders88. Therefore, prebiotic supplementation during HF challenge 
might restore host metabolism–gut microbial interactions and reduce inflammatory status of mice 
by promoting growth of Bifidobacteriaceae and SCFA production in the intestine. Prebiotics may 
lower inflammatory responses to HF diet by reducing LPS infiltration; however, additional 
measurements of intestinal and plasma LPS levels and membrane permeability would be necessary 
to confirm this hypothesis. 
 
4.7. Increased gut bacterial proteolysis contribute to 
inflammation in HF-fed mice 
In the present experiment, HF + prebiotic diets were associated with a decrease in urine PCS 
and PCG compared to the HF, HF_S or LF diet (XTable 10X). p-Cresol is produced by gut bacteria from 
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tyrosine fermentation and a large proportion of p-cresol can cross the mucosal barrier to reach 
blood circulation. Approximately 95 % of p-cresol in mice is transformed by o-sulfation into PCS in 
the colonic epithelial cells and in the liver. A remaining proportion of p-cresol (around 4 %) is phase II 
glucuronidated into PCG exclusively in the liver while 1 % stays in a free form. p-Cresol has been 
thought to have carcinogenic properties and has been found in high concentrations in the intestine 
of patient suffering of inflammatory bowel diseases (IBD) and colorectal cancer. p-Cresol and PCS 
also participate in the pathogenesis of uremic syndrome through inflammatory mechanisms275. In 
particular, in vitro studies have reported that p-cresol inhibits cytokines-stimulated expression of 
endothelial adhesion molecules which are involved in the recruitment of leukocytes in endothelial 
cells, while PCS increases the proportion of free radical leukocytes which may contribute to the 
occurrence of vascular damage in uremic populations275,276. 
Urinary PCS and PCG were positively correlated with Peptostreptococcaceae, 
Streptococcaceae and IL-1β and negatively correlated with Bifidobacteriaceae in our experiment. 
Several publications have demonstrated that p-cresol is mainly produced in the distal colon by 
anaerobic bacteria. Peptostreptococcaceae are defined as strict anaerobes while Streptococcaceae 
are facultative anaerobes, and members of both families are proteolytic277. It can be speculated that 
modulation of gut microbiota composition toward anaerobic bacteria in HF-fed mice enhances 
proteolytic activity and the production of toxic molecules such as p-cresol. In this context, elevated 
p-cresol and its conjugated derivatives may contribute to intestinal permeability and inflammatory 
responses in the gut. The proportion of p-cresol reaching the circulation and organs such as the 
kidneys may also trigger immune responses and promote the chronic inflammation associated with a 
HF diet. However, modulation of the gut microbiota towards an increase in Bifidobacteriaceae and a 
decrease in Peptostreptococcaceae and Streptococcaceae in HF + prebiotic-fed mice might lower 
bacterial proteolysis and p-cresol production. As previously mentioned in Chapter IV (section X4.5X), 
prebiotic-associated growth of Bifidobacteria in the gut has been found to increase SCFA production, 
which reduces intestinal pH and down-regulates bacterial enzymes associated with fermentation of 
amino acids95. Taken together, results presented here demonstrate that prebiotic supplementation 
during HF challenge modulates gut microbial composition and activity, resulting in lower production 
of toxic and carcinogenic metabolites such as p-cresol, which in turn might limit the inflammatory 
response to a HF diet. In addition, IL-1β is a crucial key regulator in multiple inflammatory processes; 
as a result, it may have a specific impact in the onset of diet-induced obesity (DIO). Recently, several 
studies have shown compelling evidence for the role of IL-1β in the development of type 2 diabetes 
mellitus (T2DM) and atherosclerosis62,278. For instance, anakinra (IL-1β antagonist) treatment 
210 
 
commonly used to treat rheumatoid arthritis has been found to reduce glycated hemoglobin levels 
and increase insulin production in patients with T2DM279. To conclude, the reduction of IL-1β 
mediated inflammation with prebiotics might contribute to lower HF induced metabolic 
disturbances and improves mouse physiology. 
 
5. CONCLUSION 
HF diet modulated Firmicutes and Bacteroidetes populations in C57BL/6 mice, and this 
modulation may enhance lipid digestion and contribute to the regulation of host lipid metabolism. In 
particular, Lachnospiraceae, Porphyromonadaceae, Rikenellaceae, Bacteroidetes, Coriobacteriaceae 
and Erysipelotrichaceae in HF-fed mice have been suggested to influence host mitochondrial 
oxidative pathways. Changes in gut microbial composition with HF diet toward more 
Peptostreptococcaceae, Streptococcaceae may also promote gut bacterial proteolysis and contribute 
to the HF-diet-induced inflammatory response. In particular p-cresol produced by gut microbial 
fermentation of amino acids in HF-fed mice is thought to increase circulating inflammatory status of 
mice probably through IL-1β-related pathways. Prebiotic supplementation during HF challenge 
promotes the growth of beneficial bacteria but in a qualitative manner: the proliferation of 
Bifidobacteriaceae and Lactobacillaceae is strongly dependent on prebiotic composition (e.g. purity, 
degree of polymerization, type of carbohydrates) and nutrients brought by the diet. HF + prebiotic 
diets reduced the abundance of several families belonging to the phylum Firmicutes and increased 
the abundance of several families belonging to the phylum Bacteroidetes. This suggests that other 
members of the gut microbiota are responsive to prebiotics and may have a beneficial effect on host 
metabolism. Finally, changes in gut microbial composition toward fewer Peptostreptococcaceae and 
Streptococcaceae with prebiotic supplementation might reduce bacterial proteolysis and in turn 
lower circulating inflammatory cytokine levels of HF-fed mice. 
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CHAPTER VI: THE PREBIOTIC STUDY 
IDENTIFICATION OF CANDIDATE MARKERS PREDICTING THE LONG-TERM 
EFFECT OF PREBIOTICS ON MOUSE PHYSIOLOGY DURING DIET-INDUCED 
OBESITY  
 
1. INTRODUCTION 
Individual dietary selection resulting from the combination of biological, physiological, 
behavioural and economical factors is a major determinant in individual health and particularly in 
obesity developmentH69. Obesity is also a strong predictor for cardiovascular diseases (CVDs), non 
alcoholic fatty liver diseases (NAFLD) and type 2 diabetes mellitus (T2 DM) risks9. For instance, long-
term ingestion of high saturated fat or carbohydrate diets is strongly correlated with cardio-
metabolic diseases9,69. Furthermore, the impact of food selection on host health depends on the 
complex interplay between lifestyle, genetics, and symbiotic gut microbial activity leading to various 
individual predispositions. Dietary modulation as well as obesity, has been proven to impact 
individual metabolism in several studies including ours199,280. In particular, high fat (HF) induced 
obesity was associated with a high urinary excretion of fatty acid β-oxidation intermediate 
(hexanoylglycine), BCAA catabolism intermediates (isovalerylglycine, α-keto-β-methylvalerate, and 
α-ketosisovalerate) and end-products of NAD/NADP metabolism (N-methyl-2-pyridone-5-
carboxamide: 2PY, N-methyl-4-pyridone-3-carboxamide : 4PY) in C57BL/6 mice in the chapter IV 
(section X4.2X)199. In addition, since metabolic phenotypes are influenced by a combination of genetic 
and environmental factors such as dietary habit and gut microbial activity, one can hypothesise that 
differences in basal metabolic phenotype (not modified by any drug or dietary stimuli) can be used 
to evaluate individual predisposition to metabolic diseases69,115,281. This concept has been previously 
developed in pharmacometabonomic studies by Nicholson and co-workers who reported that 
individual metabolic phenotype (metabotypes) could be used to predict individual responses to a 
drug treatment and therefore assess individual predisposition282. The authors proposed this 
approach as a population screening tool to select individuals that could appropriately react to 
particular drugs and drug doses68,282. In the context of nutrition, assessing the long-term individual 
risks could also provide the basis for adjusting dietary habits and offering suitable nutritional 
intervention. This principle has been termed “nutrimetabonomics”69. In addition, when individuals 
are subjected to a specific nutritional intervention, it is also of key importance to develop statistical 
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models based on metabolic information and to find early markers allowing the follow-up of this 
intervention in order to assess the improvement of individual physiological status281. 
In the previous chapters (Chapter IV and Chapter V), the results demonstrated that 
galactosyl-oligosaccharides (GOS), GOS and cow milk oligosaccharides (GOS_CMO) or fructosyl-
oligosaccharides and inulin (FOS_IN) supplementation during HF challenge in C57BL/6 mice limit 
obesity development and improve mouse physiology.  Indeed, HF + prebiotic fed mice had 
significantly lower body weight gain (BWG), calorie storage, fat mass, fasting glycemia and 
circulating pro-inflammatory interleukin-1β (IL-1β) levels compared to their positive control group: 
HF and HF_S fed mice 70 days (D70) after the diet switch. In particular, during the first 35 days after 
the diet switch, HF + prebiotic fed mice had a similar BWG to LF-fed mice highlighting a prevention 
of obesity development during the early phase of dietary intervention ( XFigure 47X). However, after 35 
days (D35), a divergence in weight trajectory between HF + prebiotic fed mice and LF-fed mice was 
observed which indicates that prebiotic supplementation no longer prevented obesity development 
after a long-term period of HF challenge (XFigure 47X). Importantly, mice encounter a weight loss at 
D14 because they were subjected to a 12 hours fasting followed by a challenge with 13C linoleic 
acids. This intervention explains the drop in BWG and CFE dynamic curve observed at this time point. 
Our previous results also demonstrated that prebiotic supplementation during HF diet quickly 
modify gut microbiota composition leading to profound changes in gut microbial amino acid 
degradation, host lipid metabolism and host mitochondrial metabolic pathways. Interesting 
correlations between plasma, fecal, urinary metabolic profiles, fecal microbial profiles, and 
circulating cytokine profiles, at D70 after the diet switch highlight the importance of the host 
mammalian-gut microbial interactions in the development of metabolic disorders and obesity.  
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Figure 47: Identification of metabolic/biological information from urine and feces samples predicting the long-
term prebiotic effect on obesity development during HF challenge. BWG monitoring of negative control group 
(LF), positive control groups (HF and HF_S) and prebiotic test groups (HF + GOS, HF + GOS_CMO, HF + FOS_IN) 
indicated 2 phases in the physiological adaptation to prebiotic supplementation.  Time-dependant metabolic 
and gut microbial adaptation to each diet intervention underlying the mouse physiological variations was also 
suggested. Therefore, 
1
H NMR metabolic profiles for urine and feces at each time-point, and fecal microbiota 
profiles at D7 and D70 after the diet switch were used to describe the long-term effect of prebiotic on obesity 
development and metabolic disorders. LF:  low fat, HF: high fat, HF_S: HF and glucose–lactose–galactose  
(positive control of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides (containing 
glucose–lactose–galactose). 
In the present chapter, we aimed to evaluate whether GOS, GOS_CMO or FOS_IN efficiency 
in limiting obesity development could be predicted from any metabolic information and/or specific 
bacterial composition during the early phase of dietary intervention. This would allow the 
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identification of candidate markers providing an early assessment of prebiotic interventions on 
mouse phenotype during HF challenge. Hence, a set of OPLS regression models predicting 
cumulative food efficiency at D70 after the diet switch (CFE_D70) in the positive control group (HF or 
HF_S fed mice) and the prebiotic test groups (HF + GOS, HF + GOS_CMO or HF + FOS_IN fed mice) 
were calculated using feces or urine 1 H NMR metabolic profiles at each time point.  OPLS regression 
models predicting CFE_D70 from fecal microbiota at D7 and D70 after the diet switch were also 
generated. Finally, from the identification of early candidate markers of prebiotic efficiency, 
additional mathematical models predicting the long-term effect of prebiotics on circulating IL-1β, fat 
mass, fasting hyperinsulinemia, fasting hyperglycemia, and organ weights during HF challenge were 
tested. Importantly, low fat (LF) diet containing different proportions of fat and carbohydrates do 
not induce obesity development (low mouse BWG, fasting insulinemia, fasting glycemia and 
circulating IL-1β concentration compared to HF diet). However, here, the data analysis was strictly 
focused on identifying biological markers related to prebiotic effect during HF challenge. Therefore, 
LF-fed mice were excluded from all the predicting models.  
2. MATERIALS AND METHODS 
 
2.1. Animal handling procedure and sample preparation 
See Chapter IV section X2.1X (Materials and Methods). 
  
2.2. Measurement of body weight, body weight gain, fat 
mass, food intake and food efficiency 
See Chapter IV, section X2.2X (Materials and Methods). 
  
2.3. Measuement of organ weights 
After 70 days of dietary intervention, mice were euthanized by anesthesia with isofluarane. 
Organs (kidney, liver and caecum), epididymal and mesenteric fat were also collected directly after 
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the sacrifice weighted and snap-frozen at -80 ⁰C. (n=90 for each tissue).The mouse caecum were 
emptied of undigested nutrients before being weighted. 
 
2.4. Measurement of body composition 
See Chapter IV, section X2.3X (Materials and Methods). 
  
2.5. Glucose tolerance and insulin secretion test  
See Chapter IV, section X2.4X (Materials and Methods).  
 
2.6. Measurement of circulating cytokines with Multiplexed 
Elisa assay (Meso Scale platform) 
See Chapter IV, section X2.5X (Materials and Methods). 
 
2.7. Sample preparation and 1H NMR spectroscopy 
See Chapter IV section X2.6X (Materials and Methods). 
 
2.8. 1H NMR spectra pre-processing and 1H NMR data 
processing. 
See Chapter IV section X2.7X (Materials and Methods) for 1H NMR spectra pre-processing and 
Chapter IV, section X2.8X (Materials and Methods) for 1H NMR data processing. 
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2.9. 16S rRNA gene sequencing of fecal microbiota 
See Chapter V section X2.6X (Materials and Methods). 
 
2.10. Prediction of physiological outcomes of mice fed HF and 
HF + prebiotics by OPLS regression models  
Several OPLS models predicting CFE, fat mass, fasting insulinemia, and organ weights 
(caecum, liver, kidney, epididymal fat and mesenteric fat weight) of HF and HF+ prebiotics at D70 
after the diet switch were generated using the relative abundance of p-cresol sulfate, p-cresol 
glucuronide, phenylacetylglycine and Streptococcaceae at 7 days after diet switch. Each model 
enables the calculation of a general equation predicting the physiological outcome. The significance 
of models was assessed by multiple permutation testing. 
 
3. RESULTS  
 
3.1. Prebiotic supplementation during HF diet limits energy 
storage and adipose accumulation, and affects organ weights. 
Cumulative food efficiency (CFE) defined by BWG: sum of food intake ratio, is a suitable 
parameter to estimate mouse calorie storage in the different diet groups and overcome the 
variability induced by food intake. In other words, CFE provide a good estimation of obesity 
development independently from “satiety-driven” energy intake. As previously mentioned in 
chapter IV (section X3.1.1X), all HF + prebiotic fed mice had lower CFE than HF and HF_S groups during 
the overall course of the experiment except for HF + GOS_CMO group, which was only significantly 
lower than HF_S group from D21 onward. Interestingly, the different prebiotic groups had 
comparable CFE along the study and exhibited similar energy expenditure as LF-fed mice for 4 weeks 
after the diet switch (XFigure 48X). This indicates that each prebiotic supplementation during HF 
challenge was associated with an increase in energy expenditure lowering CFE values throughout the 
experiment.  However, prebiotic benefits were not sustainable after a month of HF challenge, which 
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resulted in divergence in CFE between HF + prebiotic and LF groups. Noticeably, CFE was significantly 
higher in all HF containing diet groups at D7 compared to the other time points, and CFE became 
stable 2 weeks after the diet switch. This indicates that all mice challenged with HF had a boost in 
calorie storage 1 week after the diet switch whereas a second phase in metabolic adaptations occurs 
3 weeks after the diet switch causing an increase in energy expenditure. CFE values also dropped in 
all the animals at D14 because mice were subjected to a 12 hours fasting (see Chapter IV, section X2.1X 
(Materials and methods)). It is also important to remind that GOS, FOS_IN and GOS_CMO 
supplementation during HF diet significantly reduced fat mass, fasting hyperinsulinemia and 
hyperglycemia at D56 after the diet switch as well as circulating IL-1β concentration at sacrifice 
(XTable 10X). Therefore, as already emphasized in the Chapter IV (section X3.1.1X and section X4X), 
prebiotic supplementation during HF challenge limits obesity development, improves glucose 
metabolism and reduces HF associated inflammatory responses.  
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¥¥¥
⁰⁰⁰
ǂǂǂ
+++
###
 
Figure 48: Cumulative food efficiency of negative control group Wilcoxon-Mann-Whitney tests are presented 
at the last timepoint. 1 star for p-value<0.05, 2 stars for p-value<0.01, 3 stars for p-value<0.001 (x: HF vs 
HF+GOS, ¥ HF vs HF +FOS_IN, ⁰: HF_S vs HF+GOS_CMO, ǂ: LF vs HF+GOS, +: LF vs HF+FOS_IN, #:LF vs 
HF+GOS_CMO) (LF), positive control groups (HF, HF_S) and prebiotic test groups (HF + GOS, HF + GOS_CMO 
and HF + FOS_IN) overtime. LF:  low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose  (positive 
control of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and 
inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–
galactose). 
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At sacrifice (D70 after the diet switch), liver, kidney, caecum, mesenteric and epididymal fat 
weights were also recorded for each mouse. Non parametric Wilcoxon-Mann-Whitney tests (XTable 
10X), indicated that HF + GOS, FOS_IN or GOS_CMO fed mice had a significantly lower mesenteric and 
epididymal fat compared to their positive control groups (HF and HF_S fed mice). Liver and kidney 
weight of HF + GOS and HF + FOS_IN fed mice were also significantly lower than HF-fed mice. 
However, no significant difference in these organ weights was observed between HF + GOS_CMO 
and HF_S fed mice. This can be explained by the fact that liver and kidney weight tend to be lower in 
HF_S fed mice than those of HF-fed mice. In addition, a significant decrease in these organ weights 
were noticed, when HF + GOS_CMO fed mice were compared with HF-fed mice. Interestingly, 
caecum weight significantly increased in all HF + prebiotic fed mice compared to HF and HF_S fed 
mice.  Consequently, prebiotic supplementation during HF challenge affects mouse physiology by 
modulating organ weight and reducing adipose accumulation. 
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Table 10: Effect of long-term dietary interventions on physiological outcomes (p values calculated 
with non parametric Wilcoxon-Mann-Whitney tests) 
 
56 days (D56) after the diet switch 70 days (D70) after the diet switch 
mean ± sd 
Fat 
mass (g) 
fast 
glycemia 
(mmol/L)  
fast 
insulinemia 
(ng/mL) 
 
circulati
ng IL-1β 
(pg/ml) 
Epididy-
mal  
fat (g) 
Mesent-
eric  
fat (g) 
liver 
(g) 
Kidney 
(g) 
Caceum 
(g) 
LF 
3.34 
±0.60 
5.97 
±0.43 
0.35 
±0.22 
1.31 
±0.99 
0.13 
±0.036 
0.21 
±0.10 
0.9 
±0.11 
0.15 
±0.025 
0.24 
±0.095 
HF 
9.52 
±2.86 
6.69 
±0.70 
0.93 
±0.24 
3.764 
±1.84 
0.51 
±0.20 
0.49 
±0.19 
1.04 
±0.11 
0.21 
±0.06 
0.21 
±0.08 
HF_S 
7.71 
±2.54 
6.829 
±0.75 
0.48 
±0.12 
5.09 
±3.71 
0.40 
±0.13 
0.42 
±0.20 
0.96 
±0.20 
0.17 
±0.05 
0.21 
±0.04 
HF + GOS 
3.97 
±0.98 
6.387 
±0.64 0.21 ±0.12 
1.74 
±0.75 
0.22 
±0.09 
0.26 
±0.15 
0.91 
±0.10 
0.18 
±0.06 
0.48 
±0.10 
HF +GOS_CMO 
3.82 
±0.93 
6.166 
±0.64 0.30 ±0.23 
1.37 
±1.34 
0.23 
±0.087 
0.23 
±0.10 
0.90 
±0.10 
0.17 
±0.04 
0.34 
±0.09 
HF + FOS_IN  
4.07 
±1.27 
6.014 
±0.70 0.44 ±0.29 
1.21 
±0.82 
0.24 
±0.09 
0.28 
±0.10 
0.89 
±0.10 
0.15 
±0.05 
0.46 
±0.15 
p value                   
HF vs HF_GOS 
8.25 
 E-13 0.01 0.02 0.05 
0.87 
 E-04 
0.26 
 E-02 
0.13  
E-02 
0.11 
 E-02 
0.76  
E-05 
HFvs HF +FOS_IN 
8.55 
 E-13 0.00 0.03 0.02 
0.68 
 E-04 
0.13 E-
02 
0.51 
 E-03 
0.62 
 E-03 
0.78  
E-04 
HF_S vs HF 
+GOS_CMO 
5.85 
 E-08 0.01 0.01 0.02 
0.11  
E-03 
0.16 
 E-02 0.25 0.43 
0.31 
 E-06 
HF vs HF + 
GOS_CMO 3.3 E-13 0.1 E-3 0.01 
0.32 
 E-02 
0.11  
E-03 
0.27 
 E-03 
0.16 
 E-02 
0.37  
E-02 
0.61 
 E-03 
sd: standard deviation LF: low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose (positive 
control of HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides 
(containing glucose–lactose–galactose). 
3.2. Multivariate prediction of the long-term (D70) prebiotic 
efficiency in limiting HF induced obesity and metabolic 
disorders.  
Following this observation, we aimed to test whether urinary and fecal metabolic profiles at 
different time point could predict prebiotic efficiency to reduce calorie storage at sacrifice. 
Therefore, 1H NMR spectra from a positive control group (HF or HF_S fed mice) and a prebiotic test 
group (HF + GOS, HF + GOS_CMO or HF + FOS _IN fed mice) at different time points was correlated 
with CFE at D70 after the diet switch by using an OPLS (Orthogonal Partial Least Squares)–based 
pattern recognition method. Using the same method, supervised statistical methods were also 
applied to investigate whether mouse fecal microbiota at D7 and D70 were a suitable matrix to 
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predict the long-term prebiotic effect on calorie storage. Because, the LF diet contains a higher 
carbohydrate/fat ratio compared to HF and HF + prebiotic diets, LF-fed group was purposely 
excluded from the OPLS regression models to avoid identifying diet-composition related biomarkers. 
Furthermore, this strategy would enable the identification of early and stable biological markers 
predicting the long-term prebiotic efficiency in limiting HF associated obesity development and 
metabolic disorders.  
3.2.1. 1H NMR urinary metabolic profiles from D7 after the diet switch 
predict prebiotic efficiency in reducing long-term calorie storage 
during HF challenge. 
In order to identify early and specific urinary markers of GOS, GOS_CMO and FOS_IN 
efficiency in reducing mouse calorie storage during HF challenge, 3 OPLS regressions were 
performed using urinary metabolic data of HF and HF + GOS, HF_S and HF + GOS_CMO or HF and HF 
+ FOS_IN at D7 and CFE at D70 (CFE_D70). For each model, OPLS scores plots showed a good 
discrimination between the positive control group (HF or HF_S) and the prebiotic test group (HF + 
GOS, HF + GOS_CMO or HF + FOS _IN ) along the first component (T1). In addition, the good 
correlation between the T1 scores and CFE_D70 indicates that early metabolic profiles allow the 
prediction of long-term mouse calorie storage. (XFigure 49X.A, XFigure 49X.C, XFigure 49X.E). The OPLS-
loadings plot allowed identifying early discriminatory metabolites being positively or negatively 
correlated with CFE values for each model.  (XFigure 49X.B, XFigure 49XD, XFigure 49X.F). Furthermore, in 
order to evaluate the stability in the relationship between urinary metabolic profiles and CFE at D70 
after the diet switch, OPLS regression models predicting CFE_D70 from urinary metabolic profiles of 
HF and HF + GOS, HF and HF + FOS_IN or HF_S and HF + GOS_CMO groups at each time point (from 
D7 to D70) were calculated. The optimal number of components was determined by R2Y and Q2Y 
statistics (XFigure 50X). All models were validated by re-sampling the Y variable in permutation tests 
which showed that urine is a good matrix for energy storage prediction. Noticeably, Q2Y value under 
0.3 was observed in the predictive model with urinary metabolic profiles of HF_S and HF + 
GOS_CMO at D35 after the diet switch highlighting a lower goodness of prediction at this time point 
(XFigure 50X.B). Interestingly, Q2Y values for models derived from HF and HF_GOS urinary metabolic 
profiles (XFigure 49XA) or HF and HF + FOS_IN urinary metabolic profiles (XFigure 49X.C) dropped at D21 
after the diet switch. This is probably due to the fact that at D14 after the diet switch, all mice were 
subjected to 12 hours fasting followed by gavages with 13C linoleic acids inducing strong metabolic 
perturbations. Mouse basal urinary metabolic profile might be still affected one week after the 
221 
 
intervention resulting in a loss of matrix predictability. However, this was not observed in the 
predictive model calculated with HF_S and HF + GOS_CMO urinary metabolic profiles. 
 
Figure 49: OPLS regression models predicting mouse calorie storage at D70  after the diet switch from D7 
urinary metabolic profiles of HF and HF + GOS fed mice.(A ,B), HF_S and HF + GOS_CMO fed mice (C, D), or HF 
and HF + FOS_IN fed mice (E, F). For each model, the score plots indicate a good relationship between early 
metabolic profiles and CFE_D70 (A, C, E). The OPLS-loadings plot highlights metabolites that are positively or 
negatively correlated with CFE_D70 (B,.D,.F). LF:  low fat, HF: high fat, HF_S: HF and glucose–lactose–galactose  
(positive control of HF + GOS_CMO group,) GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-
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oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides (containing 
glucose–lactose–galactose). 
 
 
Figure 50: Goodness of fit (R
2
Y) and goodness of prediction (Q
2
Y) of OPLS-regression models predicting 
CFE_D70 with urinary metabolic profiles of HF and HF + GOS groups (A), HF_S and HF + GOS_CMO groups (B) 
or HF and HF + FOS_IN groups (C) at each time point. The models were calculated with 1 predictive component 
and various numbers of orthogonal components. For each model, the numbers of component are indicated at 
each time point on top of the R
2
Y value.  All models were validated with multiple permutation testing.(see 
Appendix 2, Table S6) LF:  low fat, HF : high fat, HF_S : HF and glucose–lactose–galactose  (positive control of 
HF + GOS_CMO group,)  GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and inulin; 
GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–galactose). 
 
The heatmaps summarised correlation values of metabolites being positively or negatively 
associated with CFE_D70 at each time-point, in the models with HF and HF + GOS groups (XFigure 
51X.A), HF_S and HF + GOS_CMO groups (XFigure 51X.B) or HF and HF + FOS_IN groups (XFigure 51X.C)  .  
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Interestingly, early and stable urinary markers positively correlated with CFE in each model were 
identified. These markers were assigned as microbial co-metabolites p-cresol sulfate (PCS), p-cresol 
glucuronide (PCG) and phenylacetylglycine (PAG)H31H. Therefore a drop of these urinary metabolites 
was consistently associated with the long-term GOS, GOS_CMO or FOS_IN efficiency in reducing 
calorie storage during HF challenge. 2 PY, 4 PY and N-methylnicotinamide were also late predictors 
of the prebiotic efficiency in reducing calorie storage since they became significantly correlated with 
GOS_CMO and FOS_IN efficiency at D42 and appeared discriminatory markers at D56 in the models 
calculating GOS efficiency.  Specific markers of prebiotic efficiency were also identified as listed in 
the following paragraphs.  
Specific markers of GOS efficiency 
OPLS regression models calculated with urinary metabolic profiles of HF and HF + GOS fed 
mice showed that urinary D-glucose, D-galactose and an unassigned (UA) hexose were negatively 
correlated with CFE_D70  from D7 to D70 (XFigure 51X.A). On the contrary, sucrose was positively 
correlated with CFE_D70 throughout the experiment. As previously mentioned GOS fibres are made 
from glucose and galactose polymerisation, therefore, the relationship between CFE_D70 and 
urinary excretion of D-glucose and D-galactose was most probably due to an increase in glucose and 
galactose supply from GOS digestion. 4-hydroxyphenylacetate and creatine were also positively 
correlated with CFE_D70 but the relationships between these metabolites and CFE_D70 were not 
stable over time.  
Specific markers of GOS_CMO efficiency 
OPLS models predicting CFE_D70 from urinary metabolic profiles of HF and HF + GOS_CMO 
fed mice also pointed out negative correlations between D-glucose, D-galactose and CFE_D70 which 
can be explained by the GOS containing prebiotic digestion (XFigure 51X.B). On the other hand, urinary 
sucrose was negatively correlated with CFE_D70 while UA hexose was positively correlated which is 
not consistent with previous observations (sucrose was positively correlated with HF diet in OPLS-DA 
model discriminating HF and HF + GOS groups at D70 (Chapter IV, section X3.2.5X). Interestingly, TMA 
and choline were found to be specific markers of GOS_CMO efficiency. As TMA is produced from 
choline degradation by the gut microbiota, our results suggest that GOS and cow milk 
oligosaccharide supplementation during HF challenge may also alter energy efficiency via a 
regulation of gut microbial choline metabolism H169H. However, only sucrose and choline were stable 
and specific predictors of GOS_CMO efficiency over time as indicated in the heatmap by high 
correlations coefficients at each time point (XFigure 51X.B). 
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Specific markers of FOS_IN efficiency 
Unlike the models predicting GOS and GOS_CMO efficiency, α/β-D glucose was found to be 
positively correlated with CFE_D70 in the models calculated with urinary metabolic profiles of HF 
and HF + FOS_IN fed mice (XFigure 51X. C). In addition, creatine and sucrose were positively correlated 
with CFE_D70 while UA hexose and UA metabolite (3.35ppm) were negatively correlated with this 
physiological outcome at several time points. However, only α-D glucose and UA metabolite 
constitute early, stable and specific markers of FOS_IN efficiency in reducing CFE over time. 
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Figure 51: Heatmaps highlighting discriminatory metabolites at each timepoint being positively or negatively 
correlated with mouse calorie storage at D70 after the diet switch. Correlation coefficients were obtained from 
the OPLS-DA coefficient plot of predicting models from urinary metabolic profiles of HF and HF + GOS fed mice 
(A), HF_S and HF +GOS_CMO fed mice (B) or HF and HF + FOS_IN fed mice (C) at each timepoint.  Positive 
values are color-coded in red shades while negative values are color-coded in blue shades. *, tentative 
assignment LF:  low fat, HF: high fat, HF_S: HF and glucose–lactose–galactose  (positive control of HF + 
GOS_CMO group,) GOS : galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and inulin; GOS_CMO, 
galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–galactose). 
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3.2.2. 1H NMR fecal metabolic profiles do not consistently predict the 
long-term prebiotic efficiency in reducing calorie storage during HF 
challenge. 
Using the same strategy as for urinary metabolic profiles, we aimed to predict the long-term 
prebiotic efficiency in reducing calorie with mouse fecal metabolic profiles at different time points. 
In particular, OPLS regression models predicting CFE_D70 using fecal metabolic profiles of HF and HF 
+ GOS, HF_S and HF + GOS_CMO or HF and HF + FOS_IN fed mice were built at each time point. In 
order to evaluate the goodness of fit and prediction of each model, R2Y and Q2Y were displayed in 
XFigure 52X. In general, the goodness of prediction (Q2Y) of the models generating with faecal 
metabolic profiles were lower than those generating with urinary metabolic profiles. Only the 
models predicting CFE_D70 of HF and HF + GOS fed mice were validated at D7, D14, D35, D42, and 
D56 with permutation tests (XFigure 52X.A). The OPLS regression models performed with HF and HF + 
FOS_IN fed mice were validated at D14, D28, D35, D42, D49, and D56 (XFigure 52X.B) while the OPLS 
regression models with HF_S and HF +GOS_CMO fed mice were significant from D63 ( XFigure 52X.C). 
Therefore, the correlation between fecal metabolic profiles and CFE_D70 was not stable over time 
which did not allow the identification of early and stable fecal biomarkers of prebiotic efficiency. To 
conclude, these results point out that urinary metabolic profile is a more suitable matrix than the 
fecal metabolic profile to consistently predict long-term prebiotic efficiency in reducing calorie 
storage during HF challenge in the present experiment. 
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Figure 52: Goodness of fit (R
2
Y) and goodness of prediction (Q
2
Y) of OPLS-regression models predicting 
CFE_D70 with fecal metabolic profiles of HF and HF + GOS groups (A), HF_S and HF + GOS_CMO groups (B) or 
HF and HF + FOS_IN groups (C) at each time point. The models were calculated with 1 predictive component 
and various numbers of orthogonal components. For each model, the numbers of component are indicated at 
each time point on top of the R
2
Y value.  *: indicates the models validated with multiple permutation testing. 
(see Appendix 2, Table S7). LF: low fat, HF: high fat, HF_S : HF and glucose–lactose–galactose  (positive control 
of HF + GOS_CMO group,) GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-oligosaccharides and inulin; 
GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides ( containing glucose–lactose–galactose). 
 
3.2.3. Fecal microbial profiles at D7 and D70 after the diet switch 
predict the long-term prebiotic efficiency in reducing calorie 
storage during HF challenge  
Fecal microbiota were analysed using high throughput 16s rRNA gene sequencing at D7 and 
D70 after the diet switch. As previously indicated in Chapter V (section X3.1X), the data analysis was 
focused at family level since it provides us detailed information about functional/compositional 
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variability among the diet groups and limit intra-individual variability. After data processing (see 
Materials and methods), 15 bacterial families were unequivocally detected in the mouse fecal 
microbiota. Here, the experiment aimed to investigate whether bacterial profiles at family level D7 
or D70 after the diet switch, could predict the long-term GOS, GOS_CMO or FOS_IN efficiency in 
reducing calorie storage. Therefore, OPLS regression models predicting CFE_D70 from fecal bacteria 
profiles of HF and HF + GOS fed mice, HF_S and HF + GOS_CMO fed mice, or HF and HF +FOS_IN fed 
mice at D7 and D70 after the diet switch were performed and validated. For each model, the 
goodness of fit (R2Y) and the goodness of prediction (Q2Y) are displayed in legend XFigure 53X. The 
loadings plots generated from predicting models with HF and HF + GOS groups ( XFigure 53X.A, XFigure 
53X.B), HF_S and HF + GOS_CMO groups (XFigure 53X.C,XFigure 53X.D), or HF and HF + FOS_IN groups 
(XFigure 53X.E,XFigure 53X.F) highlighted discriminatory families of bacteria being positively or negative 
correlated with CFE_D70. Interestingly, fecal abundance of Streptococcaceae at D7 and D70 after the 
diet switch, were highly correlated with CFE_D70 in each model. This shows that a rapid drop in fecal 
Streptococcaceae abundance with prebiotic supplementation can predict GOS, FOS_IN or GOS_CMO 
efficiency in reducing calorie storage. Hence, it constitutes a stable and common biological marker of 
prebiotic efficiency. It is important to note that the correlation coefficient (R2) between 
Streptococcaceae and FOS_IN or GOS efficiency in reducing CFE_D70 rise from 0.4 to 0.6 after 70 
days of diet intervention. On the contrary, correlation coefficient between Streptococcaceae and 
GOS_CMO efficiency drop from 0.4 to 0.25. Other bacteria families were also found to be specific 
markers of GOS, FOS_IN or GOS_CMO efficiency: 
Specific markers of GOS efficiency 
Peptostreptococcaceae were found to be highly correlated with CFE_D70 in models with HF 
and HF + GOS fed mice at D7 (R2=0.45) and D70 (R2=0.46) after the diet switch (XFigure 53X.A, XFigure 
53X.B). As a result, this family of bacteria constitutes an early and stable biological marker of GOS 
efficiency. Interestingly, the correlation coefficient between Peptostreptococcaceae and CFE_D70 
was similar at both time points which highlight the consistency of this marker in predicting CFE_D70. 
Fecal abundances of unclassified family and Ruminococcaceae at D70 after the diet switch were also 
highly correlated with CFE_D70 (XFigure 53X.B). Therefore, they are late predictors of GOS efficiency in 
reducing calorie storage.  
Specific markers of GOS_CMO efficiency 
Ruminococcaceae and unclassified family at D7 after the diet switch were highly correlated 
with CFE_D70 (R2=0.4, R2=0.38 respectively) in models with HF_S and HF + GOS_CMO fed mice. 
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Therefore they constitute early and specific predictors of GOS_CMO efficiency ( XFigure 53X.C).  
However, at D70 after the diet switch, only Ruminococcaceae was found to be highly correlated 
(R2=0.55) with CFE_D70 in our model (XFigure 53X.D).  
Specific markers of FOS_IN efficiency 
The model predicting CFE_D70 from fecal microbiota of HF and HF + FOS_IN fed mice at D7 
after the diet switch indicated that Peptostreptococcaceae (R2=0.30) and Rikinellaceae (R2=0.38) 
were early and significant predictors of FOS_IN efficiency (XFigure 53X.E). These bacteria families were 
also significantly correlated (R2=0.30 for Peptostreptococcaceae and R2=0.39 for Rikinellaceae) with 
CFE_D70, at D70 after the diet switch (XFigure 53X.F). Therefore, they constitute early, stable and 
specific markers of long-term FOS_IN efficiency in reducing calorie storage. Interestingly, the 
correlation values of these markers were consistent between D7 and D70 which confirm their 
stability in predicting CFE_D70. At D70 after the diet switch other bacteria families became good 
predictors of FOS_IN efficiency. Bifidobacteriaceae were negatively correlated (R2=0.62) with 
CFE_D70 while Ruminococcaceae (R2=0.46) and unclassified bacteria (R2=0.44) were positively 
correlated with this physiological outcome. 
To summarise, in each model, fecal microbiota profiles at early time point (D7) or at sacrifice 
(D70) were good predictors of final mouse calorie storage. Several families of bacteria were found to 
specifically predict long-term GOS, GOS_CMO and FOS_IN efficiency in reducing calorie storage.  
Streptococcaceae constitutes the only stable and common candidate marker of prebiotic efficiency.  
However, additional sampling of mouse fecal microbiota at other time-points is needed to confirm 
the stability of fecal microbiota profiles and particularly Streptococcaceae in predicting CFE_D70. 
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Figure 53: OPLS-coefficient plots indicating correlation coefficients between bacteria families at D7 and D70 
and GOS (A, B), GOS_CMO (C, D) or FOS_IN (E, F) efficiency in reducing mouse calorie storage at D70 after the 
diet switch. OPLS-DA coefficient plots were obtained from models with HF and HF + GOS fed mice (A, B), HF_S 
and HF + GOS_CMO fed mice (C, D) or HF and HF + FOS_IN fed mice (E,.F) at D7 and D70 after the diet switch. 
Correlation values (R
2
) color-coded in red shades are close to 1 while those color-coded in blue shades are 
close to 0. 
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3.2.4. Early, stable candidate markers commonly predict the long-term 
efficiency of GOS, GOS_CMO and FOS_IN in reducing calorie 
storage. 
A set of urinary and microbial candidate biomarkers allowing an early and consistent 
prediction of prebiotic efficiency were identified. The Venn diagram (XFigure 54X) illustrates the 
proportion of specific and common candidate markers of CFE_D70 among the different prebiotics. 
For each prebiotic, 8 candidate markers were found to be early and stable predictors of prebiotic 
efficiency. Among these, 4 stable candidate markers predicting GOS efficiency, 3 stable candidate 
markers predicting FOS_IN efficiency and 3 candidate markers predicting GOS_CMO efficiency were 
found. In addition, 4 candidate markers (PAG, PCG, PCS, and Streptococcaceae) were commonly 
identified as early and stable predictors of GOS, GOS_CMO and FOS_IN efficiency. PAG, PCG, PCS are 
well known end product metabolites of gut microbial amino acid degradation, therefore, it can be 
suggested that a reduction of gut bacterial amino acid fermentation by prebiotic supplementation 
during HF challenge lower calorie storage. 
 
Figure 54: Venn diagram indicating the number of specific and common markers of calorie storage at D70 after 
the diet switch among the different prebiotics. GOS: galactosyl-oligosaccharides; FOS_IN: fructosyl-
oligosaccharides and inulin; GOS_CMO, galactosyl-oligosaccharides and cow milk oligosaccharides (containing 
glucose–lactose–galactose). 
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3.2.5. Urinary abundance of PAG, PCG, PCS and fecal Streptococcaceae 
at D7 after the diet switch predicts long-term beneficial effect of 
prebiotic on calorie storage, organ weights and other physiological 
disorders during HF challenge.  
Here, prebiotic supplementation during HF challenge had beneficial impact on obesity 
development since it reduced the mouse calorie storage, fat mass and several organ weights. The 
relative abundances of PAG, PCG, PCS were calculated by integrating their peaks in 1H NMR urine 
spectra.  Using the relative abundance of PAG, PCG, PCS and fecal Streptococcaceae at D7 after the 
diet switch, robust OPLS regression models predicting CFE_D70 of the positive control groups (HF 
and HF_S) and the prebiotic test groups (HF + GOS, HF + GOS_CMO and HF + FOS_IN) were 
generated and validated. The scores plot highlighted the significant association between CFE_D70 
with this combination of markers (T1) (XFigure 55X.A). The most important variable underlying the 
model predictability are PAG and Streptococcaceae (XFigure 55X.B.). A general equation was calculated 
based on this model, which estimates at early time point, the long-term prebiotic efficiency in 
reducing calorie storage (XFigure 55X.B). 
Additionally, the combination of 4 candidate markers was tested to potentially predict other 
physiological outcomes associated with prebiotic induced improvement of obesity phenotype 
(XFigure 55X, XFigure 56X). A set of OPLS regression models was performed using the relative abundance 
of PAG, PCG, PCS and fecal Streptococcaceae at D7 to predict fat mass, fasting hyperinsulinemia, 
fasting hyperglycemia, circulating IL-1β abundance and organ weights of positive control groups (HF 
and HF_S mice) and prebiotic test groups (all HF + prebiotics fed mice). The robustness and the 
predictability of these models were tested using multiple permutations method. The models 
predicting liver and kidney weight at D70 as well as fasting glycemia at D56 from the same 
combination of markers were not significant. However, specific patterns of urinary PAG, PCG, PCS 
and fecal Streptococcaceae at D7 after the diet switch were able to predict fat mass and fasting 
hyperinsulinemia at D56, circulating IL-1β abundance, mesenteric and epidydymal fat and caecum 
weight at sacrifice (XFigure 55X, XFigure 56X). The scores plot pointed out the significant relationship 
between the marker abundances and the various physiological outcomes ( XFigure 55X.A,XFigure 
54X.D,XFigure 54X.G, and XFigure 54X.J). It is noteworthy that some overlaps among diet groups along the 
mesenteric and epididymal fat axis were observed. In particular, HF_S fed mice tend to have reduced 
mesenteric and epididymal fat compared to HF diet and comparable amount of fat to HF + prebiotic 
fed mice (Table 1).  
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The loadings plots highlighted that PCG and PCS were the most important variables 
underlying the fat mass-predicting model (XFigure 55X.E). On the other hand, Streptococcaceae, and 
PCS were the most significant variables predicting fasting insulinemia in the models (XFigure 55X.H) 
while the main factors predicting circulating IL-1β concentration were PCG and PCS (XFigure 55X.K). 
Finally, Streptococcaceae, and PCG were the main variables predicting mesenteric fat and 
epididymal fat in the OPLS regression models (XFigure 56X. B,XFigure 56X.E). The models were validated 
with multiple permutation testing (XFigure 55X.C,XFigure 55X.F,XFigure 55X.I,XFigure 55X.L,XFigure 56X.C, and 
XFigure 56X.F).  
Physiological data have shown that prebiotic supplementation during HF diet also induced a 
significant increase in caecum weight compared to the positive control groups. Interestingly, urinary 
abundance of PAG, PCG, PCS and fecal abundance Streptococcaceae at D7 after the diet switch could 
predict the caecum weight of positive control groups (HF and HF_S fed mice) and prebiotic test 
groups (all HF + prebiotic fed mice) at D70 after the diet switch. The OPLS scores plot indicated a 
relationship between caecum weight and the excretion pattern of these markers (XFigure 56X.G). The 
loadings plot showed that PAG, PCG, PCS and fecal Streptococcaceae were negatively correlated 
with the caecum weight. In particular, PCG, PCS were the most correlated variables in the predicting 
model (Figure 56.H). The model was also validated under multiple permutations testing ( XFigure 56X.I). 
Importantly, although all models were validated, the scores distribution along fasting 
hyperglycemia, circulating IL-1β, epididymal fat, mesenteric fat or caecum weight axis was not linear 
and significant within-group variability was noticed. This tends to indicate a group-driven 
stratification of the data rather than a linear prediction of these physiological outcomes. PCG, PCS, 
PAG and Streptococcaceae are qualitative candidate markers discriminating the prebiotic effects 
from the HF effect in these models. Therefore, the best predictive models were those calculated 
with CFE and fat mass at D70 as indicated by high goodness of fit (Q2Y>0.5) and well-distributed 
scores plot.  
To conclude, in the present experiment several physiological outcomes indicative of the 
beneficial prebiotic effects on mouse physiology during HF challenge were predicted by using a 
combination of biological markers from feces and urine samples at D7 after the diet switch. Based 
on each model, generic linear equations predicting the different physiological outcomes were 
calculated. As these markers were not specific of any prebiotic, these mathematical models could be 
used as a general basis to assess the long-term mouse phenotype during the early phase of any 
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prebiotic intervention. However, non-linear fitting strategy may provide better predictive models of 
these physiological outcomes.  
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Figure 55: OPLS-regression models predicting long-term physiological outcomes based on the abundance of 
Streptococcaceae (St), p-cresol sulfate (PCS), p-cresol glucuronide (PCG) and phenylacetylglycine (PAG) at D7 
after the diet switch.  For each model, the scores plots indicate a significant relationship between a specific 
pattern of excretion of these markers and the physiological outcomes (Figure 55.A for CFE_D70, Figure 55.D 
for fat mass, Figure 55.G for circulating IL-1β, Figure 55.J for fasting insulinemia). The OPLS-loadings plot 
indicated the correlation coefficients between the variables and the physiological outcomes. (Figure 55.B for 
CFE_D70, Figure 55.E for fat mass, Figure 55.H for circulating IL-1β, Figure 55.K for fasting insulinemia). All the 
models were validated with multiple permutations testing (p value <0.05) (Figure 55.C for CFE_D70, Figure 
55.F for fat mass, Figure 55.I for circulating IL-1β, Figure 55.K for fasting insulinemia). 
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Figure 56: OPLS-regression models predicting organ weight at sacrifice based on the abundance of 
Streptococcaceae (St), p-cresol sulfate (PCS), p-cresol glucuronide (PCG) and phenylacetylglycine 
(PAG) at D7 after the diet switch. For each model, the scores plots indicate a significant relationship 
between a specific pattern of excretion of these markers and organ weights (Figure 56.A for 
mesenteric fat, Figure 56.D for epididymal fat, Figure 56.G for caecum weight,). The OPLS-loadings 
plot indicated the correlation coefficients between the variables and the physiological outcomes 
(Figure 56.B for mesenteric fat, Figure 56.E for epididymal fat, Figure 56.H for caecum weight). All 
the models were validated with multiple permutations testing (p value < 0.05) outcomes (Figure 56.C 
for mesenteric fat, Figure 56.F for epididymal fat, Figure 56.I for caecum weight) 
 
4. DISCUSSION 
The prebiotic study findings show the ability to predict at early stage from urinary metabolic 
profile or fecal microbial profiles the long-term prebiotic efficiency to reduce calorie storage. More 
precisely, urinary PCS, PCG, PAG were common and stable markers of GOS, GOS_CMO and FOS_IN 
efficiency to reduce calorie storage overtime. Fecal Streptococcaceae were also found to be 
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consistently correlated with calorie storage at D7 and D70 in each predictive model. From the 
identification of these non specific markers, a general model predicting the prebiotic efficiency to 
reduce calorie storage was calculated based on the abundance of urinary PCS, PCG, PAG and fecal 
Streptococcaceae at D7 after HF the diet switch. Furthermore using the same combination of non-
specific markers, robust models predicting at early stage (D7 after the diet switch), the long-term 
beneficial effect of any prebiotic on fat mass, fasting insulin level and adiposity were also calculated. 
Hence, a combination of urinary and fecal markers at an early time point can estimate the prebiotic 
efficiency in the delay of obesity development and the associated physiological disorders. Such a 
biomarker combination may be a first step toward defining early generic biological signatures to 
assess the optimum effect of prebiotic intervention on obesity. These data also support the 
hypothesis of a functional interaction between gut microbial amino acid fermentation and host 
physiology. Therefore, potential pharmacological effects of PCS, PCG and PAG on host 
immunological/metabolic pathways were discussed in this chapter. Finally renal dysfunction which is 
commonly observed in long-term obesity may contribute to increase circulating PCS and PCG which 
may promote metabolic disturbances and inflammation during diet induced obesity (DIO). 
 
4.1. Rapid changes in colonic bacterial amino acid 
fermentation influence mouse physiology during DIO.   
Early (D7) urinary excretion of PAG, PCG, PCS and fecal excretion of Streptococcaceae was 
positively correlated with fat mass, CFE, circulating IL-1β, fasting insulinemia, epididymal and 
mesenteric adipose tissues at D70 in HF and HF + prebiotic fed mice. Indeed, PAG, PCS, and PCG are 
phase II detoxification products of microbial amino acid degradation. Tyrosine fermentation by 
colonic bacteria triggers the formation of p-cresol and phenylacetate. These colonic compounds are 
in turn excreted in the feces or absorbed by colonic bacteria and detoxified by sulfation, 
glucuronidation or glycation into PCS, PCG and PAG in the colonic mucosa or liver226. Subsequently, 
these detoxification products are shuttled in the kidney to undergo elimination in urine226. In 
addition Streptococcaceae  are anaerobic bacteria which confer high proteolytic activities277. 
Interestingly, fecal Streptococcaceae was the most important variable underlying the 
prediction of mesenteric adiposity sites. Fecal Streptococcaceae was already found to increase in HF-
fed mice compared to the other diet groups at D7 after the diet switch and were positively 
correlated with fecal bile acids, fecal and plasma lipids at D70 after the diet switch (chapter V, 
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section X3.2X). Therefore, HF diet associated gut microbiota remodelling may help extracting lipid from 
the diet and promote lipid storage241,283. In our predictive models, urinary PCS at D7 was also 
strongly correlated with insulin level, fat mass and circulating IL-1β of HF and HF + prebiotics fed 
mice. On the other hand, PAG was the least correlated variable in all the models. Amino acid 
fermentation end-products i.e. p-cresol, PAG, PCG and PCS may cross host physiological barriers, 
enter systemic circulation and biochemically affect host metabolic/immunological pathways. In 
particular, PCS may promote a pro-inflammatory response toward IL-1β related pathways which 
contributes to DIO associated low grade inflammation and physiological disorders. This will be 
further developed in this discussion. 
It has been previously demonstrated in this PhD thesis that GOS, GOS_CMO or FOS_IN 
supplementation during HF challenge for 70 days significantly lowers gut bacterial tyrosine 
fermentation through a reduced urinary level of PCS, PAG, PCG. In addition, prebiotic 
supplementation induced a significant reduction in CFE, fat mass, epididymal and mesenteric 
adipose tissue, circulating IL-1β, fasting insulinemia at D70 after the diet switch. This supports the 
hypothesis that reduced colonic amino acids fermentation by dietary intervention (i.e prebiotics) 
lowering p-cresol, PAG, PCG and PCS limits HF-induced ectopic fat accumulation, low grade 
inflammation and impaired insulin action. A significant increase in caecum weight was also observed 
in HF + prebiotics fed mice compared to HF-fed mice at D70 after the diet switch. This caceum 
hypertrophy highlights an activation of bacterial fermentation in colon probably through SCFAs 
production284. Interestingly, the same combination of markers at D7 after the diet switch was 
negatively correlated with caceum weight. These results suggest that prebiotic in the context of HF 
induced obesity rapidly modify gut microbial activity toward a decrease in amino acid fermentation 
and a concomitant increase in carbohydrate fermentation which influences host metabolism to 
improve host physiology. In the present chapter, our results raise the hypothesis of causal 
relationships among protein fermentation by colonic bacteria and host adiposity growth, low grade 
inflammation and impaired insulin action during HF diet induced obesity. This might be due to the 
fact that protein fermentation end-products confer specific pharmacological effects on host 
metabolic and inflammatory pathways. 
4.2. PCS, PCG and PAG may confer pharmacological effects 
on host fat storage and insulin signalling pathways 
Phenol and p-cresol derivatives have been suggested to have toxic properties226. In 
particular, PCS is the most abundant derivative product of p-cresol in human and mouse285,286. It has 
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recently received particular attention, since it has been identified as prognostic and diagnostic 
markers of several physiological outcomes in pharmacometabonomic and epidemiological 
studies277,282,286,287. For example, individuals producing high PCS from gut microbiota mediated p-
cresol in pre-dose were found to be less efficient in detoxifying acetaminophen by o-sulfation282. 
Hence, gut microbial activity might have an impact in determining the individual responses to drug 
treatment. PCS is also considered as one of the major uremic toxins contributing to the propensity 
for metabolic disorders and vascular diseases in uremic patients285,286. Because PCS is highly protein 
bound, it cannot be properly cleared with classic hemodialysis. As a result, it is commonly found in 
high concentration in blood of patients with kidney failure286. Serum PCS has been found to predict 
CVDs and all cause of mortality in the elderly hemodialysis patients287. A mechanistic study 
investigating the causal relationship between serum PCS and the development of metabolic 
disorders, has demonstrated PCS-induced insulin resistance in vitro and in vivo in patient suffering 
chronic kidney disorders (CKDs). In particular, PCS alters glucose uptake in C2C12 myotubule cells by 
activating ERK1/2 phosphorylation which inhibits the insulin induced PKB/AKT phosphorylation and 
triggers insulin resistance288. PCS also promoted lipolysis and fat redistribution towards ectopic sites 
in mice288. Additionally, urinary PAG and PCG have been positively correlated with obesity in mice 
although their mechanisms of actions are not well understood289. Hence, in the context of obesity, 
PAG and particularly PCS and PCG produced from the detoxification of gut microbial tyrosine 
fermentation end-products reaching blood circulation and organs (liver, kidney) might have 
pharmacological effects contributing to the development of ectopic fat accumulation and 
hyperinsulinemia in our experiment. Additional in vitro experiments studying the biochemical effects 
of PCS, PCG and PAG on triglyceride (TG) synthesis, lipoprotein formation and circulation and insulin 
signalling pathways are needed to provide new insights about their functionalities on host lipid and 
glucose metabolism. 
4.3. PCS, PCG and PAG may contribute to host IL-1β related 
inflammatory pathways  
In the Chapter V (section X3.2X), positive correlations between plasma IL-1β, urinary PCS, PCG 
and Streptococcaceae D70 after the diet switch were identified. This suggested that a modulation of 
gut microbiota composition and activation of microbial amino acid fermentation in HF-fed mice 
contribute to HF induced low grade inflammation probably through IL-1β pathway226,290. Here, 
urinary abundance of PCS, PCG, PAG and fecal abundance of Streptococcaceae at D7 after the diet 
switch also allowed the prediction of long-term circulating IL-1β production. These additional results 
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raise the hypothesis that compounds derived from gut microbial tyrosine degradation end-products 
(PCS, PCG) have a functional relationship with IL-1β production and the development of circulating 
inflammation. During the detoxification process, PCG and PCS are produced in the liver, reach the 
kidney, and may be transferred to other peripheral tissues, directly triggering local inflammatory 
responses H291H. Noticeably, patients with uremic syndrome and kidney failure are subjected to an 
impaired immunity, with an excessive cytokine excretion 286,292,293. Higuchi et al showed that 
peripheral blood mononuclear cells cultured with the serum of uremic patients rich in protein bound 
solutes such as PCS and PCG induced the production of IL-1β292. Lim et al also presented results that 
myeloid dendritic cells from healthy individuals treated with uremic serum had altered expression of 
co-stimulatory molecules and deceased IL-12 production when stimulated with LPS293.  
4.4. HF associated renal dysfunction may contribute to 
increase PCS, PCG or PAG in systemic circulation 
Interestingly, potential links among obesity, metabolic syndrome and renal damage were 
recently shown H294H. Increased body mass index and energy intake are associated with an excess 
excretory load leading to nephromegaly and renal dysfunction294. For example, Na excretion capacity 
has been found to be reduced in obese individuals295. Lipotoxicity associated with obesity is also 
recognized as afflicting renal cells and triggering inflammation294,296. Finally, recent evidence suggest 
adverse affects of hyperinsulinemia and IR on renal function294. In the present experiment, HF and 
HF_S fed mice may gradually develop renal dysfunction which raises the proportion of waste 
products in circulation including PCS, PCG and PAG. These compounds could then easily reach the 
peripheral organs directly contributing to metabolic deregulations, ectopic fat accumulation, 
inflammation and hyperinsulinemia by the abovementioned mechanisms. Prebiotic supplementation 
during HF diet on the other hand, may alleviate HF associated kidney damage by limiting energy 
intake, body weight and the production of toxic metabolites which in turn may improve mouse 
phenotype. However, PAG, PCS, PCG were not observed in 1H NMR plasma metabolic profiles in all 
diet groups. Because these compounds are highly bound with plasma proteins, it is most likely that 
their signals appear highly broadened in standard spectra or are suppressed in CPMG spectra. To 
verify this hypothesis, it would be necessary to evaluate kidney metabolism and functions in HF and 
HF + prebiotic fed mice as well as measuring plasma PCS, PCG, PAG levels by a more suitable 
method. 
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4.5. Variability in fecal metabolic profiles does not allow 
predicting the physiological outcomes 
Unlike urinary metabolic profiles, the food efficiency predicting models calculated with fecal 
metabolic profiles were not valid at each time point highlighting time related instability of metabolic 
profiles over the duration of the study. Saric et al, studying interspecies and temporal variations in 
fecal metabolic profiles have demonstrated significant  variations associated to time/age in female 
NMRI mice and female Wistar rats fed the same diet297. Therefore, it can be assumed that time 
associated perturbation of fecal metabolic profiles generating within group variability alters the 
predictive power of this matrix. 
4.6. The predictive models present some limitations  
The effects of prebiotic supplementation in HF-fed mice 7 days after the beginning of the 
intervention, were already noticed since body weight gain and calories storage were significantly 
lower in all HF + prebiotic fed mice compared to HF-fed mice. The early prebiotic associated 
reduction of bacterial proteolysis may be an early consequence of lower BWG and CFE reduction. 
Therefore, the causal effects of bacterial proteolysis regulation on host metabolism remain to be 
proven. In addition, it important to note that PCS, PCG, PAG are diet-conditioned markers of 
prebiotic efficiency as they derived from protein fermentation by colonic bacteria. It can be assumed 
that prebiotic supplementation in the context of low protein diets would not induce any changes in 
PCG, PCS and PAG production. Finally although all models were significant, PCS, PCG, PAG and 
Streptococcaceae do not provide a linear prediction of the fasting hyperglycemia, circulating IL-1β, 
epididymal fat, mesenteric fat or caecum weight of HF and HF+ prebiotic fed mice (as indicated by a 
large within group variability in the OPLS model scores plots). These metabolites can be considered 
as qualitative markers of the mouse physiological improvement by prebiotics rather than 
quantitative markers of these physiological outcomes in our experiment. Further studies are needed 
to evaluate the links between these metabolites and fasting hyperglycemia, circulating IL-1β, 
epididymal fat, mesenteric fat, and caecum weight. 
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5. CONCLUSION  
This project has provided the evidences that prebiotic supplementation during HF challenge 
significantly limits obesity development, influencing host metabolism by modulating gut microbiota 
composition/activity. In the present chapter, the abundance of 4 markers (Streptococcaceae, PCS, 
PCG, and PAG) measured at D7 after the diet switch with 1H NMR spectroscopy and 16S rRNA gene 
sequencing allowed to model the long-term prebiotics efficiency to limit calorie storage, fat mass, 
adipocity, hyperinsulinemia, and circulating IL-1β production. These results have also supported the 
hypothesis of the causal relationship between Streptococcaceae, the production of bacterial amino 
acid fermentation end-products, metabolic disturbances, and inflammation during diet induced 
obesity (DIO).Because these markers were successfully predicting GOS, GOS_CMO and FOS_IN 
efficiency in the experiment, the calculated models may provide an early stage evaluation of the 
beneficial effect of any prebiotic on obesity development and related metabolic disorders. However, 
there is a clear need to further test the reliability of these markers in other contexts because various 
diets, containing structurally different prebiotics, and different animal models might strongly 
influence the ability to predict prebiotic effect on host physiology181,249. In addition, transferring 
these mathematical models from a single strain laboratory to human subjects presenting greater 
genetic and environmental variability might be challenging281. However, it is worth investigating as 
the concept of monitoring the relevance of prebiotic intervention offers potential applications in 
relation to personalised human healthcare.Indeed in principle, this early diagnostic would allow 
healthcare professionals to quickly estimate the efficiency of a prebiotic intervention and adapt the 
prebiotic dosages according to the characteristics and needs of a specific population111,281. 
Pharmacometabonomic principles which would be used to predict BWG and host physiological 
status from pre-dose baseline samples should also be considered in nutritional studies68. Hence by 
taking into account individual predispositions which are influenced by both genetic and 
environmental factors, suitable nutritional intervention (i.e prebiotics) targeting individual needs 
could be selected before any intervention111. Altogether, the measurement of prognostic and 
diagnostic makers of individual responses, respectively before and during the early phase of any 
nutritional intervention, would allow the monitoring of its impacts on individual heath.  
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 CHAPTER VII: GENERAL DISCUSSION 
 
 The wide range of gut microbiota-mammalian host interactions associated with the 
development of obesity and metabolic disorders were widely explored in this PhD thesis via 2 
experiments. The first experiment aimed to identify the metabolic signature differentiating obesity-
prone and obesity-resistant C57BL/6 mice after 7 days and 60 days of high-fat (HF) diet feeding. The 
second experiment evaluated the impact of dietary interventions involving different prebiotics such 
as galactosyl-oligosaccharides, (GOS), fructosyl-oligosaccharides and inulin (FOS_IN), or galactosyl-
oligosaccharides with cow milk oligosaccharides (GOS_CMO) on the modulation of host metabolism 
and immune system as well as on gut microbiota composition, in C57BL/6 mice during the gradual 
development of diet induced obesity (DIO). 
 
1. KEY FINDINGS  
It has been demonstrated that host metabolism is profoundly altered by HF feeding as 
indicated by a rapid saturation of host mitochondrial oxidative pathways (β-oxidation, branched 
chain amino acid (BCCA) catabolism, Chapter III, section X3.2X and Chapter IV, section X3.2.5X). In 
addition, obesity- resistant mice fed a HF diet differentially activate ketogenic pathways and TCA 
cycle, thus maintaining energy homeostasis and protecting mitochondria against fuel overloading. 
Hence, specific regulations of host mitochondrial metabolism might play crucial role in the onset of 
obesity during HF challenge.  
The results presented in this PhD thesis also demonstrated that gut microbiota are involved 
in the onset of obesity and related metabolic disorders. In the first experiment (Chapter III), the 
heterogeneous adaptation to HF diet in a population of genetically homogenous C57BL/6 mice was 
associated with a differential excretion of microbial co-metabolites suggesting that gut microbial 
activity plays a role in the adaptation of DIO-associated traits. In the second experiment (Chapter IV, 
V and VI), gut microbial remodelling by different prebiotics (GOS, GOS_CMO, FOS_IN) during DIO 
was associated with lower weight gain and fat mass, an improvement of the host immune status and 
variations in host metabolism. In particular, various long-term (70 days) prebiotic supplementations 
during a HF challenge improved host mitochondrial metabolism and reduced dyslipidemia. 
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Interestingly, FOS_IN supplementation specifically triggered protein degradation and ketogenesis, 
and allowed the maintenance of normo-glycemia (Chapter IV, section X4.4X).  
Variations in gut bacterial composition and metabolic activity were observed with different 
diets supplemented with prebiotics. Prebiotic supplementations increased gut bacterial 
carbohydrate fermentation and decreased gut bacterial tyrosine fermentation (Chapter IV, section 
X4.5X). All prebiotics triggered commensal bacteria growth (Chapter V, section X4.3X). However, FOS_IN 
induced a faster increase in the representation of Bifidobacteriaceae compared to GOS 
supplementation, while GOS_CMO preferably triggered an increase in the representation of 
Lactobacillaceae rather than Bifidobacteriaceae. Moreover, other bacterial families were modified 
with prebiotics. Bacteroidaceae representation increased while several families of the Firmicutes 
phylum (such as Peptostreptococceae, Ruminocacceace, and Streptococcaceae) decreased with 
prebiotic supplementation. 
Correlative analysis between 1H NMR metabolic profiles (urine, feces, plasma), fecal 
microbiota (at family level) and plasma cytokines at 70 days after the diet switch using the total 
variance of the dataset (all diet groups) have highlighted new associations among gut microbiota, 
host immune system and host metabolism:  
 Lachnospiraceae, Bacteroidetes, Porphyromonadaceae, Coriobacteriaceae, and 
Rikenellaceae (increasing with HF diet) were positively correlated with urinary BCAA 
catabolism intermediates (α-keto-β-methylvalerate, α-ketoisovalerate, isovalerate, 
isovalerylglycine) and 4PY. On the other hand, Erysipelotrichaceae (decreasing with HF diet) 
were negatively correlated with these metabolites. 
 Circulating interleukin-1 β (IL-1β), was positively correlated with urinary p-cresol sulfate 
(PCS) and p-cresol glucuronide (PCG), Peptostreptococceae and Streptococcaceae and was 
negatively correlated with Bifidobacteriaceae and fecal butyrate (Chapter V, section X3.2X). 
Finally, urinary metabolic signatures at each time point (from 7 days to 70 days) and fecal 
bacterial profiles at 7 days and 70 days (at family level) predicted the long-term (70 days) cumulative 
food efficiency (CFE) of HF and prebiotic groups. These statistical models allowed the identification 
of early and stable biomarkers of GOS, FOS_IN and GOS_CMO efficiency in reducing calorie storage 
during HF challenge. These markers are urinary PCS, PCG, phenylacetylglycine (PAG) and fecal 
Streptococcaceae. Early reductions of these markers in feces and urine were associated with the 
long-term reduction of CFE by prebiotics. PCS, PCG PAG and Streptococcaceae at 7 days were also 
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used to calculate general models predicting the long-term efficiency of prebiotic in reducing IL-1β, 
fat mass, fasting insulinemia caecum weight, epididymal and mesenteric fat. 
 
2. STATEMENTS OF NOVELTY.  
The studies carried out during this PhD allowed the identification of new candidate markers 
predicting the physiological adaptations of C57BL/6 mice to DIO under different dietary conditions. 
In particular, the study of the short-term and long-term urinary metabolic signatures of obesity-
resistant and obesity-prone mice under HF diet indicated that hexanoylglycine, isovaleryglycine and 
isobutyrate were early and consistent candidate markers predicting the differential body weight gain 
(BWG) of HF-fed mice. Variations in isobutyrate and other short chain fatty acids (SCFAs) (butyrate 
and propionate) have been already observed during obesity developmentH235. In particular, increased 
isobutyrate and butyrate have been found to improve lipid metabolism, inflammatory status and 
insulin sensitivity during DIO in human and mouse studies207,208. Hexanoylglycine and 
isovalerylglycine are glycine conjugates of hexanoyl-CoA and Isovaleryl-CoA which are intermediates 
of β-oxidation and leucine catabolism respectively. Increased hexanoylglycine and isovalerylglycine 
have been previously associated with the disruption of mitochondrial oxidative pathways298,299. 
However to the extent of my knowledge, these metabolites have never been reported as predictors 
of BW and obesity development.  
PCS, PCG PAG and Streptococcaceae at early time point (7 days after the diet switch) were 
also found to predict GOS, GOS_CMO and FOS_IN efficiency to reduce long-term calorie storage and 
improve mouse physiology during DIO. Therefore, these metabolites and bacterial taxa constitute 
stable and generic candidate makers evaluating the beneficial effect of the prebiotics on obesity 
development. If these markers are validated in other biological models, they may be used as a 
generic biological signature to evaluate the individual predisposition to DIO or assess the impact of 
prebiotic intervention on obesity development. 
In addition, the novelty of this work, based on the integration of complementary data from 
several analytical methodologies, has enabled me to identify new associations between gut bacterial 
families, and host physiological mechanisms. From these results, possible relationships between gut 
microbiota and host mitochondrial oxidative pathways have been suggested. In addition, significant 
correlations between metabolites from bacterial tyrosine degradation (PCS, PCG), IL-1β, 
Peptostreptococceae and Streptococcaceae were evidenced which highlighted the interactions 
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between gut microbiota and host inflammatory responses during obesity development. 
Interestingly, a common pattern in gut microbial and host metabolic adaptation among prebiotics 
was noticed. All prebiotics were found to lower Peptostreptococceae and Streptococcaceae growth, 
urinary PCS, PCG and circulating IL-1β level at 70 days after dietary intervention. Moreover, PCS, PCG 
PAG and Streptococcaceae at early time point (7 days after the diet switch) were associated with the 
long-term prebiotic efficiency to reduce calorie storage during HF challenge. Altogether, these 
findings suggest that gut microbial changes and reduced bacterial amino acid fermentation reduces 
the production of PCS, PCG, and p-cresol which in turn might lower inflammatory response to HF 
diet and improve host physiology.  
 
3. STRENGTHS AND WEAKNESSES OF THE EXPERIMENTS 
In each experiment, the dietary interventions provided significant effects on mouse 
phenotypes and metabotypes. Weight gain and food intake measurements allowed the 
characterisation of the impact of different diets on mouse obesity development. In particular, the 
second experiment provided a detailed description of mouse physiology and mouse inflammatory 
status by measuring fat distribution, organ weights, circulating cytokines, circulating glucose and 
insulin levels. Biofluid collections at several time points were useful to establish the short-term and 
long-term metabolic adaptation to the dietary interventions. In particular, the longitudinal study in 
the second experiment enabled the identification of early and consistent candidate biomarkers of 
prebiotic effects on host physiology. It is also important to note that isogenic C57BL/6 mouse is a 
suitable model to investigate microbial-host metabolic interactions during obesity 
development144,145. This mouse strain also showed differential adaptation to HF diet, which allowed a 
better understanding of the role of environmental factors (i.e. gut microbiota) and the biochemical 
mechanisms underlying obese phenotype variability.  
However, both experiments have drawbacks:  
 In the first experiment, the mice were fed with a baseline diet (before the diet switch) 
containing different amounts of carbohydrates, proteins, vitamins and fat contents 
compared to both LF and HF diets. Hence, mouse metabolic profiles during the pre-
intervention period were strongly different to those during HF and LF intervention due to 
variations in calorie supply. This may be the reason why urinary metabolic profiles of pre-
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intervention time points (before the HF diet switch) could not efficiently predict the 
differential adaptation to HF diet during the post-intervention. 
 In the second experiment, prebiotics supplemented LF diets (for instance LF + GOS, LF + 
GOS_CMO) were not provided. Therefore, it was impossible to differentiate the prebiotic-
specific effects (independent from HF diet) and the effects associated with the interactions 
between HF and prebiotics on host physiology and host metabolism. 
Our results ultimatly showed that 1H NMR and MS based metabolic profiling are robust and 
appropriate analytical methods to establish gradual metabolic changes linked to dietary intervention 
and disease development69,108. In particular, numerous microbial co-metabolites such as SCFAs or 
bacterial amino acid degradation end-products have been measured by these analytical methods in 
plasma, urine and feces of mice fed with different diets. Metabonomic data, supported by 16s rRNA 
gene profiling and cytokine profiles, have contributed to our overall understanding of the onset of 
obesity and the metabolic syndrome (MetS). These techniques highlighting the contribution of 
metabolites involved in energy metabolism (TCA cycle, lipid and amino acid processing), microbial-co 
metabolites, as well as gut microbial composition, and inflammatory markers for these pathological 
processes. Metabonomic-based analysis generated several hypotheses that will be further 
developed in this discussion. However, additional experiments would be useful to support our 
findings. For instance, genome-wide (microarrays or RNAseq) and targeted (qPCR) transcriptomic 
analyses of peripheral organs (liver, adipose tissue, muscle...) would be useful to identify variations 
in expression of genes encoding for proteins involved in lipid metabolism, mitochondrial oxidative or 
inflammatory pathways in the different diet groups and thus confirm these hypotheses.  
16S rRNA gene sequencing is nowadays a relatively inexpensive method to specifically identify 
bacterial taxa at different taxonomic levels (down to species level). However, some bacterial taxa are 
not equally covered by the pyrosequencing technique. Full metagenomic analysis is an alternative 
and more expensive approach based on the sequencing of the entire gut bacterial genome. This 
technique is less prone to biases and could provide a broader overview of the impact of HF diet and 
prebiotic interventions on gut microbial remodelling in our experiment. In addition, it would allow 
establishing new potential functions of a set of microbial species, which are selected by HF or 
prebiotic interventions. Further investigation of gut bacterial functions may point out other bacterial 
species conferring probiotic properties. 
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4. OBESITY DEVELOPMENT OF C57BL/6 MICE UNDER NUTRITIONAL 
INTERVENTIONS. 
Metabolic adaptations to obesity development in C57BL/6 mice have been investigated 
under several conditions in this PhD thesis. In the first experiment, (Chapter III) short-term (7 days) 
and long-term (60 days) urinary metabolic signatures to HF diet induced obesity were characterised. 
Several metabolites were found to be positively or negatively correlated with HF diet at both time 
points highlighting a consistent metabolic signature associated to DIO. A stratification of the mouse 
population under HF diet based on body weight gain (BWG) distribution (Chapter III, section X3.1X) 
were performed in the same experiment and candidate markers discriminating obesity-prone (SR) 
and obesity-resistant (NR) mice under HF diet were identified. In the second experiment, the 
comparison of metabolic signatures of LF, HF and HF+ prebiotic fed mice pointed out specific 
metabolic adaptations to HF diet and different prebiotic interventions in lowering obesity (Chapter 
IV, section X3.1X). The metabolic signatures associated with different dietary intervention are 
summarised in XTable 11X. This table aims to emphasize the metabolic adaptations associated with 
increasing obesity under different dietary interventions; therefore, it shows the increased or 
decreased levels of metabolites in most obese mice (HF or SR group) by comparison to the control 
group. (LF-fed mice), or the least obese mice (NR, or HF + prebiotics fed mice) in both experiments. 
Interestingly, several metabolites were consistently affected by the different diet interventions. In 
particular, HF induced obesity consistently affects lipid metabolism, nicotinamide-adenine 
dinucleotide (NAD) metabolism, and host mitochondrial oxidative pathways (β-oxidation, BCAA 
catabolism, and the tricarboxylic acid (TCA) cycle). Specific gut microbial-mammalian host metabolic 
interactions are affected by the development of obesity, as indicated by the modulation of bacterial 
methylamines metabolism, and bacterial amino acid degradation in HF diet compared to LF diet.  
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Table 11: Summary of the main metabolic adaptations to dietary interventions in each experiment 
    
Experiment 1 Experiment 2  
 
Metabolites 
HFvs 
LF 
SR vs 
NR 
HF 
vs LF 
 HF_S vs 
LF 
HF vs 
HF+GOS 
HF vs 
 HF + 
FOS_IN 
HF_S vs HF + 
GOS_CMO 
En
er
gy
 m
et
ab
o
lis
m
 
M
it
o
ch
o
n
d
ri
al
 m
et
ab
o
lis
m
 
BCAAs 
metabolism 
Leucine   ↓           
Leucine     ↓ ↓       
Valine     ↓ ↓       
Isovalerylglycine ↑ ↓ ↑ ↑   ↓   
α-Ketoisovalerate ↑   ↑ ↑ ↓     
α-Keto-β-methylvalerate ↑   ↑ ↑       
β-oxidation 
Carnitine ↑   ↑ ↑     ↓ 
Hexanoylglycine ↑ ↓           
TCA cycle 
Citrate     ↓ ↓       
Pyruvate     ↓ ↓       
  
Ketogenesis 3-D-Hydroxybutyrate           ↓   
NAD pathways 
2PY ↑   ↑     ↑ ↑ 
4PY ↑   ↑     ↑ ↑ 
SCFAs 
Acetate           ↓   
Butyrate         ↓ ↓   
Isobutyrate   ↓           
Lipid metabolism 
Bile acids mix     ↑   ↓     
Lipids      ↑ ↑ ↓ ↑   
Carbohydrate 
metabolism 
Sucrose     ↓       ↓ 
D-Galactose       ↑     ↓ 
D-Glucose     ↑ ↑ ↓ ↑ ↓ 
α-D-Glucose     ↑ ↑ ↑ ↑ ↑ 
Muscle energy 
homeostasis 
Creatine       ↑ ↑ ↑   
Creatinine         ↑ ↑ ↑ 
C
el
l p
ro
ce
ss
es
 
Cell signalling  
myo-inositol     ↓         
scyllo-inositol     ↓ ↓ ↓ ↓   
scyllo-inositol     ↓ ↓   ↑   
Nucleic acid 
metabolism 
Xanthine     ↓     ↑   
Uracil           ↑   
G
u
t 
b
ac
te
ri
a 
ac
ti
vi
ty
 
Choline and 
methylamine 
metabolism 
Choline     ↑   ↓ ↓   
TMA ↓   ↓       ↑ 
TMAO ↓   ↓     ↑   
Bacterial amino 
acid metabolism 
Indoxylsulfate     ↓ ↓ ↑ ↑ ↑ 
Phenylacetylglycine ↓   ↓ ↓       
Hydroxyphenlyacetate               
p-cresol glucuronide         ↓ ↓ ↓ 
p-cresol sulfate   ↓     ↓ ↓ ↓ 
LF: low fat, HF: high fat, NR: non-responder to HF diet, SR: strong responder to HF diet, HF_S: HF diet with 
glucose, galactose, and lactose, GOS: galactosyl-oligosaccharides, GOS_CMO: galactosyl-oligosaccharides and cow milk 
oligosaccharides, FOS_IN: fructosyl-oligosaccharides and inulin. 2PY: N-methyl-2-pyridone-5-carboxamide 4PY: N-methyl-4-
pyridone-3-carboxamide. TMA: trimethylamine TMAO: trimethylamine-N-oxide. NAD: nicotine adenine dinucleotide. TCA: 
tricarboxylic acid ↓ negatively correlated with HF diet or SR mice compared to the other group ↑ positively correlated with 
HF diet or SR mice compared to the other group. The metabolites found in plasma, urine or feces are color-coded as 
following:  
Urine Plasma feces 
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The decrease in obesity development by prebiotic supplementation was also associated with 
a regulation of mitochondrial metabolism (BCAA catabolism, or β-oxidation) and bacterial amino 
acid metabolism. This highlights the presence of key metabolic pathways being consistently 
regulated with obesity development irrespectively of the diet. These metabolic pathways may 
influence the onset of obesity during HF challenge. The role of mitochondrial oxidative pathways and 
bacterial amino acids metabolism are further discussed in the following sections. 
 
4.1. The role of mitochondrial oxidative pathways in obesity 
development.  
As expected, HF diet led to modifications of several metabolic pathways in C57BL/6 mice in 
order to process the nutrient overflow and maintain energy homeostasis. High lipid absorption was 
associated with an activation of lipid metabolism characterised by a modulation of circulating lipid 
content and an adaptation of mitochondrial oxidative pathways (β-oxidation, BCAA catabolism). An 
excess of circulating fatty acids was also associated with an increase in lipoproteins, promoting 
ectopic fat accumulation in several organs. HF feeding was found to convey an increase in body fat 
as well as an increase in liver weight, and epididymal and mesenteric adipose tissues weights. 
Concomitantly, long-term HF feeding raised circulating glucose levels, and promoted a loss of insulin 
sensitivity and an inflammatory response to HF diet. Interestingly, several C57BL/6 mice were 
resistant to DIO and were found to have stimulated alternative mitochondrial oxidative pathways. In 
particular, a specific increase in the glycine conjugate of leucine catabolism end-product (isovaleryl-
glycine) and a concomitant decrease in TCA cycle intermediate were observed in obesity-resistant 
mice compared to obesity-prone mice to HF dietH199. It has been suggested that an activation of 
ketogenic pathways in the mitochondria may limit the saturation of mitochondrial oxidative 
pathways and improve mouse physiology199. These results provide the evidence that mitochondrial 
homeostasis, which regulates ATP synthesis and energy metabolism, plays a crucial role in obesity 
development and associated metabolic disorders34. 
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4.2. Influence of gut microbiota on host mitochondrial 
metabolism.  
It is valid to say that in isogenic C57BL/6 mice, the genetic variations among subjects have 
been cancelled. Therefore, the differential activation of mitochondrial oxidative pathways in obesity-
resistant and obesity-prone mice was exclusively governed by environmental factors in our 
experiments. Epigenetic regulations linked to stress or dietary interventions as well as gut microbial 
activity have been found to influence host metabolism and host physiology irrespective of genetic 
background in previous studies27,28. In this PhD thesis, differential urinary excretion of microbial co-
metabolites (hippurate and hydroxyphenylacetylglycine) in obesity-resistant and obesity-prone mice 
on a HF diet were observed, which indicates a specific gut microbial activity in these two groups. 
These results suggested that gut microbiota contributed to the differential adaptation to the HF diet 
and may participate in regulation of mitochondrial oxidative pathways. 
This hypothesis was further investigated in this thesis by studying the effect of prebiotic on 
C57BL/6 mouse physiology during HF challenge. Different prebiotic blends (GOS, GOS_CMO and 
FOS_IN) were tested to selectively modify the gut microbiota in the context of DIO. Our results 
demonstrated that the different prebiotics induced profound changes in gut microbial composition 
and improve mouse physiology during HF diet. In addition, prebiotic supplementation during HF diet 
improved mouse metabolic homeostasis by partially recovering a healthy metabolic phenotype. 
Indeed, a significant shift in the global metabolic signature of HF+ prebiotic fed mice toward the 
metabolic pattern of LF-fed mice was observed in plasma and feces. This shift was characterised by a 
partial return of a normal, healthy profile of lipoproteins and metabolites involved in the 
mitochondrial oxidative pathways. In particular FOS_IN was the most efficient prebiotic in recovering 
healthy metabolic profiles as indicated by a significant reduction in circulating lipids, urinary 2PY, 4PY 
and glucose. These key findings support the hypothesis that gut microbiota influence host energy 
metabolism and play a significant role in the set of obesity.  
In addition, FOS_IN supplementation during HF diet showed an activation of leucine 
catabolism and ketogenesis and maintained a normal glycemia during HF challenge. This supports 
the hypothesis that the activation of leucine catabolism and ketogenic pathways improves insulin 
signalling pathways and may contribute to mouse weight reduction in DIO.  
In the second experiment, several correlative analyses between 16S rRNA sequencing data 
and 1H NMR urinary, plasma and fecal metabolic profiles allowed the identification of correlations 
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between bacterial families and metabolites involved in host energy metabolism. In particular, 
Streptococcaceae, Ruminococcaceae, Peptostreptococcaceae and Lachnospiraceae families from the 
Firmicutes phylum were positively correlated with circulating lipoproteins and fecal bile acids. 
Lachnospiraceae, Porphyromonadaceae, Rikinellaceae families were also positively correlated with 
urinary α-keto-β-methylvalerate, isovalerylglycine, isovalerate, α-ketoisovalerate and 4PY which 
derived from BCAA catabolism and NAD pathways respectively (XTable 11X). All these bacterial families 
were found to be stimulated by HF feeding. Therefore, bacterial communities selected by HF diet 
may promote lipid digestion and absorption and the stimulation of host energy metabolism. 
However, the correlative analyses did not provide any proof of the causative links between gut 
microbiota and host mitochondrial oxidative pathways. Increased nutrient supply due to the HF diet 
may independently affect the gut bacterial ecosystem and host energy metabolism in this 
experiment. Therefore, additional experiments are needed to precisely identify the role of gut 
microbial activity and bacterial co-metabolites on host energy metabolism.  
The influence of the gut microbiota on host energy homeostasis has been already 
highlighted in previous publications33,140,259. Studies of germ free mice and re-conventionalised mice 
have shown that the presence of the gut microbiota helps harvesting energy and increase host fat 
storage33,259. Gut microbiota also influence gut physiology and gut motility, which help extracting 
calories from the diet300. Finally the gut microbiota are involved in carbohydrate digestion and the 
formation of bacterial fermentation products (mainly SCFAs), which are used by the host140,300. In 
addition, gut bacterial activity has been found to impact host energy metabolism77,301. Several 
studies have shown dramatic differences in the host gene expression of germ-free mice and 
conventionally raised mice in the different segments of the gut as well as the liver and adipose 
tissuesH301. Interestingly, BCAA catabolism related genes coding for branched chain amino transferase 
(BCAT1 and BCAT2) in subcutaneous fat were differently regulated in germ-free and colonized mice. 
BCKDH gene expressing α-ketoacids dehydrogenase was also up-regulated in the liver of germ-free 
mice compared to conventional mice301 (Hhttp://microbiota.wall.gu.se/H). 
Recently, Ridaura et al have established causal links between gut microbial communities and 
obesity development by transplanting fecal samples from obese or lean discordant co-twins into 
separate group of germ free mice302. They found that mice colonized with obese co-twin fecal 
microbiota had a greater increase in body weight and adipose tissues compared to the mice 
colonized with lean co-twin fecal microbiota. In addition, obese mouse co-housed with lean mice 
also exhibited a lower weight gain, and a shift in gut microbiota composition towards a lean-like 
status. In particular, a stimulation of Bacteroidetes growth occurred in obese mice co-housed with 
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lean mice, which was associated with an increased protein expressions involved in BCAA catabolism 
and increased circulating SCFAs302. These results were in accordance with the abovementioned 
correlative analysis. Therefore, the work presented in this thesis along with these publications 
indicates that gut microbiota strongly contribute to a differential adaptation to DIO through a 
modulation of mitochondrial oxidative pathways and energy homeostasis. It can be suggested that 
specific gut microbiota remodelling by dietary interventions (such as prebiotics or probiotics) 
inducing a reduction of calories harvest and/or the activation of ketogenic pathways, may reduce 
obesity development and improve host physiological status. Nevertheless, further investigations are 
needed to define the precise interactions between gut microbiota, host mitochondrial oxidative 
pathways and energy homeostasis.  
 
4.3. Interactions between gut microbial tyrosine fermentation, host 
inflammatory pathways and host metabolism during diet induced 
obesity 
The work presented in this thesis demonstrated that, long-term (70 days) ingestion of GOS, 
GOS_CMO or FOS_IN during HF diet limits weight gain, fat mass production, food efficiency, IL-1β 
mediated immune response and organ weights (liver, adipose tissues). Urinary decreases in PCG and 
PCS were also observed in mice fed HF + prebiotics compared to HF or LF-fed mice. These molecules 
are both derived from the colonic bacterial degradation of tyrosine226. p-Cresol and PCS have been 
associated with gut inflammatory diseases, kidney diseases in human and insulin resistance in 
mice226,288,303. In particular, PCS has been found to activate inflammatory gene expressions (Tglb1, 
Fasl,Il-6, Il-5, Csf1/3, Cxc,10) in renal tubular cells in vitro291. Therefore, their decrease indicated 
strong changes in gut microbial activity with DIO which might modify host physiology. The gut 
microbial remodelling by prebiotics was also characterised by the growth of commensal bacteria 
(Bifidobacteriacecae or Lactobacillaceae) and the reduction of other bacterial families such as 
Peptostreptococaceae and Streptococaceae. Interestingly, weak but significant correlations 
(0.3<IRI<0.5, p value<0.05) were identified between PCG, PCS, IL-1β and Peptostreptococaceae. 
These results suggest that in the context of obesity, the production of p-cresol, PCG and PCS by gut 
bacterial tyrosine degradation in the mouse colon contributes to the mouse inflammatory responses 
to HF diet and affects mouse physiology. On the other hand, decreases in Peptostreptococaceae and 
Streptococaceae counts and down-regulation of bacterial tyrosine degradation by prebiotic 
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supplementation may lower IL-1β mediated inflammatory responses to HF challenge and improve 
host physiology. 
IL-1β is a key cytokine involved in multiple inflammatory processes. IL-1β activity is 
dependent on the transcription of pro-IL-1β genes, the maturation of pro-IL-1β and the regulation of 
mature IL-1β by the expression of antagonists such as siIL1-Ra279. IL-1β is also processed and 
released in macrophages and neutrophils via two mechanisms. The first mechanism involves the 
activation of TLRs (see Chapter I, section X1.4X) and enables the transcription and the maturation of 
pro-IL-1β279. The second mechanism requires the protein caspase 1 which is activated by a 
multimeric cytosolic protein complex called the inflammasome comprising NOD-like receptors 
(NLRs) amongst other proteins. These both mechanisms can be activated by bacterial and/or dietary 
components (see Chapter I, section X1.4.1X). IL-1β plays an essential role in the pathogenesis of auto-
inflammatory diseases such as inflammatory bowel diseases (IBD) and non-hereditary inflammatory 
diseases279. For instance, increased IL-1β production has been found in mononuclear cells from 
inflamed mucosa with ulcerative colitis or Crohn’s disease in vitro304. In addition, Carvalho et al 
showed that TLR5 KO mice were predisposed of developing colitis due to an activation of IL-1β-
dependent inflammatory pathways305. In the intestine, the inflammasome pathways (NLRP3, ASC, 
TXNP and caspase-1) can be regulated by molecules derived from gram-positive and gram-negative 
bacteria48. In particular, LPS levels in inflamed mucosa enhanced IL-1β production in the activated 
macrophages304. Therefore, alterations of gut microbiota by dietary intervention such as HF diet may 
trigger IL-1β mediated inflammatory responses in the gut.In addition, IL-1β has been suggested to 
play a crucial role in impaired insulin signalling, lipid metabolism and T2DM279. In particular, this 
interleukin was found to alter β-cells in mice triggering hyperglycemia, insulin resistance in 
peripheral tissues and fat accumulation in adipocytes and hepatocytes61,279,306.On the other hand, 
SiIL1-Ra treatment on adipocytes was shown to increase adipocytes differentiation and insulin 
sensitivity61. Increased inflammatory effectors including IL-1β in renal cells of chronic kidney disease 
patients was associated with renal failure307. Kidney failure may also increase the amount of protein 
bound solutes in circulation such as PCS and PCG. Interestingly, the etiopathogenesis of ulcerative 
colitis, kidney diseases and T2DM is thought to be promoted by an increase in p-cresol and PCS and 
is also associated with IL-1β mediated inflammatory responses226,279,288. Altogether these findings 
support the hypothesis of a causal relationship between metabolites derived from gut microbial 
tyrosine degradation, host immune system and host physiology (XFigure 57X). However, the nature of 
the interactions between the gut microbiota and the host metabolism remain to be explained. 
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Figure 57: Possible mechanisms linking gut bacterial tyrosine degradation, host inflammatory pathways and 
host physiological disturbances in diet induced obesity and its regulation with prebiotics.  The production of p-
cresol and p-cresol sulfate from bacterial tyrosine degradation during HF challenge may promote interleukin-
1β (IL-1β) related inflammatory pathways in the colon. Increased level of proteolytic bacteria induced by HF 
challenge (Peptostreptococaceae and Streptococaceae) may also contribute to amino acid degradation and 
inflammation in the gut. p-Cresol and p-cresol sulfate can cross mucosa and reach the liver via the portal vein. 
p-Cresol is further detoxified in p-cresol sulfate or p-cresol glucuronide in the liver. p-Cresol sulfate and p-
cresol glucuronide can enter systemic circulation and reach peripheral tissues (i.e pancreas, adipose tissues, 
kidney, liver), triggering local inflammatory responses. p-Cresol sulfate and p-cresol glucuronide are ultimately 
transferred to the kidney and released in urine. IL-1β production may alter β cell functions in the pancreas 
inducing insulin resistance, hyperglycemia and fat accumulation (green arrows for observed phenotypes in the 
prebiotic study and dashed green arrows for hypothetic phenotypes). IL-1β associated inflammation may also 
affect various organ functions. In particular it may promote renal failure. Prebiotic supplementations during HF 
challenge lowers Peptostreptococaceae and Streptococaceae growth and urinary p-cresol sulfate and p-cresol 
glucuronide prebiotic supplementations also reduce hyperglycemia circulating IL-1β, fat mass and organ 
weight. Hence, gut microbial remodelling by prebiotic inducing a decrease in anaerobic bacteria and bacterial 
tyrosine degradation may lower host inflammatory responses to HF diet and improve mouse physiology. 
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Firstly, it is important to determine whether p-cresol, or its derivatives (PCG, PCS) have a 
pharmacological effect on host metabolic/inflammatory pathways. They are differently processed by 
the host organism and therefore may affect different tissues. Indeed, p-cresol is rapidly detoxified by 
sulfation or glucuronidation in colonic mucosa or liver226. Hence, a large amount of p-cresol 
produced by colonic amino acid degradation may be deleterious for the coloncyte and hepatocyte. 
On the other hand, PCG and PCS are transferred in the kidney and released in urine226. They can also 
easily enter blood circulation and reach peripheral organs. Therefore PCG and PCS may be 
biologically active in renal cells as well as myotubules, hepatocytes and adipocytes. PCS has been 
already found to affect insulin signalling pathways in myotube cells in vitro by activating ERK1/2 
kinase. However, the impact of p-cresol or PCG on host metabolic pathways and host immune 
system is far from being understood. 
Further experiments are therefore needed to verify this hypothesis. Several in vitro 
experiments are in the pipeline to test the pharmacological effects of PCS, PCG or PAG on host 
metabolism. The preliminary experiments will consist in testing whether these molecules have a 
positive or negative effects on pharmacological targets in the host, such as G proteins coupled 
receptors (GPCR), intracellular kinases or toll-like receptors (TLRs). GPCRs are coupled with various 
enzymatic effectors regulating many physiological processes. Intracellular kinases are involved in 
several signalling cascades such as insulin signalling pathways or growth factor cascade. Finally TLRs 
are key receptors of innate immune systems (see Chapter I, section X1.4.1X). This high-throughput 
screening will allow the identification of physiological pathways which are affected by PCS, PCG and 
p-cresol. Additionally, it will be also important to test the dose-dependent effect of these molecules 
on adipocyte, colonocyte and hepatocyte metabolism (glucose uptake, insulin secretion, ROS 
production) to assess the impact of PCS, PCG and p-cresol on energy homeostasis and oxidative 
pathways. Finally, to test the pro- or anti-inflammatory properties of PCS, PCG and p-cresol, dose 
dependent experiments on macrophage will be carried out in vitro. Altogether these experiments 
will provide the evidence for a causative link between amino acid degradation end-products and the 
deregulation of the host energy metabolism and host immune system.  
Secondly, it is unclear whether Peptostreptococaceae or Streptococaceae growths are 
directly responsible for the raise of colonic amino acid degradation. Several in vitro tests have shown 
that Peptostreptococaceae are able to degrade several amino acids such as ornithine, lysine and 
arginine (Hhttp://www.metacyc.org/META/NEW-IMAGE?type=ORGANISM&object=TAX-186804H) but 
no evidence of tyrosine digestion by Peptostreptococaceae or Streptococaceae has been reported 
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yet. HF diet may independently activate the proliferation of these bacterial families, as well as gut 
bacterial amino acid degradation. 
The potential role of Peptostreptococaceae and Streptococaceae families in the production 
of p-cresol also needs to be investigated. In particular, it is important to identify which bacterial 
species within Peptostreptococaceae and Streptococaceae are involved in amino acid degradation. 
Fermentors are commonly used to study the anaerobic fermentation by bacterial cultures. A 
complex mix of bacteria (for instance, derived from fecal cultures) or a selected group of bacteria 
can be introduced in the chamber with fermenting substrate such as proteins or fibres. More 
advanced cultures (such as artificial gut) have also been developed to reproduce the physical, 
anatomical and nutritional characteristics of a gastrointestinal tracts308. Although in vitro 
experimental conditions do not entirely reproduce the complex environment in the gut and the 
bacterial cross-feeding, these techniques would be useful to better understand the role of 
Peptostreptococaceae and Streptococaceae on gut bacterial tyrosine degradation, alone or in a 
mixed culture. Ultimately, in vivo experiments would be necessary to validate the biological 
mechanism linking Peptostreptococaceae, Streptococaceae, amino acid degradation end-products, 
and host physiology. 
 
5. PERSPECTIVES ON HUMAN HEALTH 
This PhD thesis further highlights the role of mitochondrial homeostasis in obesity. It also 
shows the potential interactions between gut microbiota and host mitochondrial oxidative 
pathways. The identification of early and stable biomarkers predicting the differential adaptation to 
HF diet in C57BL/6 mice provides promising perspectives for weigh gain management and 
personalized nutrition. If these markers are confirmed in human studies, they could be used to 
anticipate the individual or population responses to an obesogenic environment (high calorie diets, 
low physical activity).  
This PhD thesis also demonstrates that prebiotics are efficient in limiting mouse obesity 
development and therefore could be proposed as dietary complements for weight gain management 
in animals and humans. However, it is important to note that the prebiotic consumption correspond 
to 24 mg/d per mouse in our experiment. It is unsure whether this fibre proportion can be easily 
applied to other animal models and to humans in particular. The recommended dietary reference 
intake of total fibre is 25 g/d for young women and 38 g/d for young men. It has been previously 
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found that high fibre ingestion may confer side effects such as bloating, gas production and 
discomfort in the human bowel, which limits prebiotic usage309. Interestingly, in a recent study, 
obese women treated with 15 g/d of inulin type fructans for 3 months showed modest changes in 
lipid metabolism but no significant effect on weight gain114. Therefore, additional research focused 
on studying the optimal fibre portion and/or designing new prebiotics are also important to find the 
optimum prebiotic intervention in humans. 
In addition, it has been suggested that prebiotics improve mouse physiology by disturbing 
the gut microbiota-host physiology interactions involving Peptostreptococaceae and 
Streptococaceae activity, via metabolites derived from bacterial tyrosine degradation (PAG, PCS) and 
IL-1β related inflammatory pathways. Further in vitro and in vivo analyses are required to validate 
this hypothesis. Based on this mechanism, new therapies specifically targeting effectors of the 
inflammation and/or the modulation of bacterial species could be developed to alleviate obesity 
development. However, the human gut ecosystem and its function exhibits great differences 
compared with the mouse gut ecosystem81. Therefore it is uncertain whether the same combination 
of prebiotics will have a comparable effect on obesity in human.  
Finally, several urinary metabolites (PAG, PCS, and PCG) and a fecal bacteria family 
(Streptococaceae) were found to predict at early stage the prebiotic efficiency in reducing mouse 
obesity. These markers could also present a great potential for personalized nutrition if they are 
transferable to human populations as they would assess at early stage the effect of prebiotic 
intervention on obesity. However, considering that human subjects present greater genetic 
variability and are subjected to a less-controlled environment than a single mouse strain, gut 
microbiota-host metabolic interactions might be complex and less predictable. In addition, it is also 
important to note that PAG, PCS and PCG are diet-dependent markers as they derived from gut 
protein and amino acid degradation. These metabolites may not be observed in experiments using 
low protein diets. Nevertheless, it is known that the western diet responsible for the obesity 
pandemic in humans is based on the intake of high fat, high sugary diets and red meat which 
contains a large protein content1,18. Hence, the gut microbial reshaping by prebiotics is likely to 
affect gut microbial amino acids degradation in human population during obesity development. 
However, these markers may not be effective predictors of weight gain and metabolic disturbances 
in vegans. In addition, given the significant difference in gut microbial ecosystem between humans 
and rodents, the effects of prebiotics may lower other end-products of gut microbial amino acid 
degradation in human model. 
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To conclude, considerable efforts are needed to test the reliability of these results in 
humans. In particular, studying prebiotic effects on the human metabolome and gut bacterial 
functionalities on epidemiological scale will be valuable to underpin the individual responses to 
different prebiotic treatments, depending on genetic, environmental, and gut microbial factors. The 
new mechanisms of gut microbiota and host metabolic interactions, and the concept of prediction of 
the physiological outcomes under DIO proposed in this PhD thesis, offer novel perspectives in 
healthcare management and personalised nutrition. 
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APPENDIX 1: 
SUPPLEMENTARY DATA AND 2D NMR ASSIGNMENTS OF THE BODY 
WEIGHT VARIABILITY STUDY (CHAPTER III) 
 
Table S1: Diet composition. 
Products Gm (%) (g/100kg)  
 Baseline 
(3437) 
Low Fat 
(D12450B) 
High Fat  
(D12492) 
Proteins   18.5  19.5 26.2 
Fibres (cellulose) 4.5 4.7 4.7 
Fat 4.5 4.3 34.9 
Carbohydrates 54.2 66.3 26.3 
Minerals 41.9 4.3 4.3 
Vitamins 40.13 0.95 0.95 
Choline 200 0.19 0.19 
Energy  3226.6 
kcal/kg 
3850 
kcal/kg 
5240 
kcal/kg 
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Table S2: Comparison of cumulative food intake (grams) between HF diet and LF diet fed mice NR 
mice and SR mice.  
cumulative food intake  
  7 days  60 days  
LF group  (mean ± stdev) 18.8± 1.4 131.5± 6.8 
HF group (mean ± stdev) 17.5±2.4 110.9± 7.5 
Wilcoxon-Mann-Whitney test LF vs HF (p 
value) 
0.0001 9.12 10-12 
NR group (mean ± stdev) 17.4 ± 4.26 107.0± 4.9 
SR group (mean ± stdev) 18.4 ±1.06 116.1 ± 6.5 
Wilcoxon-Mann-Whitney test NR vs SR (p 
value) 
0.0013 0.001 
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Table S3: Comparison of cumulative energy intake (kcal) between HF diet and LF diet fed mice NR 
mice and SR mice.  
Cumulative energy Intake   
  7 days  60 days  
LF group  (mean ± stdev) 72.80 ± 8.1 510± 51.83 
HF group (mean ± stdev) 73.5±12.5 535.7± 39.6 
Wilcoxon-Mann-Whitney test LF vs HF (p 
value) 
0.0001 1.84 10-9 
NR group (mean ± stdev) 83.2 ± 6.9 541.49± 27.6 
SR group (mean ± stdev) 100.1 ±19.8 599.1 ± 42.7 
Wilcoxon-Mann-Whitney test NR vs SR (p 
value) 
0.00630 0.00038 
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Figure S1: Correlation heatmap highlighting the significant correlations between energy intake 
and urinary metabolic profiles of LF and HF-fed mice at 7 days and 60 days after diet switch. 
Correlation values for each metabolite are displayed by color code. (Gradient of red color for 
metabolites positively correlated with energy intake and gradient of blue colors for metabolites 
negatively correlated). 
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Figure S2: Identification of hexanoylglycine in urine metabolic profile by 2D 1H-1H COSY NMR 
experiment and experiments of spiking; 
 
Figure S3: Identification of Isovalerylglycine in urine metabolic profile by 2D 1H-1H COSY 
NMR experiment and experiments of spiking.  
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Figure S4: Identification of Vinylacetylglycine in urine metabolic profile by 2D 1H-1H COSY 
NMR experiment and experiments of spiking. 
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Table S4: value of Q
2
Y and R
2
Y and validation of models. 
group Timepoint component Q2Y R2Y Permutation test 
(1000 tests): p value 
OPLS-DA 
LF vs HF  
day 0 1 negative x x 
7 days 1+1 0.83 0.89 1.0 10-3 
60 days 1+3 0.93 0.98 5.0 10-4 
OPLS-DA 
NR vs SR 
day 0 1 0.045 0.3821 x 
7 days 1+2 0.25 0.51 0.046 
60 days 1+2 0.40 0.8572 0.01 
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Table S5: Mean ratios ± standard error of integrals at day 7 (i.e day 7/day 0) or day 60 (i.e day 60/day 0) for each group and for each metabolite used in the data mapping 
(figure 4). 
metabolites 1H ppm  7 DAY LF 7 DAY HF 7 DAY NR 7 DAY SR  60 DAY LF 60 DAY HF 60 DAY NR 60 DAY SR  
Isovalerylglycine  0.92 0.97 ± 0.01 1.27 ± 0.02 1.38 ± 0.01 1.13 ± 0.02 0.80 ± 0.02 1.20 ± 0.014 1.32 ± 0.02 1.06 ± 0.01 
α-keto-β-methylvalerate 1.99 1.16 ± 0.01 1.54 ± 0.02 1.48 ± 0.02 1.52 ± 0.02 1.01 ± 0.01 1.37 ± 0.014 1.27 ± 0.02 1.35 ± 0.02 
α-ketosiovalerate 1.12 1.46 ± 0.01 2.05 ± 0.02 1.94 ± 0.03 2.01 ± 0.02 1.33 ± 0.01 2.03 ± 0.022 1.88 ± 0.02 1.97 ± 0.02 
Isoleucine  1.029 1.37 ± 0.02 1.62 ± 0.02 1.56 ± 0.02 1.61 ± 0.03 1.20 ± 0.02 1.46 ± 0.017 1.45 ± 0.02 1.44 ± 0.02 
Valine 1.05 1.04 ± 0.02 1.18 ± 0.01 1.21 ± 0.01 1.13 ± 0.01 0.82 ± 0.01 1.06 ± 0.012 1.04 ± 0.01 1.04 ± 0.01 
Leucine 0.97 1.40 ± 0.01 1.86 ± 0.01 1.91 ± 0.01 1.77 ± 0.01 1.09 ± 0.01 1.64 ± 0.013 1.62 ± 0.01 1.53 ± 0.01 
Citrate 2.57 1.09 ± 0.05 1.12 ± 0.05 1.06 ± 0.03 0.93 ± 0.04 1.14 ± 0.04 1.40 ± 0.093 0.85 ± 0.02 1.42 ± 0.10 
Succinate 2.410 0.212 ± 0.004 0.272 ± 0.007 0.260 ± 0.004 0.292 ± 0.008 0.186 ± 0.003 0.238 ± 0.008 0.182 ± 0.003 0.301 ± 0.010 
α-ketoglutarate 2.45 0.62 ± 0.01 0.72 ± 0.01 0.72 ± 0.01 0.70 ± 0.01 0.59 ± 0.01 0.68 ± 0.012 0.65 ± 0.01 0.70 ± 0.01 
Cis.Aconitate 3.12 0.86 ± 0.03 0.83 ± 0.02 0.89 ± 0.03 0.75 ± 0.02 0.98 ± 0.04 0.84 ± 0.027 0.74 ± 0.03 0.86 ± 0.02 
Fumarate 6.53 0.102 ± 0.005 0.128 ± 0.003 0.145 ± 0.003 0.134 ± 0.004 0.074 ± 0.002 0.118 ± 0.004 0.097 ± 0.002 0.127 ± 0.006 
Carnitine 0.88 0.98 ± 0.01 1.17 ± 0.01 1.20 ± 0.01 1.19 ± 0.01 1.01 ± 0.01 1.30 ± 0.015 1.40 ± 0.02 1.27 ± 0.02 
Acyl-carnitine 3.23 1.09 ± 0.01 1.20 ± 0.01 1.19 ± 0.00 1.19 ± 0.01 1.17 ± 0.01 1.24 ± 0.022 1.20 ± 0.01 1.30 ± 0.03 
Hexanoylglycine 3.2 1.54 ± 0.03 2.13 ± 0.04 2.19 ± 0.03 1.78 ± 0.04 1.18 ± 0.03 2.03 ± 0.035 2.11 ± 0.04 1.60 ± 0.02 
vinylacetylglycine 1.88 0.85 ± 0.01 1.08 ± 0.01 1.17 ± 0.01 0.98 ± 0.01 0.77 ± 0.01 1.06 ± 0.013 1.16 ± 0.02 0.96 ± 0.01 
N methyl nicotinamide 9.27 1.20 ± 0.05 1.20 ± 0.05 1.12 ± 0.04 1.39 ± 0.08 1.14 ± 0.04 1.22 ± 0.054 1.29 ± 0.06 1.28 ± 0.08 
Nictinurate 9.25 1.02 ± 0.03 0.92 ± 0.02 0.90 ± 0.02 0.83 ± 0.02 1.37 ± 0.04 2.04 ± 0.053 1.81 ± 0.06 2.04 ± 0.06 
2 PY 6.66 0.39 ± 0.01 0.48 ± 0.01 0.48 ± 0.01 0.46 ± 0.01 0.38 ± 0.01 0.78 ± 0.022 0.70 ± 0.01 0.88 ± 0.03 
4 PY 6.70 0.091 ± 0.002 0.128 ± 0.003 0.134 ± 0.003 0.119 ± 0.002 0.082 ± 0.002 0.172 ± 0.004 0.151 ± 0.004 0.178 ± 0.005 
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Table S6: List of p value obtained from pair-wise comparison between LF, HF, NR and SR mice of integral ratios at day 7 or day 60 using non parametric 
Wilcoxon-Mann-Whitney test. 
metabolites 
1
H ppm 
HF vs LF NR vs SR  LF vs NR LF vs SR HF vs NR  HF vs SR 
7  d a y s 6 0  d a y s   7  d a y s 6 0  d a y s 7  d a y s 6 0  d a y s 7  d a y s 6 0  d a y s 7  d a y s 6 0  d a y s 7  d a y s 6 0  d a y s 
Isovalerylglycine  0.92 6 .40E -06 5.55E-08 0 .03059 0 .01855 2 .97E -05 6 .66E -05 0 . 1 1 8 3 7 0 . 0 0 1 0 8 0 .18269 0 .28954 0 .06 27 2 0 .03831 
α-Keto-β-methylvalerate 1.99 1 .15E -07 3.66E-08 0 .93139 0 . 6 2 5 1 0 . 0 0 5 7 4 0 . 0 1 0 1 3 0 . 0 0 0 1 0 . 0 0 0 1 0 .66706 0 .27049 0 .6995 2 0 .59391 
α-Ketosiovalerate 1.12 1 .30E -10 4.66E-12 0 .79609 0 .88588 0 . 0 0 1 1 0 . 0 0 0 2 7 3 .78E -06 8 .36E -08 0 .48 207 0 .27049 0 .6494 1 0 . 1 8 6 9 
Isoleucine  1.029 0 . 0 0 1 4 6 0 . 0 0 0 4 8 0 .84075 0 .75209 0 . 0 7 9 3 4 0 . 0 3 4 8 2 0 . 1 1 0 4 8 0 . 0 1 6 1 4 0 .57815 0 .63 021 0 .5312 4 0 .90953 
Valine 1.05 0 . 0 1 4 8 6 2.35E-05 0 .50801 0 .79609 0 . 0 5 9 1 8 0 . 0 1 7 1 0 . 2 9 3 0 8 0 . 0 0 5 5 6 0 .84199 0 .48681 0 .5089 8 0 .70703 
Leucine 0.97 3 .75E -13 2.14E-15 0 .34074 0 .31192 4 .51E -08 4 .51E -08 1 .04E -06 3 .88E -08 0 .74498 0 .83892 0 .2399 8 0 .04724 
Citrate 2.57 0 . 5 7 0 9 8 0 . 2 9 1 2 0 .31192 0 .09564 0 . 7 8 7 1 8 0 . 2 3 2 8 3 0 . 2 0 9 7 2 0 . 9 0 7 4 6 0 .79 309 0 .52791 0 .2331 9 0 .11364 
Succinate 2.41 0 . 0 1 6 6 5 0 . 1 3 6 1 5 0 .93139 0 .00478 0 . 0 3 8 8 9 0 . 7 2 3 9 8 0 . 0 4 0 4 9 0 . 0 0 4 9 5 0 .82 561 0 .14274 0 .7509 8 0 .07316 
α-Ketoglutarate 2.45 0 . 0 5 0 0 0 0 . 0 5 1 0 0 0 .88588 0 .50801 0 . 3 4 7 7 7 0 . 4 1 6 4 0 . 1 7 4 9 8 0 . 0 5 1 9 9 0 .95816 0 .61509 0 .8035 7 0 .64319 
cis.Aconitate 3.12 0 . 9 4 7 5 1 0 . 2 6 1 3 6 0 .54577 0 .37116 0 . 7 2 3 9 8 0 . 1 2 4 4 1 0 . 7 2 7 1 7 0 . 6 0 6 3 0 .69786 0 .29939 0 .6868 6 0 .78642 
Fumarate 6.53 0 . 0 0 1 9 5 0 . 0 0 0 2 0 .37116 0 .70883 0 . 0 0 3 1 0 . 0 5 9 1 8 0 . 0 1 7 8 1 0 . 0 2 6 0 1 0 . 2 1 9 6 0 .20298 0 .8168 7 0 .68122 
Carnitine 0.88 0 . 0 0 0 2 9 2.43E-07 0 .02602 0 .01855 0 . 0 0 4 2 4 0 . 0 0 0 1 8 0 . 2 4 9 0 3 0 . 0 1 1 9 2 0 .68239 0 .88939 0 .0456 7 0 .00622 
Acyl-carnitine 3.23 0 . 0 0 0 5 7 1.23E-06 0 .70883 0 .19153 0 . 0 0 4 9 4 0 . 0 0 0 6 3 0 . 0 1 7 8 1 0 . 0 0 0 5 2 0 .65187 0 .21 067 0 .8840 7 0 .60607 
Hexanoylglycine 3.2 0 . 0 0 3 4 3 0 . 0 2 1 1 2 0 .02139 0.001883 0 . 0 1 7 1 0 . 2 1 6 5 7 0 . 0 2 8 4 9 0 . 1 1 8 3 7 0 .66706 0 .52791 0 .6868 6 0 . 9 2 3 4 
Vinylacetylglycine 1.88 1 .05E -07 4.89E-11 0 .01295 0 . 0 4 8 4 2 .03E -06 3 .02E -06 0 . 0 0 8 6 8 7 .15E -05 0 .07974 0 .33 028 0 .0847 1 0 .08831 
N-methyl-nicotinamide 9.27 0 . 6 7 3 3 9 0 . 3 6 4 4 8 0 . 9 7 7 1 0 .88588 0 . 9 1 7 3 3 0 . 7 8 7 1 8 0 . 6 2 9 7 8 0 . 6 2 9 7 8 0 .99163 0 .92329 0 .9521 2 0 .69408 
Nictinurate 9.25 0 . 5 5 3 1 7 0 . 0 0 2 2 0 .84075 0 .43662 0 . 6 0 3 2 2 0 . 2 1 6 5 7 0 . 4 1 4 4 4 0 . 0 3 1 1 7 0 .87494 0 .30 946 0 .6371 2 0 .90953 
2PY 6.66 0 . 0 3 4 0 6 2.17E-10 0 .58484 0 .47159 0 . 0 6 5 3 8 1 .21E -05 0 . 2 9 3 0 8 1 .82E -05 0 .71345 0 . 6 7 6 5 0 .6249 2 0 .56994 
4PY 6.7 7 .77E -05 3.57E-11 0 .19153 0 .50801 0 . 0 0 1 1 0 . 0 0 0 6 3 0 . 0 2 1 5 8 3 .78E -06 0 .36133 0 .43481 0 .4555 5 0 .99 303 
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APPENDIX 2: 
SUPPLEMENTARY DATA OF THE PREBIOTIC STUDY 
(CHAPTER IV, V, VI) 
Table S1:  Diet composition.  
 
 
Low fat with cellulose: LF diet 
High fat with cellulose: HF diet 
Mix A: Galactosyl-oligosaccharides prebiotic blend (GOS) 
Mix B: Galactosyl-oligosaccharides and cow milk oligosaccharides prebiotic blend (GOS_CMO)   
Mix C: Fructosyl-oligosaccharides and inulin prebiotic blend (FOS_IN) 
Mix D: galactose-lactose-destrose for HF_S diet. 
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Table S2: Percentage of calories (kcal) brought by fat, carbohydrates, proteins and vitamins in each diet. 
groupe diet  total Kcal 
Protein% 
(ckal) 
 Fat %(kcal)  Carbohydrate % (kcal) 
Vitamins 
        
soybean 
oil 
lard total fat  
corn 
starch 
Maltodextrine Sucrose 
other 
sugars  
other 
fibre  
cellulose 
total 
carboyhdrate    
A 
LF 
4057 20 5 4 9 31 3 34 0 0 0 70 1 
B 
HF 
4057 20 5 54 59 0 12 7 0 0 0 19 1 
C 
HF_S 
4057 20 5 54 59 0 12 0 7 0 0 19 1 
D 
HF_GOS 
4058 20 5 54 59 0 6 0 0 13 0 19 1 
E 
HF_GOS_CMO 
4057 20 5 54 59 0 10 0 0 8 0 18 1 
F 
HF_FOS_IN 
4057 20 5 54 59 0 9 6 0 4 0 19 1 
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Table S3 results of non parametric Wilcoxon-Mann-Whitney test for weight gain (A.) and cumulative 
food efficiency (B.) (Chapter IV).  
A. Body 
weight gain 
          p values D7 D14 D21 D28 D35 D42 D49 D56 D63 D70 
LF vs HF 
5.70E
-11 
1.6.E-
9 
1.80E
-08 
3.32E
-06 
1.00E
-13 
3.10E
-15 
2.00E-
16 
1.29E
-08 
3.32E
-06 
4.80E
-02 
LF vs HF_S 
5.30E
-06 
2.93E
-05 
5.11E
-05 
4.47E
-06 
3.20E
-07 
8.40E
-09 
2.90E-
11 
1.26E
-08 
4.47E
-06 
9.00E
-03 
LF vs HF+GOS 0.4 0.82 0.42 
0.000
87 0.5 0.43 
0.000
723 
2.30E
-03 
8.70E
-04 
0.005
1 
LF vs 
HF+FOS_IN 0.156 0.2 0.99 
0.000
88 0.039 
0.041
4 0.024 
6.90E
-04 
1.18E
-03 
0.003
29 
LF vs HF+ 
GOS_CMO 0.36 0.47 0.62 
0.001
2 0.016 0.035 
0.004
26 
4.10E
-03 
8.70E
-03 
0.001
46 
HF vs HF+GOS 
4.40E
-10 
1.40E
-08 
3.90E
-07 
4.49E
-06 
3.00E
-11 
5.10E
-12 
6.10E-
14 
1.29E
-08 
4.99E
-06 
3.08E
-03 
HF vs HF+ 
FOS_IN 
8.60E
-06 
1.50E
-07 
1.50E
-06 
5.02E
-06 
3.00E
-11 
8.48E
-11 
6.60E-
13 
9.02E
-08 
5.02E
-06 
6.94E
-03 
HF_S vs 
HF+GOS_CMO 0.016 
0.039
24 
3.96E
-02 
1.57E
-05 
5.80E
-04 
1.30E
-05 
3.80E-
06 
2.50E
-06 
6.67E
-05 
4.90E
-02 
HF vs HF_S 0.069 
0.152
9 
3.86E
-01 
3.00E
-03 
8.20E
-03 
1.00E
-02 
2.00E-
03 
6.60E
-03 
3.00E
-03 
8.90E
-01 
 
B. cumulative 
food efficiency   
         p values D7 D14 D21 D28 D35 D42 D49 D56 D63 D70 
LF vs HF 
1.21E
-07 
1.32E
-08 
1.19E
-07 
6.97E
-09 
6.02E
-10 
6.02E
-10 
2.07E
-10 
1.52E
-11 
3.22E
-12 
1.00E
-12 
LF vs HF_S 
0.000
369 
4.59E
-06 
2.65E
-08 
4.34E
-10 
2.36E
-10 
2.36E
-10 
1.17E
-09 
1.94E
-11 
5.82E
-12 
9.15E
-11 
LF vs HF+GOS 
0.139
236 
0.879
1 
0.008
161 
0.003
984 
0.001
497 
0.001
497 
0.000
162 
1.69E
-05 
6.09E
-06 
4.54E
-06 
LF vs HF+FOS_IN 
0.199
014 
0.894
663 
0.022
852 
0.005
097 
0.007
04 
0.007
04 
0.000
105 
9.66E
-05 
3.58E
-06 
4.26E
-06 
LF vs 
HF+GOS_CMO 
0.013
683 
0.059
146 
0.004
432 
0.000
95 
0.000
569 
0.000
569 
0.000
586 
0.000
409 
3.01E
-05 
7.51E
-06 
HF vs HF+GOS 
2.45E
-07 
7.86E
-09 
7.62E
-06 
2.13E
-06 
3.16E
-07 
3.16E
-07 
9.02E
-08 
1.09E
-08 
1.75E
-08 
1.10E
-08 
HF vs HF+FOS_IN 
5.33E
-06 
7.73E
-08 
8.57E
-06 
6.52E
-07 
1.25E
-07 
1.25E
-07 
2.40E
-07 
1.30E
-08 
2.42E
-08 
1.51E
-08 
HF_S vs 
HF+GOS_CMO 
0.070
722 
0.004
976 
4.80E
-05 
4.90E
-06 
3.53E
-05 
3.53E
-05 
5.36E
-06 
4.91E
-06 
3.09E
-06 
3.18E
-05 
HF vs HF_S 
0.160
352 
0.024
572 
0.290
605 
0.145
861 
0.031
026 
0.059
855 
0.022
596 
0.018
676 
0.010
385 
0.822
345 
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Table S4: Goodness of fit (R2Y) and prediction (Q2Y) for pair-wise OPLS-DAs at baseline (D0) 
The pair-wise OPLS DAs models at D0 show no significant differences in urinary, and fecal metabolic 
profiles between the different diet groups. No plasma sample at baseline was run and no 1H NMR 
plasma metabolic profiles were performed before diet intervention. 
  OPLS-DAs time points components R
2
Y Q
2
Y 
Urine 
LF, HF D0 1+1 0.5 -0.19 
LF,HF_S D0 1+0 0.75 0.14 
HF, HF+GOS D0 1+1 0.79 -0.32 
HF+ HF+FOS_IN D0 1+0 -0.92 0.4 
HF_S + HF+ GOS_CMO D0 1+1 -0.1 0.67 
Feces 
LF, HF D0 1+2 0.98 0.08 
LF,HF_S D0 1+0 0.9 0.14 
HF, HF+GOS D0 1+1 0.97 -0.006 
HF+ HF+FOS_IN D0 1+1 0.96 -0.28 
HF_S + HF+ GOS_CMO D0 1+1 0.89 -0.15 
plasma         
LF, HF D0 x x x 
LF,HF_S D0 x x x 
HF, HF+GOS D0 x x x 
HF+ HF+FOS_IN D0 x x x 
HF_S + HF+ GOS_CMO D0 x x x 
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Table S5: List of metabolites analysed with HAbsoluteIDQ p180 Kit BiocratesLife Sciences AGH and their 
corresponding abbreviations (Chapter IV)  
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Table S6: Goodness of fit (R2Y) and prediction (Q2Y) and p values for OPLS regression models 
predicting the cumulative food efficiency at 70 days after diet switch (CFE_70D) from urinary 
metabolic profiles at each time point (Chapter VI). 
  
OPLS models with HF and HF+GOS fed mice (urine profiles) 
timepoints cpnts Q2Y R2Y p value 
D7 3 0.64 0.9 1. 10-3 
D14 4 0.61 0.91 1. 10-3 
D21 3 0.44 0.86 1. 10-3 
D28 3 0.62 0.89 1. 10-3 
D35 3 0.65 0.94 1. 10-3 
D42 2 0.6 0.76 1. 10-3 
D49 4 0.7 0.93 1. 10-3 
D56 3 0.67 0.91 1. 10-3 
D63 3 0.66 0.93 1. 10-3 
D70 3 0.69 0.95 1. 10-3 
OPLS models with HF_S and HF+FOS_IN  fed mice (urine profiles) 
timepoints cpnts Q2Y R2Y p value 
D7 3 0.64 0.9 1. 10-3 
D14 4 0.58 0.87 1. 10-3 
D21 3 0.35 0.86 1. 10-3 
D28 2 0.65 0.8 1. 10-3 
D35 3 0.63 0.88 1. 10-3 
D42 4 0.6 0.95 1. 10-3 
D49 4 0.6 0.91 1. 10-3 
D56 3 0.67 0.89 1. 10-3 
D63 3 0.69 0.92 1. 10-3 
D70 3 0.72 0.92 1. 10-3 
OPLS models with HF and HF+GOS_CMO fed mice (urine profiles) 
timepoints cpnts Q2Y R2Y p value 
D7 2 0.38 0.74 1. 10-3 
D14 4 0.39 0.73 1. 10-3 
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D21 2 0.39 0.69 1. 10-3 
D28 4 0.37 0.95 0.01 
D35 1 0.22 0.39 0.03 
D42 2 0.42 0.71 1. 10-3 
D49 3 0.6007 0.91 1. 10-3 
D56 3 0.68 0.87 1. 10-3 
D63 2 0.48 0.8 1. 10-3 
D70 2 0.71 0.93 1. 10-3 
 
Table S7: Goodness of fit (R2Y) and prediction (Q2Y) and p values for OPLS regression models 
predicting the cumulative food efficiency at 70 days after diet switch (CFE_70D) from fecal metabolic 
profiles at each time point. (Chapter VI). 
OPLS models with HF and HF+GOS fed mice (feces profiles)  
timepoints cpnts Q2Y R2Y p value 
D7 3 0.44 0.99 0.01 
D14 2 0.37 0.95 0.01 
D21 3 0.19 0.99 0.048 
D28 4 0.3 0.99 0.14 
D35 2 0.34 0.94 0.03 
D42 2 0.28 0.95 0.08 
D49 2 0.14 0.96 0.39 
D56 3 0.31 0.99 0.05 
D63 4 0.38 0.99 0.06 
D70 4 0.26 0.99 0.05 
OPLS models with HF_S and HF+GOS_CMO fed mice (feces profiles)  
timepoints cpnts Q2Y R2Y p value 
D7 7 -0.1 0.99 0.86 
D14 1 0.25 0.97 0.14 
D21 1 0.01 0.95 0.46 
D28 7 -0.12 0.99 0.83 
D35 3 0.16 0.99 0.24 
D42 1 0.06 0.96 0.53 
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D49 1 0.15 0.94 0.32 
D56 4 0.3 0.99 0.02 
D63 3 0.34 0.99 0.08 
D70 4 0.38 1 0.01 
OPLS models with HF and HF+FOS_ IN fed mice (feces profiles)  
timepoints cpnts Q2Y R2Y p value 
D7 3 0.31 0.99 0.06 
D14 1 0.43 0.95 0.01 
D21 4 0.31 0.99 0.13 
D28 4 0.39 0.99 0.02 
D35 2 0.47 0.97 0.01 
D42 3 0.33 0.99 0.04 
D49 4 0.47 0.99 0.03 
D56 4 0.53 0.99 0.01 
D63 4 0.28 0.99 0.15 
D70 2 0.12 0.97 0.24 
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Figure S1 : Curves of glucose OGTT. LF: Low fat group, HF : High fat group; HF_S : HF + sugars, 
HF+GOS :  HF + galactosyl-oligosaccharides, HF + GOS_CMO : HF + galactosyl-oligosaccharides and 
cow milk oligosachharides, HF + FOS_IN : HF + Fructosyl-oligosachharides and inulin. T: time in 
minutes 
Table S8 : Statistics of OGTT glucose for each diet group 
 
N Mean SD SEM Median Rob. SD 
SE 
Median Min Max 
Baseline insulin (ng/mL) LF 15 0.35 0.22 0.06 0.34 0.20 0.07 0.00 0.80 
HF 15 0.95 0.93 0.24 0.88 0.57 0.18 0.00 3.75 
HF_S 15 0.69 0.48 0.12 0.56 0.41 0.13 0.00 1.83 
HF+GOS 15 0.42 0.21 0.05 0.37 0.18 0.06 0.00 0.83 
HF+ GOS_CMOS 15 0.30 0.23 0.06 0.32 0.30 0.10 0.00 0.64 
HF+ FOS_IN 15 0.44 0.29 0.08 0.41 0.29 0.09 0.00 1.00 
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N Mean SD SEM Median Rob. SD 
SE 
Median Min Max 
Max insulin (ng/mL) LF 15 0.52 0.18 0.05 0.47 0.13 0.04 0.30 0.90 
HF 15 1.70 0.80 0.21 1.34 0.42 0.14 0.77 3.75 
HF_S 15 1.13 0.34 0.09 1.05 0.31 0.10 0.68 1.83 
HF+GOS 15 0.66 0.16 0.04 0.66 0.17 0.05 0.43 0.96 
HF+ GOS_CMOS 15 0.63 0.26 0.07 0.62 0.25 0.08 0.10 1.18 
HF+ FOS_IN 15 0.72 0.36 0.09 0.74 0.41 0.13 0.14 1.38 
T30 insulin (ng/mL) LF 15 0.39 0.27 0.07 0.38 0.24 0.08 0.00 0.90 
HF 15 1.56 0.81 0.21 1.32 0.70 0.23 0.00 3.12 
HF_S 15 1.01 0.40 0.10 1.03 0.37 0.12 0.02 1.67 
HF+GOS 15 0.56 0.25 0.06 0.59 0.22 0.07 0.00 0.96 
HF+ GOS_CMOS 15 0.41 0.30 0.08 0.42 0.39 0.13 0.00 0.87 
HF+ FOS_IN 15 0.69 0.36 0.09 0.74 0.43 0.14 0.14 1.38 
T60 insulin (ng/mL) LF 15 0.18 0.18 0.05 0.21 0.25 0.08 0.00 0.51 
HF 15 0.99 0.67 0.17 1.05 0.57 0.19 0.00 2.22 
HF_S 15 0.72 0.49 0.13 0.60 0.28 0.09 0.00 1.72 
HF+GOS 15 0.38 0.26 0.07 0.40 0.25 0.08 0.00 0.79 
HF+ GOS_CMOS 15 0.47 0.34 0.09 0.45 0.33 0.11 0.00 1.18 
HF+ FOS_IN 15 0.57 0.38 0.10 0.48 0.38 0.12 0.00 1.21 
 
294 
 
 
Figure S2 : Curves of insulin OGTT. LF : Low fat group, HF : High fat group; HF_S : HF + sugars, 
HF+GOS :  HF + galactosyl-oligosaccharides, HF + GOS_CMO : HF + galactosyl-oligosaccharides and 
cow milk oligosachharides, HF + FOS_IN : HF + Fructosyl-oligosachharides and inulin. T : Time in 
minutes 
 
Table S9 : Statistics of OGTT insulin for each diet group 
 
N Mean SD SEM Median Rob. SD 
SE 
Median Min Max 
Baseline insulin (ng/mL) LF 15 0.35 0.22 0.06 0.34 0.20 0.07 0.00 0.80 
HF 15 0.95 0.93 0.24 0.88 0.57 0.18 0.00 3.75 
HF_S 15 0.69 0.48 0.12 0.56 0.41 0.13 0.00 1.83 
HF+GOS 15 0.42 0.21 0.05 0.37 0.18 0.06 0.00 0.83 
HF+ GOS_CMOS 15 0.30 0.23 0.06 0.32 0.30 0.10 0.00 0.64 
HF+ FOS_IN 15 0.44 0.29 0.08 0.41 0.29 0.09 0.00 1.00 
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N Mean SD SEM Median Rob. SD 
SE 
Median Min Max 
Max insulin (ng/mL) LF 15 0.52 0.18 0.05 0.47 0.13 0.04 0.30 0.90 
HF 15 1.70 0.80 0.21 1.34 0.42 0.14 0.77 3.75 
HF_S 15 1.13 0.34 0.09 1.05 0.31 0.10 0.68 1.83 
HF+GOS 15 0.66 0.16 0.04 0.66 0.17 0.05 0.43 0.96 
HF+ GOS_CMOS 15 0.63 0.26 0.07 0.62 0.25 0.08 0.10 1.18 
HF+ FOS_IN 15 0.72 0.36 0.09 0.74 0.41 0.13 0.14 1.38 
T30 insulin (ng/mL) LF 15 0.39 0.27 0.07 0.38 0.24 0.08 0.00 0.90 
HF 15 1.56 0.81 0.21 1.32 0.70 0.23 0.00 3.12 
HF_S 15 1.01 0.40 0.10 1.03 0.37 0.12 0.02 1.67 
HF+GOS 15 0.56 0.25 0.06 0.59 0.22 0.07 0.00 0.96 
HF+ GOS_CMOS 15 0.41 0.30 0.08 0.42 0.39 0.13 0.00 0.87 
HF+ FOS_IN 15 0.69 0.36 0.09 0.74 0.43 0.14 0.14 1.38 
T60 insulin (ng/mL) LF 15 0.18 0.18 0.05 0.21 0.25 0.08 0.00 0.51 
HF 15 0.99 0.67 0.17 1.05 0.57 0.19 0.00 2.22 
HF_S 15 0.72 0.49 0.13 0.60 0.28 0.09 0.00 1.72 
HF+GOS 15 0.38 0.26 0.07 0.40 0.25 0.08 0.00 0.79 
HF+ GOS_CMOS 15 0.47 0.34 0.09 0.45 0.33 0.11 0.00 1.18 
HF+ FOS_IN 15 0.57 0.38 0.10 0.48 0.38 0.12 0.00 1.21 
 
